

Date: 4th September 2026

To, Manager - Listing Compliance National Stock Exchange of India Limited , Exchange Plaza. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 SYMBOL: JSLL	To, Head – Listing Operations Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 SCRIP Code: 544476

Subject: Submission of Business Responsibility and Sustainability Report for the financial year 2025-26 pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ("SEBI Listing Regulations"), we hereby submit the **Business Responsibility and Sustainability Report ("BRSR") of Jeena Sikho Lifecare Limited ("the Company") for the Financial Year 2025-26.**

The BRSR forms an integral part of the Integrated Annual Report of the Company for the Financial Year 2025-26 and is enclosed herewith for your information and record.

The Integrated Annual Report, including the BRSR, is also available on the website of the Company at <https://jeenasikho.com/wp-content/uploads/2026/09/Annual-Report-2026.pdf>

You are requested to take the above information on record.

Thanking you.

Yours faithfully,

For Jeena Sikho Lifecare Limited

MANISH Digitally signed by
MANISH GROVER
GROVER Date: 2026.09.04
17:05:18 +05'30'

Manish Grover
Managing Director
DIN: 07557886

Place: Zirakpur, Punjab

Date: 04.09.2026

JEENA SIKHO LIFECARE LIMITED

120⁺ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

Registered Office Address:

SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:

B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID: cs@jeenasikho.com | www.jeenasikho.com



Advancing Holistic Healthcare





Advancing Holistic Healthcare

For more info contact us, or visit the website
www.jeenasikho.com



Health is a journey of balance, shaped by prevention, timely care, lifestyle and long-term well-being. This belief has guided Jeena Sikho from the beginning. Rooted in Ayurveda, we understand health at its source and work to bring holistic care within reach of the masses.

Over the years, that philosophy has grown into a connected healthcare ecosystem, bringing together hospitals, clinics, day-care centres, consultations and Ayurvedic products. Each part strengthens the next, and together they answer a widening range of healthcare needs.

FY26 marked another step forward in this journey. The network expanded, care

capabilities deepened, and the product portfolio continued to grow. Digital consultations and technology-led initiatives widened patient engagement, while the first presence beyond India began to take shape. Together, these efforts shaped a more connected experience of care.

The road ahead calls for steady evolution. Reach is widening, capabilities are strengthening, and new markets are opening, even as the shift from cure to prevention is still settling into everyday habit. Alongside this, the Company continues to find fresh ways to make Ayurveda relevant to modern healthcare.

Advancing Holistic Healthcare reflects that direction. It means taking what has been built and carrying it further: making holistic care more accessible, more relevant, and ready for the needs of tomorrow.



Inside this report

Strategic Review

About Us	02
Our Founder and Leadership Team	04
Our Journey	06
Our Offerings	08
Our Network and Credentials	12
Our Footprint	14
Business Model Positioning	16
Message from Managing Director	20
Key Performance Indicators	22
Board of Directors	24
Corporate Governance	28
Outlook	30
Testimonials	32

Statutory Reports

Management Discussion and Analysis	34
Notice	42
Board Report and Annexures	79
Report on Corporate Governance	110
Business Responsibility and Sustainability Report (BRSR)	135

Financial Statements

Independent Auditor's Report	167
Standalone Financial Statements	179
Independent Auditor's Report	258
Consolidated Financial Statements	269

Forward Looking Statement

This Annual Report contains forward-looking statements intended to provide investors with insights into our future outlook and assist in informed decision-making. These statements, along with other periodic written and verbal communications, reflect our current plans, expectations, and assumptions made by management. Words such as 'anticipate', 'believe', 'estimate', 'expect', 'intend', 'plan', 'project', and other similar expressions typically indicate such forward-looking statements. While these statements are based on assumptions we believe to be reasonable at the time, they are inherently subject to known and unknown risks, uncertainties, and other factors that could cause actual outcomes to differ materially from those expressed or implied. Any such divergence may result from changes in the business environment, market dynamics, regulatory shifts, or inaccuracies in assumptions. Given these inherent uncertainties, readers are advised to exercise caution in relying on forward-looking information. We undertake no obligation to update any forward-looking statements publicly, whether as a result of new information, future developments, or otherwise.

ABOUT US

An Integrated Ayurveda Healthcare Platform

Jeena Sikho Lifecare is one of India's leading Ayurveda healthcare platforms, delivering holistic wellness through the discipline of mainstream, science-backed medicine. We treat prevention and cure as one continuum, pairing clinical care with a portfolio of Ayurvedic products so that healing extends well beyond the hospital or clinic. Our practice stays evidence-led, drawing on clinical research and documented outcomes rather than tradition alone. Through this approach, the Company is bringing the rigour and reach of modern healthcare to one of the world's oldest medical sciences.



Our Vision

To make the world healthy.

To create awareness about the causes and prevention of disease.

To use the benefits of Ayurveda and alternative treatments for recovery from disease.



Our Mission

Our mission centres on providing enhanced Ayurvedic healthcare services, spreading vital awareness about healthy lifestyles, and revitalising India's rich medical heritage through innovative approaches.



Our Values

With values rooted in integrity, authenticity, and efficacy, Jeena Sikho places a paramount focus on creating genuine products, offering ethical services, and delivering effective solutions.

Two Verticals, One Ecosystem

Founded in 2009 and incorporated in 2017, the Company operates under the Shuddhi brand, a name drawn from the Sanskrit for purification that reflects our focus on natural detoxification and holistic healing. Our platform brings healthcare services and Ayurvedic products together so that each strengthens the other: patients treated at a centre continue on a medicine regimen after discharge, while product customers often turn to a centre for fuller care. This interplay gives the business recurring engagement and a low-cost route to new patients, with each vertical widening the reach of the other.

Care That Reaches Deeper Into Communities

We deliver care through a network of Panchakarma hospitals, clinics, and day-care centres operating on a hub-and-spoke model across 23 states and more than 100 cities and towns. Larger hospitals provide advanced inpatient treatment, while clinics and day-care centres extend consultations, therapies, and follow-up care closer to where patients live. Empanelment with major government schemes and health insurers widens access further, bringing specialised Ayurvedic treatment within reach of communities that mainstream healthcare often leaves underserved.

Evidence-Led Ayurveda

Traditional knowledge is reinforced at the Company by scientific validation, through clinical research, documented outcomes, and standardised treatment protocols. Several of our products are validated through registered clinical trials, and a growing body of published research supports our practice. Together, these strengthen confidence in Ayurveda as a structured healthcare system for both preventive and chronic disease management.

A Scalable Platform for Future Growth

The Company's model is deliberately capital-light, allowing us to add capacity and enter new locations without straining the balance sheet. We continue to expand healthcare infrastructure, widen product access through digital channels and OTC retail, and pursue innovative opportunities. Listed on the NSE since 2022 and on the NSE and BSE mainboard in 2025, Jeena Sikho has scaled into one of the fastest-growing enterprises in the sector, with each avenue aligned to our objective of making Ayurveda a mainstream healthcare choice.

Jeena Sikho at a Glance

₹ 801 Cr

Revenue from Operations

119

Operational Centres

2,861

Total Beds

23

States Covered

100+

Cities & Towns Covered

61

Operational Hospitals

58

Operational Clinics & Day Care Centres

330+ SKU

Ayurveda & Wellness Product Portfolio

50

NABH-Accredited Facilities

2,300

Beds operational

OUR FOUNDER AND LEADERSHIP TEAM

The Vision That Leads Us

At the centre of Jeena Sikho Lifecare stands its founder, Acharya Manish Ji, a healer, educator, and reformer whose life's work is the pursuit of a disease-free, drug-free Bharat. What began as a personal search for healing during a childhood illness grew, over time, into a nationwide movement, one that reclaims Ayurveda as a primary path to wellness rather than a fallback when other options run out.

Acharya Manish Ji's Motto is
"Prevention is the only cure"

The Minds Behind the Mission

Acharya Ji is supported by a panel of accomplished clinicians and scientists who bring depth and rigour to the Company's practice across Ayurveda, naturopathy, and specialised care.



Dr. Sonali
 HOMEOPATHIC
 PHYSICIAN
*Expert in
 Relationship,
 Intimacy
 & Sexual Health
 Concerns*

**Prof. Ish
 Sharma**
 MD, PH.D AYURVEDA
*Former Ayurveda
 Ambassador
 In Mauritius
 Expert in Lifestyle
 Disease*

**Acharya
 Manish Ji**
 NATUROPATHY &
 DIET EXPERT
*Guiding Globe
 Towards Drug-Free,
 Natural Wellness*

**Dr. Satya
 Pal Chhabra**
 GAMS 1974-
 79 BATCH MD
 UNIVERSITY ROHTAK
 (HARYANA)
*Expertise in Mind
 Healing*

**Dr. Rajshree
 Gupta**
*Ayurvedic Physician,
 BAMS, Expert in
 Natural Healing,
 Lifestyle Disorders, &
 Preventive Wellness*



From a Personal Search to a National Mission

Acharya Ji's journey began when conventional medicine could not resolve the health challenges of his early years. Introduced to Ayurveda by his uncle, he watched his own condition improve, and that turning point became something larger than a personal recovery. It set him on a lifelong purpose: to revive Ayurveda as a mainstream, science-backed, and lifestyle-oriented system of care, accessible to everyone.

Rooted in India, Grounded in Science

Central to Acharya Ji's conviction is that Ayurveda is India's gift to the world, a science born in India with the power to heal India and beyond, captured in the idea of "We Heal in India". His approach treats tradition and evidence as partners rather than opposites, drawing on modern scientific understanding, including Nobel-recognised work on how the body renews its cells, regulates its internal clock, and manages its metabolism, to explain why time-tested Ayurvedic practices work. This grounding lets the Company present Ayurveda as a structured system of medicine rather than a matter of belief.

A Vision for the Future

For Acharya Ji, holistic health is a right rather than a privilege. He envisions a future in which authentic Ayurvedic care reaches every corner of India and travels to the world beyond, and he measures the Company's progress by how close it comes to that goal. With every patient healed, every centre opened, and every product created, that vision moves a step nearer.

Be Your Own Doctor

Acharya Ji's philosophy rests on a single, resonant idea, captured in his mantra "अपना डॉक्टर खुद बनो", or "Be your own doctor". He believes lasting health comes not from dependence on medication but from self-awareness, prevention, and a life lived in balance with nature. Drawing on years of study across Ayurveda and Naturopathy, he developed the Golden Therapy, a holistic treatment approach designed to address chronic and lifestyle conditions gently. His wider call is for a national awakening, a Bharat where every individual takes charge of their own health.

Reach Beyond the Clinic

Acharya Ji's influence extends far past the walls of any hospital. Over more than fifteen years, his expertise has shaped product formulation, treatment protocols, patient care, and public education across the Company's network. Through television, digital platforms, and community health camps, he carries the message of preventive health to millions, turning a clinical practice into a broad public conversation about how India can live healthier.

Media Presence

Acharya Ji reaches one of the largest audiences in the Ayurveda space, with millions of followers across YouTube, Facebook, and Instagram, alongside a regular presence on national and regional television. This reach carries preventive health into homes far beyond the Company's clinical network, making Ayurveda part of everyday conversation.

More on Business
 Model Positioning
 Page 16



A Journey of Expanding Impact

What began with a mission to make Ayurveda the first choice for preventive and chronic care has steadily evolved into one of India's fastest-growing integrated Ayurveda healthcare platforms. Every milestone has strengthened the ecosystem, expanding access, clinical capabilities, patient trust and nationwide reach.

2009 The Beginning of a Purpose

MISSION TO REVIVE AYURVEDA

Established with a vision to make Ayurveda the first choice for preventive and chronic healthcare. The journey began with the distribution of Ayurvedic medicines, laying the foundation for an integrated healthcare enterprise.

2013 From Products to Patient Care

1st AYURVEDA HEALTHCARE CENTRE

Established the first Ayurveda healthcare centre in Chandigarh, marking the Company's entry into organised healthcare services and bringing holistic consultations and treatment closer to patients.

2018 A Unified Healthcare Identity

LAUNCH OF SHUDDHI AYURVEDA

Developed the Shuddhi Project to establish dedicated Ayurveda healthcare centres, creating a structured platform for delivering consultations, therapies and holistic patient care.

2017 Creating the Foundation for Scale

JEENA SIKHO LIFECARE INCORPORATED

The formal incorporation of the Company established the institutional framework required to strengthen governance, organise operations and support long-term expansion.

2020 Entering Advanced Clinical Care

FIRST PANCHAKARMA HOSPITAL

Expanded the scope of healthcare delivery by introducing inpatient treatment and specialised Ayurvedic therapies, strengthening the Company's clinical capabilities.

2021 Taking Ayurveda Closer to Communities

50+ OPERATIONAL CENTRES


The growing network improved accessibility across regions and reinforced the Company's hub-and-spoke model for delivering integrated healthcare services.



2026 An Integrated Ayurveda Ecosystem

2,300 OPERATIONAL BEDS

The Company broadened its reach across 23 states and over 100 cities, launched the Jeena Sikho Health Card, entered the OTC retail segment, and increased the number of NABH-accredited facilities, reinforcing its position as an integrated Ayurveda healthcare platform.



2025 Strengthening the Platform

115 CENTRES 1,600 BEDS

Investments during the year focused on expanding healthcare capacity and preparing the organisation for its next phase of nationwide growth.

2024 Growth Reflected in Scale

₹324 CRORE LANDMARK REVENUE

The year reflected stronger patient acceptance and a more diversified business model, supported by continued expansion across healthcare services and Ayurvedic products.

2022 A New Chapter in Growth

RAISED ₹55.5 Cr THROUGH IPO

Listing on the public markets strengthened the Company's capital base and created new opportunities to accelerate expansion while enhancing governance standards.

2023 Deepening the Healthcare Network

MULTI-CITY HOSPITAL EXPANSION

Continued investments in healthcare infrastructure by strengthening presence across Lucknow, Jaipur, Navi Mumbai along with 20 other small and mid-sized centres across the country.

OUR OFFERINGS

Services and Solutions for Every Stage of Health

Jeena Sikho's offerings span the full arc of health, from staying well to recovering from chronic illness. We deliver this through two connected verticals: a network of hospitals, clinics, and camps that provides clinical Ayurvedic care, and a portfolio of Ayurvedic products that carries treatment into daily life. Care begins with a consultation and continues well after it, at a centre, at a camp, or at home, letting a patient move through prevention, treatment, and recovery without stepping outside the Ayurvedic system.

Ayurveda Healthcare Services

Our services run on a hub-and-spoke model, with large hospitals anchoring clinical care in major cities and clinics and day-care centres extending consultations and follow-up closer to where people live. Care reaches patients through different formats.

In-patient Department through Hospitals



Our hospitals provide round-the-clock medical supervision in a healing environment, with comfortable rooms, customised Ayurvedic diet plans, and dedicated units for Panchakarma and allied therapies. In-patient care is built around detoxification, recovery, and lasting improvement for chronic and complex conditions.

Out-patient Department via Clinics and Day Care Centres



Staffed by experienced Ayurvedic doctors, our clinics offer consultations that begin with root-cause diagnosis and extend to herbal prescriptions, diet and lifestyle guidance, and follow-up monitoring. Day-care facilities deliver structured interventions with same-day discharge for patients who do not need overnight admission, and consultations are available both in person and by video.

72-hour Health Camps



Held regularly across locations, these camps raise awareness of Ayurvedic care, provide basic consultations and check-ups, and introduce preventive practices. They act as a first point of contact, with a meaningful share of attendees progressing to fuller treatment within the network.

Panchakarma Therapies



The centrepiece of our care model, Panchakarma is delivered by trained therapists using authentic procedures and herbal formulations. The therapies focus on deep detoxification, physical rejuvenation, and restoration of internal balance, strengthening immunity by rebalancing the body's doshas.

Diet Care



Guided by the principle that food is the first medicine, our dieticians provide individualised nutrition counselling aligned with Ayurvedic principles, supporting both treatment and prevention.

Medical Kits



Curated kits extend treatment into the home, allowing patients to continue prescribed regimens and manage chronic conditions with ongoing remote support from our care team.

Ailments Treated



Our clinical scope is deliberately broad, spanning everyday concerns to long-standing chronic conditions:

METABOLIC AND LIFESTYLE
Thyroid, Obesity and Weight Loss, Cholesterol, Acidity and Gas

PAIN AND MOBILITY
Joint Pain, Back Pain, Fissure

SKIN
Psoriasis, Leukoderma, and General Skincare

RESPIRATORY
Asthma

MENTAL HEALTH AND NEUROLOGICAL
Anxiety, Depression, Migraine

OTHER CONDITIONS
Ulcer, Eye Treatment, and Sexually Transmitted Diseases

OUR OFFERINGS

Top-Selling Products

The portfolio's established performers span detox, joint care, immunity, and condition-specific support:



Launched in FY26

New introductions during the year broadened the range across nutrition and wellness:



Over-the-Counter Range

To reach buyers beyond our own network, we have built a dedicated OTC line:



Upcoming Pipeline

Planned launches will deepen the portfolio across nutrition and pain management:

Plant-based protein powder

Gyno syrup

A dedicated joint-pain range across oil, ointment, balm, and tablets



Centres



Products

One Connected Model

The two verticals are designed to reinforce each other. A patient treated at a centre continues care at home through a prescribed product regimen, while a product customer who comes to trust the brand naturally turns to our centres when they need consultations, preventive care, or therapies. The Jeena Sikho Health Card, launched during the year, strengthens this link, tying referral benefits, diagnostic discounts, and service integration into a single loyalty framework across the ecosystem.

Distribution and Reach

Products move through three channels:

In-house client support centres and e-commerce

Direct sales at our healthcare centres

Over-the-counter pharmacy retail, a growing channel that opens the portfolio to customers well beyond the Company's own network

330+
SKUs in Portfolio

~85%
Overall Gross Margin in Products



Trust, Built Into the Network

Behind the Company's reach is a network built to be trusted. Marquee hospitals anchor clinical care in key regions, accreditation holds our facilities to recognised national standards, and acceptance by government schemes and insurers keeps quality treatment within reach for a wide cross-section of patients. This is the credibility that mainstream healthcare demands, and it runs through every part of how we operate.

Hospitals That Anchor the Network

We have established premier Ayurvedic hospitals across strategic locations, each serving as a clinical and referral anchor for the surrounding network with five of the seven accredited by the National Accreditation Board for Hospitals and Healthcare Providers (NABH).



Meerut, Uttar Pradesh

Beds: 612

Operational Since: December 2022




Navi Mumbai, Maharashtra

Beds: 163

Operational Since: November 2022




Lucknow, Uttar Pradesh

Beds: 115

Operational Since: June 2022




Derabassi, Punjab

Beds: 113

Operational Since: October 2020




Panchkula, Haryana

Beds: 70


Operational Since: August 2024




Manesar, Gurugram

Beds: 100


Operational Since: May 2025




Panvel, Mumbai

Beds: 230

Operational Since: October 2025



Accredited, and Independently Assured

Accreditation is central to how we assure quality. As on 31 March 2026, the Company operated 50 NABH-accredited hospitals and clinics, with a further three AYUSH accreditations in the pipeline. In a sector where standardised, independently assessed care remains uncommon, this depth of accreditation places Jeena Sikho among the leading organised players in India's Ayurveda healthcare chain, and reflects a continued emphasis on clinical rigour, patient safety, and consistency of care across the network.

Doctors & Medical Staff

~592

Certified Ayurveda Doctors

~779

Supporting Health Care Personnel

Covered Across Public and Private Care

We are empanelled with a broad spectrum of insurance providers and government health schemes, making our services more affordable, accessible, and inclusive. These affiliations extend the reach of Ayurvedic care across the public and private sectors and reaffirm the ethical and quality standards we uphold.


Our services are covered by all major private health insurers on both cashless and reimbursement terms.



Government Panel

- Empanelled for treatment of government employees of Uttar Pradesh, Bihar, Haryana and Punjab, with direct settlement of eligible medical bills as per state norms.
- Empanelled with CGHS, CAPF and ECHS for comprehensive healthcare services to beneficiaries.
- Also empanelled with: DDA, CBSE, CSIR, DERC, DHC, BIS, Narmada Control Authority, Haryana Govt Employee Panel, TRAI, CERC, NHAI, MMTC, Iwai, DFCCIL, Air India, GAIL (India) Limited, GYPSA, MPPGCL, Navodaya, Maruti Suzuki Limited and leading private insurance companies.

Fintech-Financing



We are also empanelled with the seven central armed police forces.

AR – Assam Rifles
BSF – Border Security Force
CISF – Central Industrial Security Force
CRPF – Central Reserve Police Force
ITBP – Indo-Tibetan Border Police
NSG – National Security Guard
SSB – Sashastra Seema Bal



OUR FOOTPRINT

Ayurveda, Closer to Every Community

Widening access to Ayurveda is what shapes the Company’s growth. By expanding steadily and keeping care patient-centric, Jeena Sikho has built one of the most extensive networks of Ayurvedic hospitals and clinics in the country, bringing structured, standardised treatment within reach of communities that have long had few Ayurvedic options nearby.

The Hub-and-Spoke Model

Our network runs on a hub-and-spoke model. Large, well-equipped hospitals in major cities act as clinical hubs, anchoring advanced treatment and drawing referrals from a wider constellation of clinics and day-care centres in the towns around them. This decentralised design carries preventive, curative, and lifestyle care across both urban and rural India, while keeping delivery efficient as the network grows. Most facilities are operated by the Company, with doctors on its own payroll and medicines supplied exclusively through it, which keeps clinical quality and continuity of care firmly in hand even as the footprint widens.



Bringing Ayurvedic Care Closer

The network spanned 23 states and more than 100 cities and towns in FY26.

61
Operational Hospitals

58
Operational Clinics and Day Care Centres

2,300
Operational Beds


445
Beds in Pipeline

5
Facilities in Pipeline

23
States Covered

100+
Cities and Towns Covered

1. Assam: 1 hospital	7. Gujarat: 3 hospitals 1 clinic 1 franchise	13. Maharashtra: 5 hospitals 2 clinics 4 franchises	19. Telangana: 1 hospital
2. Bihar: 2 hospitals 9 franchises	8. Haryana: 6 hospitals 1 clinic 5 franchises	14. Madhya Pradesh: 2 hospitals 1 clinic 1 franchise	20. Tripura: 1 franchise
3. Chandigarh: 1 hospital	9. Himachal Pradesh: 2 clinics	15. Odisha: 2 franchises	21. Uttar Pradesh: 12 hospitals 4 clinics 5 franchises
4. Chhattisgarh: 2 hospitals 1 franchise	10. Jammu & Kashmir: 1 hospital	16. Punjab: 4 hospitals 5 clinics 1 franchise	22. Uttarakhand: 1 hospital 1 franchise
5. Delhi: 3 hospitals 7 clinics 1 franchise	11. Jharkhand: 2 hospitals 1 franchise	17. Rajasthan: 10 hospitals	23. West Bengal: 2 hospitals 2 clinics
6. Goa: 1 hospital	12. Karnataka: 1 hospital	18. Tamil Nadu: 1 hospital	



Pan-India Presence

Our corporate headquarters in Zirakpur, Punjab, together with a key business execution centre in Delhi, serve as the strategic anchors from which we extend the reach and impact of Ayurveda across the nation. The Company’s presence now runs from the northern plains to the south and the east, spanning 23 states.

Note: Map only for illustration purposes, not to scale.

BUSINESS MODEL POSITIONING

Two Verticals, Built to Compound

Jeena Sikho runs a dual-vertical model where scalable healthcare services and a high-margin Ayurvedic product business grow together. Services build operating leverage as utilisation climbs, products generate healthy cash, and each channel feeds the other.

- Significant operating leverage from the services vertical as utilisation rises

01
- Steady cash generation from the high-margin products vertical

02
- Cross-selling and synergy that carry patients from services into products, and product customers into care

03

Ayurvedic Healthcare Services

₹383 Cr

Revenue (FY26)

47.84%

Contribution (FY26)

Ayurvedic Products/Medicines

₹416 Cr

Revenue (FY26)

51.87%

Contribution (FY26)

Others

₹2 Cr

Revenue (FY26)

0.29%

Contribution (FY26)

As the Company extends its footprint across India and takes its first steps abroad, this design keeps growth balanced and self-reinforcing, creating value for patients, franchisees, partners, and shareholders alike.

Care Delivered through a Hub-and-Spoke Network

The services vertical is built around large hospitals that anchor clinical care in major cities, supported by a wider spread of clinics and day-care centres in the towns around them. Out-patient footfall at the spokes converts into in-patient admissions at the hubs, giving the network both reach and efficiency. In FY26, services contributed ₹385 crore, close to half of total revenue.

A High-Margin Product Engine


The products vertical extends care beyond the clinic through a portfolio of more than 330 Ayurvedic SKUs, sold through the Company's own centres, its tele-calling channel, e-commerce, and now over-the-counter retail. With gross margins near 85%, this vertical generates the cash that supports the wider business, and in FY26 it contributed ₹416 crore, just over half of revenue.

Where the Two Verticals Meet

The real strength of the model lies in the link between the two. A patient treated at a centre continues care at home through a product regimen, and a customer who comes to trust those products turns to the Company's centres when fuller treatment is needed. This synergy lifts lifetime value, deepens patient relationships, and adds recurring revenue across both verticals.

Growth that Stays Light on Capital

Expansion is engineered to be capital-efficient. A hospital bed costs only ₹3 lakh to ₹4 lakh to set up on leased premises, and a deliberate mix of owned and franchise assets extends reach without extending capital, with 33 of 119 facilities run by franchisees whose doctors remain on the Company's payroll and whose medicines are supplied exclusively by the Company. Together these choices deliver a three-year average ROCE of around 46%, rapid scalability, and a debt-free balance sheet.



A Flywheel that Compounds

At Jeena Sikho, growth is self-reinforcing. Quality care earns patient trust, that trust widens the patient base, and the resulting scale funds better care still, allowing the Company to grow while improving returns and keeping acquisition costs low.

From Reach to Recovery

1. Reach

Building Awareness at Scale

One of the largest social-media followings in the Ayurveda space, alongside a broad presence across national and regional television, radio, newspapers, and cinema advertising, and an e-commerce channel.

National & Regional Presence



Social Media Channels


youtube.com/@acharyamanishji 1.24M subscribers 4.8K videos	instagram.com/hiimsofficial 1.1M followers	instagram.com/jeenasikhoshop 96.2K followers
facebook.com/GuruManishAyurveda 3M Followers	youtube.com/haveshuddhi 629K subscribers 4K videos	facebook.com/PetShuddhi/ 641K followers
instagram.com/acharyamanishji 1.8M followers	facebook.com/HaveShuddhi 1M Followers	instagram.com/petshuddhi/ 265K followers
youtube.com/@Hiimsofficial 736K subscribers 4.9K videos	instagram.com/haveshuddhi 350K followers	youtube.com/@Khul_Ke_Pucho 238K subscribers 167 videos
facebook.com/hiimsofficial 2.3M followers	youtube.com/jeenasikhoshop 4.89K subscribers 480 videos	facebook.com/khulkepucho 97K Followers
	facebook.com/jeenasikhoshop/ 2.4M Followers	instagram.com/khul.kepucho 50.5K followers

2. Engage

Turning Interest into Consultations

The Client Support Centre maintains continuous, proactive contact with prospective and existing patients, converting enquiries into booked consultations and supporting them beyond the first visit.

Consultations (OPD & VOPD) (#)



3. Health Camps

Care taken to the Community

The 72-hour health camps extend Ayurvedic care directly into communities, identifying patients who need fuller treatment. They serve a dual purpose: a direct source of revenue, and a steady channel of qualified referrals into the hospitals.


During FY26, we conducted 14 healthcare camps, attended by 1,387 cumulative visitors, each of whom entered our ecosystem through real-time, on-ground engagement.

4. Consultations

A Widening Base

Cumulative OPD, COD, and consultation customers rose to 14.10 lakh in FY26, from 5.46 lakh in FY25.

(In Lakhs)




5. In-Patient Care

Where the Funnel Leads

In-patient volumes climbed to 40,454 in FY26, from 24,578 in FY25, each admission representing a patient who moved from first contact to advanced care.

(#)



MESSAGE FROM MANAGING DIRECTOR

From Promise to Proof

Dear Shareholders,

It is a privilege to write to you at the close of what has been the most defining year in Jeena Sikho Lifecare's journey so far. For much of our history, we have asked you to judge us by our promise: a belief that prevention is the truest form of medicine, and that Ayurveda, practised with rigour and evidence, can take its place in mainstream healthcare. In FY26, that promise turned into proof. We grew faster, earned more patient trust, and reached further, while staying true to the single idea that started this Company, that our first duty is to the patient.



Growth, with Profitability

Revenue from operations reached ₹801 crore, a growth of 71% over the previous year. The top line, though, is only part of the story; what stands behind it is the quality of that growth. Our EBITDA margin expanded to 44% from 30%, and profit after tax rose 178% to ₹222 crore, even after we absorbed a few one-time provisions in the closing quarter. We continued to maintain a debt free balance sheet.

What these numbers reflect is that we have not achieved scale by spending our way to it. Instead, they are the result of a model that grows more efficient as it expands, as higher patient volumes and a rising share of product sales flow through a cost base we have kept deliberately lean. Reflecting this performance and our continued focus on rewarding shareholders, the Board has recommended a final dividend of ₹4.50 per equity share of face value ₹2 for FY26, subject to your approval at the ensuing Annual General Meeting.

A Place on the Main Board

In August 2025, the Company migrated from the SME Emerge platform to the main board of both the NSE and the BSE. This step reflects the trust you have placed in us and the maturity of our governance, opening the Company to a wider community of investors while holding us to a fuller standard of accountability, one we intend to honour in everything we do.

Care at Greater Scale

Behind every figure is a patient who chose us. During the year, we added 561 beds to reach 2,300 operational beds, with total capacity now standing at 2,861 across 119 centres, 61 hospitals and 58 clinics and day-care centres, spread over 23 states and more than 100 cities and towns. In-patient admissions grew 65% to over 40,000, and out-patient consultations rose 69% to nearly 5.7 lakh. Each of those visits is a patient that came to us seeking relief, and increasingly, coming to us to stay well rather than only to get well.

The Engine Behind our Growth

Our strength lies in how our two verticals work as one. A patient treated at a centre continues care at home through our products, and a customer who comes to trust those products turns to our centres when fuller treatment is needed. This year we deepened that engine, extending our portfolio of over 330 Ayurvedic products, entering over-the-counter retail so that our medicines reach far beyond our own network, and launching the Jeena Sikho Health Card to bind the whole ecosystem into a single relationship with the patient. These steps will lift both our reach and our margins, and they carry a conviction I hold closely, that India's own science, made in India and offered to Indians first, deserves to lead.

Taking Ayurveda beyond India

For the first time, our care now extends past our borders. We have made our first international centres operational in the UAE with further centres under construction. This is an early step, but it reflects a growing belief around the world that India's ancient wisdom has something to offer modern health, and we intend to carry it there.

People, Evidence, and Trust

Our people are the reason any of this is possible, the doctors, therapists, and teams who deliver care with commitment each day. Our treatment is delivered by a team of around 592 certified Ayurvedic doctors, supported by trained clinical staff, and we have continued to invest in hiring, training, and onboarding talent through the year. We have also deepened the evidence behind our practice, with a growing body of published clinical research and registered trials that hold our therapies to scientific scrutiny. Alongside, we have strengthened our assurance framework, bringing on reputed independent firms as our statutory and internal auditors.

2,300 operational beds

During the year, we added 561 beds to reach 2,300 operational beds, with total capacity now standing at 2,861 across 119 centres, 61 hospitals and 58 clinics and day-care centres, spread over 23 states and more than 100 cities and towns. In-patient admissions grew 65% to over 40,000, and out-patient consultations rose 69% to nearly 5.7 lakh.

The Road Ahead

We have come a long way, yet the larger share of our ambition still lies ahead. Over the next three to five years, we aim to scale toward 7,000 to 10,000 operational beds, largely through our capital-light model, while building our over-the-counter business into a meaningful, high-margin engine in its own right. Wider insurance coverage, deeper inclusion under government and AYUSH programmes, a broadening product range, and our international entry each give us a distinct path to grow. Yet the ambition behind all of them is the same as the one we began with: to move India toward a healthier, more self-reliant future, where prevention comes before cure.

I thank you for the trust you continue to place in us. To our patients, who put their health in our care, and to our teams, who honour that trust each day, I am deeply grateful. The work ahead is larger than any single year or milestone: it is the steady making of a healthier, more self-reliant India, and I am proud that you stand with us in it.

Warm regards,


Acharya Manish Ji
Managing Director

KEY PERFORMANCE INDICATORS


The Measure of Progress

The Company's performance during FY26 reflects the strength of its integrated healthcare model. Growth in capacity, patient volumes and operational efficiency translated into healthier financial outcomes, demonstrating sustained momentum across key areas of the business.


EBITDA
(In ₹ Crore)



ROCE
(In %)




PAT Margin
(In %)




Financial Indicators


Revenue from Operations
(In ₹ Crore)




PAT
(In ₹ Crore)



EBITDA Margin
(In %)




ROE
(In %)




Note: PAT Ratio = Profit After Tax (PAT) ÷ Revenue from Operations × 100

Operational Indicators


Operational Beds
(In #)




Beds Occupied
(In #)




Average Revenue Per Bed
(In ₹)




IPD Patient Volumes
(In #)




OPD Patient Volumes
(In # Lakh)




Medicine Order Volumes
(In # Lakh)




Revenue-Mix
(In ₹ Crore)



Government Panel Revenue
(In ₹ Crore & %)




Active Operational Centres
(#)



BOARD OF DIRECTORS

The Leadership Behind the Vision

Guided by purpose and strengthened by experience, the Board brings together diverse perspectives that shape the Company's strategic direction. Its collective leadership continues to support responsible governance, operational excellence and the long-term vision of making authentic Ayurveda more accessible



Mr. Manish Grover

Managing Director

As the Founder of Shuddhi Ayurveda and the driving force behind Jeena Sikho Lifecare, Mr. Manish Grover has been instrumental in advancing Ayurveda as a credible and accessible healthcare system. With nearly 17 years of experience in the sector, he has remained committed to promoting natural healing since embarking on his entrepreneurial journey in 2009.

His leadership led to the incorporation of the Company in 2017, laying the foundation for its sustained expansion. He has also been the face of the Shuddhi brand across television and digital platforms, championing holistic wellness while strengthening the Company's footprint across India. Mr. Grover holds a B.Com degree from Chaudhary Charan Singh University, Meerut.

Mrs. Bhavna Grover

Whole-time Director

Bringing over seven years of experience in human resources, legal administration and organisational management, Mrs. Bhavna Grover has been associated with the Company since its inception. Her expertise in governance, compliance and internal systems has played a key role in reinforcing the organisation's operational discipline.

She has contributed significantly towards institutionalising governance practices and strengthening the Company's administrative framework. Mrs. Grover is a graduate in Arts from Punjab University.

Ms. Shreya Grover

Whole-Time Director

Representing the Company's next generation of leadership, Ms. Shreya Grover brings a contemporary outlook to marketing, branding and business development. Her understanding of evolving consumer preferences supports stronger engagement with patients while enhancing the Company's market presence.

She continues to drive initiatives focused on building a future-ready brand and expanding Jeena Sikho's connect with newer audiences through innovative communication and strategic business initiatives.

Mr. Ankush Kaushal*

Executive Director

With over 26 years of experience across hospitality, healthcare, wellness and business transformation, Mr. Ankush Kaushal brings extensive expertise in corporate strategy, business development, operational excellence and brand building. He has held senior leadership positions with national and international organisations, leading business expansion and organisational transformation.

As Principal Advisor & Director, his experience in healthcare and wellness expansion, hospital operations, process optimisation and strategic growth supports the Company's operational and long-term strategic priorities.

Dr. Ish Sharma*

Executive Director

With over 20 years of experience spanning Ayurveda education, research, healthcare administration and clinical practice, Dr. Ish Sharma brings extensive medical and institutional expertise. He holds BAMS, M.D. and Ph.D. qualifications in Ayurveda, along with an MBA in Human Resource Management.

His experience in academic leadership, clinical research, healthcare administration and international collaborations supports the Company's medical, research and institutional development initiatives as Director Medical Services & Research.

Mr. Karan Vir Bindra

Independent Director

Extensive expertise in corporate governance and regulatory compliance defines Mr. Karan Vir Bindra's contribution to the Board. Having held senior positions, including Company Secretary at Ind-Swift and Marble Finvest, he now advises organisations on corporate compliance and GST matters.

An Associate Member of the Institute of Company Secretaries of India, he also holds degrees in Law and Commerce. His experience enhances the Board's oversight of governance, compliance and regulatory affairs.

*Appointed wef 15th July, 2026.



Mr. Chandan Kumar Kaushal
Independent Director

A distinguished career spanning more than 37 years in Ayurveda and Unani medicine has equipped Mr. Chandan Kumar Kaushal with deep clinical and public healthcare expertise. Beginning his professional journey as an Ayurveda Medical Officer, he retired as District Ayurveda and Unani Officer-cum-Drug Inspector in Moga, Mohali.

His extensive understanding of healthcare systems, medical practice and regulatory standards brings valuable perspective to the Company's governance and healthcare delivery framework.

Ms. Priyanka Bansal
Independent Director

Combining expertise in finance, taxation and audit, Ms. Priyanka Bansal brings over 15 years of professional experience to the Board. She holds a B.Com (Hons.), is a Chartered Accountant, and has also earned a Diploma in Web Software Engineering.

Her strong financial acumen and regulatory knowledge support effective oversight of the Company's financial management, governance and risk management functions in her capacity as an Independent Director.

Mr. Ajay Sharma*
Independent Director

With over 25 years of professional experience across real estate, hospitality, finance and travel, Mr. Ajay Sharma brings broad business and entrepreneurial expertise to the Company. He holds a Bachelor's degree in Humanities and has pursued Hospitality Management studies in Australia.

His experience in property advisory, business management, client relationship management and strategic leadership, gained across India and Australia, supports the Company's business growth, strategic decision-making and corporate governance.

Mr. Sahil Jain
Chief Operating Officer

With over eight years of experience at Jeena Sikho, Mr. Sahil Jain brings broad expertise across operations, technology, marketing and administration. He has previously led key functions including IT, Marketing, Call Centre Operations and Administration, and has also gained experience with IBM and HCL Australia.

As Chief Operating Officer, he oversees operational strategy and execution across functions, drawing on his B.Com and Master of Computer Applications qualifications to strengthen systems, efficiency and customer engagement.

Ms. Sapna Singh*
Independent Director

Mrs. Sapna Singh brings over five years of experience in customer service operations and team management. She holds a Bachelor of Education from CMJ University, Meghalaya, and a Bachelor of Arts from Panjab University.

Her experience in customer relationship management, performance monitoring, training and development, grievance handling and people management contributes to service quality and effective team leadership.

Ms. Priya Goyal#
Company Secretary

An Associate Member of the Institute of Company Secretaries of India, Ms. Priya Goyal brings over three years of experience in secretarial, legal and regulatory matters. Her expertise spans listed company compliances, corporate governance, securities laws, Board and Committee matters, and capital market transactions.

Her experience in regulatory filings, due diligence, secretarial audits, corporate restructuring and FEMA/RBI matters supports effective governance and compliance oversight.

Mr. Nanak Chand
Chief Financial Officer

With over 15 years of experience across financial management, strategic planning and business development, Mr. Nanak Chand brings broad expertise in finance and corporate functions. He holds a B.Com. (Hons.) and is a CMA Executive, with experience spanning cost and financial management, internal audit, corporate restructuring and equity research.

As Chief Financial Officer, he oversees the Company's financial management, while his experience in statutory compliance, corporate governance, ERP implementation and business process re-engineering supports effective financial and operational oversight.

Our Management Team



Mr. Gaurav Mohan Garg
Business Development Head

Dr. Avira Gautam
BAMS, MD (Ayurveda), PhD, MBA

Mr. Mukesh Grover
Administration Head

Ms. Akansha Jain
HR Head

Dr. Rajshree Gupta
Ayurvedic Physician, BAMS

Dr. Sonali
Homeopathic Physician

Ms. Namrta Chaudhary
Client Support Centre Head

*Appointed wef 15th July, 2026.

#Appointed wef 15th July, 2026 pursuant to resignation by Mrs. Smita Chaturvedi wef 14th July, 2026.

CORPORATE GOVERNANCE

Our Governance Philosophy

Sound governance is the foundation on which the Company builds lasting trust with its shareholders, patients, employees, and the communities it serves. For Jeena Sikho, governance means far more than meeting regulatory requirements; it reflects a way of working built on transparency, accountability, and ethical conduct at every level. The Board sets the tone from the top, guiding the Company with clear oversight and strategic foresight, while a culture of integrity runs through day-to-day operations.

A defining milestone during the year was the Company's migration from the SME Emerge Platform of the NSE to the Main Board of both the NSE and the BSE, with effect from 11 August 2025. Beyond the visibility and liquidity it brings, the move reflects the Company's consistent performance and rising governance standards, and places it within the fuller framework of corporate governance expected of a main-board listed enterprise.

Board Oversight

The Company is led by a Board that brings together entrepreneurial drive, clinical understanding, and independent oversight. Its executive and whole-time directors steer the business day to day, while its independent directors bring objective judgement and safeguard the interests of all stakeholders. This balance keeps ambition and accountability in step, guiding both the pace of growth and the discipline with which it is pursued.

Committees of the Board

The Board discharges much of its oversight through dedicated committees, each operating under a defined charter and reporting back to the Board on the matters within its remit.

01 Chairperson	02 Members	10 Meetings Held in FY26	Audit Committee
01 Chairperson	02 Members	05 Meetings Held in FY26	Nomination & Remuneration Committee
01 Chairperson	02 Members	02 Meetings Held in FY26	Stakeholders Relationship Committee
01 Chairperson	02 Members	02 Meetings Held in FY26	Risk Management Committee
01 Chairperson	02 Members	02 Meetings Held in FY26	Corporate Social Responsibility Committee

A Framework Built for the Long Term

Good governance, for the Company, is inseparable from its purpose. The same principles that shape its clinical practice, evidence, consistency, and care for the patient, shape how it is run as an enterprise. As Jeena Sikho extends its reach across India and beyond, it remains committed to upholding the highest standards of corporate conduct, ensuring that the trust placed in it by every stakeholder is honoured through transparency and responsible growth.

- 01 **Audit Committee:** oversees the integrity of financial reporting, the adequacy of internal controls, and the work of the internal and statutory auditors, providing independent assurance on the reliability of financial disclosures.
- 02 **Nomination and Remuneration Committee:** guides the composition of the Board and senior management and frames the criteria for appointments and remuneration, aligning leadership incentives with long-term performance.
- 03 **Stakeholders Relationship Committee:** focuses on the interests of shareholders and investors, overseeing the resolution of grievances and the quality of investor communication.
- 04 **Risk Management Committee:** reviews the risks facing the business and the adequacy of the mitigation framework, helping the Board anticipate and manage uncertainty as the Company scales.
- 05 **Corporate Social Responsibility Committee:** directs the Company's social commitments and oversees the design and impact of its initiatives, in keeping with its mission of making healthcare more accessible.



OUTLOOK

Scaling Ayurveda, Responsibly

The Company's path forward is guided by a clear ambition: to make holistic, affordable, evidence-led Ayurvedic healthcare accessible to more people, across more of India and beyond. Growth rests on a model that pairs the wisdom of Ayurveda with operational discipline and clinical rigour, and on a set of strengths that position the Company to scale steadily, serve a wider patient base, and lead the shift toward mainstream alternative medicine.

Improving Utilisation of Existing Assets

The Company is working to raise occupancy and service throughput across its current hospitals and clinics, drawing greater value from the capacity already in place.

Adding Capacity

New centres and additional beds within existing ones will widen both service coverage and reach, allowing the network to serve more patients across more locations.

Expanding the OTC Medicine Channel

Entry into the over-the-counter segment will make Ayurvedic medicines available through pharmacies and retail alongside online platforms, lifting product visibility, access, and revenue.

The Road Ahead

As Ayurveda gains wider acceptance across India and internationally, the Company is building on these strengths to scale sustainably, deepen its presence, and broaden its offerings. Its roadmap centres on several growth levers.

Expanding Overseas

Building on its entry into the UAE, the Company intends to extend its presence into further international markets, carrying its model of Ayurvedic care to patients beyond India.

Broadening the Product Portfolio

Continued launches of Ayurvedic products and kits tailored to specific health and lifestyle needs will deepen the portfolio and strengthen consumer engagement.

Enabling Cashless Insurance

Wider cashless insurance arrangements at the Company's facilities will ease the cost of treatment for patients and support higher patient volumes.

Deepening Government and AYUSH Coverage

The Company expects greater inclusion of its centres under government health panels and AYUSH programmes, extending affordable Ayurvedic care to government employees and their families.

What Positions Us to Scale

01

One platform, Complete Care

By bringing Ayurveda, Panchakarma, Homeopathy, and Naturopathy together under a single roof, the Company covers the full span of a patient's needs, from prevention and diagnosis through treatment and recovery. That integration is what allows it to treat a wide range of chronic and lifestyle conditions with natural, time-tested care rather than piecemeal intervention.

04

Depth of Clinical Talent

Behind the network sits a large in-house team of qualified Ayurvedic doctors and trained clinical staff, experienced in managing complex and long-standing conditions. Their expertise is what holds the quality and consistency of outcomes steady as the Company adds centres and patients.

06

Evidence at the Core

A growing body of published clinical research and registered clinical trials supports the Company's therapies and products. This grounding in evidence is what sets its approach apart in a field where much goes unproven.

02

A Founder's Conviction, a Team's Discipline

Acharya Manish Ji's belief in Ayurveda gave the Company its purpose and its direction, and that vision now runs through a qualified professional team that turns it into consistent, compassionate care at every centre. Leadership and execution pull in the same direction, which keeps the model coherent as it grows.

05

Care Held to Recognised Standards

With 50 NABH-accredited hospitals and clinics and further accreditations in progress, the Company measures its facilities against national benchmarks for quality and safety. In a sector where standardised care is still uncommon, that accreditation carries real weight.

07

A Record That Speaks for Itself

A record that speaks for itself. Rising patient volumes and sustained revenue growth through FY26 show a model performing at scale, not in theory. Each year of delivery deepens the confidence that patients, partners, and investors place in the Company.

03

Growth That Stays Capital-Light

A blend of Company-operated and franchise centres, modest per-bed investment, and break-even at low occupancy lets the network expand at pace without straining the balance sheet. Speed and financial strength reinforce each other here, making scale sustainable rather than costly.



TESTIMONIALS

Voices of Healing

The truest measure of the Company’s work lies in the people it has helped. Drawn from cities, towns, and villages across India, these are the voices of patients and families who came to Jeena Sikho carrying long-standing, often difficult conditions, and found in Ayurveda a path back to health. Each account, captured on video, speaks with sincerity and conviction about a personal journey toward recovery, and together they stand as an expression of trust in the Company’s commitment to compassionate, consistent, and evidence-led care, and in its resolve to make authentic Ayurvedic treatment accessible across the country.



**Prahlad Modi,
Brother of PM Narendra Modi**

“When he first came to Jeena Sikho, he was undergoing dialysis three times a week, with 4.5 litres of water drawn from his body during each session. After treatment, the water content reduced to three litres, and he looks forward to becoming free from dialysis altogether.”



**Justice Kolse Patil,
Retired Judge,
Bombay High Court**

“His blood sugar had climbed to 500. By leaving aside allopathic medicines and following only the DIP Diet and regular exercise, his sugar levels normalised within a short time. His wife’s glaucoma also improved, with doctors declaring that no further treatment was needed, a recovery he credits to the DIP Diet and an Ayurvedic way of life.”



**Ashwini Upadhyay,
Advocate, Supreme
Court of India**

“When leading hospitals recommended knee surgery for his father, he brought him to the HIMS Chandigarh centre instead. Just ten days of Ayurvedic and rehabilitation care had his father walking pain-free, with no surgery needed, an outcome he sees as proof of effective and affordable healing.”



**Arun Sharma,
National President, Media
Federation of India**

“Having lost the vision in one eye, he sought treatment at the Company’s Delhi hospital. Within just ten days, the eyesight in that eye returned. He describes the recovery as nothing short of a miracle.”



**Rajiv Thakur,
Renowned Comedian**

“When his parents came to Jeena Sikho after years of declining health, Acharya Manish’s personalised Ayurvedic care began reversing their chronic issues within three months. Half of their conditions healed, with steady progress on the rest. More than caregivers, he says, the team advocated fearlessly for its patients, challenging medical doubt with results.”



**Comedian Bharti
Singh’s Mother**

“Admitted to the Company’s facility after doctors had advised dialysis, a course she chose to avoid, she noticed significant improvement once her treatment began. Having been on insulin for 12 to 15 years, she was off it within four days, and off her blood-pressure medication as well.”



Ganesh Ji

“Diagnosed with 52 lumps in his body and severe swelling, he had become dependent on a wheelchair. After a month of Ayurvedic and natural therapy at Jeena Sikho HiiMS, his swelling reduced, the lumps subsided, and he regained mobility and improved health.”



**Avadh Ojha,
Renowned UPSC Teacher**

“An irregular lifestyle had led to diabetes. By following the DIP Diet recommended by Acharya Manish Ji, he achieved a complete recovery without medication. He regards Acharya Ji as a true servant of humanity, whose guidance not only addressed his illness but also helped him overcome stress.”



**Suresh Chavhanke,
Sudarshan News**

“A respected journalist, he brought his father to Jeena Sikho after being told surgery was necessary. Two and a half weeks of Ayurvedic and Panchakarma care later, his father’s reports came back clear, an example, he says, of compassionate, evidence-based healing.”



Voices on Ayurveda

**Governor Gulab
Chand Kataria,
Punjab**

He warmly praised Acharya Manish Ji and the role of Ayurveda in promoting holistic health and India’s traditional wisdom, appreciating the effort to take authentic Ayurvedic care to the masses and inspire people toward healthier living.



**Prime Minister
Narendra Modi,
on the Power of Ayurveda**

He shared how Ms. Rosemary Odinga, daughter of Kenyan leader Raila Odinga, regained her eyesight after receiving Ayurvedic treatment in India, highlighting it as a powerful example of how India’s ancient Ayurvedic wisdom continues to offer hope and healing to the world.



**Bollywood Actor
Akshay Kumar,
on Ayurveda**

He shares that he has followed Ayurveda for over 25 years, even staying at Ayurvedic centres for deep healing. Just as a car is serviced regularly, he explains, the body too must be cared for through Ayurveda and allied systems to maintain health and prevent disease.



Management Discussion and Analysis

Indian Economic Overview

FY26 marked another year of resilience and strong economic fundamentals for India, even as global conditions stayed uneven. India retained its position as the fastest-growing major economy, supported by firm domestic demand, healthy investment activity, and sustained public capital expenditure. On the new 2022-23 base series, real GDP growth is estimated at 7.6% for FY26, higher than the 7.1% recorded in FY25, reinforced by private consumption, government capex, and a strong revival in manufacturing and services. Manufacturing recorded double-digit growth, while the secondary and tertiary sectors expanded by over 9%.

Inflationary pressures eased considerably during the year, aided by favourable food prices and effective supply-side management, with headline retail inflation touching multi-year lows. The Reserve Bank of India maintained a calibrated balance between supporting growth and anchoring inflation, while financial stability remained intact. Bank credit grew steadily, underpinned by strong capital adequacy and improved asset quality.

The government's continued thrust on infrastructure, health, and digital connectivity, together with rationalisation of Goods and Services Tax rates, spurred consumption, employment, and enterprise development. Particularly relevant to our industry, the preventive and wellness healthcare ecosystem gained further momentum through expanded

attention to AYUSH systems, wider insurance linkages, and the 'Heal in India' initiative. The environment remained conducive for traditional healthcare players like Jeena Sikho Lifecare Limited to build scale and deepen patient engagement across urban and rural markets.

Source: Second Advance Estimates of National Income FY 2025-26, Ministry of Statistics and Programme Implementation



Outlook

Looking ahead, India's economic outlook remains constructive. The foundations laid over recent years, spanning policy reform, formalisation, and infrastructure investment, are expected to yield durable dividends. Real GDP growth for FY27 is projected in the range of 6.4% to 6.9%, with the International Monetary Fund and World Bank placing it near the lower end and the Reserve Bank of India at the higher end, driven by resilient domestic demand, a recovery in private capital expenditure, and steady services momentum.

Certain external factors could introduce volatility. Trade frictions with the United States remained a live theme through the year, though the moderation of additional United States tariffs on Indian goods from 50% to 10% has improved export prospects and trade sentiment. Elevated global energy prices and geopolitical tensions in West Asia continue to represent the principal downside risks, and policymakers are expected to remain agile in monitoring the evolving environment. With inflation expected to stay within manageable bounds, monetary policy may retain room to support growth where needed.

Rural and semi-urban consumption is likely to strengthen further with better agricultural output, while services expansion and export opportunities are expected to broaden. For the healthcare sector, the outlook is especially promising. Continued promotion of traditional systems of medicine under the Ministry of AYUSH, wider insurance coverage for AYUSH treatments, the expansion of Ayushman Arogya Mandirs, and the empanelment of day care therapy centres are likely to deepen access to holistic healthcare. The 'Heal in India' medical value travel programme, backed by a dedicated allocation of around INR 20,000 crore in the Union Budget 2025-26, further enhances the export potential of Ayurvedic treatments.

At Jeena Sikho Lifecare Limited, we view these macroeconomic tailwinds as closely aligned with our growth strategy. The rising demand for alternative medicine, coupled with digital health adoption, improved affordability through insurance, and a growing preference for preventive care, presents a compelling opportunity. As we expand our

hospital footprint, strengthen our product portfolio, and enter new geographies including international markets, we remain confident of sustained growth and long-term value creation for all our stakeholders.

Source: IMF World Economic Outlook; Reserve Bank of India; World Bank India Development Update.





Industry Overview

Indian Ayurvedic Products Market

The Indian Ayurvedic products market continued to build strong momentum during the year. The market was valued at INR 1,017.51 billion in 2025, having crossed the trillion-rupee mark, as consumer preference shifted decisively towards natural and chemical-free remedies driven by rising health awareness and concern over the side effects of synthetic alternatives.

Looking forward, the market is projected to grow at a CAGR of 15.52% over 2026-2034, reaching an anticipated value of INR 3,728.75 billion by 2034. This trajectory keeps the sector among the fastest-growing in wellness and personal care, underpinned by widening distribution, rising digital adoption, and increasing interest in preventive care.

Several core dynamics are driving this expansion:

1
Branded, Organised Players Consolidate Share

The organised market, comprising branded and standardised products, leads with an estimated 70% share in 2025, reflecting stronger consumer trust, regulatory compliance, and brand visibility.

2
North India anchors National Demand

North India remains the largest region with around a 35% share, benefiting from established manufacturing hubs, deep-rooted consumption patterns, and high e-commerce penetration.

3
Therapeutic and Nutraceutical Categories Lead

Within the product mix, healthcare categories such as nutraceuticals, dietary supplements, and Ayurvedic medicines occupy the largest share at about 58%, driven by demand for wellness-oriented supplements and herbal formulations.

4
Deeper Distribution meets Policy Backing

Availability across urban and rural centres through online and offline channels is improving accessibility, while government support continues to strengthen. The Union Budget 2025-26 raised the Ministry of AYUSH allocation to INR 3,992.90 crore from INR 3,497.64 crore in the previous year, and the WHO Global Centre for Traditional Medicine in Gujarat is reinforcing India's global positioning.

5
Digital Discovery and Product Innovation

The market is witnessing strong interest across organic skincare, home remedies, and herbal-infused products, alongside greater digital awareness. According to the NSSO AYUSH Survey (2022-23), around 95% of Indians are aware of AYUSH systems, with roughly 53% of urban and 46% of rural individuals using them for prevention or treatment.

We remain committed to scientific validation, through our ongoing research and NABH standards, to differentiate and build consumer trust in a market where organised, quality-backed brands are winning out. Backed by economic tailwinds, institutional support, and changing consumer preferences, the market sets a compelling stage for Jeena Sikho to deepen its presence, innovate responsibly, and generate sustainable value.

Source: IMARC Group; Ministry of AYUSH; Union Budget 2025-26

Indian Health and Wellness Industry

The Indian health and wellness sector is evolving into a multifaceted ecosystem that embraces both clinical and preventive care. The overall wellness market reached approximately USD 164.35 billion in 2025 and is projected to reach USD 257.94 billion by 2034 at a CAGR of 5.14%. A closely related segment, health and wellness tourism, was valued at USD 20.6 billion in 2025 and is expected to grow to USD 38.6 billion by 2034 at a CAGR of 7.01%.

Underlining this momentum, the Ministry of Health and Family Welfare and the Ministry of AYUSH have scaled the Ayushman Arogya Mandir network to around 1.78 lakh operational centres, of which 12,292 are dedicated Ayush centres providing primary AYUSH-based care through yoga, medicinal plants, and lifestyle counselling. These efforts signal a firm government commitment to promoting holistic health across urban and rural India.

Source: IMARC Group; Ministry of AYUSH; Ministry of Health and Family Welfare

Strategic Alignment

This market backdrop maps closely to the Company's own priorities. Its position within the organised, branded segment, which now commands the larger share of the market, aligns with the decisive consumer shift towards standardised, quality-assured products. A proprietary portfolio of more than 330 SKUs under the 'Shuddhi' brand is well placed to serve rising demand across both healthcare and personal care categories, while a strong presence in North India, the country's largest regional market, adds further leverage. Product gross margins of around 85%, together with a widening reach across client support centres, e-commerce, clinics, and newly opened over-the-counter channels, allow the Company to translate industry growth into scalable, cash-generative revenue. Its hub-and-spoke, capital-light model supports rapid expansion at modest cost, while continued investment in research, NABH accreditation, and evidence-based protocols reinforces the credibility that increasingly separates trusted, organised players from the unorganised fringe. In short, the same forces powering the market are the ones the Company is built to capture.

Emerging trends

Preventive and integrative wellness moves mainstream

Consumer preference is tilting towards prevention, with nutrition, yoga, naturopathy, and mind-body practices marking a shift from episodic treatment to continuous wellness journeys.

Wellness Tourism becomes a Growth Engine

India's reputation as a wellness hub keeps rising, with retreats, yoga hubs, and Ayurvedic resorts drawing domestic and international travellers. Expanding at around 7% CAGR, wellness tourism is being reinforced by the 'Heal in India' thrust.

Digital Enablement and Tele-Ayush Deepen Reach

Telemedicine, e-health, and mobile platforms are extending reach, while artificial intelligence is enabling dosha-based assessments and tailored recommendations. The WHO technical brief on AI in traditional medicine (July 2025) recognised India's pioneering work, including Prakriti-based models and the Ayurgenomics project.

Quality-Led, Organised providers gain Trust

Buyers increasingly favour certified, evidence-based providers, with NABH accreditation and Good Manufacturing Practices professionalising the sector.

Insurance Parity Improves Affordability

Following the IRDAI Master Circular on Health Insurance (April 2024), AYUSH treatments are now covered on par with allopathic care, with sub-limits removed and cashless networks mandated, materially improving affordability.

Global standardisation and export potential

Rising international demand, WHO benchmarks, and progress on quality standardisation are opening export pathways for Indian Ayurveda, reinforced by institutional support and growing scientific validation.

Source: IMARC Group; Ministry of AYUSH; IRDAI; WHO

SCOT

Analysis



S

Strengths

- An integrated model combining Ayurveda healthcare services and products, with strong cross-selling synergies between the two verticals.
- A capital-light structure with low setup cost per bed, break-even at around 35% occupancy, and superior returns on capital employed.
- A broad product portfolio of over 330 SKUs with product gross margins of around 85%, supported by around 592 certified Ayurvedic doctors and a debt-free balance sheet.
- Clinical credibility, evidenced by 50 NABH-accredited facilities and over 180 published research papers.

C

Challenges

- Regulatory harmonisation across AYUSH, the National AYUSH Mission, NABH, and state bodies remains complex to navigate across geographies.
- Standardisation, quality assurance, and consistent evidence-based validation are essential to sustain consumer trust.
- Attracting and retaining skilled AYUSH practitioners, and securing quality-certified herbal raw materials, remain ongoing constraints.
- Limited public awareness and the perception of insufficient scientific rigour continue to affect wider acceptance.

O

Opportunities

- Wellness tourism and the 'Heal in India' programme, including Ayush visa facilitation, open scale opportunities for integrated centres.
- The Ayushman Arogya Mandir rollout, government panels, and Uttar Pradesh's newly launched cashless Ayurveda scheme broaden institutional demand.
- AYUSH insurance parity, digital and tele-wellness, corporate wellness, OTC expansion, and international entry beginning with the UAE widen the addressable market.
- Rising lifestyle disorders such as diabetes, hypertension, and cardiovascular conditions continue to lift demand for alternative healthcare.

T

Threats

- Competition is intense across organised, unorganised, and overseas players, with easy access to free online information.
- Wellness demand is sensitive to macroeconomic shifts, tariffs, energy prices, and travel disruption.
- Any lapse in quality or service consistency could affect brand equity, while evolving regulation may raise compliance costs.

Source: IMARC Group; Ministry of AYUSH; Union Budget 2025-26

Conclusion

India's health and wellness industry is in the midst of a structural transformation, powered by supportive policy, rising health consciousness, the growth of wellness travel, and rapid digital enablement. Government initiatives, from the expansion of AYUSH centres and insurance parity to the 'Heal in India' medical value travel push, are widening both access and credibility, while consumers increasingly treat preventive care as a lifelong commitment rather than an occasional choice. This creates a fertile platform for organised, quality-led operators to deepen geographical reach, integrate services from clinical care to holistic retreats and digital wellness, and reinforce trust through scientific validation. Positioned at the meeting point of tradition and modern delivery, players that pair clinical rigour with scale and brand trust are well placed to emerge as national leaders in holistic healthcare, delivering measurable outcomes for patients and lasting value for stakeholders over the FY27 horizon and beyond.

Company Overview

Rooted in a mission to bring Ayurveda into everyday, mainstream healthcare, Jeena Sikho Lifecare Limited (JSLL) has grown into one of India's foremost organised players in alternative medicine. The Company pairs ancient healing systems with modern clinical delivery and scientific validation, offering care across in-patient treatment, out-patient consultation, and a fast-growing range of Ayurvedic products that span both prevention and cure. With each passing year, we strengthen our resolve to become the trusted choice for natural, side-effect-free healthcare across the country and beyond.

We operate a network of wellness centres, hospitals, and clinics under the 'Shuddhi Ayurveda' brand. As of FY26, we ran 61 operational hospitals and 58 clinics and day-care centres across 23 states and more than 100 cities and towns, supported by a capital-light business model that keeps operations agile while enabling rapid expansion. Our facilities provide treatments rooted in Ayurveda, Panchakarma, Naturopathy, and Homeopathy, delivered by around 592 certified Ayurvedic doctors and

around 779 supporting healthcare personnel, and reinforced by robust quality protocols. With 2,300 operational beds and the largest expansion pipeline in our history, we are committed to reaching more lives, especially in underserved markets.

Our product vertical complements our services with a wide portfolio of over 330 proprietary Ayurvedic medicines, health kits, and wellness products developed in-house. Distributed through client support centres, e-commerce, pharmacies, and our healthcare centres, and carrying gross margins of around 85%, this segment continued to see strong traction and contributed 52% of revenue in FY26. With expansion into over-the-counter markets and international entry beginning with the UAE, we are well positioned to capture growing demand for natural health solutions.

FY26 was a landmark year. We migrated to the NSE and BSE mainboards in August 2025, and adopted Ind AS post migration to the main board. Our strategic clarity, experienced leadership, and deep-rooted brand ethos enable us to operate with purpose and foresight, laying the foundation for sustainable long-term growth as we blend tradition with innovation and continue to create meaningful impact for our patients and stakeholders.

Operational Highlights

FY26 marked a significant phase of expansion and operational scale-up for Jeena Sikho Lifecare Limited. We increased inpatient capacity from 1,600 operational beds in the previous year to 2,300 by year-end, with beds occupied rising from 850 to 1,288. This scale-up is supported by a robust pipeline, taking total announced capacity to 2,861 beds, with 561 beds recently added and a further 445 beds in the pipeline, setting the stage for continued growth. Our IPD volumes rose 65% year on year to 40,454 patients, while OPD footfalls increased 69% to 5.70 lakh. Medicine order volumes more than doubled, from 4.43 lakh to 11.83 lakh, and active operational centres increased from 115 to 119. This growing trust reflects both patient satisfaction and our ability to deliver integrated, high-touch alternative healthcare at scale.

In parallel, we strengthened our revenue mix through focused growth across both verticals, expanding high-incidence, high-margin therapies such as liver care, infertility, sexual wellness, and musculoskeletal conditions, supported by free screening campaigns and health camps that convert around 30% of attendees into inpatient treatment. Average revenue per bed improved to ₹8,300 from ₹8,200. We advanced cashless integration with insurers and remained empanelled with CGHS, CAPF, ECHS, and Air India, as well as the state governments of Uttar Pradesh, Bihar, Haryana, and Punjab.

We also expanded to 50 NABH-accredited facilities, with three more in the pipeline. During the year, we deliberately reduced our government panel exposure, with government panel revenue moderating from ₹117.8 crore to ₹36.0 crore, or from 25% to 4% of revenue, to lower receivables risk and protect cash flows.



Financial Highlights

Particulars	FY26	FY25	Change
Revenue from Operations (INR Crore)	801	469	71%
EBITDA (INR crore)	350	141	148%
EBITDA margin (%)	44	30	-
PAT (INR crore)	222	80	178%
PAT Margin (%)	28	17	-
Net Worth (INR crore)	467	256	82%

Note: PAT Ratio = Profit After Tax (PAT) ÷ Revenue from Operations × 100

Key Financial Ratios

Particulars	FY26	FY25	Change
Current Ratio	3.19	1.84	73.60%
Debt-Equity Ratio	0.27	0.46	(40.31%)
Net Profit ratio (%)	27.80	17.04	63.15%
Return on Capital Employed (%)	52.25	31.67	64.96%
Return on Equity (%)	61.56	36.14	70.32%
Trade Receivables Turnover Ratio	10.35	7.90	31.02%



Risk and Concerns

At Jeena Sikho Lifecare Limited (JSLL), we have established a robust risk management framework designed to proactively identify, evaluate, and mitigate potential business risks. This structured approach ensures continuity, compliance, and competitiveness across all aspects of our operations. The key risks and our strategic responses are outlined below.

Regulatory Risk

Oversight of the safety, efficacy, and standardisation of herbal and alternative treatments is tightening, and each change to the rulebook can lift compliance costs and paperwork. The Company stays ahead of this by working strictly within applicable laws and standards, a discipline reflected in its 50 NABH-accredited facilities, with three more under way, and by holding tight quality controls from formulation through to bedside care.

Reputational Risk

Brand Equity is central to our expansion strategy, and any damage, whether from quality issues, misinformation, or dissatisfaction, could adversely affect operations and stakeholder trust. We continue to invest in

building and protecting the ‘Shuddhi’ brand under the active leadership of our founder, Acharya Manish Ji, maintaining visibility through national campaigns, digital platforms, and public awareness initiatives, while focusing on service consistency across all touchpoints.

Third-Party Dependency Risk

Product manufacture and franchise-run service delivery lean on outside partners, which brings exposure around quality, compliance, and reputation. These ties are held together by firm contracts and regular audits, with the Company partnering only reputed manufacturers that meet its standards and keeping a close watch on franchisee performance.

Litigation and Receivables Risk

Treatment-related grievances can spill into legal action and adverse publicity,

and heavy reliance on government panels can stretch collection cycles. The Company holds a zero-tolerance line on quality, places care only with qualified doctors, and runs dedicated contact centres to settle concerns quickly; during the year it also trimmed government panel exposure to shorten receivable cycles and safeguard liquidity.

Cybersecurity and Data Privacy Risk

Growing reliance on tele-consultation, e-commerce, and the new health card means more patient and transaction data flows through digital systems, raising the stakes on security and privacy. The Company addresses this through access controls, its integrated IT framework, and continued strengthening of data-protection practices as digital channels expand.

Human resources

People are the foundation on which the Company’s growth is built, and investing in them stays a constant priority. Its clinical and support base brings together around 592 certified Ayurvedic and Naturopathy doctors and around 779 supporting healthcare personnel, with practitioners at franchise centres kept on the Company’s own payroll so that standards of care never waver. As of 31 March 2026, the total workforce stood at 4,299 full-time employees. A spirit of enquiry runs deep, evidenced by more than 180 research papers published during the year, and is nurtured through steady investment in training and capability-building. By pairing experienced specialists with ambitious younger talent, the Company sustains a workforce that is at once stable and inventive, with several long-serving leaders anchoring its culture and steering it through each new phase of growth.

Internal control systems

The Company’s internal control architecture is scaled to match the reach, complexity, and character of its operations. It brings together well-documented policies and procedures, integrated information-technology systems, a considered delegation of authority, clear segregation of duties, and a structured cycle of internal audit and review. With the shift to the mainboard and the adoption of Ind AS, the incoming statutory auditors carried out a close examination of leasehold and related accounting treatments. Together, these controls work to keep operations efficient, protect the Company’s assets, and secure compliance with the laws and regulations that frame the business, above all those governing the stewardship of resources and the integrity of financial reporting. The Audit Committee returns to key findings and control measures at regular intervals, tightening governance, sharpening accountability, and keeping improvement continuous across the organisation.

Disclaimer

The statements in this section that look ahead reflect the Company’s current reading of its prospects, its intentions, and its expectations for the period to come. Being forward-looking, they carry risks and uncertainties, some foreseeable and some not, along with other variables that could push actual results some distance from what is expressed or implied here. Shifts in the broader economy, movements in the regulatory environment, or events that cannot be anticipated may each weigh materially on how the business performs. The assumptions on which these statements rest are built from information drawn from internal and external sources as at the date of this report, and they remain open to change, so outcomes may differ. Readers should therefore regard these statements as speaking only as of the date they are made. Save where the law requires it, the Company takes on no obligation to revisit or revise them in light of fresh information, later events, or changed circumstances.

Notice of the 9th Annual General Meeting of the Company

NOTICE IS HEREBY GIVEN THAT THE 9TH ANNUAL GENERAL MEETING OF THE MEMBERS OF JEENA SIKHO LIFECARE LIMITED WILL BE HELD ON MONDAY 28 SEPTEMBER 2026 AT FIRST FLOOR, PARLE G GODOWN, CITY ENCLAVE, BACK SIDE JP HOSPITAL, NEAR ANAND COMPLEX, ZIRAKPUR, MAIN ROAD, SAS NAGAR, PUNJAB 140603 AT 12:00 NOON TO TRANSACT THE FOLLOWING BUSINESS:

ORDINARY BUSINESSES:

1. **To receive, consider and adopt the Audited Standalone Financial Statement of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and the Statutory Auditors thereon.**

To consider, and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

RESOLVED THAT the Audited Standalone Financial Statement of the Company for the financial year ended 31st March 2026 and the reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted.

2. **To receive, consider and adopt the Audited Consolidated Financial Statement of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and the Statutory Auditors thereon.**

To consider, and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

RESOLVED THAT the Audited Consolidated Financial Statement of the Company for the financial year ended 31st March 2026 and the reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted.

3. **To declare a final dividend of ₹ 4.50/- per equity share of face value of ₹ 2/- each for the financial year ended March 31, 2026.**

To consider, and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT a final dividend of ₹ 4.50/- (Rupees Four and fifty Paise only) per equity share of face value of ₹ 2/- each, for the financial year ended March 31, 2026, as recommended by the Board of Directors, be and is hereby declared and approved for payment to the eligible shareholders of the Company."

4. **To reappoint Mrs. Bhavna Grover (DIN: 07557913) as the Director, who retires by rotation & being eligible, offers herself for re-appointment.**

To consider, and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT Mrs. Bhavna Grover (DIN: 07557913) Director of the Company, who retires by rotation in

terms of Section 152 of the Companies Act, 2013, and being eligible, offers herself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

SPECIAL BUSINESS

5. **To Re-appoint Mr. Karan Vir Bindra (DIN: 09283623) as an Independent Director of the Company.**

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150 and 152 and other applicable provisions, if any, read with Schedule IV to the Companies Act, 2013 ('the Act'), the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Regulation 17 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), as amended from time to time, **Mr. Karan Vir Bindra (DIN: 09283623)**, who was appointed as Independent Director of the Company for a first term commencing from August 25, 2021 and holds office up to August 24, 2026 (both days inclusive), and who, being eligible for re-appointment as an Independent Director, has submitted his consent along with a declaration confirming that he meets the criteria of independence as prescribed under Section 149(6) of the Act, the Rules framed thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations, and based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company, be and is hereby **re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of five (5) consecutive years commencing from August 25, 2026 to August 24, 2031 (both days inclusive).**

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197 and other applicable provisions of the Act read with the Rules made thereunder and Regulation 17(6) of the SEBI Listing Regulations, Mr. Karan Vir Bindra be paid such sitting fees and commission, if any, as may be approved by the Board of Directors from time to time, subject to the limits prescribed under the Act and the SEBI Listing Regulations.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) and the Company Secretary be and are hereby authorised to do all such acts, deeds, matters and things, and to execute all such documents, writings and filings as may be necessary, expedient or desirable for the purpose of giving effect to this Resolution."

6. To Reappoint Mrs. Bhavna Grover (DIN: 07557913) as a Whole-time Director and Key Managerial Personnel of the Company.

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, including any statutory modification(s) or re-enactment thereof for the time being in force, and subject to such other approvals, permissions and sanctions as may be required, approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mrs. Bhavna Grover (DIN: 07557913) as the Whole-time Director and Key Managerial Personnel of the Company for a further period of five (5) consecutive years commencing from 25 August, 2026 to 24 August, 2031**, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorised to alter, vary, revise or modify the remuneration, perquisites and other terms and conditions of appointment of Mrs. Bhavna Grover from time to time, subject to the applicable provisions of the Companies Act, 2013, read with Schedule V thereto, the rules made thereunder and other applicable laws, as may be in force from time to time."

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be considered necessary, desirable or expedient to give effect to this Resolution."

7. To Reappoint Mr. Manish Grover (DIN: 07557886), as Managing Director and Key Managerial Personnel of the Company.

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, including any statutory modification(s) or re-enactment thereof for the time being in force, and subject to such

other approvals, permissions and sanctions as may be required, approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mr. Manish Grover (DIN: 07557886) as the Managing Director and Key Managerial Personnel of the Company for a further period of five (5) Consecutive years commencing from 25 August 2026 up to 24 August 2031**, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorised to alter, vary, revise or modify the remuneration, perquisites and other terms and conditions of appointment of Mr. Manish Grover from time to time, subject to the applicable provisions of the Companies Act, 2013, read with Schedule V thereto, the rules made thereunder and other applicable laws, as may be in force from time to time."

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be considered necessary, desirable or expedient to give effect to this Resolution."

8. To Appoint Mr. Ajay Sharma (DIN: 07671350) as a Non-Executive Independent Director of the Company.

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule IV thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment thereof for the time being in force, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, **Mr. Ajay Sharma (DIN: 07671350)**, who was appointed by the Board of Directors as an Additional Director (Non-Executive Independent Director) of the Company with effect from **15th July, 2026** under Section 161 of the Act and the Articles of Association of the Company, and who holds office up to the date of this Annual General Meeting, and who has submitted a declaration that he meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and being eligible for appointment, **be and is hereby appointed as a Non-Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a term of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July 2028**, on the terms and conditions as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT Mr. Ajay Sharma (DIN: 07671350), being a Non-Executive Independent

Director of the Company, shall be entitled to receive sitting fees for attending the meetings of the Board of Directors and Committees thereof, as may be approved by the Board of Directors from time to time, within the limits prescribed under the Companies Act, 2013, the Rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be considered necessary, desirable or expedient to give effect to this Resolution."

9. To Appoint Mrs. Sapna Singh (DIN: 11812894) as a Non-Executive Woman Independent Director of the Company.

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152, 161 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule IV thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment thereof for the time being in force, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, **Mrs. Sapna Singh (DIN: 11812894)**, who was appointed by the Board of Directors as an Additional Director (Non-Executive Woman Independent Director) of the Company with effect from 15th July, 2026 under Section 161 of the Act and the Articles of Association of the Company, and who holds office up to the date of this Annual General Meeting, and who has submitted a declaration that she meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and being eligible for appointment, **be and is hereby appointed as a Non-Executive Woman Independent Director of the Company, not liable to retire by rotation, to hold office for a term of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July 2028**, on the terms and conditions as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT Mrs. Sapna Singh (DIN: 11812894), being a Non-Executive Woman Independent Director of the Company, shall be entitled to receive sitting fees for attending the meetings of the Board of Directors and Committees thereof, as may be approved by the Board of Directors from time to time, within the limits prescribed under the Companies Act, 2013, the Rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby

authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be necessary, desirable or expedient to give effect to this Resolution."

10. To Appoint Dr. Ish Sharma (DIN: 11815526) as a Director of the Company

To consider and, if thought fit, to pass, with or without modification, the following Resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 152 and all other applicable provisions, if any, of the Companies Act, 2013 (the Act), the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force), and pursuant to the recommendation of the Nomination and Remuneration Committee, **Dr. Ish Sharma (DIN: 11815526)**, who was appointed as an Additional Director of the Company by the Board of Directors with effect from 15th July, 2026 in terms of Section 161 of the Act and the Articles of Association of the Company and who holds office upto the date of this Annual General Meeting (AGM), be and is hereby appointed as a Director of the Company, liable to retire by rotation."

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be necessary, desirable or expedient to give effect to this Resolution."

11. To Appoint Dr. Ish Sharma (DIN: 11815526) as a Whole-Time Director and Key Managerial Personnel of the Company

To consider and, if thought fit, to pass, with or without modification, the following Resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 152, 196, 197, 198, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment thereof for the time being in force, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, **Dr. Ish Sharma (DIN: 11815526)**, **be and is hereby appointed as the Whole-time Director and Key Managerial Personnel of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July 2028**, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT the remuneration, perquisites and other benefits payable to Dr. Ish Sharma during his tenure as the Whole-time Director shall be paid in accordance with the terms and conditions set out in the Explanatory Statement annexed to this Notice and the provisions of Sections 196, 197, 198 and other applicable provisions of the Companies Act, 2013 read with Schedule V thereto.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be necessary, desirable or expedient to give effect to this Resolution."

12. To Appoint Mr. Ankush Kaushal (DIN: 03308862) as a Director of the Company

To consider and, if thought fit, to pass, with or without modification, the following Resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 152 and all other applicable provisions, if any, of the Companies Act, 2013 (the Act) and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force), and pursuant to the recommendation of the Nomination and Remuneration Committee, **Mr. Ankush Kaushal (DIN: 03308862)**, who was appointed as an Additional Director of the Company by the Board of Directors with effect from 15th July, 2026 in terms of Section 161 of the Act and the Articles of Association of the Company and who holds office upto the date of this Annual General Meeting (AGM), be and is hereby appointed as a Director of the Company, whose period of office shall be liable to determination by retirement of Directors by rotation.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be necessary, desirable or expedient to give effect to this Resolution

13. To Appoint Mr. Ankush Kaushal (DIN: 03308862) as a Whole-Time Director and Key Managerial Personnel of the Company

To consider and, if thought fit, to pass, with or without modification, the following Resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 152, 196, 197, 198, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment thereof for the time being in force, and pursuant to the recommendation of the Nomination and

Remuneration Committee, and approval of the Board of Directors, **Mr. Ankush Kaushal (DIN: 03308862), be and is hereby appointed as a Director of the Company and further as the Whole-time Director and Key Managerial Personnel of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July 2028**, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT the remuneration, perquisites and other benefits payable to Mr. Ankush Kaushal during his tenure as the Whole-time Director shall be paid in accordance with the terms and conditions set out in the Explanatory Statement annexed to this Notice and the provisions of Sections 196, 197, 198 and other applicable provisions of the Companies Act, 2013 read with Schedule V thereto.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings and filings as may be necessary, desirable or expedient to give effect to this Resolution."

14. To take approval of members for granting loan, giving guarantee and/or providing security to all person covered under Section 185 of the Companies Act, 2013

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"**RESOLVED THAT** in supersession of all the earlier resolutions passed in this regard if any, and pursuant to the provisions of Section 185 and all other applicable provisions, if any, of the Companies Act, 2013 ("Act") read with the rules made thereunder (including any statutory modification(s), amendment(s) or re-enactment thereof for the time being in force), and subject to such approvals, consents, permissions and sanctions as may be necessary, the consent of the Members of Jeena Sikho Lifecare Limited ("Company") be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include any Committee thereof and any person(s) authorised by the Board to exercise the powers conferred by this Resolution), to grant, from time to time, in one or more tranches, any loan including loan represented by way of book debt, and/or to provide any guarantee and/or security in connection with any loan availed or to be availed by any entity which is a subsidiary, associate, joint venture of the Company or any other person in whom any of the Directors of the Company is deemed to be interested, as specified in the Explanation to sub-section (2) of Section 185 of the Act (collectively referred to as the "Entities"), for an aggregate amount **not exceeding ₹ 100 Crore (Rupees One Hundred Crore Only)** outstanding at any point of time, on such terms and conditions as the Board, in its absolute discretion, may deem beneficial and in the best interest of the Company, provided that such loan(s) are utilised by such persons or entities only for their principal business activities.

RESOLVED FURTHER THAT any of the Director of the company be and is hereby authorised to negotiate, finalise and determine the terms and conditions of such loans, guarantees and/or securities, including the tenure, interest rate, security, repayment schedule and other related matters, and to execute all agreements, deeds, documents, declarations, writings and other instruments, and to do all such acts, deeds, matters and things as may be necessary, desirable, proper or expedient for giving effect to this Resolution and to settle any question, difficulty or doubt that may arise in this regard, without requiring any further approval of the Members."

15. To take approval for members for granting loans, giving guarantees or securities and making investments under Section 186 of the Companies Act, 2013

To consider and, if thought fit, to pass, with or without modification, the following Resolution as a **Special Resolution**:

"RESOLVED THAT in supersession of all the earlier resolutions passed in this regard if any, and pursuant to the provisions of Section 186 and all other applicable provisions, if any, of the Companies Act, 2013 ("Act") read with the Companies (Meetings of Board and its Powers) Rules, 2014 and other applicable rules made thereunder (including any statutory modification(s), amendment(s) or re-enactment thereof for the time being in force), and subject to such approvals, consents, sanctions and permissions as may be necessary, the consent of the Members of Jeena Sikho Lifecare Limited ("Company") be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board", which expression shall include any Committee thereof or any person(s) authorised by the Board for exercising the powers conferred by this Resolution) to:

- a. to invest/acquire from time to time by way of subscription, purchase, conversion or otherwise Equity Shares, Preference Shares, Debentures (whether convertible or non-convertible) or any other financial instruments of one or more Bodies Corporate, whether in India or outside;
- b. to give from time to time any loan or loans to any Body or Bodies Corporate, whether in India or outside, or any other person, body or entity;
- c. to give from time to time any guarantee(s) and/or provide any security, in connection with any loan(s) made, by any other person(s) to, or to any other person(s) by, any Body Corporate, whether in India or outside;

notwithstanding the fact that such loan/guarantee/investment to be so given, provided or made together with the loans/guarantees/investments already given, provided or made may exceed sixty percent of the aggregate of the Paid-up Share Capital, free reserves and securities premium account of the Company or one hundred percent of its free reserves and securities premium account, whichever is more."

"RESOLVED FURTHER THAT in addition to the above, the Board of the Company be and is hereby authorized to make investments, give loans and/or provide guarantee(s)/security to other bodies corporate or other persons and entities provided that the aggregate of the investments made, loans given and security/guarantee(s) provided shall not at any time exceed **₹ 700 Crores (Rupees Seven Hundred Crore only).**"

"RESOLVED FURTHER THAT the Board be and is hereby authorized to determine the actual sum or sums to be loaned to and/or guaranteed or invested in the Equity Share Capital or Preference Share Capital or other securities of the said Bodies Corporate out of the above limit and to determine the time and manner of making such loans and/or providing guarantees/security or making such investments and generally to deal with and decide all or any matter arising out of or incidental to the same and to do all such acts, deeds, matters and things for giving effect to this resolution including any change(s), amendment(s) or modification(s) as it may in its absolute discretion deem fit and proper."

"RESOLVED FURTHER THAT for the purpose of giving effect to the above Resolution, the Board be and is hereby authorized to agree, make, accept and finalize all such terms, condition(s), modification(s) and alteration(s) as it may deem fit including the terms and conditions within the above limit up to which such investments/loans/guarantees, that may be made or given, as may be determined by the Board or the Committee thereof, including with the power to transfer/dispose of the investments so made, from time to time, and generally to deal with and decide all or any matter arising out of or incidental to the same and the Board is also hereby authorized to resolve and settle all questions, difficulties or doubts that may arise in regard to making such investments, loans and/or providing guarantee or security and to finalize and execute all agreements, documents, and writings and to do all acts, deeds and things in this connection and incidental as the Board/Committee in its absolute discretion may deem fit without being required to seek any further consent or approval of the members or otherwise to the end and intent that they shall be deemed to have been given approval thereto expressly by the authority of this resolution."

By Order of the Board of Directors
For **JEENA SIKHO LIFECARE LIMITED**

Date: 31.08.2026
Place: Zirakpur, Punjab

Sd/-
Priya Goyal
Company Secretary

Notes:

- 1) The respective Explanatory Statements, pursuant to Section 102 of the Companies Act 2013, in respect of the Special business under item no 5 to 15 of accompanying notice is annexed hereto.
- 2) The Notice of the 09th AGM along with the Annual Report for the Financial Year 2025-26 is being sent by electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories as on 28.08.2026.
- 3) **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE INSTRUMENT APPOINTING THE PROXY IS ANNEXED HERewith AS ANNEXURE B.**
- 4) Proxy forms, in order to be effective, must be deposited at the Registered Office of the Company not later than 48 hours before the time fixed for the meeting, duly completed and signed. A proxy does not have the right to speak at the meeting and cast votes only on a poll. A proxy form is annexed to this report. Proxies submitted on behalf of limited companies, societies, etc. must be supported by an appropriate resolution/authority, as applicable.
- 5) **Pursuant to Section 105 of the Act read with Rule 19 of the Companies (Management and Administration) Rules, 2014, a person can act as a proxy on behalf of members not exceeding 50 (Fifty) and holding in the aggregate not more than 10% (Ten Percent) of the total share capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more than 10% (Ten Percent) of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other member.**
- 6) Institutional/Corporate Members are required to send a scanned copy of their Board or Governing Body Resolution/Authorization etc., authorizing its representative to attend the AGM on its behalf and to vote through e-Voting/remote e-Voting. The said Resolution/Authorization shall be sent to Scrutinizer by email at vivekrawal89@gmail.com with a copy marked to investors@jeenasikho.com and evoting@nsdl.co.in.
- 7) In case of joint holders attending the meeting, the Member whose name appears as the first holder in the order of names as per the Register of Members/List of Beneficial Owners of the Company will be entitled to vote at the AGM.
- 8) The Company has fixed Monday, September 21, 2026 as the 'Record Date' for determining the entitlements of Members to dividend for the Financial Year ended 31 March 2026, if approved at the AGM.
- 9) In case the dividend on equity shares, as recommended by the Board of Directors, is approved at the AGM, such dividend will be paid, subject to deduction of tax at source, as applicable within stipulated timeline as per the act.
- 10) Pursuant to Regulation 12 of the SEBI Listing Regulations, dividend payments shall be made through electronic mode, wherever applicable. Members are requested to ensure that their bank account details are correctly updated with their respective Depository Participants to enable timely receipt of dividend.
- 11) Relevant documents referred to in the accompanying Notice and the statement pursuant to Section 102(1) of the Companies Act, 2013 shall be available for inspection through electronic mode, basis the request being sent at investors@jeenasikho.com.
- 12) The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and the Register of Contracts or Arrangements in which Directors are interested maintained under Section 189 of the Act, and all the documents referred to in the accompanying Notice, are open for inspection at the option of shareholders the members during the AGM. All documents referred to in the Notice will also be available for inspection by the members at the registered office of the Company during office hours on all working days between 11.00 a.m. and 4.00 p.m. on all days except Saturdays, Sundays and public holidays, from the date hereof up to the date of the Meeting and at the venue of the Meeting for the duration of the Meeting. Members seeking to inspect such documents can send an email to investors@jeenasikho.com
- 13) Members who have not registered their e-mail IDs are requested to register/update the same with their Depository Participants to promote the green initiative and thus, help preserve the environment.
- 14) In continued compliance of Rule 18(3)(i) of the Companies (Management and Administration) Rules, 2014, the Company is pleased to provide another opportunity to the members to register/update their email IDs by providing the requisite details in the Proforma annexed hereto with the Notice as **Annexure C**.
- 15) Members are requested to notify change, if any, in their email ID and/or mailing address, quoting their Folio No. to the Company at its Registered Office or through email at investors@jeenasikho.com.
- 16) Members holding shares in electronic form should notify any change, if any, in their email ID and/or mailing address including PIN Code, bank details etc. directly to their respective Depository Participants.
- 17) Members/proxies should bring duly filled Attendance Slip to attend the annual general meeting. Attendance slip is annexed herewith as **ANNEXURE D**.
- 18) Members may note that the Notice and Annual Report 2025-26 will also be available on the Company's website at www.jeenasikho.com, websites of the Stock Exchanges i.e National Stock Exchange of India Limited at www.nseindia.com and BSE Limited at www.bseindia.com

- 19) The Final Dividend of ₹ 4.50/- on Equity Shares having face value of ₹ 2/- each of the Company as recommended by the Board of Directors of the Company for the financial year ended March 31, 2026, if declared at the AGM, will be paid within 30 days of the AGM to those members whose names appear in the Register of Members as on Monday, September 21, 2026 ("the Record Date").
- 20) Members holding shares in dematerialized mode are requested to register/update their bank details with their Depository Participants, to enable expeditious credit of the dividend to their bank accounts electronically.
- 21) Under Section 125 of the Companies Act, 2013 and IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date

and the underlying Shares in respect of those Unclaimed Dividends are required to be transferred to the Investor Education and Protection Fund (IEPF), constituted by the Central Government. The shares in respect of such unclaimed dividends are also liable to be transferred to the Demat account of the IEPF Authority.

- 22) With effect from April 1, 2024, dividend to security holders (holding securities in physical form), shall be paid only through electronic mode. Such payment shall be made upon folio being KYC compliant i.e. the PAN, contact details including mobile no., bank account details and specimen signature are registered with the RTA/Company. [SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024, read with SEBI Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/81 dated June 10, 2024].

23) Tax Deducted at Source ("TDS") on dividend:

As per the applicable provisions of the Income-tax Act, 2025, dividend paid or distributed by the Company shall be taxable in the hands of the Members. Accordingly, the Company shall be required to deduct tax at source (TDS) from the dividend at the prescribed rates under the Income-tax Act, 2025 and the rules made thereunder. The rate of TDS would depend upon the residential status and category of the Member and the documents furnished and accepted by the Company.

For the prescribed rates applicable to various categories of Members, Members are requested to refer to the applicable provisions of the Income-tax Act, 2025 and the Finance Act, 2026, as amended from time to time. Members are also requested to ensure that their PAN and other relevant details are updated with their respective Depository Participants (DPs), in case the shares are held in dematerialised form, and with the Company/Registrar and Transfer Agent (RTA), in case the shares are held in physical form.

To avail exemption of TDS, shareholders are requested to submit required documents/declaration by e-mail to compliances@skylinerta.com by 11.59 p.m. (IST) on Monday, September 21, 2026. Members may also refer the e-mail sent to their registered e-mail ID for more details on submission of exemption documents.

Category of Shareholder	Document(s) to be submitted/uploaded
Resident individual Members eligible to furnish declaration for non-deduction of TDS	Form No. 121 under Section 393(6) of the Income-tax Act, 2025 (Erstwhile Forms 15G or 15 H) , as applicable
Non-resident Members, including Foreign Portfolio Investors (FPIs), who are eligible to avail beneficial tax rates under an applicable tax treaty between India and the country of their tax residence	Tax Residency Certificate, Form No. 41, where applicable, and such other documents as may be required to substantiate eligibility for treaty benefits
Non-resident Members claiming beneficial tax treaty rates	Declaration of beneficial ownership, Tax Residency Certificate, Form No. 41, where applicable, and such other documents as may be required under the applicable tax laws

In case of an invalid or inoperative PAN, or failure to furnish a valid PAN, tax shall be deducted at the higher applicable rate in accordance with the provisions of the Income-tax Act, 2025. Members are therefore requested to ensure that their PAN is valid and operative and that the same is appropriately linked with Aadhaar, wherever applicable.

Members are requested to note that the Company shall determine the applicable rate of TDS based on the information and documents available with the Company/RTA as on the date of deduction of TDS. The Company shall not be liable for any consequences arising from incorrect or incomplete information furnished by the Member.

- 24) Additional information(s), pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard for General Meetings (SS-2) in respect of Director(s) recommended for appointment/reappointment are annexed with this AGM Notice as **Annexure A**.
- 25) Any person, who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice and holding shares as on cut-off date, may cast vote as provided in the Notice convening the Meeting, which is available on the website of the Company.
- 26) Members seeking clarifications on the Annual Report are requested to send in writing through email at investors@jeenasikho.com at least 7 days before the date of meeting. This would enable the company to compile the information and give replies to all the clarifications sought by the members, in the meeting.

- 27) In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of SEBI Listing Regulations, the Members are provided with the facility of voting through electronic means ("remote e-Voting" or "e-Voting during AGM") on all the resolutions set out in this AGM Notice, through remote e-Voting services provided by National Securities Depository Limited (NSDL).
- 28) The facility for e-Voting will also be made available during the AGM and the Members attending the AGM who have not cast their vote by remote e-Voting shall be eligible to vote through the e-Voting system during the AGM. The Members who have cast their vote by remote e-Voting may also attend the AGM but shall not be entitled to cast their vote again. In case the members cast their votes through remote e-voting as well as at the AGM, votes cast through remote e-voting shall only be considered valid.
- 29) The remote e-voting period commences on **Friday 25.09.2026 at 9:00 A.M. and ends on Sunday 27.09.2026 at 5:00 P.M.** Thereafter, the remote e-voting module shall be disabled for e-voting. E-vote once cast cannot be altered subsequently.
- 30) The voting rights of members shall be in proportion to their shares in the paid-up equity share capital of the Company as on cut-off date. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date i.e., **21.09.2026** shall be entitled to vote on the proposed resolutions; and their shareholding on such date shall only be reckoned for the purpose of arriving at the results of the remote e-voting and voting at the AGM. Any person who is not the member of the Company as on the cut-off date should treat this notice for information purpose only.
- 31) The Board of Directors of the Company has appointed Mr. Vivek Rawal Proprietor of **M/s Rawal & Co., Company Secretaries**, as the Scrutinizer to scrutinize the voting through remote e- voting and e-voting process, in a fair and transparent manner.
- 32) Dividend, if approved at the AGM, will be paid within 30 days from the date of the AGM.
- 33) The Scrutinizer shall immediately after the conclusion of the Meeting, count the e-voting cast at the Meeting and the vote cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, within the time permissible under the applicable laws, a consolidated Scrutinizer's report of the total votes cast in favor or against, if any, and submit the same to the Chairman or a person authorized by him, who shall counter sign the same.
- 34) The results declared along with the report of the Scrutinizer shall be placed in the website of the Company www.jeeenasikho.com and on the website of NSDL immediately after the declaration of results by the Chairman or a person authorized by him and the results shall also be communicated to National Stock Exchange of India Limited and BSE Limited.
- 35) Route-map to the venue of the Meeting is provided in this Notice.
- 36) Pursuant to Section 91 of the Companies Act, 2013, The Register of Members and Share Transfer Books of the Company will be closed from **22.09.2026 to 28.09.2026 (both days inclusive)**.
- 37) **THE INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:**
- The voting period begins on **Friday 25.09.2026 at 9:00 A.M. and ends on Sunday 27.09.2026 at 5:00 P.M.** During this period, shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date i.e. **21 September, 2026** may cast their vote electronically. The e-voting module shall be disabled by NSDL for voting thereafter.
 - Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
 - Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.
- Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.
- In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the Demat account holders, by way of a single login credential, through their Demat accounts/websites of Depositories/Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.
- In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in Demat mode are allowed to vote through their Demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their Demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode is given below:

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in Demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	- Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp - Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. - Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience.
NSDL Mobile App is available on  App Store  Google Play  	
Individual Shareholders holding securities in demat mode with CDSL	- Users who have opted for CDSL Easi/Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi/Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then use your existing my easi username & password. - After successful login the Easi/Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.

Login method for Individual shareholders holding securities in demat mode is given below: (Contd.)

Type of shareholders	Login Method
	- If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. - Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility, upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period

Important note: Members who are unable to retrieve User ID/Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at 022 - 4886 7000 and 022 -2499 7000.
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33.

B) Login Method for e-Voting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

- Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/either> on a Personal Computer or on a mobile.
- Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
- A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/with> your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

- Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***.

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - If your email ID is registered in your Demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'
 - If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - Click on "Forgot User Details/Password?" (If you are holding shares in your Demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your Demat account number/folio number, your PAN, your name and your registered address etc.
 - Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

- After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle is in active status.
- Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period.
- Now you are ready for e-Voting as the Voting page opens.
- Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- Upon confirmation, the message "Vote cast successfully" will be displayed.
- You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to vivekrawal89@gmail.com with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution/Power of Attorney/Authority Letter etc. by clicking on "Upload Board Resolution/Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to evoting@nsdl.co.in.

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhaar Card) by email to investors@jeenasikho.com
2. In case shares are held in Demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhaar Card) to investors@jeenasikho.com. If you are

an Individual shareholder holding securities in Demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in Demat mode.

3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

In terms of SEBI circular dated December 9, 2020, on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in Demat mode are allowed to vote through their Demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their Demat account in order to access e-Voting facility.

By Order of the Board of Directors
For **JEENA SIKHO LIFECARE LIMITED**

Sd/-
Priya Goyal
Company Secretary

Date: 31.08.2026
Place: Zirakpur, Punjab

EXPLANATORY STATEMENTS PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

ITEM NO. 5

Reappointment of Mr. Karan Vir Bindra (DIN: 09283623) as an Independent Director of the Company

Background:

Mr. Karan Vir Bindra (DIN: 09283623) is currently serving as an Independent Director of the Company.

The Members of the Company, at the Extra Ordinary General Meeting held on 25th August, 2021 approved his appointment as an Independent Director of the Company, not liable to retire by rotation, for a first term of five (5) consecutive years commencing from August 25, 2021 up to August 24, 2026 (both days inclusive), in accordance with the provisions of Sections 149, 150 and 152 read with Schedule IV to the Companies Act, 2013 ("the Act"), the Companies (Appointment and Qualifications of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board:

The Nomination and Remuneration Committee ("NRC"), taking into consideration the skills, expertise, knowledge, business acumen, experience, integrity and competencies required on the Board in the context of the Company's business, and based on the annual performance evaluation of Mr. Karan Vir Bindra during his first term as an Independent Director, recommended to the Board his re-appointment for a second term of five (5) consecutive years.

Based on the recommendation of the NRC, the Board of Directors of the Company, at its meeting held on 07 August, 2026, after considering his performance evaluation and noting that his continued association would be of immense benefit to the Company, has proposed the re-appointment of Mr. Karan Vir Bindra as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from August 25, 2026 up to August 24, 2031 (both days inclusive).

Brief Profile:

Mr. Karan Vir Bindra (DIN: 09283623) is a Non-Executive Independent Director of Jeena Sikho Lifecare Limited. He is a Fellow Member of the Institute of Company Secretaries of India (FCS) and holds a Bachelor's degree in Law (LL.B.) and a Bachelor's degree in Commerce.

He brings more than 12 years of professional experience in corporate laws, secretarial compliance, corporate governance, regulatory advisory, and compliance management. He is a practicing Company Secretary and the proprietor of M/s K. V. Bindra & Associates, providing advisory services in areas relating to corporate compliance, securities laws, governance matters, FEMA, and regulatory requirements.

Over the years, Mr. Bindra has advised various listed and unlisted companies on matters relating to statutory

compliances, corporate governance frameworks, regulatory filings, and corporate law matters. His extensive knowledge and experience in governance and regulatory affairs enable him to provide valuable guidance to the Board in strengthening compliance practices, enhancing governance standards, and ensuring adherence to applicable statutory requirements.

Skills, Expertise and Competencies:

Mr. Karan Vir Bindra possesses Corporate laws, corporate governance and regulatory compliance, enabling him to provide objective oversight and independent judgement to the Board. The Board is of the view that Mr. Bindra fulfils the conditions specified under the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment/re-appointment as an Independent Director, and is independent of the management of the Company.

Disclosures and Consents Received:

The Company has received from Mr. Karan Vir Bindra his consent to act as a Director in terms of Section 152 of the Act and Form DIR-2, confirmation in Form DIR-8 that he is not disqualified from being re-appointed as a Director under Section 164 of the Act, declaration confirming that he continues to meet the criteria of independence prescribed under Section 149(6) of the Act read with the Rules framed thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations, and confirmation pursuant to Regulation 25(8) of the SEBI Listing Regulations that he is not aware of any circumstance or situation which exists or may reasonably be anticipated that could impair or impact his ability to discharge his duties as an Independent Director.

Further, Mr. Karan Vir Bindra has also confirmed that he has complied with the requirements relating to registration with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs ("IICA") in accordance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014. He has further confirmed that he is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority pursuant to the Circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited.

In the opinion of the Board, Mr. Karan Vir Bindra fulfils the conditions specified in the Act, the Rules made thereunder and the SEBI Listing Regulations for re-appointment as an Independent Director and is independent of the management of the Company. The terms and conditions of his re-appointment shall be available for inspection by the Members in accordance with the applicable provisions of the Act and the SEBI Listing Regulations.

In compliance with the provisions of Sections 149, 150 and 152 read with Schedule IV to the Act, the applicable Rules made thereunder and Regulations 17 and other applicable provisions of the SEBI Listing Regulations, the re-appointment of Mr. Karan Vir Bindra as an Independent Director of the Company is placed before the Members for approval by way of a Special Resolution.

The additional information required to be disclosed pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 (SS-2) issued by the Institute of Company Secretaries of India is provided in **Annexure A** forming part of this Notice.

Except Mr. Karan Vir Bindra and his relatives, none of the Directors or Key Managerial Personnel of the Company or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the Special Resolution set out at Item No. 05 of the accompanying Notice.

The Board recommends the Special Resolution set out at Item No. 05 of the accompanying Notice for approval of the Members.

ITEM NO. 6

Reappointment of Mrs. Bhavna Grover (DIN: 07557913) as a Whole-time Director and Key Managerial Personnel of the Company

Background:

The Members of the Company had, at the Extra Ordinary General Meeting held on 25th August, 2021, approved the appointment of Mrs. Bhavna Grover (DIN: 07557913) as Whole-time Director of the Company for a period of five (5) consecutive years commencing from **25 August 2021 and ending on 24 August 2026**, pursuant to the provisions of Sections 196, 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company's Remuneration Policy and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board:

Based on the recommendation of Nomination and Remuneration Committee ("NRC"), the board of Directors at its Meeting held on 07 August, 2026, approved her re-appointment as Whole-time Director and Key Managerial Personnel of the Company for a further period of five (5) consecutive years commencing from **25th August 2026** and ending on **24th August 2031**, on the terms and conditions, including remuneration, perquisites, allowances and other benefits, as set out in the Resolution forming part of this Notice, subject to the approval of the Members.

Brief Profile:

Mrs. Bhavna Grover is the Whole-Time Director of the Company and has been associated with the Board of Jeena Sikho Lifecare Limited since its incorporation.

She brings experience in human resource management, legal administration, finance, and organizational processes. Over the years, she has played an important role in managing and strengthening the Company's internal systems, financial planning processes, administrative frameworks, and operational controls.

Her focus on process improvement, compliance, and effective resource management has contributed to the Company's operational stability, governance practices, and sustainable growth.

Skills, Expertise and Competencies:

Her areas of expertise include financial oversight, organizational management, human resource administration, and regulatory compliance. She actively contributes to ensuring robust internal processes, efficient governance practices, and adherence to applicable statutory and regulatory requirements.

Terms and Conditions of Remuneration of Mrs. Bhavna Grover (DIN: 07557913) as Whole-Time Director and KMP

Particulars	Terms of Remuneration
1. Gross Salary	Aggregating to ₹ 1,80,00,000/- per annum (Rupees One Crore Eighty Lakh only per annum).
2. Commission/ Performance Incentive	Commission and/or performance-linked incentive, subject to the availability of profits and as may be determined by the Board from time to time, within the limits prescribed under the Companies Act, 2013.
3. Perquisites and Allowances	In addition to the salary, Mrs. Bhavna Grover shall be entitled to perquisites and allowances including, but not limited to: 1. Company-maintained motor car with driver and reimbursement of fuel, maintenance and other official expenses, wherever applicable. 2. Telephone, mobile phone, internet and other communication facilities at residence and/or for official use. 3. Reimbursement of business travel and entertainment expenses incurred in the performance of official duties. 4. Such other perquisites, benefits and allowances as may be approved by the Board from time to time.

Terms and Conditions of Remuneration of Mrs. Bhavna Grover (DIN: 07557913) as Whole-Time Director and KMP (Contd.)

Particulars	Terms of Remuneration
4. Minimum Remuneration	Where in any financial year during the tenure of Mrs. Bhavna Grover as Whole-time Director, the Company has no profits or its profits are inadequate, she shall be paid salary, perquisites, allowances and other benefits as set out herein, as minimum remuneration, subject to the limits and conditions specified under Schedule V to the Companies Act, 2013 and other applicable provisions thereof.
5. Other Terms	(i) Mrs. Bhavna Grover shall be liable to retire by rotation during her tenure as Whole-time Director. (ii) She shall not be entitled to sitting fees for attending meetings of the Board or Committees thereof. (iii) The appointment shall otherwise be governed by the provisions of the Companies Act, 2013, the Articles of Association of the Company and such other terms as may be approved by the Board from time to time.

The remuneration proposed to be paid shall be within the limits prescribed under the Act, the Rules made thereunder and Schedule V thereto. The Board (including the NRC) shall be entitled to revise, vary, alter or modify the remuneration, perquisites, allowances and other terms and conditions of appointment from time to time, within the overall limits approved by the Members and as may be permissible under the applicable provisions of the Act, the SEBI Listing Regulations and other applicable laws.

Disclosures and Consents Received:

The Company has received from Mrs. Bhavna Grover, inter alia:

- Consent to act as a Director in Form DIR-2 pursuant to Section 152 of the Act read with Rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014;
- Disclosure of her interest in accordance with the provisions of the Act;
- Confirmation that she is not debarred from holding the office of Director pursuant to any Order issued by the Securities and Exchange Board of India or any other statutory or regulatory authority; and
- Other related declarations, disclosures and confirmations as may be required under the Act, the Rules framed thereunder and the SEBI Listing Regulations.

The Board is satisfied that Mrs. Bhavna Grover fulfils all the conditions specified under the Act and the applicable Rules made thereunder for her re-appointment as Whole-time Director and that she is not disqualified from being appointed or continuing as a Director under the provisions of the Act.

The information required to be disclosed pursuant to Regulation 36(3) of the SEBI Listing Regulations, Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India and other applicable provisions of the Act, relating to the proposed re-appointment of Mrs. Bhavna Grover, forms part of **Annexure A** to this Notice.

Except Mrs. Bhavna Grover and her relatives, to the extent of their shareholding, if any, in the Company, none of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 6 of this Notice.

The Board considers that the re-appointment of Mrs. Bhavna Grover as Whole-time Director is in the best interests of the Company and accordingly recommends the **Special Resolution** set out at Item No. 6 of this Notice for approval by the Members.

ITEM NO. 7**Re-Appointment of Mr. Manish Grover (Din: 07557886), as Managing Director and Key Managerial Personnel of the Company.****Background:**

The Members of the Company had, at the Extra Ordinary General Meeting held on 25th August, 2021, approved the appointment of Mr. Manish Grover (DIN: 07557886) as the Managing Director of the Company for a term of five (5) consecutive years commencing from **25 August 2021** and ending on **24 August 2026**, pursuant to the provisions of Sections 196, 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company's Remuneration Policy and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board:

Upon the recommendation of the Nomination and Remuneration Committee ("NRC"), the Board of Directors ("Board"), at its Meeting held on 07 August, 2026, subject to the approval of the Members, approved, the re-appointment of Mr. Manish Grover as the Managing Director and Key Managerial Personnel of the Company for a further term of five (5) consecutive years commencing from **25 August 2026** and ending on **24 August 2031**, upon the terms and conditions, including remuneration, set out in the Resolution forming part of this Notice.

Brief Profile:

Mr. Manish Grover is the Managing Director of Jeena Sikho Lifecare Limited and the founder of Shuddhi Ayurveda. He is an entrepreneur and healthcare professional having experience in the Ayurvedic healthcare sector.

He has dedicated his professional journey to the revival and promotion of traditional Ayurvedic wisdom and preventive healthcare practices in India. With a focused mission to address the root causes of chronic and lifestyle-related diseases through natural and integrative therapies.

Since commencing his professional journey in 2009, Mr. Grover has been actively involved in promoting Ayurveda, preventive healthcare, and holistic wellness practices. He has played a significant role in establishing and expanding the Company's healthcare ecosystem, including the growth of Shuddhi Ayurveda and HIIMS (Hospital & Institute of Integrated Medical Sciences), with a focus on integrating Ayurveda, lifestyle management, yoga, and wellness practices.

Under his leadership, the Company has expanded its presence in the Ayurvedic healthcare segment and developed a structured healthcare ecosystem supported by a team of healthcare professionals, including doctors and researchers, engaged in advancing Ayurvedic treatment approaches through clinical experience and research-based practices.

His areas of expertise include Ayurvedic healthcare, preventive wellness, lifestyle management, healthcare operations, business strategy, and organizational leadership. He continues to contribute towards strengthening the Company's vision of providing holistic and integrative healthcare solutions.

Skills, Expertise and Competencies:

Mr. Manish Grover possesses Healthcare and Ayurveda business leadership, strategic decision-making and sustainable growth planning. The Board is of the view that Mr. Grover fulfils the conditions specified under the Act, the Rules made thereunder.

Terms and Conditions of Appointment/Remuneration:

Sr. No.	Particulars	Terms of Remuneration
1.	Salary	Aggregating to ₹ 6,00,00,000/- per annum (Rupees Six Crore only per annum).
2.	Commission	Commission and/or performance-linked incentive, subject to the availability of profits and as may be determined by the Board from time to time, within the limits prescribed under the Companies Act, 2013.
3.	Perquisites and Allowances	In addition to the salary, Mr. Manish Grover shall be entitled to perquisites and allowances including, but not limited to: - Company-maintained motor car with driver and reimbursement of fuel, maintenance and other official expenses, wherever applicable. - Telephone, mobile phone, internet and other communication facilities at residence and/or for official use. - Reimbursement of business travel and entertainment expenses incurred in the performance of official duties. - Such other perquisites, benefits and allowances as may be approved by the Board from time to time.
4.	Minimum Remuneration	In the event of inadequacy or absence of profits in any financial year during the tenure of appointment, Mr. Manish Grover shall be entitled to remuneration by way of salary, perquisites and allowances as approved by the Members, subject to the provisions of Schedule V to the Companies Act, 2013.
5.	Other Terms and Conditions	- Mr. Manish Grover shall be liable to retire by rotation during his tenure as Managing Director. - He shall not be entitled to sitting fees for attending meetings of the Board or Committees thereof. - The appointment shall otherwise be governed by the provisions of the Companies Act, 2013, the Articles of Association of the Company and such other terms as may be approved by the Board from time to time.

The remuneration proposed to be paid to Mr. Manish Grover has been recommended by the NRC after considering, inter alia, the Company's Remuneration Policy, his qualifications, experience, responsibilities, performance, prevailing industry practices, remuneration levels in comparable companies, the size and complexity of the Company's operations and other relevant factors. The proposed remuneration is within the limits prescribed under the Act read with Schedule V thereto and other applicable laws.

The Board (including the NRC) shall have the authority to revise, vary, alter or modify the remuneration and other terms and condition of appointment of Mr. Manish Grover from time to time, within the overall limits approved by the Members and as may be permissible under the Act, the Rules made thereunder, Schedule V to the Act and other applicable laws.

Disclosures and Consents Received:

The Company has received from Mr. Manish Grover, inter alia:

- Consent to act as a Director in Form DIR-2 pursuant to Section 152 of the Act read with Rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014;
- Disclosure of his interest in accordance with the provisions of the Act;
- Confirmation that He is not debarred from holding the office of Director pursuant to any Order issued by the Securities and Exchange Board of India or any other statutory or regulatory authority; and
- Other related declarations, disclosures and confirmations as may be required under the Act, the Rules framed thereunder and the SEBI Listing Regulations.

The Board is satisfied that Mr. Manish Grover fulfils the conditions specified under the Act and the Rules made thereunder for his re-appointment as the Managing Director of the Company.

The information required to be disclosed pursuant to Regulation 36(3) of the SEBI Listing Regulations, Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India and other applicable provisions of the Act forms part of **Annexure A** to this Notice.

Except Mr. Manish Grover and his relatives, to the extent of their shareholding, if any, in the Company, none of the Directors or Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 7 of this Notice.

The Board considers that the re-appointment of Mr. Manish Grover as the Managing Director is in the best interests of the Company and accordingly recommends the **Special Resolution** set out at Item No. 7 of this Notice for approval by the Members.

ITEM NO. 8

Appointment of Mr. Ajay Sharma (DIN: 07671350) as a Non-Executive Independent Director of the Company.

Background:

Based on the recommendation of the Nomination and Remuneration Committee ("NRC"), the Board of Directors of the Company ("Board"), at its Meeting held on **July 15th, 2026**, appointed **Mr. Ajay Sharma (DIN: 07671350)** as an Additional Director in the category of **Non-Executive Independent Director** of the Company with effect from **July 15th, 2026**, for a term of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July 2028, not liable to retire by rotation, subject to the approval of the Members by way of an Special Resolution.

Pursuant to the provisions of Section 161(1) of the Companies Act, 2013 ("the Act"), Regulation 17(IC) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

read with the Articles of Association of the Company, Mr. Ajay Sharma holds office as an Additional Director up to the date of the ensuing Annual General Meeting or three months from the date of his appointment, whichever is earlier.

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board:

The NRC, while considering the appointment of Mr. Ajay Sharma, took into account his professional background, qualifications, experience, expertise, skills and knowledge spanning across the real estate, hospitality, finance and travel sectors, which are aligned with the skills and competencies identified by the Board for effective functioning of the Board and its Committees.

The Board believes that the association of Mr. Ajay Sharma as an Independent Director would bring valuable insights, independent judgement and diverse perspectives to the deliberations of the Board and its Committees. His diverse experience and expertise would contribute towards strengthening the Company's governance framework, strategic initiatives and long-term objectives.

In the opinion of the NRC and the Board, Mr. Ajay Sharma is a person of integrity and possesses the requisite qualifications, expertise, experience, skills and capabilities required for the role of an Independent Director. He fulfils the conditions specified under the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment as an Independent Director and is independent of the management of the Company.

The Board has recommended the appointment of Mr. Ajay Sharma as a Non-Executive Independent Director, not liable to retire by rotation, for a term of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028 (both days inclusive), subject to approval of the Members of the Company.

Brief Profile:

Mr. Ajay Sharma holds a Bachelor's degree in Humanities (B.A.) and has pursued Hospitality Management studies in Australia. He possesses over 25 years of diverse professional experience spanning real estate, hospitality, finance, and travel.

He is an accomplished business leader and real estate consultant with extensive expertise in property advisory, business management, client relationship management, and strategic leadership. Over the course of his career, he has successfully led and managed businesses in the hospitality, travel, and finance sectors, both in India and Australia.

His broad industry exposure, entrepreneurial acumen, and strong leadership capabilities enable him to contribute effectively to business growth, corporate governance, and strategic decision-making.

Skills, Expertise and Competencies:

Mr. Ajay Sharma possesses Hospitality, real estate and finance-driven strategic insight into business development and operational excellence. The Board is of the view that Mr. Sharma fulfils the conditions specified under the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment/re-appointment as an Independent Director, and is independent of the management of the Company.

Disclosures and Consents Received:

The Company has received the following from Mr. Ajay Sharma:

- (i) Consent in writing to act as a Director in Form DIR-2 pursuant to Rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014 ("Rules");
- (ii) Intimation in Form DIR-8 confirming that he is not disqualified under Section 164 of the Act;
- (iii) Declaration confirming that he meets the criteria of independence prescribed under Section 149(6) of the Act read with Regulation 16(1)(b) of the SEBI Listing Regulations;
- (iv) confirmation pursuant to Regulation 25(8) of the SEBI Listing Regulations that he is not aware of any circumstance or situation which exists or may reasonably be anticipated that could impair or impact his ability to discharge his duties as an Independent Director; and
- (v) Declaration pursuant to the Circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited confirming that he has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other statutory or regulatory authority.

Mr. Ajay Sharma has also confirmed that he has complied with the requirements relating to registration with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs ("IICA") in accordance with Rules 6(1) and 6(2) of the Rules.

The information required to be disclosed pursuant to Regulation 36(3) of the SEBI Listing Regulations, Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India and other applicable provisions of the Act forms part of **Annexure A** to this Notice.

In compliance with the provisions of Sections 149, 150, 152 and 161 read with Schedule IV to the Act, the applicable Rules made thereunder and Regulations 17 and other applicable provisions of the SEBI Listing Regulations, the appointment of Mr. Ajay Sharma as a Non-Executive Independent Director of the Company is placed before the Members for approval by way of **Special Resolution**.

The Board recommends the Special Resolution set out at **Item No. 8** of the accompanying Notice for approval by the Members.

Except Mr. Ajay Sharma and his relatives, none of the Directors, Key Managerial Personnel of the Company or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the Resolution set out at **Item No. 8** of the accompanying Notice.

ITEM NO. 9

Appointment of Mrs. Sapna Singh (DIN: 11812894) as a Non-Executive Woman Independent Director of the Company.

Background:

Based on the recommendation of the Nomination and Remuneration Committee ("NRC"), the Board of Directors of the Company ("Board"), at its Meeting held on **July 15th, 2026**, appointed **Mrs. Sapna Singh (DIN: 11812894)** as an Additional Director in the category of **Non-Executive Independent Director** of the Company with effect from **July 15th, 2026**, for a term of Two (2 consecutive years commencing from 15th July, 2026 up to 14th July 2028, not liable to retire by rotation, subject to the approval of the Members by way of Special Resolution.

Pursuant to the provisions of Section 161(1) of the Act, Regulation 17(1C) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Articles of Association of the Company, Mrs. Sapna Singh holds office as an Additional Director up to the date of the ensuing Annual General Meeting or three months from the date of appointment, whichever is earlier.

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board:

The NRC, while considering the appointment of Mrs. Sapna Singh, took into account her professional background, qualifications, experience, expertise, skills and knowledge in the areas of in team leadership, customer relationship management, performance monitoring, training and development, and handling customer escalations. Which are aligned with the skills and competencies identified by the Board for effective functioning of the Board and its Committees.

The Board believes that the association of Mrs. Sapna Singh as an Independent Director would bring valuable insights, independent judgement and diverse perspectives to the deliberations of the Board and its Committees. Her experience and expertise would contribute towards strengthening the Company's governance framework, strategic initiatives and long-term objectives.

In the opinion of the NRC and the Board, Mrs. Sapna Singh is a person of integrity and possesses the requisite qualifications, expertise, experience, skills and capabilities required for the role of an Independent Director. She fulfils the conditions specified under the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment as an Independent Director and is independent of the management of the Company.

The Board has recommended the appointment of Mrs. Sapna Singh as a Non-Executive Woman Independent Director, not liable to retire by rotation, for a term of Two (2 consecutive years commencing from 15th July, 2026 up to 14th July 2028 (both days inclusive), subject to approval of the Members of the Company.

Brief Profile:

Mrs. Sapna Singh holds a Bachelor of Education (B.Ed.) from CMJ University, Meghalaya, and a Bachelor of Arts from Panjab University. She has over five years of experience in customer service operations and team management. Over the course of her career, she has developed expertise in team leadership, customer relationship management, performance monitoring, training and development, and grievance handling. She is known for her strong organizational and interpersonal skills, effective people management, and commitment to operational excellence and service quality.

Skills, Expertise and Competencies:

Mrs. Sapna Singh possesses Customer relationship management, service operations and people management, strengthening customer-centric governance. The Board is of the view that Mrs. Singh fulfils the conditions specified under the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment/re-appointment as an Independent Director, and is independent of the management of the Company.

Disclosures and Consents Received:

The Company has received the following disclosures and confirmations from Mrs. Sapna Singh:

- (i) consent in writing to act as a Director in Form DIR-2 pursuant to Rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014 ("Rules");
- (ii) Intimation in Form DIR-8 confirming that she is not disqualified under Section 164 of the Act;
- (iii) Declaration confirming that she meets the criteria of independence prescribed under Section 149(6) of the Act read with Regulation 16(1)(b) of the SEBI Listing Regulations;
- (iv) Confirmation pursuant to Regulation 25(8) of the SEBI Listing Regulations that she is not aware of any circumstance or situation which exists or may reasonably be anticipated that could impair or impact her ability to discharge her duties as an Independent Director; and
- (v) Declaration pursuant to the circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited confirming that she has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other statutory or regulatory authority.

Mrs. Sapna Singh has also confirmed that she has complied with the requirements relating to registration with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs ("IICA") in accordance with Rules 6(1) and 6(2) of the Rules.

The terms and conditions of appointment of Mrs. Sapna Singh as an Independent Director shall be governed by the applicable provisions of the Act, Schedule IV thereto, the SEBI Listing Regulations and the Company's Policy on Appointment and Remuneration of Directors.

The information required to be disclosed pursuant to Regulation 36(3) of the SEBI Listing Regulations, Secretarial Standard on General Meetings (SS-2) issued by the Institute

of Company Secretaries of India and other applicable provisions of the Act forms part of **Annexure A** to this Notice.

In compliance with the provisions of Sections 149, 150, 152 and 161 read with Schedule IV to the Act, the applicable Rules made thereunder and Regulation 17 and other applicable provisions of the SEBI Listing Regulations, the appointment of Mrs. Sapna Singh as a **Non-Executive Woman Independent Director** of the Company is placed before the Members for approval by way of **Special Resolution**.

Except Mrs. Sapna Singh and her relatives, to the extent of their shareholding, if any, in the Company, none of the Directors, Key Managerial Personnel of the Company or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the Resolution set out at **Item No. 09** of this Notice.

The Board considers that the appointment of Mrs. Sapna Singh as a Non-Executive Woman Independent Director would be beneficial to the Company and accordingly recommends the Special Resolution set out at **Item No. 09** of this Notice for approval by the Members.

ITEM NOS. 10 & 11

Appointment of Dr. Ish Sharma (DIN: 11815526) as Director and Whole-Time Director as well key Managerial Personnel of the Company

The Board of Directors of the Company ("Board"), at its meeting held on 15th July, 2026, based on the recommendation of the Nomination and Remuneration Committee ("NRC"), appointed Dr. Ish Sharma (DIN: 11815526) as an **Additional Director of the Company in the Executive category** with effect from 15th July, 2026, pursuant to the provisions of Section 161 of the Companies Act, 2013 ("Act") and the Articles of Association of the Company.

Pursuant to Section 161 of the Act, Dr. Ish Sharma holds office as an Additional Director up to the date of the ensuing Annual General Meeting and is eligible for appointment as a Director of the Company.

Accordingly, **Item No. 10** of the Notice seeks the approval of the Members for the appointment of Dr. Ish Sharma as a **Director of the Company, liable to retire by rotation**, in accordance with the provisions of Section 152 and other applicable provisions of the Act.

Further, at the aforesaid meeting, based on the recommendation of the NRC, the Board also approved the appointment of **Dr. Ish Sharma as the Whole-Time Director of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028**, subject to the approval of the Members of the Company.

Accordingly, **Item No. 11** of the Notice seeks the approval of the Members for the appointment of Dr. Ish Sharma as the **Whole-Time Director of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028**, pursuant to the provisions of Sections 196, 197, 198 and 203 of the Act read with Schedule V thereto and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Upon his appointment as Whole-Time Director, Dr. Ish Sharma shall also hold the position of Key Managerial Personnel of the Company in accordance with the applicable provisions of Section 2(51) read with Section 203 of the Act.

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board

The NRC, while considering the appointment of Dr. Ish Sharma, took into account his qualifications, professional experience, expertise, leadership capabilities, skills and knowledge, as well as the responsibilities entrusted to him and his contribution towards the Company's growth and development. The NRC also considered the prevailing industry practices, remuneration levels for similar positions and the Company's Nomination and Remuneration Policy.

The Board, based on the recommendation of the NRC, is of the opinion that Dr. Ish Sharma possesses the requisite qualifications, experience, expertise, skills, capabilities and integrity required for the positions proposed to be held by him. The Board believes that his leadership and experience would contribute significantly towards strengthening the Company's business operations, governance framework and long-term strategic objectives.

The NRC and the Board have accordingly recommended the appointment of Dr. Ish Sharma as a Director of the Company, liable to retire by rotation, and further as the Whole-Time Director of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

Skills, Expertise and Competencies:

Dr. Ish Sharma possesses Academic, clinical research and healthcare administration expertise supporting the Company's healthcare and research initiatives. The Board is of the view that Dr. Sharma fulfils the conditions specified under the Act, the Rules made thereunder.

The main terms and conditions of appointment and remuneration of Dr. Ish Sharma, as approved by the Board based on the recommendation of the NRC, are set out below:

Particulars	Terms and Conditions
Period of Appointment	Two (2 consecutive years commencing from 15 th July, 2026 up to 14 th July 2028)
Designation	Whole-Time Director
Remuneration	₹ 49,22,400 per annum.
Annual Increment	Such increment as may be determined by the Board of Directors on the recommendation of the Nomination and Remuneration Committee, subject to applicable limits.
Benefits, Perquisites and Allowances	In addition to the remuneration, Dr. Ish Sharma shall be entitled to such perquisites, allowances and other benefits as may be determined by the Board of Directors from time to time, in accordance with the provisions of the Companies Act, 2013, read with Schedule V thereto, the rules made thereunder and the applicable policies of the Company.
Commission/Variable Pay	Dr. Ish Sharma may be paid such commission and/or variable remuneration as may be determined by the Board on the recommendation of the NRC, subject to the applicable provisions of the Act
Minimum Remuneration	Notwithstanding anything contained herein, where in any financial year during the tenure of Dr. Ish Sharma as Whole-Time Director, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to Dr. Ish Sharma in accordance with the applicable provisions of Schedule V to the Act, subject to such approvals as may be required.
Sitting Fees	Dr. Ish Sharma shall not be entitled to receive any sitting fees for attending meetings of the Board or Committees thereof.
Other Terms and Conditions	The terms and conditions of appointment and remuneration of Dr. Ish Sharma may be altered, varied, modified or revised by the Board on the recommendation of the NRC, from time to time, subject to the provisions of the Act, Schedule V thereto and other applicable laws.

The appointment and remuneration of Dr. Ish Sharma shall be subject to the provisions of Sections 196, 197, 198, 203 and other applicable provisions of the Act read with Schedule V thereto and the rules made thereunder.

Brief Profile:

Dr. Ish Sharma is a distinguished Ayurveda professional with over 20 years of experience in academics, research, healthcare administration, and clinical practice. He holds a BAMS degree, an M.D. and Ph.D. in Ayurveda, along with an MBA in Human Resource Management.

He has held several prestigious academic and administrative positions, including Academic Chair in Ayurveda Medicine at the University of Mauritius, Controller of Examinations at Guru Ravidas Ayurved University, Punjab, and Principal of Babeke Ayurveda Medical College, Punjab.

Dr. Ish Sharma has made significant contributions to the advancement and global promotion of Ayurveda through academic leadership, clinical research, international collaborations, and healthcare policy initiatives. He has authored books, published numerous research papers in reputed journals, led research projects, and received several national and international awards in recognition of his contributions to Ayurveda and integrative healthcare.

His extensive expertise in medical education, research, institutional administration, and healthcare management enables him to contribute effectively to strategic decision-making and corporate governance.

Disclosures and Consents Received:

Dr. Ish Sharma has confirmed that he is not disqualified from being appointed as a Director in terms of the provisions of Section 164(1) and Section 164(2) of the Act. He has provided his consent to act as Director in terms of Section 152 of the Act and has confirmed that he has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other statutory authority pursuant to the Circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited pertaining to enforcement of SEBI orders regarding appointment of Directors by listed companies.

The information required to be disclosed pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India and other applicable provisions of the Act, including brief profile, qualifications, experience, terms of appointment, remuneration details, shareholding and other directorships, is provided in **Annexure A** forming part of this Notice.

Except Dr. Ish Sharma and his relatives, to the extent of their shareholding, if any, in the Company, none of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 10 & 11 of this Notice.

The Board considers that the appointment of Dr. Ish Sharma as Whole-Time Director would be in the best interests of the Company and accordingly recommends the **Ordinary Resolution** set out at Item No. 10 & 11 of this Notice for approval by the Members.

ITEM NOS. 12 & 13

Appointment of Mr. Ankush Kaushal (DIN: 03308862) as Director and Whole-Time Director as well as Key Managerial Personnel of the Company

The Board of Directors of the Company ("Board"), at its meeting held on 15th July, 2026, based on the recommendation of the Nomination and Remuneration Committee ("NRC"), appointed Mr. Ankush Kaushal (DIN: 03308862) as an **Additional Director of the Company in the Executive category** with effect from 15th July, 2026, pursuant to the provisions of Section 161 of the Companies Act, 2013 ("Act") and the Articles of Association of the Company.

Pursuant to Section 161 of the Act, Mr. Ankush Kaushal holds office as an Additional Director up to the date of the ensuing Annual General Meeting and is eligible for appointment as a Director of the Company.

Accordingly, **Item No. 12** of the Notice seeks the approval of the Members for the appointment of Mr. Ankush Kaushal as a Director of the Company, liable to retire by rotation, in accordance with the provisions of Section 152 and other applicable provisions of the Act.

Further, at the aforesaid meeting, based on the recommendation of the NRC, the Board also approved the appointment of Mr. Ankush Kaushal as the **Whole-Time Director of the Company for a period of Two**

(2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028, subject to the approval of the Members of the Company.

Accordingly, **Item No. 13** of the Notice seeks the approval of the Members for the appointment of Mr. Ankush Kaushal as the **Whole-Time Director of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028**, pursuant to the provisions of Sections 196, 197, 198 and 203 of the Act read with Schedule V thereto and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Upon his appointment as Whole-Time Director, Mr. Ankush Kaushal shall also hold the position of Key Managerial Personnel of the Company in accordance with the applicable provisions of Section 2(51) read with Section 203 of the Act.

Recommendation of the Nomination and Remuneration Committee ('NRC') and the Board

The NRC, while considering the appointment of Mr. Ankush Kaushal, took into account his qualifications, professional experience, expertise, leadership capabilities, understanding of the Company's business operations, strategic vision, skills and knowledge, as well as the responsibilities entrusted to him and his contribution towards the Company's growth and development. The NRC also considered the prevailing industry practices, remuneration levels for similar positions and the Company's Nomination and Remuneration Policy.

The Board, based on the recommendation of the NRC, is of the opinion that Mr. Ankush Kaushal possesses the requisite qualifications, experience, expertise, skills, capabilities and integrity required for the positions proposed to be held by him. The Board believes that his leadership, expertise and experience would contribute significantly towards strengthening the Company's business operations, governance framework and long-term strategic objectives.

The NRC and the Board have accordingly recommended the appointment of Mr. Ankush Kaushal as a Director of the Company, liable to retire by rotation, and further as the Whole-Time Director of the Company for a period of Two (2) consecutive years commencing from 15th July, 2026 up to 14th July, 2028, on the terms and conditions, including remuneration, perquisites and other benefits, as set out in the Explanatory Statement annexed to this Notice.

Brief Profile:

Mr. Ankush Kaushal is a seasoned business leader with over 26 years of experience across the hospitality, healthcare, wellness, and business transformation sectors. He has extensive expertise in corporate strategy, business development, operational excellence, organizational transformation, and brand building.

During his distinguished career, he has held senior leadership positions with reputed national and international organizations in the hospitality and healthcare industries, where he successfully led business expansion, operational improvement, premium brand development, and strategic growth initiatives. He has played a key role in driving organizational transformation, enhancing customer experience, improving operational efficiency, and building high-performing teams.

Mr. Kaushal possesses significant experience in strategic planning, healthcare and wellness expansion, hospital operations, business process optimization, revenue growth, stakeholder management, and leadership development.

His extensive industry knowledge and leadership capabilities enable him to contribute effectively to the Company's strategic growth, operational excellence, and corporate governance.

Skills, Expertise and Competencies:

Mr. Ankush Kaushal possesses Hospitality, healthcare operations and business transformation expertise supporting the Company's expansion and operational excellence. The Board is of the view that Mr. Kaushal fulfils the conditions specified under the Act, the Rules made thereunder.

The main terms and conditions of appointment and remuneration of Mr. Ankush Kaushal, as approved by the Board on the recommendation of the NRC, are set out below:

Particulars	Terms and Conditions
Period of Appointment	Two (2 consecutive years commencing from 15 th July, 2026 up to 14 th July 2028
Designation	Whole-Time Director
Remuneration	₹ 65,02,800 per annum.
Annual Increment	Such increment as may be determined by the Board of Directors on the recommendation of the Nomination and Remuneration Committee, subject to applicable limits.
Benefits, Perquisites and Allowances	In addition to the remuneration, Mr. Ankush Kaushal shall be entitled to such perquisites, allowances and other benefits as may be determined by the Board of Directors from time to time, in accordance with the provisions of the Companies Act, 2013, read with Schedule V thereto, the rules made thereunder and the applicable policies of the Company.
Commission/Variable Pay	Mr. Ankush Kaushal may be paid such commission and/or variable remuneration as may be determined by the Board on the recommendation of the NRC, subject to the applicable provisions of the Act
Minimum Remuneration	Notwithstanding anything contained herein, where in any financial year during the tenure of Mr. Ankush Kaushal as Whole-Time Director, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to Mr. Ankush Kaushal in accordance with the applicable provisions of Schedule V to the Act, subject to such approvals as may be required.
Sitting Fees	Mr. Ankush Kaushal shall not be entitled to receive any sitting fees for attending meetings of the Board or Committees thereof.
Other Terms and Conditions	The terms and conditions of appointment and remuneration of Mr. Ankush Kaushal may be altered, varied, modified or revised by the Board on the recommendation of the NRC, from time to time, subject to the provisions of the Act, Schedule V thereto and other applicable laws.

Disclosures and Consents Received:

Mr. Ankush Kaushal has confirmed that he is not disqualified from being appointed as a Director in terms of the provisions of Section 164(1) and Section 164(2) of the Act. He has provided his consent to act as Director in terms of Section 152 of the Act and has confirmed that he has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other statutory authority pursuant to the Circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited pertaining to enforcement of SEBI orders regarding appointment of Directors by listed companies.

The information required to be disclosed pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India and other applicable provisions of the Act, including brief profile, qualifications, experience, terms of appointment, remuneration details, shareholding and other directorships, is provided in **Annexure A** forming part of this Notice.

Except Mr. Ankush Kaushal and his relatives, to the extent of their shareholding, if any, in the Company, none of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 12 & 13 of this Notice.

The Board considers that the appointment of Mr. Ankush Kaushal as Whole-Time Director would be in the best interests of the Company and accordingly recommends the **Ordinary Resolution** set out at Item No. 12 & 13 of this Notice for approval by the Members.

ITEM NO. 14

Approval to advance loans/give guarantees/ provide securities under Section 185 of the Companies Act, 2013

Background:

Pursuant to the provisions of Section 185 of the Companies Act, 2013 ("the Act"), as amended, a company may advance any loan, including any loan represented by a book debt, or give any guarantee or provide any security in connection

with any loan taken by any entity covered under the category of "a person in whom any of the Directors of the Company is interested", as specified in the Explanation to Section 185(2) of the Act, subject to the prior approval of the Members by way of a Special Resolution.

Purpose and Rationale:

In the ordinary course of its business, the Company may, from time to time, provide financial assistance by way of loans, guarantees and/or securities to its subsidiaries, associate companies, joint ventures, sister concerns and other entities for meeting their business requirements, working capital requirements, capital expenditure, strategic investments, business expansion and other lawful corporate purposes. Certain such entities may fall within the ambit of Section 185(2) of the Act.

Accordingly, in order to facilitate timely financial support to such entities and to enable the Company to respond efficiently to future business opportunities, the approval of the Members is being sought to authorise the Board of Directors of the Company to advance loans (including loans represented by book debts), give guarantees and/or provide securities, from time to time, in one or more tranches, to any person or entity covered under Section 185(2) of the Act, up

to an aggregate outstanding limit not exceeding **₹ 100 Crore (Rupees One Hundred Crore only)** at any point of time, on such terms and conditions, including the rate of interest, tenure and security, as the Board may consider appropriate and in the best interests of the Company.

The Board shall ensure that all loans, guarantees and securities are provided in compliance with the applicable provisions of the Companies Act, 2013 and other applicable laws. The financial assistance shall be extended only for the principal business activities of the borrowing entity and after due evaluation of the business requirements, financial position and creditworthiness of such entity.

The proposed authorization is intended to provide operational flexibility to the Company in supporting its subsidiaries, associate companies, joint ventures, sister concerns and other eligible entities and to facilitate efficient deployment of financial resources in furtherance of the Company's business objectives and long-term strategic growth.

The Audit Committee has reviewed and recommended the proposal, and the Board of Directors, at its meeting held on **31 August, 2026**, approved the same, subject to the approval of the Members by way of a Special Resolution.

The disclosures required under the proviso to Section 185(2) of the Act are set out below:

Particulars	Details
Nature of transaction	Grant of loans (including loans represented by book debts), giving of guarantees and/or provision of securities.
Persons/Entities covered	Grant of loans (including loans represented by book debts), giving of guarantees and/or provision of securities. Subsidiaries, associate companies, joint ventures, sister concerns and/or any other person or entity covered under the Explanation to Section 185(2) of the Companies Act, 2013 including but not limited to: 1. Jeena Green Resources Private Limited 2. Jeena Sikho International LLC 3. Jeena Sikho Foundation & Shuddhi Green Charcoal Pvt Ltd
Aggregate limit	Up to ₹ 100 Crore (Rupees One Hundred Crore only) outstanding at any point of time.
Purpose of utilisation	Working capital requirements, capital expenditure, business expansion, strategic investments and other principal business activities of the borrowing entity.
Terms and conditions	As may be determined by the Board of Directors from time to time, having regard to the business requirements and in the best interests of the Company.

Except to the extent of their directorships, shareholding or other interest, if any, in the entities that may receive such loans, guarantees or securities, none of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the proposed resolution.

The Board of Directors recommends the Special Resolution set out at **Item No. 14** of the accompanying Notice for approval of the Members.

ITEM NO. 15**Approval for loans, guarantees, securities and investments under Section 186 of the Companies Act, 2013****Background:**

The Company, as part of its business operations, growth strategy and long-term objectives, may be required to deploy its surplus funds, make strategic investments, provide financial assistance, grant loans, provide guarantees or securities and support business requirements of various entities, including but not limited to its subsidiaries, associates, joint ventures, sister concerns, group companies and other bodies corporate or persons, from time to time.

Pursuant to the provisions of Section 186(2) of the Companies Act, 2013 ('Act'), the Company shall not directly or indirectly:

- (a) Give any loan to any person or other body corporate;
- (b) Give any guarantee or provide security in connection with a loan to any other body corporate or person; and
- (c) Acquire by way of subscription, purchase or otherwise, the securities of any other body corporate.

exceeding sixty percent (60%) of its paid-up share capital, free reserves and securities premium account or one hundred percent (100%) of its free reserves and securities premium account, whichever is higher.

However, in case such transactions exceed the prescribed limits, prior approval of shareholders by way of a special resolution is required.

Further, pursuant to the provisions of Section 186(3) of the Act, where the giving of any loan or guarantee, providing any security or acquisition of securities exceeds the limits specified under Section 186(2) of the Act, prior approval of the Members by way of a Special Resolution is required.

Further, in terms of Rule 11(1) of the Companies (Meetings of Board and its Powers) Rules, 2014, where a loan or guarantee

is given or security has been provided by a company to its wholly-owned subsidiary or a joint venture, or where acquisition is made by a holding company by way of subscription, purchase or otherwise of the securities of its wholly-owned subsidiary, the requirement of obtaining prior approval of the Members under Section 186(3) of the Act shall not apply. However, such transactions shall be reckoned for the purpose of computing the overall limits prescribed under Section 186 of the Act.

Accordingly, considering the future business requirements, strategic opportunities and efficient deployment of surplus funds, approval of the Members is sought to authorise the Board of Directors of the Company to make investments, grant loans, provide guarantees and/or securities, whether by way of one or more transactions, up to an aggregate outstanding limit of **₹ 700 Crore (Rupees Seven Hundred Crore only)** at any point of time, notwithstanding that such investments, loans, guarantees and/or securities may exceed the limits prescribed under Section 186(2) of the Act.

The proposed authorisation will enable the Company to efficiently deploy its financial resources, undertake strategic investments, support business expansion, meet funding requirements and capitalise on business opportunities as may arise from time to time.

The Board of Directors shall evaluate each proposal on its commercial merits and shall ensure that all such transactions are undertaken in accordance with the applicable provisions of the Companies Act, 2013, the rules made thereunder and other applicable laws.

The terms and conditions of such investments, loans, guarantees and/or securities, including the recipient(s), amount, tenure, interest rate, security and other commercial terms, shall be determined by the Board of Directors from time to time, considering the best interests of the Company.

The Audit Committee has reviewed and recommended the proposal, and the Board of Directors at its meeting held on **31 August, 2026** approved the same, subject to the approval of the Members by way of a Special Resolution.

The disclosures as required under Section 186 of the Act and Section 102 of the Act are as follows:

Particulars	Details
Nature of transaction	Making investments, granting loans, providing guarantees and/or securities
Category of recipients	Any person(s), body corporate(s) or other eligible entity(ies), whether in India or outside India, as permitted under applicable law
Maximum limit	₹700 Crore (Rupees Seven Hundred Crore only) outstanding at any point of time
Purpose	Strategic investments, business expansion, treasury management, financial assistance, deployment of surplus funds and other business purposes
Authority sought	Authorisation to the Board of Directors to determine the recipient(s), amount, timing, terms, conditions and manner of such transactions

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the proposed resolution, except to the extent of their shareholding, if any, in the Company.

The Board of Directors recommends the **Special Resolution** set out at **Item No. 15** of the accompanying Notice for approval of the Members.

Annexure A

DETAILS OF DIRECTOR SEEKING SHAREHOLDERS APPROVAL FOR APPOINTMENT/RE-APPOINTMENT PURSUANT TO REGULATION 36 (3) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH CLAUSE 1.2.5 OF SECRETARIAL STANDARD SS- 2 ON GENERAL MEETINGS

Mr. Karan Vir Bindra (Independent Director)

Name of Director	Mr. Karan Vir Bindra
DIN	09283623
Category/Designation	Non-Executive Independent Director
Date of Birth (Age)	27 th September 1987 (38 years)
Date of First Appointment on the Board	25.08.2021
Qualification	Fellow Member of the Institute of Company Secretaries of India (FCS), LL.B., B.Com.
Experience (in years)	More than 12 years in corporate laws, corporate governance and regulatory advisory
Area of Expertise	Corporate, legal and regulatory matters
Brief Resume/Profile	Mr. Karan Vir Bindra (DIN: 09283623) is a Non-Executive Independent Director of Jeena Sikho Lifecare Limited. He is a Fellow Member of the Institute of Company Secretaries of India (FCS) and holds a Bachelor's degree in Law (LL.B.) and a Bachelor's degree in Commerce. He brings more than 12 years of professional experience in corporate laws, secretarial compliance, corporate governance, regulatory advisory, and compliance management. He is a practicing Company Secretary and the proprietor of M/s K. V. Bindra & Associates, providing advisory services in areas relating to corporate compliance, securities laws, governance matters, FEMA, and regulatory requirements. Over the years, Mr. Bindra has advised various listed and unlisted companies on matters relating to statutory compliances, corporate governance frameworks, regulatory filings, and corporate law matters. His extensive knowledge and experience in governance and regulatory affairs enable him to provide valuable guidance to the Board in strengthening compliance practices, enhancing governance standards, and ensuring adherence to applicable statutory requirements.
Terms and Conditions of Appointment/Re-appointment	Re-appointment as an Independent Director for a second term of five (5) consecutive years commencing from August 25, 2026 up to August 24, 2031, not liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	₹ 15000/- for attending the meeting of board and committees thereof.
Remuneration sought to be paid	Eligible for sitting fees for attending meetings of the Board and Committees, as approved by the Board. In line with the internal guidelines of the Company, no payment is made towards Commission to the Non-Executive Directors of the Company
Relationship with other Directors/KMP	None
Shareholding in the Company	NIL
No. of Board Meetings attended during FY 2025-26	17
Directorships held in other companies (excluding foreign companies and Section 8 companies)	Bulls Eye Knowledge Systems Limited, Astonea Labs Limited, Kapedome Enterprises Limited
Chairmanship/ Membership of Committees of the Board of this Company	Audit Committee: Member Nomination & Remuneration Committee: Chairperson Corporate Social Responsibility Committee: Chairperson

Mr. Karan Vir Bindra (Independent Director) (Contd.)

Chairmanship/ Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	Audit Committee: Chairperson Stakeholders' Relationship Committee: Member
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/ Competencies identified by the Board for the role	Corporate laws, corporate governance and regulatory compliance, enabling him to provide objective oversight and independent judgement to the Board
Confirmation of meeting criteria of independence (Section 149(6) of the Act and Regulation 16(1) (b) of the SEBI Listing Regulations)	Mr. Karan Vir Bindra has confirmed that he meets the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI Listing Regulations and is independent of the management of the Company.
Registration with Independent Directors' Databank (IICA), pursuant to Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014	Mr. Karan Vir Bindra has registered himself with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs (IICA), in accordance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

Mrs. Bhavna Grover (Whole time Director)

Name of Director	Mrs. Bhavna Grover
DIN	07557913
Category/Designation	Whole-time Director (Executive)
Date of Birth (Age)	5 th June 1975 (51 years)
Date of First Appointment on the Board	25.08.2021
Qualification	Graduate in Arts
Experience (in years)	More than 24 years in finance, administration and human resources
Area of Expertise	Finance, human resources, administration and Organizational management
Brief Resume/Profile	Mrs. Bhavna Grover is the Whole-Time Director of the Company and has been associated with the Board of Jeena Sikho Lifecare Limited since its incorporation. She brings experience in human resource management, legal administration, finance, and organizational processes. Over the years, she has played an important role in managing and strengthening the Company's internal systems, financial planning processes, administrative frameworks, and operational controls. Her focus on process improvement, compliance, and effective resource management has contributed to the Company's operational stability, governance practices, and sustainable growth.
Terms and Conditions of Appointment/Re-appointment	Re-appointment as Whole-time Director for a further period of five (5) consecutive years commencing from 25 August, 2026 up to 24 August, 2031, liable to retire by rotation

Mrs. Bhavna Grover (Whole time Director) (Contd.)

Remuneration last drawn (including sitting fees, if any)	₹1,80,00,000/- per annum (Rupees One Crore Eighty Lakh only)
Remuneration sought to be paid	₹1,80,00,000/- per annum (Rupees One Crore Eighty Lakh only)
Relationship with other Directors/KMP	Mrs. Bhavna Grover is the spouse of Mr. Manish Grover, Managing Director of the Company, and the mother of Ms. Shreya Grover, Whole-time Director of the Company. Mr. Manish Grover and Mrs. Bhavna Grover have been serving on the Board since the incorporation of the Company and are Promoters of the Company.
Shareholding in the Company	2,43,000 Equity Shares
No. of Board Meetings attended during FY 2025-26	17
Directorships held in other companies (excluding foreign companies and Section 8 companies)	Jeena Sikho Foundation, Shuddhi Lifecare Private Limited, Dupont Clean Biofuels LLP
Chairmanship/Membership of Committees of the Board of this Company	Stakeholder Relationship Committee: Member Corporate Social Responsibility Committee: Member Risk Management Committee: Member
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Finance, administration, HR and operational management, enabling her to strengthen the Company's governance, internal controls and business operations

Mr. Manish Grover (Managing director)

Name of Director	Mr. Manish Grover
DIN	07557886
Category/Designation	Managing Director (Executive)
Date of Birth (Age)	6 th May 1974 (52 years)
Date of First Appointment on the Board	25.08.2021
Qualification	B.COM and Honorary Doctorate in Ayurveda & Naturopathy
Experience (in years)	More than 30 years in Ayurveda, healthcare and wellness management
Area of Expertise	Ayurveda, healthcare management, preventive healthcare, wellness and strategic leadership
Brief Resume/Profile	Mr. Manish Grover is the Managing Director of Jeena Sikho Lifecare Limited and the founder of Shuddhi Ayurveda. He is an entrepreneur and healthcare professional having experience in the Ayurvedic healthcare sector. He has dedicated his professional journey to the revival and promotion of traditional Ayurvedic wisdom and preventive healthcare practices in India. With a focused mission to address the root causes of chronic and lifestyle-related diseases through natural and integrative therapies.

Mr. Manish Grover (Managing director) (Contd.)

	Since commencing his professional journey in 2009, Mr. Grover has been actively involved in promoting Ayurveda, preventive healthcare, and holistic wellness practices. He has played a significant role in establishing and expanding the Company's healthcare ecosystem, including the growth of Shuddhi Ayurveda and HIMS (Hospital & Institute of Integrated Medical Sciences), with a focus on integrating Ayurveda, lifestyle management, yoga, and wellness practices. Under his leadership, the Company has expanded its presence in the Ayurvedic healthcare segment and developed a structured healthcare ecosystem supported by a team of healthcare professionals, including doctors and researchers, engaged in advancing Ayurvedic treatment approaches through clinical experience and research-based practices. His areas of expertise include Ayurvedic healthcare, preventive wellness, lifestyle management, healthcare operations, business strategy, and organizational leadership. He continues to contribute towards strengthening the Company's vision of providing holistic and integrative healthcare solutions.
Terms and Conditions of Appointment/ Re-appointment	Re-appointment as Managing Director for a further term of five (5) consecutive years commencing from 25 August, 2026 up to 24 August, 2031, liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	₹ 2,40,00,000 per annum (Rupees Two Crore Forty Lakh only)
Remuneration sought to be paid	₹ 6,00,00,000 per annum (Rupees Six Crores only)
Relationship with other Directors/KMP	Mr. Manish Grover is the spouse of Mrs. Bhavna Grover, Whole-time Director of the Company, and the father of Ms. Shreya Grover, Whole-time Director of the Company. Mr. Manish Grover and Mrs. Bhavna Grover have been serving on the Board since the incorporation of the Company and are Promoters of the Company
Shareholding in the Company	78,64,190 Equity Shares
No. of Board Meetings attended during FY 2025-26	17
Directorships held in other companies (excluding foreign companies and Section 8 companies)	Jeena Green Resources Private Limited, CSAIPL AIF Fund Management Private Limited, Shuddhi Lifecare Private Limited, Jeena Sikho Foundation, DVM Goa Developers Associates Private Limited, Shuddhi Green Charcoal Private Limited, Ayush Bharti Foundation, Dupont Clean Biofuels LLP
Chairmanship/Membership of Committees of the Board of this Company	Audit Committee: Member Stakeholder Relationship Committee: Member Corporate Social Responsibility Committee: Member Risk Management Committee: Member
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Healthcare and Ayurveda business leadership, strategic decision-making and sustainable growth planning

Mr. Ajay Sharma (Independent Director)

Name of Director	Mr. Ajay Sharma
DIN	07671350
Category/Designation	Non-Executive Independent Director
Date of Birth (Age)	25 th March 1981 (45 years)

Mr. Ajay Sharma (Independent Director) (Contd.)

Date of First Appointment on the Board	15.07.2026
Qualification	B.A. (Hospitality Management), Australia
Experience (in years)	More than 25 years in hospitality, real estate, finance and travel
Area of Expertise	Hospitality, real estate, business strategy, finance and travel
Brief Resume/Profile	Mr. Ajay Sharma holds a Bachelor's degree in Humanities (B.A.) and has pursued Hospitality Management studies in Australia. He possesses over 25 years of diverse professional experience spanning real estate, hospitality, finance, and travel. He is an accomplished business leader and real estate consultant with extensive expertise in property advisory, business management, client relationship management, and strategic leadership. Over the course of his career, he has successfully led and managed businesses in the hospitality, travel, and finance sectors, both in India and Australia. His broad industry exposure, entrepreneurial acumen, and strong leadership capabilities enable him to contribute effectively to business growth, corporate governance, and strategic decision-making.
Terms and Conditions of Appointment/ Re-appointment	Appointment as a Non-Executive Independent Director for a term of two (2) consecutive years commencing from 15 th July, 2026 up to 14 th July, 2028, not liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	Not Applicable
Remuneration sought to be paid	Eligible for sitting fees for attending meetings of the Board and Committees, as approved by the Board
Relationship with other Directors/KMP	Not Applicable
Shareholding in the Company	NIL
No. of Board Meetings attended during FY 2025-26	Not Applicable (appointed during FY 2026-27)
Directorships held in other companies (excluding foreign companies and Section 8 companies)	Netzwerk Wagen Private Limited
Chairmanship/Membership of Committees of the Board of this Company	Chairman: NIL Member: NIL
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	Chairman: NIL Member: NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Hospitality, real estate and finance-driven strategic insight into business development and operational excellence
Confirmation of meeting criteria of independence (Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations)	Mr. Ajay Sharma has confirmed that he meets the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI Listing Regulations and is independent of the management of the Company.
Registration with Independent Directors' Databank (IICA), pursuant to Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014	Mr. Ajay Sharma has registered himself with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs (IICA), in accordance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

Mrs. Sapna Singh (Independent director)

Name of Director	Mrs. Sapna Singh
DIN	11812894
Category/Designation	Non-Executive Woman Independent Director
Date of Birth (Age)	19 th August 1980 (45 years)
Date of First Appointment on the Board	15.07.2026
Qualification	Bachelor of Education (B.Ed.) from CMJ University, Meghalaya, and Bachelor of Arts from Panjab University
Experience (in years)	More than 5 years in customer relationship management and team leadership
Area of Expertise	Customer service operations, team management and training & development
Brief Resume/Profile	Mrs. Sapna Singh was appointed as an Additional Director (Non-Executive Woman Independent Director) of the Company with effect from 15 th July, 2026. She holds a Bachelor of Education (B.Ed.) from CMJ University, Meghalaya, and a Bachelor of Arts from Panjab University. She has over five years of experience in customer service operations and team management. Over the course of her career, she has developed expertise in team leadership, customer relationship management, performance monitoring, training and development, and grievance handling. She is known for her strong organizational and interpersonal skills, effective people management, and commitment to operational excellence and service quality.
Terms and Conditions of Appointment/ Re-appointment	Appointment as a Non-Executive Woman Independent Director for a term of two (2) consecutive years commencing from 15 th July, 2026 up to 14 th July, 2028, not liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	Not Applicable
Remuneration sought to be paid	Eligible for sitting fees for attending meetings of the Board and Committees, as approved by the Board
Relationship with other Directors/KMP	Not Applicable
Shareholding in the Company	NIL
No. of Board Meetings attended during FY 2025-26	Not Applicable (appointed during FY 2026-27)
Directorships held in other companies (excluding foreign companies and Section 8 companies)	NIL
Chairmanship/Membership of Committees of the Board of this Company	Chairman: NIL Member: NIL
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	Chairman: NIL Member: NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Customer relationship management, service operations and people management, strengthening customer-centric governance
Confirmation of meeting criteria of independence (Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations)	Mrs. Sapna Singh has confirmed that she meets the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI Listing Regulations and is independent of the management of the Company.
Registration with Independent Directors' Databank (IICA), pursuant to Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014	Mrs. Sapna Singh has registered herself with the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs (IICA), in accordance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

Dr. Ish Sharma (Whole time Director)

Name of Director	Dr. Ish Sharma
DIN	11815526
Category/Designation	Whole-time Director (Executive)
Date of Birth (Age)	21 st December 1970 (55 years)
Date of First Appointment on the Board	15.07.2026
Qualification	BAMS, M.D. (Ayurveda), Ph.D. (Ayurveda), MBA (HR)
Experience (in years)	More than 20 years in academics, healthcare administration, clinical practice and research
Area of Expertise	Ayurveda, clinical research, medical education, healthcare administration and institutional leadership
Brief Resume/Profile	Dr. Ish Sharma was appointed as an Additional Director and Whole-time Director of the Company with effect from 15th July, 2026. He is a distinguished Ayurveda professional with over 20 years of experience in academics, research, healthcare administration, and clinical practice. He holds a BAMS degree, an M.D. and Ph.D. in Ayurveda, along with an MBA in Human Resource Management. He has held several prestigious academic and administrative positions, including Academic Chair in Ayurveda Medicine at the University of Mauritius, Controller of Examinations at Guru Ravidas Ayurved University, Punjab, and Principal of Babeke Ayurveda Medical College, Punjab. Dr. Ish Sharma has made significant contributions to the advancement and global promotion of Ayurveda through academic leadership, clinical research, international collaborations, and healthcare policy initiatives. He has authored books, published numerous research papers in reputed journals, led research projects, and received several national and international awards in recognition of his contributions to Ayurveda and integrative healthcare. His extensive expertise in medical education, research, institutional administration, and healthcare management enables him to contribute effectively to strategic decision-making and corporate governance.
Terms and Conditions of Appointment/ Re-appointment	Appointment as Whole-time Director for a period of two (2) consecutive years commencing from 15 th July, 2026 up to 14 th July, 2028, liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	Not Applicable
Remuneration sought to be paid	₹49,22,400/- per annum (Rupees Forty Nine Lakhs Twenty Two Thousand and Four Hundred Only)
Relationship with other Directors/KMP	Not Applicable
Shareholding in the Company	NIL
No. of Board Meetings attended during FY 2025-26	Not Applicable (appointed during FY 2026-27)
Directorships held in other companies (excluding foreign companies and Section 8 companies)	NIL
Chairmanship/Membership of Committees of the Board of this Company	Chairman: NIL Member: NIL
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	Chairman: NIL Member: NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Academic, clinical research and healthcare administration expertise supporting the Company's healthcare and research initiatives

Mr. Ankush Kaushal (Whole time Director)

Name of Director	Mr. Ankush Kaushal
DIN	03308862
Category/Designation	Whole-time Director (Executive)
Date of Birth (Age)	22 nd August 1983 (42 years)
Date of First Appointment on the Board	15.07.2026
Qualification	B.Sc. (Hotel & Hospitality Management)
Experience (in years)	More than 26 years in hospitality, healthcare and business transformation
Area of Expertise	Business strategy, healthcare operations, hospitality, organisational transformation and corporate governance
Brief Resume/Profile	Mr. Ankush Kaushal was appointed as an Additional Director and Whole-time Director of the Company with effect from 15th July, 2026. He is a seasoned business leader with over 26 years of experience across the hospitality, healthcare, wellness, and business transformation sectors. He has extensive expertise in corporate strategy, business development, operational excellence, organizational transformation, and brand building. During his distinguished career, he has held senior leadership positions with reputed national and international organizations in the hospitality and healthcare industries, where he successfully led business expansion, operational improvement, premium brand development, and strategic growth initiatives. He has played a key role in driving organizational transformation, enhancing customer experience, improving operational efficiency, and building high-performing teams. Mr. Kaushal possesses significant experience in strategic planning, healthcare and wellness expansion, hospital operations, business process optimization, revenue growth, stakeholder management, and leadership development. His extensive industry knowledge and leadership capabilities enable him to contribute effectively to the Company's strategic growth, operational excellence, and corporate governance.
Terms and Conditions of Appointment/ Re-appointment	Appointment as Whole-time Director for a period of two (2) consecutive years commencing from 15 th July, 2026 up to 14 th July, 2028, liable to retire by rotation
Remuneration last drawn (including sitting fees, if any)	Not Applicable
Remuneration sought to be paid	₹65,02,800/- per annum (Rupees Sixty Five Lakhs Two Thousand Eight Hundred Only)
Relationship with other Directors/KMP	Not Applicable
Shareholding in the Company	NIL
No. of Board Meetings attended during FY 2025-26	Not Applicable (appointed during FY 2026-27)
Directorships held in other companies (excluding foreign companies and Section 8 companies)	NIL
Chairmanship/Membership of Committees of the Board of this Company	Chairman: NIL Member: NIL
Chairmanship/Membership of Committees of other companies (Audit Committee and Stakeholders' Relationship Committee only, per Regulation 26 of the SEBI Listing Regulations)	Chairman: NIL Member: NIL
Listed entities from which the Director has resigned in the past three years	NIL
Skills/Expertise/Competencies identified by the Board for the role	Hospitality, healthcare operations and business transformation expertise supporting the Company's expansion and operational excellence

Annexure B

Form No. MGT-11

Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: L52601PB2017PLCO46545

NAME OF THE COMPANY: JEENA SIKHO LIFECARE LIMITED

REGISTERED OFFICE: SCO 11 First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab-140604

VENUE FOR MEETING:

Name of the members (s):

Registered address:

E-Mail Id:

Folio No/Client Id:

DP ID:

I/We, being the member (s) of shares of the above-named company, hereby appoint

1. Name:

Address:

E-mail Id:

Signature:, or failing him.

2. Name:

Address:

E-mail Id:

Signature:, or failing him

3. Name:

Address:

E-mail Id:

Signature:

as my proxy to attend and vote (on a poll) for me and on my behalf at the 09th Annual General Meeting of the company to be held on **Monday, 28th September, 2026** at 12:00 Noon at **First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, Main Road, SAS Nagar, Punjab 140603** and at any adjournment thereof in respect of such resolutions as are indicated below:

S. No.	Resolution(s)	Vote	
		For	Against
1	To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended 31 st March, 2026, together with the Reports of the Board of Directors and the Statutory Auditors thereon		
2	To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended 31 st March, 2026, together with the Reports of the Board of Directors and the Statutory Auditors thereon		
3	To declare a final dividend of ₹₹ 4.50/- per equity share of face value of ₹2/- each for the financial year ended March 31, 2026.		
4	To reappoint Mrs. Bhavna Grover (DIN: 07557913) as the Whole-Time Director, who retires by rotation & being eligible, offers herself for re-appointment.		
5	To Reappoint of Mr. Karan Vir Bindra (DIN: 09283623) as an Independent Director of the Company		
6	To Reappoint Mrs. Bhavna Grover (DIN: 07557913) as a Whole-time Director and Key Managerial Personnel of the Company.		
7	To Reappoint Mr. Manish Grover (DIN: 07557886), as Managing Director and Key Managerial Personnel of the Company		
8	To Appoint Mr. Ajay Sharma (DIN: 07671350) as a Non-Executive Independent Director of the Company		
9	To Appoint Mrs. Sapna Singh (DIN: 11812894) as a Non-Executive Woman Independent Director of the Company		
10	To Appoint Dr. Ish Sharma (DIN: 11815526) as a Director of the Company		
11	To Appoint Dr. Ish Sharma (DIN: 11815526) as a Whole-Time Director and Key Managerial Personnel of the Company		
12	To Appoint Mr. Ankush Kaushal (DIN: 03308862) as a Director of the Company		
13	To Appoint Mr. Ankush Kaushal (DIN: 03308862) as a Whole-Time Director and Key Managerial Personnel of the Company		
14	To take approval of members for granting loan, giving guarantee and/or providing security to all person covered under Section 185 of the Companies Act, 2013		
15	To take approval for members for granting loans, giving guarantees or securities and making investments under Section 186 of the Companies Act, 2013		

Signed this _____ day of _____ 2026

Signature of shareholder: _____

Signature of Proxy holder(s) _____

Signature of the shareholder across the Revenue Stamp

Annexure C

PROFORMA FOR REGISTRATION/UP-DATION OF E-MAIL IDs

Date:

JEENA SIKHO LIFECARE LIMITED

SCO 11 First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab-140604

Folio No. _____

Dear Sirs,

Please register/up-date my/our e-mail ID for forwarding all official communications including the general meeting notices/ postal ballot notices/annual reports etc. of the Company through electronic mail.

My/our e-mail ID is as follows:

Email ID: _____

Name of the shareholder:

Address:

Signature of the sole/first holder

Annexure D

ATTENDANCE SLIP

09th Annual General Meeting of "JEENA SIKHO LIFECARE LIMITED"

Place of meeting: First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, Main Road, SAS Nagar, Punjab 140603

Reg. Folio: No. of Shares Held:

Full Name of Shareholder:

Full Name of Proxy/Authorised Representative:

Regd. Folio No.:

DP Id:

No. of Shares Held:

Client Id:

I hereby record my presence at the 09th Annual General Meeting of the Company held on **Monday, 28th September, 2026** at 12:00 Noon at First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, Main Road, SAS Nagar, Punjab 140603.

.....

Name of the member/Proxy/Authorised Representative

(In BLOCK LETTERS)


.....

Signature of member/Proxy/Authorised Representative

Note: Please fill in this attendance slip and hand it over at the venue.

*Strike out whichever is not applicable.

ROUTE MAP TO THE AGM VENUE



<https://maps.app.goo.gl/goYHBaqqtewg4Neh9>

JEENA SIKHO LIFECARE LIMITED

Venue: First Floor, Parle G Godown, City Enclave,
Back Side JP Hospital, Near Anand Complex,
Zirakpur, Main Road,
SAS Nagar, Punjab 140603

Nearest Landmark: Paras Down Town Square Mall,
Paras Down Town Square Mall The Golden Plaza Hotel,
Near, Ambala – Chandigarh Expy, Zirakpur, Punjab 140603

9th Annual General Meeting

28th Day of September, 2026, at 12:00 NOON.

Board Report

To,
The Members,

Your Directors have pleasure in presenting the 9th Annual Report on the business and operations of the Company, together with the audited standalone and consolidated financial statements for the financial year ended March 31, 2026 ("FY 2025-26").

FINANCIAL RESULTS

A summary of standalone and consolidated financial results of the Company for the Financial Year 2025-26 and Financial Year 2024-25 is as follows:

Particulars	Standalone		Consolidated	
	FY 2025-2026	FY 2024-2025	FY 2025-2026	FY 2024-2025
Revenue from Operations	80,134.64	46,907.19	80,136.39	46,907.19
Other Income	865.89	673.54	849.61	673.54
Total Income	81,000.53	47,580.73	80,986.00	47,580.73
Less: Expenses				
Cost of material consumed	-	-	-	-
Purchase of Stock in Trade	10,011.39	5,857.99	10,020.21	5,857.99
Changes in Inventories of Stock in Trade	(862.53)	(435.71)	(867.23)	(435.71)
Employee Benefit Expenses	14,840.48	10,074.28	14,840.48	10,074.28
Finance Cost	1,283.35	1,065.49	1,283.35	1,065.49
Depreciation and Amortization Expenses	4,757.82	2,910.54	4,769.20	2,910.54
Other Expenses	21,182.55	17,350.38	21,200.64	17,350.38
Total Expenses	51,213.06	36,822.97	51,246.65	36,822.97
Profit before exceptional and extraordinary items and tax	29,787.47	10,757.76	29,739.35	10,757.76
Exceptional and Extraordinary items				
Profit Before Tax	29,787.47	10,757.76	29,739.35	10,757.76
Tax Expenses	7,569.90	2,763.43	7,569.54	2,763.43
Net Profit for the Year	22,217.57	7,994.33	22,169.81	7,994.33
Total other Comprehensive Income for the year	22,276.70	7,992.58	22,229.26	7,992.58

FINANCIAL PERFORMANCE

STANDALONE:

During the current period, your company has shown an increase in total income of ₹ 81,000.53 Lakhs as against ₹ 47,580.73 Lakhs in the previous year on standalone basis. The Company has earned a net profit of ₹ 22,217.57 Lakhs as compared to a profit of ₹ 7,994.33 Lakhs in the previous year on standalone basis. The company will continue to pursue expansion in the domestic market, to achieve sustained and profitable growth.

CONSOLIDATED:

During the current period, your company has shown an increase in total income of ₹ 80,986.00 Lakhs as against ₹ 47,580.73 Lakhs in the previous year on consolidated basis. The Company has earned a net profit of ₹ 22,169.81 Lakhs as compared to a profit of ₹ 7,994.33 Lakhs in the previous year on consolidated basis. The company will continue to pursue expansion in the domestic market, to achieve sustained and profitable growth.

Any member intending to have a copy of Balance Sheet and other Financial Statement of these Companies shall be made available on the website of the Company at www.jeenasikho.com.

It shall also be kept for inspection during business hours by any shareholder in the registered office of the Company.

SHARE CAPITAL

Authorised Share Capital

As on March 31, 2026, the Authorised Share Capital of the Company stood at ₹ 25,00,00,000/- (Rupees Twenty-Five Crores Only) divided into 12,50,00,000 (Twelve Crores Fifty Lakhs) Equity Shares of ₹. 2/- (Rupees Two) each.

During the financial year under review, pursuant to the approval of the Members through Postal Ballot on **May 23, 2025**, the Company subdivided its equity shares from 1 **(One) equity share of face value ₹ 10/- each into 5 (Five) equity shares of face value ₹ 2/- each**. The Record Date for the purpose of the sub-division was June 12, 2025.

Consequent to the aforesaid sub-division, the authorised share capital of the Company was reclassified into equity shares of face value of ₹2/- each without any change in the aggregate amount of the authorised share capital.

Paid Up Share Capital

As on March 31, 2026, the Paid-up Share Capital of the Company stood at ₹. 24,86,01,460/- (Rupees Twenty-Four Crores Eighty-Six Lakhs One Thousand Four Hundred and Sixty) divided into 12,43,00,730 (Twelve Crore Forty-Three Lakh Seven Hundred Thirty) equity shares of ₹ 2/- (Rupees Two only) each.

During the financial year under review, pursuant to the approval of the Members through Postal Ballot on May 23, 2025, the Company subdivided its equity shares from **1 (One) equity share of face value ₹ 10/- each into 5 (Five) equity shares of face value ₹ 2/- each**. The Record Date for the purpose of the sub-division was June 12, 2025.

Consequent to the sub-division, the number of issued, subscribed and paid-up equity shares increased proportionately; however, the aggregate paid-up share capital of the Company and the percentage shareholding of each shareholder remained unchanged.

The Company has not issued any shares with differential voting rights, sweat equity shares or equity shares with differential rights during the Financial Year 2025-26.

MIGRATION FROM SME PLATFORM TO MAIN BOARD

Your Company was initially listed on the SME Emerge Platform of National Stock Exchange of India Limited (NSE) on **19th April, 2022**. During the year under review, with the continued trust and confidence of our valued shareholders and stakeholders, your Company successfully migrated to the Main Board of both **NSE and BSE Limited w.e.f. 11th August, 2025**.

The equity shares of the Company are presently listed and traded on the Main Board of NSE and BSE under the following details:

- NSE Symbol: JSLL
- BSE Scrip Code: 544476

The migration marks a significant milestone in the Company's growth journey, reflecting its consistent performance, strong corporate governance practices, and enhanced credibility in the capital markets. Listing on the Main Board will provide wider visibility, increased participation from institutional investors, enhanced liquidity for the Company's equity shares, and create greater long-term value for all stakeholders.

The Board places on record its sincere appreciation for the continuous support extended by shareholders, regulators, employees, and business partners in achieving this important step in the Company's growth trajectory.

DEMATERIALISATION OF EQUITY SHARES

All the Equity shares of the Company are in dematerialized form with either of the depositories viz NSDL and CDSL. The ISIN No. allotted to the company is **INEOJ5801029**.

DIVIDEND

Based on the Company's performance during the financial year 2025-26 and in line with the Dividend Distribution Policy of the Company, your directors are pleased to recommend a Dividend of **₹ 4.50/- per equity share** on the face value of ₹ 2/- each, fully paid-up, for the financial year ended March 31, 2026. The payment of dividend is subject to the approval of the Members at the ensuing Annual General Meeting ("AGM") and shall be subject to deduction of tax at source, as applicable.

As per the provisions of Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), your Company has formulated a Dividend Distribution Policy. This Policy is available on the https://jeenasikho.com/wp-content/uploads/2024/07/Dividend-Distribution-Policy_JSLL.pdf

TRANSFER OF UNCLAIMED DIVIDENDS/ SHARES TO INVESTOR EDUCATION & PROTECTION FUND AUTHORITY

Pursuant to Section 124 of the Companies Act, 2013, read with Investors Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, all unpaid or unclaimed dividends are required to be transferred by the Company to the Investors Education and Protection Fund (IEPF) established by the Central Government of India, after the completion of seven years. Further, all shares in respect of which dividend has not been paid or claimed for seven consecutive years or more shall also be required to be transferred by the Company to the Demat Account of the IEPF Authority.

There were no unclaimed dividends due for transfer to the IEPF during the financial year 2025-26.

TRANSFER TO GENERAL RESERVE

The Company has not transferred any amount to General Reserve during the year. The dividend payment is subject to approval of the members at the 9th Annual General Meeting, which will be paid, if declared, to the shareholders within 30 days from the date of declaration.

DEPOSITS

During the year under review, the Company has not accepted or renewed any deposit from the public/members falling within the ambit of section 73 or section 74 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

CORPORATE GOVERNANCE

The Company's business and operations are managed by a professional management team of managers led by the Managing Director, under the supervision and control of the Board of Directors. The Company maintains and adheres to the highest standards of corporate governance as stipulated by the Securities and Exchange Board of India ("SEBI") and the Companies Act, 2013.

A comprehensive report on Corporate Governance, as required under Regulation 34 of the SEBI Listing Regulations, forms part of this Annual Report. A certificate issued by Mr. Vivek Rawal, Proprietor of M/s Rawal & Co., Practicing Company Secretary, on compliance with the conditions of Corporate Governance is annexed as a part of this Annual Report.

MD AND CFO CERTIFICATION

As required by Regulation 17(8) of the SEBI (LODR) Regulations, 2015, the Managing Director and Chief Financial Officer of Jeena Sikho Lifecare Limited have furnished the requisite certificate for the financial year ended March 31, 2026, confirming the accuracy and integrity of the financial statements and compliance with applicable requirements.

A copy of such certificate forms part of Corporate Governance Report.

EMPLOYEES STOCK OPTION SCHEMES

Your Company believes in rewarding its employees and aligning their interests with the long-term objectives of the organization. Employee Stock Option Schemes form an integral part of the Company's retention and compensation strategy, enabling wealth creation opportunities for employees while ensuring their commitment towards sustained growth. In line with this philosophy, the shareholders of the Company approved the "Jeena Sikho Employees Stock Option Scheme 2024" at the Extraordinary General Meeting held on **27th February, 2024** and Jeena Sikho Employees Stock Option Scheme 2025 at the Annual General Meeting held on **29th September, 2025**.

Under the said Schemes, the Company grants stock options on an equity-settled basis, which entitle eligible employees to purchase one equity share of the Company for each option granted, at a pre-determined exercise price, upon completion of the vesting period. The ESOPs thus represent a call option providing a right, but not an obligation, to the employees to exercise such options by paying the exercise price.

During the financial year 2023-24, the Company granted **61,275 options** to its employees under Jeena Sikho Employees Stock Option Scheme 2024. Pursuant to the corporate action of share split, these options stand adjusted to **3,06,375 options**. No fresh grants were made under Jeena Sikho Employees Stock Option Scheme 2024 during the Financial Year 2025-26.

During the Financial Year 2025-26, the Company granted **2,18,875 (Two Lakh Eighteen Thousand Eight Hundred Seventy-Five) Employee Stock Options** to eligible employees under the Jeena Sikho Employees Stock Option Scheme, 2025, in accordance with the terms of the Scheme and the applicable provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The applicable disclosures pursuant to Regulation 14 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and Rule 12(9) of the Companies (Share Capital and Debentures) Rules, 2014, for the year ended **31st March, 2026** are available on the Company's website at www.jeenasikho.com.

There has been no material change in the Jeena Sikho Employees Stock Option Scheme 2024 and Jeena Sikho Employees Stock Option Scheme 2025 during the year and the Scheme continues to be in compliance with the aforesaid SEBI Regulations.

A certificate from the Secretarial Auditors of the Company confirming that the Scheme has been implemented in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the resolutions passed

by the Members, is also available on the Company's website at www.jeenasikho.com.

SUBSIDIARIES/ASSOCIATES/JOINT VENTURE

During the year under review, the Company expanded its corporate structure by incorporating its wholly-owned subsidiary, **Jeena Sikho International LLC**, under the Sharjah Media City (Shams) Free Zone Authority, United Arab Emirates. The said wholly-owned subsidiary was successfully incorporated and was granted a business licence to commence its operations under the name "Jeena Sikho International LLC" on **11th September, 2025**.

Accordingly, as at 31 March 2026, the Company had two subsidiaries, namely **Jeena Green Resources Private Limited** and Jeena Sikho International LLC, of which **Jeena Sikho International LLC** is a wholly owned subsidiary of the Company.

The Company did not have any associate company or joint venture company during the financial year under review.

In accordance with the provisions of Section 129 (3) of the Act read with the Companies (Accounts) Rules, 2014, a report on the performance and financial position of each subsidiary company is provided in the prescribed **Form AOC-1**, in **Annexure I** to this Report. In accordance with the provisions of Section 136 of the Act, the Annual Report of the Company, including the audited standalone and consolidated financial statements and related information of the Company are available on the Company's website at <https://jeenasikho.com/investors/>.

Further, the audited financial statements of the subsidiary companies are also available on the website of the Company at <https://jeenasikho.com/investors/>.

Further, the Company does not have any Material Subsidiary within the meaning of the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, during the financial year under review.

The Audit Committee and the Board review the financial statements and significant transactions of all subsidiary companies.

BOARD EVALUATION

Pursuant to the provisions of the Act and SEBI Listing Regulations, the Board of Directors adopted a formal mechanism for evaluating its performance as well as that of its committees and individual Directors, including the Chairperson of the Board. The evaluation was conducted using a structured questionnaire that covered various aspects of the functioning of the Board and its Committees.

The Board expressed satisfaction with the overall functioning of the Board and its Committees based on the evaluation results.

To familiarize Independent Directors with the Company, its stakeholders, leadership team, senior management, operations, policies and industry landscape, a familiarisation program is conducted. The program aims to provide an insight and understanding of the Company's business. Independent Directors are informed about their roles, rights, and responsibilities through a formal letter of appointment at the time of their appointment or re-appointment.

Further details regarding the annual evaluation of the performance of the Board, its Chairperson, its committees and individual Directors are provided in the Corporate Governance Report, which forms an integral part of this Report.

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis for the year, as stipulated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as the "SEBI Listing Regulations"), is presented in a separate section, forms part of the Annual Report.

DECLARATION OF INDEPENDENCE

Your Company has received declarations from all its Independent Directors, confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations. These declarations also affirm that there have been no changes in the circumstances affecting their status as Independent Directors of the Company.

The Board is of the opinion that the Independent Directors possess the requisite qualifications, experience, expertise and proficiency and they uphold the highest standards of integrity.

DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL WHO WERE APPOINTED OR HAVE RESIGNED DURING THE YEAR

Your Company believes that a strong Board is imperative to create a culture of leadership to provide a long-term vision and policy approach to improve the quality of governance. As on March 31, 2026, the Board of Directors of the Company consist of optimum combination of Executive Directors and Independent Directors of the Company.

Director Retiring by Rotation

Pursuant to Section 152 of the Companies Act, 2013, and the Articles of Association of the Company, Mrs. Bhavna Grover (DIN: 07557913), Whole Time Director, retires by rotation at the ensuing AGM of the Company and, being eligible, offers herself for re-appointment.

Accordingly, a resolution is included in the Notice of the 09th Annual General Meeting of the Company, seeking approval of members for her re-appointment as a Director of the Company.

Changes in the Board During the Financial Year 2025–26, the following changes took place in the composition of the Board of Directors of the Company:

- The designation of Ms. Shreya Grover (DIN: 09199495) was changed from Non-Executive Director to Whole-Time Director of the Company for a period of five (5) years with effect from 27th August, 2025. The said change was approved by the Board of Directors at its meeting held on 27th August, 2025 and subsequently approved by the Members of the Company in the Annual General Meeting held on 29th September, 2025, in accordance with the provisions of the Companies Act, 2013.

- Mrs. Priyanka Bansal (DIN: 09051665) was appointed as an Additional Director under the category of Independent Non-Executive Director of the Company by the Board of Directors with effect from 21st April, 2025 for a first term of five consecutive years commencing from 21st April, 2025 up to 20th April, 2030 (both days inclusive).

The appointment of Mrs. Priyanka Bansal as an Independent Director was subsequently approved by the Members of the Company through a Postal Ballot resolution passed on 23rd May, 2025.

Subsequent to the close of the financial year, the Board of Directors at its meeting held on 15th July, 2026, based on the recommendation of the Nomination and Remuneration Committee, approved the following appointments, subject to the approval of the shareholders wherever applicable:

- Mr. Ajay Sharma (DIN: 07671350) was appointed as an Additional Director in the category of Non-Executive Independent Director. Further, his appointment as a Non-Executive Independent Director, not liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, was approved, subject to the approval of the shareholders.
- Mrs. Sapna Singh (DIN: 11812894) was appointed as an Additional Director in the category of Non-Executive Woman Independent Director. Further, her appointment as a Non-Executive Independent Director, not liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, was approved, subject to the approval of the shareholders.
- Dr. Ish Sharma (DIN: 11815526) was appointed as an Additional Director in the Executive category and designated as the Whole-Time Director and Key Managerial Personnel of the Company, liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, subject to the approval of the shareholders.
- Mr. Ankush Kaushal (DIN: 03308862) was appointed as an Additional Director in the Executive category and designated as the Whole-Time Director and Key Managerial Personnel of the Company, liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, subject to the approval of the shareholders.

During the Financial Year 2025–26, the following changes took place in the Key Managerial Personnels (KMPs) of the Company:

During the year under review, Ms. Anshika Garg resigned from the position of Company Secretary & Compliance Officer of the Company with effect from 1st August, 2025.

Subsequently, Mrs. Smita Chaturvedi was appointed as the Company Secretary & Compliance Officer and designated as the Key Managerial Personnel of the Company with effect from 4th August, 2025.

Subsequent to the close of the financial year, Mrs. Smita Chaturvedi resigned from the position of Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 14th July, 2026. The Board of Directors, at its meeting held

on 15th July, 2026, approved the appointment of Ms. Priya Goyal (ACS-71180) as the Company Secretary & Compliance Officer and designated her as the Key Managerial Personnel of the Company with effect from 15th July, 2026.

Except as stated above, there were no other changes in the Key Managerial Personnel of the Company during the year under review.

Board Composition

As of 31 March 2026, the Company's Board has a strength of 6 (Six) Directors, including 3 (Three) Woman Directors. The composition of the Board is as below:

Category	Number of Directors
Executive Director	3 (Three)
Independent Non-Executive Directors	3 (Three)

FAMILIARIZATION PROGRAMME OF INDEPENDENT DIRECTORS

In compliance with the requirements of the Listing Regulations, the Company has put in place a familiarization programme for the Independent Directors to familiarize them with their roles, rights and responsibilities as Directors, the working of the Company, nature of the industry in which the Company operates, business model etc. At the time of appointment/re-appointment of Independent Directors, a formal letter of appointment is given to him/her, which, inter-alia, explains the role, functions, duties and responsibilities expected from him/her as an Independent Director of the Company. The Independent Director is also explained in detail the nature, business model of the industry and compliances under the Act, the Listing Regulations and other relevant rules & regulation.

Details of the familiarization programme for Independent Directors are uploaded on the website of the company at https://jeenasikho.com/wp-content/uploads/2023/12/Code-of-Familiarization-for-Independent-Directors_2025_26.pdf

NOMINATION AND REMUNERATION POLICY

On the recommendation of the Nomination and Remuneration Committee, the Board has framed a policy for selection and appointment of Directors, Senior Management including Key Managerial Personnel and their remuneration. The Nomination and Remuneration Policy includes the criteria for determining qualification, positive attributes, independence, etc. is placed on the website of the Company at www.jeeenasikho.com/policies.

The salient features of the Nomination and Remuneration Policy are mentioned below:

- The Nomination and Remuneration Policy of the Company is designed to attract, motivate, improve productivity and retain manpower by creating a congenial work environment, encouraging initiatives, personal growth, team work and inculcating a sense of belongingness and involvement, besides offering appropriate remuneration packages and superannuation benefits.

- The Committee shall comprise at least three (3) Directors, all of whom shall be non-executive Directors and at least two-third shall be Independent.
- Quorum of the meeting shall be either two members or one-third of the members of the committee, whichever is greater, including at least one independent director in attendance.
- The Role of the Committee includes: Periodically reviewing the size and composition of the Board to have an appropriate mix of executive and independent Directors to maintain its independence and separate its functions of governance and management and to ensure that it is structured to make appropriate decisions, with a variety of perspectives and skills, in the best interests of the Company;
- Formulate the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board, relating to the remuneration for the Director, key managerial personnel and other employees.
- Establishing and reviewing Board, KMP and Senior Management succession plans in order to ensure and maintain an appropriate balance of skills, experience and expertise on the Board and Senior Management.
- The Board as per the criteria approved by the Nomination and Remuneration Committee shall carry out evaluation of performance of its own, its committees, and individual Directors and the Chairman.

VIGIL MECHANISM/WHISTLE BLOWER POLICY:

Pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013, a Vigil Mechanism/Whistle Blower Policy for directors and employees to report their genuine concerns has been established. The Vigil Mechanism/Whistle Blower Policy has been uploaded on the website of the Company at <https://jeenasikho.com/wp-content/uploads/2023/12/Whistle-Blower-Policy-1.pdf> under 'Investor Section'.

The Policy is an extension of the Code of Conduct for Directors & Senior Management Personnel and covers any unethical and improper actions or malpractices and events which have taken place/suspected to take place.

As per the policy all Protected Disclosures should be addressed to the Vigilance Officer/Company Secretary or to the Chairman of the Audit Committee in exceptional cases.

RISK MANAGEMENT POLICY

The Company has in place a mechanism to identify, assess, monitor and mitigate various risks to key business objectives. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. Major elements of risk/threats for Ayurveda Industry are regulatory concerns, consumer perceptions and competition. These are discussed at the meetings of the Audit Committee and the Board of Directors of the Company. The Board of Directors has adopted a risk management policy for the company outlining the parameters of identification, assessment, monitoring and mitigation of various risks

which is available on the website of the company at https://jeenasikho.com/wp-content/uploads/2023/12/5.-JSLR_Risk_Management_Policy.pdf

COMMITTEES OF THE BOARD

The Committees of the Board focus on certain specific areas and make informed decisions in line with the delegated authority.

The following Committees constituted by the Board function according to their respective roles and defined scope:

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholder Relationship Committee
4. Corporate Social Responsibility Committee
5. Risk Management Committee

During the year under review, all recommendations made by the various committees of the Board have been duly accepted by the Board.

The Composition of the said Committees are as under:

Audit Committee:

As on date, the Audit Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mrs. Priyanka Bansal*	Chairperson	Independent Director
Mr. Karan Vir Bindra	Member	Independent Director
Mr. Manish Grover	Member	Managing Director

*Mrs. Priyanka Bansal was appointed as the chairperson of the Committee w.e.f. October 06, 2025 pursuant to Reconstitution of the Audit Committee.

Company Secretary and Compliance officer will act as the secretary of the Committee.

Nomination and Remuneration Committee:

As on date the Nomination and Remuneration Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mr. Karan Vir Bindra	Chairperson	Independent Director
Mr. Chandan Kumar Kaushal	Member	Independent Director
Mrs. Priyanka Bansal*	Member	Independent Director

*Mrs. Priyanka Bansal was appointed as the member of the Committee w.e.f. August 27, 2025 pursuant to Reconstitution of the Nomination and Remuneration Committee.

*Ms. Shreya Grover ceased to be a member of the Committee w.e.f. August 27, 2025 pursuant to Reconstitution of the Nomination and Remuneration Committee.

Company Secretary and Compliance officer will act as the secretary of the Committee.

Stakeholders' Relationship Committee:

As on date the Stakeholders' Relationship Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mr. Chandan Kumar Kaushal	Chairperson	Independent Director
Mrs. Bhavna Grover	Member	Whole Time Director
Mr. Manish Grover	Member	Managing Director

There is no change in the composition of Stakeholders' Relationship Committee during the financial year under review.

Company Secretary and Compliance officer will act as the secretary of the Committee.

Corporate Social Responsibility Committee:

As on date CSR committee comprises of:

Name	Designation	Nature of Directorship
Mr. Karan Vir Bindra	Chairman	Independent Director
Mr. Manish Grover	Member	Managing Director
Mrs. Bhavna Grover	Member	Whole Time Director

There is no change in the composition of Corporate Social Responsibility Committee during the financial year under review.

Company Secretary and Compliance officer will act as the secretary of the Committee.

Risk Management Committee:

As on date Risk Management committee comprises of:

Name	Designation	Nature of Directorship
Mr. Manish Grover	Chairman	Managing Director
Mrs. Bhavna Grover	Member	Whole Time Director
Mrs. Priyanka Bansal	Member	Independent Director

There is no change in the composition of Risk Management committee during the financial year under review.

Company Secretary and Compliance officer will act as the secretary of the Committee.

CODE OF CONDUCT

The Board has laid down a Code of Conduct for all Board members and Senior Management Personnel of the Company. The Code is displayed on the website of the Company https://jeenasikho.com/wp-content/uploads/2023/12/1.-JSLR_Code_of_Conduct_Board_Senior_Management_Final.pdf. All Board members and Senior Management Personnel have affirmed compliance with the said Code of Ethics & Conduct.

STATUTORY AUDITORS & AUDITOR'S REPORT

M/s. KRA & Co., Chartered Accountants (Firm Registration No. 020266N), tendered their resignation as the Statutory Auditors of the Company vide resignation letter dated 13th August, 2025, effective from 14th August, 2025, after completion of the Limited Review of the financial results of the Company for the quarter ended 30th June, 2025. The Board of Directors placed on record its appreciation for the professional services rendered by the firm during its tenure as Statutory Auditors of the Company.

Pursuant to the provisions of Sections 139, 140 and other applicable provisions of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, and based on the recommendation of the Audit Committee, the Board of Directors appointed M/s. Walker Chandio & Co LLP, Chartered Accountants (Firm Registration No. 001076N/N500013), as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. KRA & Co., with effect from 14th August, 2025, to hold office until the conclusion of the ensuing Annual General Meeting.

Further, the Members of the Company at the Annual General Meeting held on 29th September, 2025 approved the appointment of M/s. Walker Chandio & Co LLP, Chartered Accountants (Firm Registration No. 001076N/N500013), as the Statutory Auditors of the Company for a term of five (5) consecutive years, commencing from the conclusion of the said Annual General Meeting till the conclusion of the 13th Annual General Meeting of the Company, on such remuneration as may be determined by the Board of Directors.

Statutory Auditors' Report

The Statutory Auditors' Report on the Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2026 forms part of this Annual Report. The Auditors' Report contains an unmodified opinion on the Standalone and Consolidated Financial Statements. Except as otherwise stated in the Auditors' Report attached to this Annual Report, there are no observations, comments or explanations which require any further disclosure or comments by the Board of Directors pursuant to Section 134(3)(f) of the Companies Act, 2013.

Details with respect to frauds reported by Auditors

During the year, the Statutory Auditors have not reported any matter under the second proviso of Section 143(12) of the Companies Act, 2013, and therefore no details are required to be disclosed under Section 134(3)(ca) of the Companies Act, 2013.

MEETINGS OF BOARD OF DIRECTORS

During the financial year 2025-2026, your Board of Directors met **17 (Seventeen) times**. The details of meeting & attendance are given hereunder. The intervening gap between the Meetings was within the prescribed period.

Sr. No.	Date of Board Meeting	No. of Directors eligible to attend	No. of Directors attended meeting
1	21-04-2025	5	5
2	30-04-2025	6	6
3	16-05-2025	6	6
4	28-07-2025	6	6
5	04-08-2025	6	6

SECRETARIAL AUDITORS AND THEIR REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and based on the recommendation of the Board of Directors, the Members of the Company at the Annual General Meeting held on 29th September, 2025 approved the appointment of M/s. Ankur Singh & Associates, Company Secretaries (FRN: S2022DE845000), as the Secretarial Auditors of the Company for a term of five (5) consecutive years commencing from Financial Year 2025-26 till Financial Year 2029-30.

The Secretarial Audit Report issued by M/s. Ankur Singh & Associates, Company Secretaries, in Form MR-3 for the Financial Year ended 31st March, 2026 is annexed to this Board's Report as **Annexure II**.

The Secretarial Compliance Report pursuant to Regulation 24A of SEBI (LODR) Regulations, is annexed as **Annexure III**, forming part of this Report.

The Secretarial Auditors have observed that there was a delay in filing the intimation of the Board Meeting convened for consideration of the financial results, as required under Regulations 29(2) and 29(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Consequently, the Company paid the applicable penalty levied by the Stock Exchange(s) for the said delay.

Management's Reply: The delay was an isolated procedural lapse and was neither deliberate nor intended to withhold any material information from the stakeholders. The Company has already complied with the applicable regulatory requirements and paid the prescribed penalty. Further, the Company has strengthened its internal compliance monitoring mechanism by implementing enhanced review processes, maintaining a comprehensive compliance calendar, and instituting additional levels of oversight to ensure timely regulatory filings and to prevent recurrence of such instances.

Further, except for the above observation, the Secretarial Audit Report does not contain any other qualification, reservation, adverse remark or disclaimer requiring explanation by the Board. The Secretarial Auditors have also confirmed that no fraud has been reported under Section 143(12) of the Companies Act, 2013 during the financial year under review.

COST AUDITORS

The provisions of maintenance of Cost Records as specified by the Central Government under subsection (1) of Section 148 of the Act are not applicable on the Company.

MEETINGS OF BOARD OF DIRECTORS (Contd.)

Sr. No.	Date of Board Meeting	No. of Directors eligible to attend	No. of Directors attended meeting
6	14-08-2025	6	6
7	27-08-2025	6	6
8	06-10-2025	6	6
9	13-10-2025	6	6
10	06-11-2025	6	6
11	01-12-2025	6	6
12	23-12-2025	6	6
13	13-01-2026	6	6
14	21-01-2026	6	6
15	07-02-2026	6	6
16	24-02-2026	6	6
17	09-03-2026	6	6

MEETING OF INDEPENDENT DIRECTORS

Pursuant to Regulation 25(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-1 on Meetings of the Board of Directors issued by the Institute of Company Secretaries of India, the Independent Directors of the Company are required to hold at least one meeting in a financial year and, being a top 1000 listed entity, at least two meetings in a financial year without the attendance of Non-Independent Directors and members of the management.

Accordingly, the Independent Directors of the Company held two (2) separate meetings during the financial year, i.e. on 1st January 2026 and 7th February 2026 without the presence of Non-Independent Directors and members of the management. At these meetings, the Independent Directors reviewed the performance of the Non-Independent Directors and the Board as a whole, reviewed the performance of the Chairman of the Company, taking into account the views of Executive Directors, and assessed the quality, quantity and timeliness of the flow of information between the Company's management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3) (a) of the Companies Act, 2013, and Companies (Management and Administration) Rules, 2014, the Annual Return of the Company containing the particulars as prescribed under Section 92 of the Companies Act, 2013, in Form MGT-7, is available on the Company's website at the weblink https://jeenasikho.com/annual-return/?page_slug=annual-return.

CORPORATE SOCIAL RESPONSIBILITY

The Company falls under the criteria as mentioned in section 135 of the Companies Act, 2013 i.e., Corporate Social Responsibility and accordingly the amount has been spent on CSR activities in the financial year 2025-2026 to comply with the requirements of necessary social expenditure which is ₹ 169.88 Lakhs i.e. (2% of the average net profit of immediate preceding three (3) financial years). The constitution of CSR Committee was applicable for FY 2025-26, subsequently

the CSR Committee is formulated and the composition is also given. The CSR Report is annexed as **Annexure IV**.

The Board of Directors of your Company has formulated and adopted a policy on CSR which can be accessed at <https://jeenasikho.com/wp-content/uploads/2023/12/2.-CSR-Policy.pdf>.

The CSR Policy of your Company outlines the Company's philosophy for undertaking socially useful programs for welfare and sustainable development of the community at large as part of its CSR Obligation.

NATURE OF BUSINESS

There has been no change in business of the Company.

Jeena Sikho Lifecare Limited has a diverse portfolio consisting of a number of brands and sub-brands including "Shuddhi". The Company offers a variety of Ayurvedic Products and services through Shuddhi clinics and HIIMS, all over the Country. The Company has presence across various channels such as general groceries, chemists, organized retail and ecommerce.

MANAGEMENT DISCUSSION AND ANALYSIS

Management Discussion and Analysis Report for the year under review, as stipulated under the SEBI Listing Regulations, is presented in a separate section and forms an integral part of this Report.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186

The details of loans and Investments and guarantees covered under the provisions of Section 186 of the Act are given in the Notes to the Financial Statements forming a part of Annual Report.

Current borrowings of the company are compliant with Section 180(1)(c) of the Companies Act, 2013.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

During the year under review, the Company entered into related party transactions, all of which were on an arm's length basis. Certain related party transactions were entered into in the ordinary course of business, while certain transactions were not in the ordinary course of business and accordingly were approved by the Board of Directors pursuant to the provisions of Section 188 of the Companies Act, 2013 and other applicable provisions, wherever required.

All related party transactions are presented to the Audit Committee and the Board for their review and approval. Omnibus approval is obtained before the commencement of the financial year for transactions which are repetitive in nature and also for transactions which cannot be foreseen and accordingly require omnibus approval.

During the year, the Company did not enter into any related party transactions that had a conflict with the interests of the Company. Further, none of the related party transactions entered into by the Company during the year were material in nature requiring shareholders' approval under the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The details of related party transactions as entered into by the Company are disclosed in the standalone financial statements of the Company.

Further, pursuant to the provisions of Section 188 of the Companies Act, 2013, read with the rules framed thereunder, the disclosure of particulars of contracts/arrangements with related parties in Form AOC-2 is annexed to this Report as **Annexure V**.

In line with the requirements of the applicable laws, the Company has formulated a policy on related party transactions which is uploaded on the website of the Company at: https://jeenasikho.com/wp-content/uploads/2025/05/Revised-RPT_JSLL-1.pdf.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has zero tolerance towards sexual harassment at the workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. As required under law, an Internal Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace.

During the year under review, the Company has not received any sexual harassment complaints during the financial year nor any complaint is pending at the end of the financial year.

The Policy for Prevention of Sexual Harassment of the Company is available on the Company's website at the web link <https://jeenasikho.com/investors/>.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERNS STATUS AND COMPANY'S OPERATIONS IN FUTURE

There is no significant and material order passed by the regulators or courts or tribunals impacting the going concern status and the Company's operations in future.

DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE AVAILING LOANS FROM THE BANKS OR FINANCIAL INSTITUTIONS

Not Applicable.

MATERIAL CHANGES AND COMMITMENT AFFECTING THE FINANCIAL POSITION

No material changes or commitments that could affect the financial position of the Company have occurred between the end of the financial year and the date of this report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

Pursuant to provisions of Section 134(3)(m) & Rule 8(3) of Companies (Accounts) Rules, 2014 the details of energy conservation, technology absorption and foreign exchange earnings and outgo have been given in **Annexure VI** to this report.

INTERNAL FINANCIAL CONTROLS AND THEIR ADEQUACY

Our rapid growth, while a matter of great satisfaction, continues to put pressure on our internal systems and processes. It is crucial that we ensure these systems continue to keep up with our business growth and that our policies remain relevant in the everchanging business landscape. Information systems are being continuously evaluated and revamped to provide timely and relevant information to various stakeholders, equipping them with the necessary tools to compete in a challenging market and environment.

We recognize the critical role of IT and information systems in today's world, and we have several dedicated teams constantly working to enhance and improve these systems to stay ahead of the rapidly changing environment. The Company's system of continuous internal audits ensures that the laid-down processes and practices are followed and complied with and that quality processes are strictly adhered to. Financial discipline is emphasized at all levels of the business and adherence to quality systems and a focus on customer satisfaction are critical for the Company to retain and attract customers and business and these are followed rigorously. At the same time, the company is strengthening its core business systems to enhance robustness and achieve uniformity and consistency in practices and processes across the company.

The Internal Auditors, who function independently Within the Company, review the adequacy and efficacy of the key internal controls. The annual audit plan, approved by the Audit Committee, guides the scope of audit activities. Additionally, the Company engages professional and reputable audit firms from time to time to conduct internal audits of the larger and more critical operations of the Company.

In addition to financial audits, quality management system procedures are continuously audited by internal and external auditors to ensure that the Company's business practices conform to the requirements of customers.

The Directors believe that the Company has in place adequate internal financial controls with reference to financial statements. The Company's internal control systems are commensurate with the nature, size and complexity of its business and ensure the proper safeguarding of assets, maintenance of proper accounting records and provision of reliable financial information. The Internal Audit team of the Company evaluates the effectiveness and quality of internal controls and reports on their adequacy through periodic reporting. During the year under review, these controls were tested and no reportable material weakness in the design or operation of such controls was identified.

HUMAN RESOURCES

Your Company treats its "human resources" as one of its most important assets. Your Company continuously invests in attraction, retention and development of talent on an ongoing basis. A number of programs that provide focused people attention are currently underway. Your Company's thrust is on the promotion of talent internally through job rotation and job enlargement.

PARTICULARS OF EMPLOYEES

In terms of the provisions of Section 197 (12) of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, disclosure pertaining to remuneration and other details are provided in the **Annexure VII** to this Report.

Particulars of employee remuneration, as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms an integral part of this Annual Report. In terms of the provisions of the first proviso to Section 136 (1) of the Companies Act, 2013, the Annual Report is being sent to Members, excluding the aforementioned information. Any Member interested in obtaining a copy of such statement may write to the Company Secretary of the Company at cs@jeenasikho.com

COMPLIANCE WITH SECRETARIAL STANDARDS

The Company complies with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India and approved by the Central Government under Section 118(10) of the Companies Act, 2013.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT ("BRSR")

Pursuant to Regulation 34(2)(f) of the SEBI Listing Regulations, a separate section on Business Responsibility and Sustainability Report, describing the initiatives taken by

the Company from an environmental, social and governance perspective, forms an integral part of this Report.

Sustainability for your Company is about being responsible to its various stakeholders and creating shared value for each of them in a way that reinforces and amplifies our commitment. Our approach aligns with the ESG framework, which emphasizes creating economic value in an ecologically sustainable, socially responsible and governance-driven manner. We extend our considerations beyond economic and financial aspects and address our broader role in society and the communities in which we operate. Consistent efforts have been made to minimize environmental footprint, reduce emissions and pollution, and optimize land and water usage.

INDUSTRIAL RELATIONS

The Company maintained healthy, cordial and harmonious industrial relations at all levels. The enthusiasm and unstinting efforts of employees have enabled the Company to remain in the leadership position in the industry. It has taken various steps to improve productivity across organization.

REGISTRAR AND SHARE TRANSFER AGENT:

During the year under review, Skyline Financial Services Pvt. Ltd. was the Registrar and Transfer Agent of the Company.

COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. All eligible women employees are provided with maternity benefits as prescribed under the Maternity Benefit Act, 1961, including paid maternity leave, nursing breaks, and protection from dismissal during maternity leave.

The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the provisions under Section 134(5) of the Act, with respect to Directors' Responsibility Statement, the Directors confirm:

- a) That in the preparation of the annual accounts, the applicable accounting standards have been followed and no material departures have been made from the same;
- b) That they had selected such accounting policies and applied them consistently, and made judgements and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
- c) That they had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

- d) That they had prepared the annual accounts on a going concern basis;
- e) That they had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively; and
- f) That they had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

OTHER DISCLOSURES

There were no transactions on the following matters during the year and hence no reporting or disclosure is required:

- Issue of equity shares with differential rights as to dividend, voting, or otherwise.

- Issue of shares (including sweat equity shares) to employees of the Company under any scheme save and except the Employees' Stock Option Scheme referred to in this Report.
- There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.

APPRECIATION

Your directors take this opportunity to thank the customers, shareholders, suppliers, bankers, business partners/ associates, and Central and State Governments for their consistent support and encouragement of the Company. We place on record our appreciation for the contribution made by our employees at all levels. Our consistent growth was made possible by their hard work, solidarity, cooperation, and support.

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Bhavna Grover
Whole Time Director
DIN: 07557913

Date: 31.08.2026
Place: Zirakpur, Punjab

Annexure I

FORM AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures

Part A – Subsidiaries

(₹ In Lakhs)

Sl. No.	Name of the Subsidiary	Jeena Green Resources Private Limited	Jeena Sikho International LLC
Particulars			
1	The date since when subsidiary was acquired	10 th March, 2025	11 th September, 2025
2	Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	FY 25-26	FY 25-26
3	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries.	N.A	Reporting currency: AED, Exchange rate: 25.7694
4	Share capital	5.00	24.38
5	Reserves and surplus	(31.16)	(15.21)
6	Total assets	156.36	1056.33
7	Total Liabilities	182.51	1047.16
8	Investments	0.00	0.00
9	Turnover	7.53	0.00
10	Profit/(Loss) before taxation	(31.52)	(16.60)
11	Provision for taxation	(0.36)	0.00
12	Profit/(Loss) after taxation	(31.16)	(16.60)
13	Proposed Dividend	0.00	0.00
14	Extent of shareholding (in percentage)	51%	100%

Notes:

- 1. Names of subsidiaries which are yet to commence operations: **Nil**
- 2. Names of subsidiaries which have been liquidated or sold during the year: **Nil**
- 3. Name of subsidiaries which have been merged with the Company during the: **Nil**

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Bhavna Grover
Whole Time Director
DIN: 07557913

Date: 31.08.2026
Place: Zirakpur, Punjab

Annexure II

FORM NO. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members
Jeena Sikho Lifecare Limited
CIN: L52601PB2017PLCO46545
SCO 11 First Floor, Kalgidhar Enclave,
Mohali, Zirakpur, Punjab, India, 140604

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **JEENA SIKHO LIFECARE LIMITED** ("the Company"). The Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Auditor's responsibility

My responsibility is to express an opinion on the compliance of the applicable laws and maintenance of records based on audit. I have conducted the audit in accordance with the applicable Auditing Standards issued by The Institute of Company Secretaries of India. The Auditing Standards require that the Auditor shall comply with statutory and regulatory requirements and plan and perform the audit to obtain reasonable assurance about compliance with applicable laws and maintenance of records.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company has, during the audit period from **April 01, 2025 to March 31, 2026 ("the audit period")** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March 2026 according to the provisions of the following list of laws and regulations. The following are our observations on the same:

- i. **The Companies Act, 2013 (the Act) and the rules made thereunder:** The Company has satisfactorily complied with the provisions of the Companies Act, 2013 and the Rules made there under and there are no discrepancies observed by us during the period under review.
- ii. **The Securities Contracts (Regulation) Act, 1956 (SCRA') and the rules made thereunder:** The Company has complied with the provisions of The Securities Contracts (Regulation) Act 1956 (SCRA').

- iii. **The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder:** The Company is a listed public company and 100% shares are in dematerialized form and the Company has complied with the provisions of The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.
- iv. The Company has satisfactorily complied with the provisions of the Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings and there are no discrepancies observed by us during the period under review.
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
 - d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
 - e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021. **(Not applicable to the Company during the Audit Period);**
 - f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009. **(Not applicable to the Company during the Audit Period);**

- h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018. **(Not applicable to the Company during the Audit Period);**
- i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015: **The Company has satisfactorily complied with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as applicable to the Company. However, there was delay in filing an intimation for board meeting for purposes of financial results as required under Regulation 29(2) & 29(3) of SEBI (LODR) Regulations, 2015. The Company has made the payment of the penalty for the said delay.**

The Company is a listed Company and provisions of Regulations and Guidelines mentioned above and prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') are duly complied by the Company.

I further report that, as per the opinion of the officers of the Company and information provided by them there are following specific applicable laws on the basis of activities of the Company have been substantially complied with:

- The Drugs and Cosmetics Act, 1940 and The Drugs and Cosmetics Rules, 1945;
- Food Safety and Standards Act, 2006.
- Workmen's compensation Act, 1923 and all other allied labor laws,
- Prevention of Money Laundering Act, 2002.
- Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.
- All other Labour, Employee and Industrial Laws to the Extent applicable to the Company.
- Applicable Direct and Indirect Tax Laws.

I have also examined compliance with the applicable clauses of the following:

- Secretarial Standards issued by The Institute of Company Secretaries of India.
- The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments made thereunder ("Listing Regulations").

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, and Guidelines to the extent applicable, Standards, etc. made thereunder.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors, and Independent Directors. The changes in the

composition of the Board of Directors that took place during the audit period were carried out in compliance with the provisions of the Act and Listing Regulations.

Adequate notice was given to all Directors to schedule the Board Meetings and the agenda along with detailed notes on agenda were generally circulated at least seven days in advance. A system exists for seeking and obtaining further information and clarifications on agenda items before the meeting and for meaningful participation at the meetings.

In cases where Board Meetings were convened at shorter notice, the consent of the Directors, including at least one Independent Director, wherever applicable, was obtained in accordance with the provisions of the Companies Act, 2013, Secretarial Standard-1 on Meetings of the Board of Directors and the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015. The agenda and notes on agenda for such meetings were circulated within the prescribed timelines and all applicable statutory requirements were duly complied with.

I further report that during the audit period no major decisions, specific events/actions have occurred which has a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. except the following:

- Board of Directors of the Company through board resolution dated 21st April 2025 has approved the Sub-division/split of existing equity share of the Company from one equity share having face value of ₹ 10/- (Rupees Ten only) each, fully paid-up into five (5) equity shares having face value of ₹ 2/- (Rupees Two only) each fully paid-up.
- Board of Directors of the Company through board resolution dated 21st April 2025 has approved the Migration of listed scrip (equity shares) of the company from Emerge (SME) Platform of National Stock Exchange of India Limited (NSE EMERGE) to the Main Board of National Stock Exchange of India Limited (NSE) as well as on main board of BSE Ltd (BSE).
- Board of Directors of the Company through board resolution dated 21st April 2025 has approved Appointment of Ms. Priyanka Bansal (DIN: 09051665) as an Additional Director designated as Non-Executive Independent Director.
- Ms. Anshika Garg has resigned from the post of Company Secretary & Compliance Officer w.e.f. 01st August 2025.
- Board of Directors of the Company through board resolution dated 04th August 2025 has approved the appointment of Mrs. Smita Chaturvedi a qualified Company Secretary (Mem. No. A48303) as Company Secretary & Compliance Officer designated as Key Managerial Personnel of the Company.
- The statutory auditors of the Company, M/s. KRA & Co., Chartered Accountants (Firm Registration No.: 020266N), have resigned on 13th August 2025 from the position of Statutory Auditors with effect from 14th August, 2025.

- g) Board of Directors of the Company through board resolution dated 14th August 2025 has approved Appointment of M/s. Walker Chandiok & Co LLP as the statutory auditors of the Company.
- h) Board of Directors of the Company through board resolution dated 27th August 2025 has approved Employee Stock Option Scheme 2025.
- i) Board of Directors of the Company through board resolution dated 27th August 2025 has approved the Appointment of Mr. Sahil Jain as the Chief Operating Officer ("COO").
- j) The Nomination and Remuneration Committee of the Board of Directors of the Company through its resolution dated 01st January, 2026 has approved the grant of 2,18,875 (Two Lakh Eighteen Thousand Eight Hundred Seventy-Five) Employee Stock Options to eligible employees of the Company, in accordance with the JEENA SIKHO EMPLOYEES STOCK OPTION SCHEME, 2025 ("ESOP 2025").
- k) The Company has passed following through postal ballot dated 23rd May, 2025:
 - i. Sub-division/split of equity share.
 - ii. Migration from NSE EMERGE platform to the Main Board of NSE and Main Board of BSE.
- iii. Appointment of Ms. Priyanka Bansal (DIN: 09051665) as a Non-Executive Independent Director of the Company.
- l) Other than the ones mentioned above, we further report that during the period under audit the Company has passed following special resolutions:
 - i. Approval of Jeena Sikho Employees Stock Option Scheme, 2025 for Eligible Employees of the Company.
 - ii. Extension of the Jeena Sikho Employee Stock Option Scheme 2025, to the Eligible Employees of the Group Companies.
 - iii. Re-designation of Ms. Shreya Grover (DIN: 09199495) as Whole-time Director and Key Managerial Personnel of the Company from the position of Non-Executive Director.

I further report that there were no instances of:

- i. Public/Rights/Preferential issue of shares/debentures.
- ii. Buy-Back of securities.
- iii. Merger/amalgamation/reconstruction etc.
- iv. Foreign technical collaborations.

For and on behalf of.

Ankur Singh & Associates
(Company Secretaries)

Ankur Singh

Proprietor,
Membership No: A60761
C.P No: 22820
UDIN: AO60761H001149618

Date: 19.08.2026

Place: Delhi

ANNEXURE A

Our Secretarial Audit Report of event date issued to M/s. Jeena Sikho Lifecare Limited (CIN: L52601PB2017PLC046545) is to be read along with this letter:

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial record and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For and on behalf of.

Ankur Singh & Associates
(Company Secretaries)

Ankur Singh

Proprietor,
Membership No: A60761
C.P No: 22820
UDIN: A060761H001149618

Date: 19.08.2026

Place: Delhi

Annexure III

SECRETARIAL COMPLIANCE REPORT

FOR THE FINANCIAL YEAR ENDED ON 31ST MARCH, 2026

(Pursuant to Regulation 24A (2) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015)

To,
The Board of Directors
Jeena Sikho Lifecare Limited
CIN: L52601PB2017PLCO46545
SCO 11 First Floor, Kalgidhar Enclave,
Mohali, Zirakpur, Punjab, India, 140604.

We have conducted the review of compliance of the applicable statutory provisions and the adherence to good corporate practices by Jeena Sikho Lifecare Limited Bearing CIN: L52601PB2017PLCO46545 (hereinafter referred to as the listed entity), having its registered office at SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur, Punjab, India, 140604, in terms of Regulation 24A (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. Secretarial Review was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the listed entity's books, papers, minutes books, forms and returns filed and other records maintained by the listed entity and also the information provided by the listed entity, during the conduct of Review, we hereby report that the listed entity has, during the Review Period covering the Financial Year ended on March 31, 2026, complied with the statutory provisions listed hereunder in the manner and subject to the reporting made hereinafter.

We, Ankur Singh & Associates, Practicing Company Secretaries, have examined:

- (a) All the documents and records made available to us and explanation provided by Jeena Sikho Lifecare Limited ("the listed entity"),
- (b) The filings/submissions made by the listed entity to the stock exchanges,
- (c) Website of the listed entity,
- (d) Any other document/filing, as may be relevant, which has been relied upon to make this certification.

For the year ended 31st March, 2026 in respect of compliance with the provisions of:

1. The Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and

2. The Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the Circulars/Guidelines issued thereunder, have been examined, include:

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(Not applicable for the period under review);**
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(Not applicable for the period under review);**
- (e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
- (f) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2021; **(Not applicable for the period under review);**
- (g) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (h) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 and circulars/guidelines issued thereunder;
- (i) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. and circulars/guidelines issued thereunder and based on the above examination, we hereby report that, during the Review Period.

I. A. The listed entity has complied with the provisions of the above Regulations and circulars/guidelines issued thereunder, except in respect of matters specified below:

Sr. No.	Compliance Requirement (Regulations/ circulars/ guide- lines including specific clause)	Regulation/ Circular No.	Deviations	Action Taken by	Type of Action (Advisory/ Clarification/ Fine/Show Cause Notice/ Warning, etc)	Details of Violation	Fine Amount	Observations/Remarks of the Practicing Company Secretary	Management Response	Remarks
1.	Regulation 29(2)/29(3) BSE Limited	Regulation 29(2)/29(3)	Delay in furnishing prior intimation about the meeting of the board of directors. Quarter 2 ending 30 September, 2025	BSE Limited	Fine	Delay in furnishing prior intimation about the meeting of the board of directors. Quarter 2 ending 30 September, 2025	₹ 10,000+GST, Total Fine paid ₹ 11,800	The Company had delayed in furnishing the prior intimation of the Board Meeting for the quarter ended 30 th September, 2025, to the Stock Exchange(s) under the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Consequently, a fine of Rs. 10,000/- plus applicable GST aggregating to Rs. 11,800/- was levied by the Stock Exchange and the same has been duly paid by the Company	The delay was inadvertent in nature and not intentional. The Company has taken note of the lapse and has strengthened its internal compliance monitoring mechanism to ensure timely intimations and adherence to the applicable provisions of SEBI (LODR) Regulations, 2015 going forward.	NA
2.	Regulation 29(2)/29(3) National Stock Exchange of India Limited	Regulation 29(2)/29(3)	Delay in furnishing prior intimation about the meeting of the board of directors. Quarter 2 ending 30 September, 2025	National Stock Exchange of India Limited	Fine	Delay in furnishing prior intimation about the meeting of the board of directors. Quarter 2 ending 30 September, 2025	₹ 10,000+GST, Total Fine paid ₹ 11,800	The Company had delayed in furnishing the prior intimation of the Board Meeting for the quarter ended 30 th September, 2025, to the Stock Exchange(s) under the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Consequently, a fine of Rs. 10,000/- plus applicable GST aggregating to Rs. 11,800/- was levied by the Stock Exchange and the same has been duly paid by the Company	The delay was inadvertent in nature and not intentional. The Company has taken note of the lapse and has strengthened its internal compliance monitoring mechanism to ensure timely intimations and adherence to the applicable provisions of SEBI (LODR) Regulations, 2015 going forward.	NA

B. The listed entity has taken the following actions to comply with the observations made in previous reports

Sr. No.	Compliance Requirement (Regulations/ circulars/ guide- lines including specific clause)	Regulation/ Circular No.	Deviations	Action Taken by	Type of Action (Advisory/ Clarification/ Fine/Show Cause Notice/ Warning, etc)	Details of Violation	Fine Amount	Observations/ Remarks of the Practicing Company Secretary	Management Response	Remarks
NA										

II. We further hereby report that, during the Review Period the compliance status of the listed entity is appended as below:

Sl. No.	Particulars	Compliance Status (Yes/No/NA)	Observation/Remarks by PCS
1.	Secretarial Standards: The compliances of the listed entity are in accordance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries India (ICSI), as notified by the Central Government under section 118(10) of the Companies Act, 2013 and mandatorily applicable.	Yes	-
2.	Adoption and timely updating of the Policies: ➤ All applicable policies under SEBI Regulations are adopted with the approval of board of directors of the listed entities ➤ All the policies are in conformity with SEBI Regulations and have been reviewed & updated on time, as per the regulations/circulars/guidelines issued by SEBI	Yes Yes	-
3.	Maintenance and disclosures on Website: ➤ The Listed entity is maintaining a functional website ➤ Timely dissemination of the documents/information under a separate section on the website ➤ Web-links provided in annual corporate governance reports under Regulation 27(2) are accurate and specific which re- directs to the relevant document(s)/section of the website	Yes Yes Yes	-
4.	Disqualification of Director: None of the Director(s) of the Company is/are disqualified under Section 164 of Companies Act, 2013 as confirmed by the listed entity.	Yes	-
5.	Details related to Subsidiaries of listed entities have been examined w.r.t.: (a) Identification of material subsidiary companies (b) Disclosure requirement of material as well as other subsidiaries	Yes	The Company has two subsidiaries namely Jeena Sikho International LLC and Jeena Green Resources Private Limited; however, neither of them is a material subsidiary of the Company.
6.	Preservation of Documents: The listed entity is preserving and maintaining records as prescribed under SEBI Regulations and disposal of records as per Policy of Preservation of Documents and Archival policy prescribed under SEBI LODR Regulations, 2015.	Yes	-
7.	Performance Evaluation: The listed entity has conducted performance evaluation of the Board, Independent Directors and the Committees at the start of every financial year/during the financial year as prescribed in SEBI Regulations.	Yes	-

II. We further hereby report that, during the Review Period the compliance status of the listed entity is appended as below: (Contd.)

Sl. No.	Particulars	Compliance Status (Yes/No/NA)	Observation/Remarks by PCS
8.	Related Party Transactions:		-
	(a) The listed entity has obtained prior approval of Audit Committee for all related party transactions; or	Yes	
	(b) The listed entity has provided detailed reasons along with confirmation whether the transactions were subsequently approved/ratified/rejected by the Audit Committee, in case no prior approval has been obtained.	Not Applicable	
9.	Disclosure of events or information: The listed entity has provided all the required disclosure(s) under Regulation 30 along with Schedule III of SEBI LODR Regulations, 2015 within the time limits prescribed thereunder.	Yes	-
10.	Prohibition of Insider Trading: The listed entity is in compliance with Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.	Yes	-
11.	Actions taken by SEBI or Stock Exchange(s), if any: No action(s) has been taken against the listed entity/its promoters/directors/subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under SEBI Regulations and circulars/guidelines issued thereunder except as provided under separate paragraph herein.	No	It was observed that BSE Limited and the National Stock Exchange of India Limited had levied fines on the Company for delay in furnishing prior intimation of Board Meetings pursuant to Regulations 29(2) and 29(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has duly complied with the directions of the Stock Exchanges and paid the aforesaid fines within the stipulated timeline. Further, no other actions were initiated or taken by SEBI or the Stock Exchanges against the Company during the review period.
12.	Resignation of statutory auditors from the listed entity or its material subsidiaries: In case of resignation of statutory auditor from the listed entity or any of its material subsidiaries during the financial year, the listed entity and/or its material subsidiary(ies) has/ have complied with paragraph 6.1 and 6.2 of section V-D of chapter V of the Master Circular (SEBI Circular CIR/CFD/CMD1/114/2019) on compliance with the provisions of the LODR Regulations by listed entities.	Yes	It was observed that M/s. KRA & Co., Chartered Accountants (Firm Registration No. 020266N), Statutory Auditors of Jeena Sikho Lifecare Limited ("the Company"), tendered their resignation vide letter dated 13 th August, 2025 from the office of Statutory Auditors of the Company with effect from 14 th August, 2025. The resignation was tendered consequent to the Company's migration to the Main Board and its decision, in line with investor suggestions, to appoint a global audit firm as Statutory Auditors, considering enhanced visibility and stakeholder expectations associated with a listed entity. In this regard, it is observed that the Company is in compliance with Para 6.1 and 6.2 of Section V-D of Chapter V of the SEBI Master Circular on compliance with SEBI (LODR) Regulations, 2015 relating to resignation of statutory auditors.

II. We further hereby report that, during the Review Period the compliance status of the listed entity is appended as below: (Contd.)

Sl. No.	Particulars	Compliance Status (Yes/No/NA)	Observation/Remarks by PCS
13.	Additional Non-compliances, if any: No additional non-compliance observed for any SEBI regulation/circular/guidance note etc.	NA	No further Non-Compliance observed.
14.	The listed entity to comply with the following requirements for disclosure of Employee Benefit Scheme Documents in terms of regulation 46(2)(za) of the LODR: a) The scheme document shall be uploaded on the website of the listed entity after obtaining shareholder approval as required under SEBI (SBEB) Regulations, 2021. b) The documents uploaded on the website shall mandatorily have minimum information to be disclosed to shareholders as per SEBI (SBEB) Regulations, 2021.	Yes	–

III. Compliances related to 'Resignation of Statutory Auditors' from listed entities and their material subsidiaries as per SEBI Circular CIR/CFD/CMD1/114/2019 dated 18th October, 2019:

Sl. No.	Particulars	Compliance Status (Yes/No/NA)	Observation/Remarks by PCS
Compliances with the following conditions while appointing/re-appointing an Auditor:			
1.	(i) If the auditor resigns within 45 days from the end of a quarter of a financial year, then the auditor shall, before such resignation, issue the limited review/audit report for such quarter. (ii) If the auditor resigns after 45 day from the end of a quarter of a financial year, then the auditor shall, before such resignation, issue the limited review/audit report for such quarter as well as the next quarter. (iii) Notwithstanding the above, if the auditor has signed the limited review/audit report for the first three quarters of a financial year, then the auditor shall, before such resignation, issue the limited review/audit report for the last quarter of such financial year as well as the audit report for such financial year.	Yes	During the period under review, M/s KRA & Co., Chartered Accountants (Firm Registration No. 020266N), resigned as Statutory Auditors of the Company w.e.f. 14 th August, 2025 after issuance of the Limited Review Report for the quarter ended 30 th June, 2025. Subsequently, M/s Walker Chandio & Co LLP were appointed as Statutory Auditors of the Company on 14 th August, 2025 and the appointment was regularized by the shareholders at the Annual General Meeting held on 29 th September, 2025. The Company has complied with the applicable provisions of SEBI Circular CIR/CFD/CMD1/114/2019 dated 18 th October, 2019 in relation to such resignation and appointment.
Other conditions relating to resignation shall include:			
2.	i) Reporting of concerns with respect to the listed entity/its material subsidiary to the Audit Committee: a. In case of any concern with the management of the listed entity/material subsidiary such as non-availability of information/non-cooperation by the management which may hamper the audit process, the auditor shall approach the Chairman of the Audit Committee of the listed entity and the Audit Committee shall receive such concern directly and immediately without specifically waiting for the quarterly Audit Committee meetings.	NA	Based on the information and explanations provided by the management and records examined by us, no concerns relating to non-availability of information or non-cooperation by the management were reported by the resigning Statutory Auditors to the Audit Committee. Further, the resignation process was carried out in compliance with the applicable provisions of SEBI Circular CIR/CFD/CMD1/114/2019 dated 18 th October, 2019.

III. Compliances related to 'Resignation of Statutory Auditors' from listed entities and their material subsidiaries as per SEBI Circular CIR/CFD/CMD1/114/2019 dated 18th October, 2019: (Contd.)

Sl. No.	Particulars	Compliance Status (Yes/No/NA)	Observation/Remarks by PCS
	b. In case the auditor proposes to resign, all concerns with respect to the proposed resignation, along with relevant documents shall be brought to the notice of the Audit Committee. In cases where the proposed resignation is due to non-receipt of information/explanation from the company, the auditor shall inform the Audit Committee of the details of information/explanation sought and not provided by the management, as applicable. c. On receipt of such information from the auditor relating to the proposal to resign as mentioned above, the Audit Committee/board of directors, as the case may be, shall deliberate on the matter and communicate its views to the management and the auditor. ii) Disclaimer in case of non-receipt of information: In case the listed entity/its material subsidiary does not provide information required by the auditor, to that extent, the auditor shall provide an appropriate disclaimer in the audit report, which may be in accordance with the Standards of Auditing as specified by ICAI/NFRA.		
3.	The listed entity/its material subsidiary has obtained information from the Auditor upon resignation, in the format as specified in Annexure- A in SEBI Circular CIR/CFD/CMD1/114/2019 dated 18 th October, 2019.	NA	The listed entity has obtained the requisite information and resignation letter from the resigning Statutory Auditors in the format prescribed under Annexure-A of SEBI Circular CIR/CFD/CMD1/114/2019 dated 18 th October, 2019 and the same was duly submitted to the Stock Exchanges.

Assumptions & limitation of scope and review:

1. Compliance of the applicable laws and ensuring the authenticity of documents and information furnished, are the responsibilities of the management of the listed entity.
2. My responsibility is to report based upon our examination of relevant documents and information. This is neither an audit nor an expression of opinion.
3. I have not verified the correctness and appropriateness of financial records and books of account of the listed entity.
4. This report is solely for the intended purpose of compliance in terms of Regulation 24A (2) of the SEBI (LODR) Regulations, 2015 and is neither an assurance as to the future viability of the listed entity nor of the efficacy or effectiveness with which the management has conducted the affairs of the listed entity.

For Ankur Singh & Associates

(Company Secretaries)
FRN: S2022DE845000

Ankur Singh

Proprietor,
C. P. No.: 22820
M. No.: A60761

Date: 28.05.2026

Place: Delhi
UDIN: AO60761H000519384

Annexure IV

CORPORATE SOCIAL RESPONSIBILITY (CSR) REPORT

[Pursuant to clause (o) of sub-section (3) of section 134 of the Act and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014]

1. A brief outline of the Company's CSR policy.

The Company, through its Corporate Social Responsibility initiatives, shall strive to enrich the quality of life in different segments of the society.

2. The Composition of the CSR Committee.

Sl. No.	Name of Director	Designation/Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Manish Grover	Director/Member	2	2
2	Mrs. Bhavna Grover	Director/Member	2	2
3	Mr. Karan Vir Bindra	Independent Director/Chairperson	2	2

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

https://jeenasikho.com/wp-content/uploads/2023/12/2.-CSR_Policy.pdf.

4. Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable.:

Not Applicable

5.

(a)	Average net profit of the Company as per Section 135(5):	8,493.78 lakhs
(b)	Two percent of average net profit of the company as per section 135(5):	169.88 lakhs
(c)	Surplus arising out of the CSR Projects or programmes or activities of the previous financial years:	Nil
(d)	Amount required to be set off for the financial year, if any:	1.33 lakhs
(e)	Total CSR obligation for the financial year [(b)+(c)-(d)]:	168.55 lakhs

6.

(a)	Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project):	170.00 lakhs
(b)	Amount spent in Administrative Overheads:	Nil
(c)	Amount spent on Impact Assessment, if applicable:	Nil
(d)	Total amount spent for the Financial Year [(a)+(b)+(c)]:	170.00 lakhs
(e)	CSR amount spent or unspent for the Financial Year:	

Total Amount Spent for the Financial Year. (in ₹)	Amount Unspent (in ₹)					
	Total Amount transferred to Unspent CSR Account as per subsection (6) of section 135.			Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135		
	Amount	Date of transfer	Name of the fund	Amount	Date of transfer	
₹ 170.00 Lakhs	-	-	-	-	-	

(f) Excess amount for set-off, if any:

Sl. No.	Particular	Amount (in ₹)
(i)	Two percent of average net profit of the company as per section 135(5)	169.88 lakhs
(ii)	Total amount spent for the Financial Year	170.00 lakhs
(iii)	Excess amount spent for the financial year [(ii)-(i)]	1.45 lakhs
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	1.45 lakhs

7. Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years:

Sr. No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under subsection (6) of section 135 (in ₹)	Balance Amount in Unspent CSR Account under subsection (6) of section 135 (in ₹)	Amount Spent in the Financial Year (in ₹)	Amount transferred to a Fund as specified under Schedule VII as per second proviso to subsection (5) of section 135, if any		Amount remaining to be spent in succeeding Financial Years (in ₹)	Deficiency, if any
					Amount (in ₹)	Date of transfer		
1	FY-1	-	-	-	-	-	-	-
2	FY-2	-	-	-	-	-	-	-
3	FY-3	-	-	-	-	-	-	-

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

Not applicable

9. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per subsection (5) of section 135:

Not applicable

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Karan Vir Bindra
Chairman of CSR Committee and Independent Director
DIN: 09283623

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Date: 31.08.2026
Place: Zirakpur, Punjab

Annexure V

FORM NO. AOC 2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of contracts or arrangements or transactions not at arm's length basis

Sl. No.	Particular	Amount
(a)	Name(s) of the related party and nature of relationship	
(b)	Nature of contracts/arrangements/transactions	
(c)	Duration of the contracts/arrangements/transactions	
(d)	Salient terms of the contracts or arrangements or transactions including the value, if any	
(e)	Justification for entering into such contracts or arrangements or transactions	NA
(f)	date(s) of approval by the Board	
(g)	Amount paid as advances, if any:	
(h)	Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

Sl. No.	Particular	Amount
1.	Details of material contracts or arrangement or transactions at arm's length basis	During the Financial Year 2025-26, the Company did not enter into any Related Party Transactions which were material in nature as defined under the Companies Act, 2013 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, disclosure of material Related Party Transactions in Form AOC-2 is not applicable. However, for the sake of completeness and transparency, details of Related Party Transactions entered into by the Company during the Financial Year 2025-26, for which prior approval of the Audit Committee and the Board of Directors was obtained, are annexed herewith.
a	Name(s) of the related party and nature of relationship	
b	Nature of contracts/arrangements/transactions	
c	Duration of the contracts/arrangements/transactions	
d	Salient terms of the contracts or arrangements or transactions including the value, if any:	
e	Date(s) of approval by the Board, if any:	
f	Amount paid as advances, if any:	
As per table 1 attached below		

Sl. No.	Particular	Amount
1.	Details of material contracts or arrangement or transactions at arm's length basis	
a	Name(s) of the related party and nature of relationship	
b	Nature of contracts/arrangements/transactions	
c	Duration of the contracts/arrangements/transactions	NA
d	Salient terms of the contracts or arrangements or transactions including the value, if any:	
e	Date(s) of approval by the Board, if any:	
f	Amount paid as advances, if any:	

TABLE 1

During the Financial Year 2025-26, the Company did not enter into any Related Party Transactions which were material in nature as defined under the Companies Act, 2013 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Accordingly, disclosure of material Related Party Transactions in Form AOC-2 is not applicable. However, for the sake of completeness and transparency, details of Related Party Transactions entered into by the Company during the Financial Year 2025-26, are annexed herewith.

Sl. No.	Related Party	Nature of Relationship	Nature of Transaction	Value (₹)	Duration
1	Mr. Manish Grover	Managing Director	Remuneration	2,40,00,000	1 year, Financial Year: 2025-26
2	Mr. Manish Grover	Managing Director	Rent Paid	3,00,000	1 year, Financial Year: 2025-26
3	Manish Grover (HUF)	Karta is Managing Director	Rent Paid	6,00,000	1 year, Financial Year: 2025-26
4	Mrs. Bhavna Grover	Whole-time Director	Remuneration	1,80,00,000	1 year, Financial Year: 2025-26
5	Ms. Shreya Grover	Whole-time Director	Remuneration	7,00,000	1 year, Financial Year: 2025-26
6	Shuddhi Lifecare Private Limited	Entity under common control/promoters	Sale of Goods/Products and Royalty	4,91,64,553	1 year, Financial Year: 2025-26
7	Shuddhi Lifecare Private Limited	Entity under common control/promoters	Sale of Fixed Assets	32,751	1 year, Financial Year: 2025-26
8	Shuddhi Lifecare Private Limited	Entity under common control/promoters	Rent Income	3,71,700	1 year, Financial Year: 2025-26
9	Shuddhi Green Charcoal Private Limited	Entity under common control/promoters	Loan Recovered	2,12,00,000	1 year, Financial Year: 2025-26
10	Shuddhi Green Charcoal Private Limited	Entity under common control/promoters	Interest Received	21,20,000	1 year, Financial Year: 2025-26
11	Ms. Akansha Jain	Promoter Group	Salary	28,50,000	1 year, Financial Year: 2025-26
12	Mr. Ashish Grover	Promoter Group	Salary	19,60,000	1 year, Financial Year: 2025-26
13	Mr. Sahil Jain	Promoter Group	Salary	51,00,000	1 year, Financial Year: 2025-26
14	Mr. Mukesh Grover	Promoter Group	Salary	19,45,000	1 year, Financial Year: 2025-26
15	Jeena Sikho International LLC	Wholly Owned Subsidiary	Investment in Equity	25,44,880	1 year, Financial Year: 2025-26
16	Jeena Sikho International LLC	Wholly Owned Subsidiary	Loan and Advances	10,37,40,000	1 year, Financial Year: 2025-26
17	Jeena Sikho International LLC	Wholly Owned Subsidiary	Interest Accrued	14,88,271	1 year, Financial Year: 2025-26
18	Jeena Green Resources Private limited	Subsidiary	Investment in Equity	2,55,000	1 year, Financial Year: 2025-26
19	Jeena Green Resources Private limited	Subsidiary	Loan and Advances	25,00,000	1 year, Financial Year: 2025-26
20	Jeena Green Resources Private limited	Subsidiary	Interest Accrued	1,55,342	1 year, Financial Year: 2025-26

Accordingly, disclosure of material Related Party Transactions in Form AOC-2 is not applicable. However, for the sake of completeness and transparency, details of Related Party Transactions entered into by the Company during the Financial Year 2025-26, are annexed herewith. (Contd.)

Sl. No.	Related Party	Nature of Relationship	Nature of Transaction	Value (₹)	Duration
21	Jeena Green Resources Private limited	Subsidiary	Purchases	5,77,500	1 year, Financial Year: 2025-26
22	Jeena Green Resources Private limited	Subsidiary	Sale of Fixed Asset	1,28,94,747	1 year, Financial Year: 2025-26
23	Mr. Nanak Chand	CFO	Salary	31,50,000	1 year, Financial Year: 2025-26
24	Ms. Anshika Garg	Company Secretary	Salary	1,00,000	1 year, Financial Year: 2025-26
25	Mrs. Smita Chaturvedi	Company Secretary	Salary	2,00,000	1 year, Financial Year: 2025-26
26	Mr. Karan Vir Bindra	Independent Director	Sitting fees	1,56,000	1 year, Financial Year: 2025-26
27	Mr. Chandan Kumar Kaushal	Independent Director	Sitting fees	6,50,000	1 year, Financial Year: 2025-26
28	Mrs. Priyanka Bansal	Independent Director	Sitting fees	2,20,000	1 year, Financial Year: 2025-26
29	Mr. Nanak Chand	CFO	Share Based Payments to KMP	2,40,000	1 year, Financial Year: 2025-26
30	Mr. Manish Grover	Managing Director	Loan Repaid	10,00,00,000	1 year, Financial Year: 2025-26

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Bhavna Grover
Whole Time Director
DIN: 07557913

Date: 31.08.2026
Place: Zirakpur, Punjab

Annexure VI

INFORMATION RELATING TO ENERGY CONSERVATION, TECHNOLOGY ABSORPTION, AND FOREIGN EXCHANGE EARNINGS AND OUTGO FORMING PART OF DIRECTORS' REPORT IN TERMS OF SECTION 134(3)(m) OF THE COMPANIES ACT, 2013 READ WITH THE COMPANIES (ACCOUNTS) RULES, 2014

(A) CONSERVATION OF ENERGY

(i)	the steps taken or impact on conservation of energy	N.A.
(ii)	the steps taken by the company for utilizing alternate sources of energy	N.A.
(iii)	the capital investment on energy conservation equipment's	N.A.

(B) TECHNOLOGY ABSORPTION

(i)	the efforts made towards technology absorption	N.A.
(ii)	the benefits derived like product improvement, cost reduction, product development or import substitution	N.A.
(iii)	in case of imported technology (imported during the last three years reckoned from the beginning of the financial year):	N.A.
	(a) the details of technology imported	N.A.
	(b) the year of import;	N.A.
	(c) whether the technology been fully absorbed	N.A.
	(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof	N.A.
(iv)	the expenditure incurred on Research and Development	N.A.

(C) FOREIGN EXCHANGE EARNINGS AND OUTGO

The Foreign Exchange earned in terms of actual inflows during the year: ₹ 246.14 lakhs

The Foreign Exchange outgo during the year in terms of actual outflows: ₹ 1162.61 lakhs

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Bhavna Grover
Whole Time Director
DIN: 07557913

Date: 31.08.2026
Place: Zirakpur, Punjab

Annexure VII

EMPLOYEES DETAILS

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) & 5(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are mentioned below:

(A) Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel Rules, 2014

1. Remuneration of each Director and Key Managerial Personnel (KMP) along with particulars of increase in remuneration during the financial year, Ratio of remuneration of Directors to the Median Remuneration of employees.

Name of the Director/and KMP	Designation	Remuneration (₹) 2025-2026	Remuneration (₹) 2024-2025	Increase (%)	Ratio of Director's Remuneration to Median remuneration*
Manish Grover	Managing Director	2,40,00,000	2,40,00,000	0%	
Bhavna Grover	Whole Time Director	1,80,00,000	1,80,00,000	0%	
Shreya Grover	Whole Time Director	7,00,000	Not Applicable	Not Applicable	Not Applicable
Nanak Chand	CFO	31,50,000	19,85,000	58.69%	Not Applicable
Ms. Anshika Garg*	Company Secretary	1,00,000	3,00,000	-	Not Applicable
Mrs. Smita Chaturvedi*	Company Secretary	2,00,000	Not Applicable		

*The median is calculated for per year remuneration.

*Ms. Anshika Garg resigned from the position of Company secretary of the Company with effect from 01st August, 2025 and Mrs. Smita Chaturvedi was appointed as the Company Secretary of the Company with effect from 04th August, 2025.

2. The median remuneration of the Company for all its employees is ₹ 1,45,221 per year for the financial year 2025-2026.
3. The Percentage Increase in median remuneration of employees in the Financial Year: 29.73%.
4. Number of permanent employees on the rolls of the Company: 4299 As on March 31, 2026.
5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration.

The average percentage increase in the salaries of employees other than the managerial personnel during the financial year 2025-26 was 35.73%, primarily attributable to the increase in the number of employees during the financial year.

During the year, the remuneration of Mr. Nanak Chand, Chief Financial Officer, increased by 58.69%. The increase in remuneration was made in accordance with the responsibilities and role entrusted to him. Except as stated above, there was no change in the remuneration of any other managerial personnel during the financial year.

The Company does not have any other exceptional circumstances to report in relation to the increase in managerial remuneration during the year.
6. We, hereby affirm that pursuant to Rule 5(1)(xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the remuneration paid to the Directors, Key Managerial Personnel is as per the remuneration policy of the Company.

(B) Information relating to Top 10 employees

Name of Employee	Designation	Nature of Employment	Qualification	Age	Experience	Remuneration (2025-2026) (IN ₹)	Relative of any director/ manager
Manish Grover	Managing Director	Permanent	B.COM and Honorary Doctorate in Ayurveda & Naturopathy	52.	30 Years	2,40,00,000	Yes
Bhavna Grover	Whole time Director	Permanent	B.A.	51	24 Years	1,80,00,000	Yes
Sahil Jain	Chief Operating Officer (COO)	Permanent	MCA	37	16 Years	51,00,000	Yes
Gaurav Mohan Garg	Business Development Head	Permanent	B.Com and Diploma in Software Engineering	47	26 Years	41,05,000	No
Vishal Aggarwal	Regional Business Head	Permanent	B.A.	46	9 Years	40,55,519	Yes
Sunil Malik	Doctor	Permanent	Post Graduate Diploma in Health Insurance management	48	16 Years	33,17,741	No
Nanak Chand	Chief Financial Officer (CFO)	Permanent	B.Com Honours and CMA Executive	38	16 Years	31,50,000	No
Akansha Jain	HR Head	Permanent	MCA	37	13 Years	28,50,000	Yes
Ish Sharma	Director Medical Services & Research	Permanent	BAMS/MD/PHD/ MBA HRM	55	20 Years	27,54,839	No
Avira Gautam	Doctor	Permanent	BAMS/MD	39	7 Years	25,08,804	No
Suyash Pratap Singh	Doctor	Permanent	BAMS	33	11 Years	24,74,660	No
Akshay Agarwal	General Manager Operations	Permanent	B.com	40	20 Years	24,57,394	No

For and on behalf of Board
Jeena Sikho Lifecare Limited

Sd/-
Bhavna Grover
Whole Time Director
DIN: 07557913

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Date: 31.08.2026
Place: Zirakpur, Punjab

Chairman's Declaration on Code of Conduct

To,
The Members of
Jeena Sikho Lifecare Limited

This is to certify that the Company has laid down a Code of Conduct (the Code) for all Board Members and Senior Management Personnel of the Company and a copy of the Code is put on the website of the Company viz www.jeenasikho.com.

It is further confirmed that all Board Members and Senior Management Personnel have affirmed compliance with the Code of Conduct for Board of Directors and Senior Management Personnel, as approved by the Board, for the financial year ended on March 31, 2026.

By Order of the Board of Directors
For **JEENA SIKHO LIFECARE LIMITED**

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Date: 31.08.2026
Place: Zirakpur, Punjab

Report on Corporate Governance

1. THE COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

Jeena Sikho Lifecare Limited ("JSLL" or "the Company"), is committed to maintaining the highest standards of Corporate Governance, ethical business conduct, transparency, accountability, and integrity in all our operations. The Company's governance framework is founded on the principles of fairness, responsibility, sustainable growth, and long-term value creation for all stakeholders, including shareholders, patients, employees, customers, business partners, regulators, and society at large.

The Company firmly believes that an effective Corporate Governance framework is essential for sustainable business growth, operational excellence, and strengthening stakeholder confidence. In line with its philosophy of "Prevention is the Only Cure" and its mission of promoting holistic healthcare through Ayurveda, the Company conducts its business in a responsible, transparent, and ethical manner while ensuring compliance with all applicable statutory and regulatory requirements.

The Company has evolved into one of India's leading Ayurveda healthcare and wellness services providers with a growing network of hospitals, clinics, day-care centres, and Wellness Centres and healthcare products. Our integrated business model, strong governance practices, and patient-centric approach enable us to deliver sustainable value while remaining committed to the well-being of the communities we serve.

The Board of Directors plays a pivotal role in overseeing the Company's affairs and ensuring that management actions are aligned with the interests of stakeholders. Various Committees comprising experienced professionals and Independent Directors who provide guidance, oversight, and strategic direction to the Company support the Board.

The Company promotes a culture of transparency, professionalism, accountability, and continuous improvement across all levels of the organization. It encourages innovation, operational efficiency, and ethical decision-making while maintaining robust internal controls and risk management practices. The Company remains focused on delivering quality healthcare services, enhancing patient satisfaction, and creating sustainable long-term value for shareholders.

The Company has adopted a comprehensive Code of Conduct applicable to all Directors and employees, including Senior Management Personnel. The Company has also adopted a separate Code of Conduct for Independent Directors, incorporating the duties and responsibilities prescribed under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company remains committed to complying with the applicable provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other statutory and regulatory requirements governing its operations. The Board continuously reviews and strengthens the Company's governance practices to ensure alignment with evolving regulatory standards and global best practices.

Through its commitment to ethical business conduct, transparency, accountability, and stakeholder-centric decision-making, Jeena Sikho Lifecare Limited seeks to uphold the highest standards of Corporate Governance and contribute meaningfully to sustainable growth and value creation.

2. BOARD OF DIRECTORS (BOARD)

(A) Composition and size of the Board

The Company's Board is constituted of highly experienced professionals from diverse backgrounds. The Board's constitution is in compliance with the Companies Act, 2013, SEBI LODR and is in accordance with the highest standards of Corporate Governance, which ensures an appropriate mix of Executive, Woman and Independent Directors with demonstrated skill sets and relevant experience. The Board members have professional knowledge and experience in diverse fields viz. finance, audit, secretarial, public policy, taxation and legal, thereby bringing about an enabling environment for value creation through sustainable business growth.

As on March 31, 2026, the Board consists of six directors, three of whom, Mr. Manish Grover, and Mrs. Bhavna Grover and Ms. Shreya Grover are Executive Directors. The remaining three directors, namely, Mr. Karan Vir Bindra, Mr. Chandan Kumar Kaushal, and Mrs. Priyanka Bansal, are Non-Executive Independent Directors. Mr. Manish Grover, Managing Director, serves as the Chairman of the Board. Since the Chairman is an Executive Director, the Company is required to maintain at least fifty percent of the Board as Independent Directors in terms of Regulation 17 of the SEBI LODR. Accordingly, Independent Directors constitute 50% of the total Board strength, ensuring compliance with the applicable regulatory requirements.

Mrs. Bhavna Grover and Ms. Shreya Grover are related to Mr. Manish Grover. Mr. Manish Grover is the spouse of Mrs. Bhavna Grover and father of Ms. Shreya Grover. Except as stated above, none of the other Directors are related to each other.

The Board comprises Directors possessing expertise and experience in diverse areas such as healthcare services, business management, finance, accounting, legal affairs, corporate governance, strategy, risk management, regulatory compliance, operations, human resources and stakeholder management. The collective experience and diverse perspectives of the Directors contribute significantly to the effective functioning of the Board and the sustainable growth of the Company.

The Board has identified core skills, expertise and competencies required in the context of the Company's business and sector. These include Healthcare and Hospital Management, Business Strategy, Corporate Governance, Finance and Accounting, Risk Management, Regulatory Compliance, Legal Affairs, Human Resources, Operations Management, Stakeholder Relationship Management, Marketing, Technology and Value Creation. The Directors possess expertise in one or more of these areas, thereby enabling the Board to discharge its responsibilities effectively and provide strategic guidance to the management.

The Company has received declarations from its Independent Directors stating that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations and under Section 149(6) of the Act and are qualified to act as Independent Directors. As per Regulation 25(8) of the SEBI Listing Regulations and Section 149(7) of the Act, the Independent Directors have also confirmed that they do not have any knowledge of circumstances or situations that could impair or impact their ability to discharge their duties with an objective of independent judgement and without any external influence. In the opinion of the Board, the Independent Directors fulfill the conditions specified in the SEBI Listing Regulations and are independent of the management. Further, the Independent Directors have included their names in the Independent Directors data bank maintained by the Indian Institute of Corporate Affairs under Section 150 of the Act and Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

The names and categories of the directors on the Board, along with their positions in other listed entities and the number of directorships, and committee chairmanships/memberships they hold in other public limited companies as on March 31, 2026 are as follows:

Sr. no.	Name of the Director	Nature of Office	Special Knowledge/Practical Experience/Skills/Expertise/Competencies	Names of the other listed entities where the person is a director	Category of directorship in other listed entities where the person is a director	No. of Directorship			No. of Memberships/ Chairmanships in Board Committees of various companies (including this Company)**	
						in other Listed Companies (excluding Debt listed Companies)	in other Companies*	Memberships	Chairmanships	
1.	Mr. Karan Vir Bindra (DIN: 09283623)	Non-Executive/Independent Director	Mr. Karan Vir Bindra is a Fellow Member of the Institute of Company Secretaries of India (FCS) and holds a Bachelor's degree in Law (LL.B.) and a Bachelor's degree in Commerce. He is a practicing Company Secretary and proprietor of M/s K. V. Bindra & Associates.	1.Astonea Labs Limited	Non-Executive – Independent Director	1	0	3	1	
			With extensive experience in corporate laws, regulatory compliance, and governance matters, he provides valuable guidance to the Board in strengthening governance frameworks and ensuring adherence to applicable statutory and regulatory requirements.							

The names and categories of the directors on the Board, along with their positions in other listed entities and the number of directorships, and committee chairmanships/memberships they hold in other public limited companies as on March 31, 2026 are as follows: (Contd.)

Sr. no.	Name of the Director	Nature of Office	Special Knowledge/Practical Experience/Skills/Expertise/Competencies	Names of the other listed entities where the person is a director	Category of directorship in other listed entities where the person is a director	No. of Directorship		No. of Memberships/ Chairmanships in Board Committees of various companies (including this Company)**	
						in other Listed Companies (excluding Debt listed Companies)	in other Companies*	Memberships	Chairmanships
2.	Mr. Chandan Kumar Kaushal (DIN: 10515819)	Non-Executive/ Independent Director	Mr. Chandan Kumar Kaushal holds a Bachelor of Ayurvedic Medicine and Surgery (B.A.M.S.) degree from the Punjab State Faculty of Ayurvedic & Unani Systems of Medicine, Chandigarh, awarded in 1985. He commenced his professional career as an Ayurveda Medical Officer in June 1987 and was subsequently promoted to the position of Senior Ayurveda Medical Officer in 2016 in recognition of his dedicated service and contribution to the field of Ayurveda. His extensive experience in Ayurvedic healthcare and clinical practices provides valuable industry insights and supports the Company's vision of promoting holistic healthcare solutions..	N.A	N.A.	N.A	N.A	1	1

The names and categories of the directors on the Board, along with their positions in other listed entities and the number of directorships, and committee chairmanships/memberships they hold in other public limited companies as on March 31, 2026 are as follows: (Contd.)

Sr. no.	Name of the Director	Nature of Office	Special Knowledge/Practical Experience/Skills/Expertise/Competencies	Names of the other listed entities where the person is a director	Category of directorship in other listed entities where the person is a director	No. of Directorship			No. of Memberships/Chairmanships in Board Committees of various companies (including this Company)**	
						in other Listed Companies (excluding Debt listed Companies)	in other Companies*	Memberships	Chairmanships	
3.	Mrs. Priyanka Bansal (DIN: 09051665)	Non-Executive/ Independent Director	Mrs. Priyanka Bansal is a Commerce graduate (B.Com), holds a Diploma in Web & Software Engineering, and is a qualified Chartered Accountant. She brings over 14 years of professional experience in finance, taxation, auditing, and corporate advisory services. Her expertise includes financial management, regulatory compliance, audit oversight, and strategic financial planning. Her financial acumen and professional experience contribute significantly to strengthening financial governance and oversight processes of the Company.	N.A.	N.A.	1	0	1	1	
4.	Mr. Manish Grover(DIN: 07557886)	Executive/ Managing Director	Mr. Manish Grover is an Ayurveda promoter, health educator, and advocate of holistic wellness, with over two decades of experience in natural healthcare, Ayurveda, yoga, and meditation.	N.A	N.A.	0	0	2	0	

The names and categories of the directors on the Board, along with their positions in other listed entities and the number of directorships, and committee chairmanships/memberships they hold in other public limited companies as on March 31, 2026 are as follows: (Contd.)

Sr. no.	Name of the Director	Nature of Office	Special Knowledge/Practical Experience/Skills/Expertise/Competencies	Names of the other listed entities where the person is a director	Category of directorship in other listed entities where the person is a director	No. of Directorship		No. of Memberships/Chairmanships in Board Committees of various companies (including this Company)**	
						in other Listed Companies (excluding Debt listed Companies)	in other Companies*	Memberships	Chairmanships
5.	Mrs. Bhavna Grover (DIN: 07557913)	Executive/ Whole Time Director	His expertise includes preventive healthcare, Ayurvedic therapies, lifestyle and wellness management, and strategic leadership in the healthcare sector. He has played a key role in shaping the Company's vision and establishing its presence in the Ayurveda and wellness industry.						
			Mrs. Bhavna Grover possesses extensive experience in managing finance, human resources, and administrative functions of the Company.	N.A	N.A	0	0	1	0
			She has contributed significantly towards strengthening operational systems, financial planning processes, administrative controls, and organizational effectiveness.						
			Her areas of expertise include financial oversight, organizational management, human resource administration, and regulatory compliance, supporting the Company's robust governance framework and operational growth.						

The names and categories of the directors on the Board, along with their positions in other listed entities and the number of directorships, and committee chairmanships/memberships they hold in other public limited companies as on March 31, 2026 are as follows: (Contd.)

Sr. no.	Name of the Director	Nature of Office	Special Knowledge/Practical Experience/Skills/Expertise/Competencies	Names of the other listed entities where the person is a director	Category of directorship in other listed entities where the person is a director	No. of Directorship		No. of Memberships/Chairmanships in Board Committees of various companies (including this Company)**	
						in other Listed Companies (excluding Debt listed Companies)	in other Companies*	Memberships	Chairmanships
6.	Ms. Shreya Grover (DIN: 09199495)	Executive/ Whole Time Director	Ms. Shreya Grover brings a dynamic and forward-looking perspective to the Board and actively contributes to the Company's strategic initiatives, particularly in branding, sales, marketing, and business development of Ayurvedic and wellness products. Her expertise includes brand positioning, digital outreach, customer engagement, and market expansion strategies. She provides innovative insights and supports the Company's growth initiatives and enhanced market presence in the Ayurveda and wellness sector.	N.A	N.A.	N.A.	N.A.	0	0

*Excludes directorship(s) held in foreign companies & private limited companies and Companies under section 8 of the Companies Act, 2013. Partnership Firms, LLP, HUF, Sole Proprietorships and Association of Individuals (Trust, Society etc.).

**Only memberships of the Audit Committee/Stakeholders' Relationship Committee in various public limited companies and chairmanship of the Audit Committee/Stakeholders' Relationship Committee in various listed companies, including this listed company are considered, as per Regulation 26 of the SEBI LODR.

The Board do hereby confirm that all the present Independent Directors of the Company fulfill the conditions specified in the SEBI LODR and are independent of the management of the Company and none of them have resigned before the expiry of their respective tenure(s).

The Board had accepted all recommendations of committees of the Board which are mandatorily required, during the financial year 2025-26.

(B) Number and Dates of Board Meetings held, attendance of Directors thereat and at the last AGM held

The Board meets at regular intervals to discuss and make decisions regarding the Company's results, operations, business policies, strategies, and other matters.

During the FY 2025-26, the Board met 17 (Seventeen) times. Meetings were held on April 21, 2025, April 30, 2025, May 16, 2025, July 28, 2025, August 04, 2025, August 14, 2025, August 27, 2025 and October 06, 2025, October 13, 2025, November 06, 2025, December 01, 2025, December 23, 2025, January 13, 2026, January 21, 2026, February 07, 2026, February 24, 2026 and March 09, 2026. The maximum interval between any two meetings did not exceed 120 days, as prescribed by the Act.

During the year, separate meeting of the Independent Directors was held on January 01, 2026 and February 07, 2026, without the attendance of Non-Independent Directors and the members of the management. At the meeting, the Independent Directors reviewed/assessed the performance of Non-Independent Directors and the Board, the quality, quantity and timeliness of the flow of information between the Company's management and the Board and the performance of the Chairperson of the Company, taking into account views of Executive Directors.

The last Annual General Meeting of the Company was held on September 29, 2025.

Attendance of Directors at the Board Meetings held during the FY 2025-26 and at the last Annual General Meeting are as under:

Sr. No.	Name of the Director	No. of Board meetings attended	Attendance at the last AGM
1.	Mr. Manish Grover (DIN: 07557886)	17	Yes
2.	Mrs. Bhavna Grover (DIN: 07557913)	17	Yes
3.	Ms. Shreya Grover (DIN: 09199495)	17	Yes
4.	Mrs. Priyanka Bansal (DIN: 09051665)	16	Yes
5.	Mr. Karan Vir Bindra (DIN: 09283623)	17	Yes
6.	Mr. Chandan Kumar Kaushal (DIN: 10515819)	17	Yes

The minutes of the Board Meetings of the unlisted subsidiary companies of the Company are placed in the Board Meetings of the Company.

(C) Directors with pecuniary relationship or business transaction with the Company

The Company has Executive Directors and Independent Directors on its Board. The Independent Directors do not have any pecuniary relationship or business transactions with the Company, its Promoters, Management, Subsidiaries or Associate Companies, except for the sitting fees paid for attending the meetings of the Board of Directors and its Committees, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Executive Directors receive remuneration comprising salary, allowances and perquisites, as approved by the shareholders. There are no other pecuniary relationships or business transactions between the Independent Directors and the Executive Directors or with the Company, other than those disclosed above.

(D) Meeting of Independent Directors

A separate meeting of the Independent Directors was held on 01st January, 2026 and 07th February, 2026, without the presence of Non-Independent Directors and the management, inter-alia, to discuss (a) Evaluation of the performance of the Non-Independent Directors and the Board of Directors as a whole, (b) Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive Directors and Non-Executive Directors and (c) Evaluation of the quality, quantity and timeliness of flow of information between the Management and the Board, that is necessary for the Board to effectively and reasonably perform its duties.

The Independent Directors expressed satisfaction with the overall performance of the Directors and the Board as a whole

(E) Directors and Officers Insurance

Pursuant to Regulation 25(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has obtained a Directors and Officers (D&O) Liability Insurance Policy for its Independent Directors. The policy provides coverage for such quantum and such risks as may be determined by the Board from time to time.

(F) Familiarization Programme for Independent Directors

The Familiarization program aims to provide insight to the Independent Directors to understand the nature of the Industry in which the Company operates, business model of the Company, its stakeholders, leadership team, senior management, operations, policies and industry perspective and issues. The Independent Directors are made aware of their roles, rights, and responsibilities at the time of their appointment/re-appointment through a formal letter of appointment.

In addition to the above, the familiarization program for Independent Directors forms part of the Board process. On an ongoing basis, the Directors are familiarized with the Company's business, its operations, business plans, strategy, functions, policies and procedures and the performance of subsidiaries at the Board and Committee meetings. Changes in the regulatory framework and its impact on the operations of the Company are also presented at the Board/Committee meetings.

The details of the familiarization program for Independent Directors are available on the Company's website and the web link https://jeenasikho.com/wp-content/uploads/2023/12/Code-of-Familiarization-for-Independent-Directors-2025_26.pdf

3. COMMITTEES OF THE BOARD

The Board has constituted various Committees to take informed decisions in the best interest of the Company. These Committees monitor the activities falling within their terms of reference. Further, terms of reference were revised to align with the provisions of Companies Act, 2013 and SEBI LODR, and other applicable regulatory requirements.

The number of Directorships held by all Directors as well as their Membership/Chairmanship in Committees is within the prescribed limits under the Companies Act, 2013 and SEBI LODR.

The role and the composition of these Committees including number of meetings held during the financial year ended March 31, 2026 are set out below:

(A) Audit Committee

Composition

The Audit Committee comprises of three Directors, namely, Mrs. Priyanka Bansal (Independent Director) as the Chairman, Mr. Karan Vir Bindra (Independent Director) and Mr. Manish Grover (Managing Director), as members.

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, acts as the Secretary to the Audit Committee. She was appointed as the Company Secretary & Compliance Officer with effect from July 15, 2026, pursuant to the resignation of Mrs. Smita Chaturvedi, who ceased to hold the office of Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

Terms of reference

The terms of reference of the Audit Committee, inter-alia, include:

- To oversee the financial reporting process and disclosure of financial information;
- To review with Management, Quarterly, Half Yearly and Annual Financial Statements and ensure their accuracy and correctness before submission to the Board;
- To review with Management and Internal Auditors, the adequacy of internal control systems, approving the internal audit plans/reports and reviewing the efficacy of their function, discussion and review of periodic audit reports including findings of internal investigations;
- To recommend the appointment of the Internal and Statutory Auditors and their remuneration;
- To review and approve the adequacy of provisions for doubtful debts/receivables and other write-off decisions in accordance with the Company's accounting policies;
- To hold discussions with the Statutory and Internal Auditors;
- Review and monitoring of the Auditor's independence and performance, and effectiveness of audit process;
- Examination of the Auditors' report on financial statements of the Company (in addition to the financial statements) before submission to the Board;
- Approval or any subsequent modification of transactions of the Company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Review of Internal Audit Reports relating to internal control systems and the operations of the Company;
- Valuation of undertakings or assets of the Company, wherever it is necessary;
- Monitoring the end use of funds raised through public offers and related matters as and when such funds are raised and also reviewing with the management the utilization of the funds so raised, for purposes other than those stated in the relevant offer document, if any and making appropriate recommendations to the Board in this regard;
- Evaluation of the risk management systems (in addition to the internal control systems);
- Review and monitoring of the performance of the Statutory Auditors and effectiveness of the audit process;
- To hold post audit discussions with the Auditors to ascertain any area of concern;
- To review the functioning of the whistle blower mechanism;
- Approval to the appointment of the CFO after assessing the qualifications, experience and background etc. of the candidate;
- Approval of write-off of bad and doubtful debts/receivables in terms of the Company's policy, where applicable;
- Review of information system audit of the internal systems and processes to assess the operational risks faced by the Company and also ensures that the information system audit of internal systems and processes is conducted periodically; and
- Reviewing the utilization of loans and/or advances and/or investment by the Company to its Subsidiary Companies, exceeding rupees 100 Crores or 10% of the assets side of the respective Subsidiary Companies, whichever is lower, including existing loans/advances/investment existing as on April 1, 2019.

Meetings and Attendance during the year

During the financial year ended March 31, 2026 the Committee met 10 (Ten) times. The dates of the meetings being April 21, 2025, May 16, 2025, August 14, 2025, August 27, 2025, October 06, 2025 and November 06, 2025, December 23, 2025, January 21, 2026, February 07, 2026 and March 09, 2026.

(B) The attendance of Committee members in these meetings is as under:

Name of the Member	No. of meetings attended
Mrs. Priyanka Bansal*	6
Mr. Chandan Kumar Kaushal*	4
Mr. Karan Vir Bindra	10
Mr. Manish Grover	10

*Mrs. Priyanka Bansal was appointed as the chairperson of the Committee and Mr. Chandan Kumar Kaushal ceased to be member w.e.f. October 06, 2025 pursuant to Reconstitution of the Audit Committee.

(C) Nomination & Remuneration Committee**Composition**

The Nomination & Remuneration Committee (N&R) of the Board comprises of three Independent Directors as its members, namely, Mr. Karan Vir Bindra as Chairman, Mr. Chandan Kumar Kaushal and Mrs. Priyanka Bansal as the other two members.

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, acts as the Secretary to the Nomination & Remuneration Committee. She was appointed as the Company Secretary & Compliance Officer with effect from July 15, 2026, pursuant to the resignation of Mrs. Smita Chaturvedi, who ceased to hold the office of Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

Terms of reference

The terms of reference of Nomination & Remuneration Committee, inter-alia, include:

- To formulate the criteria for determining qualifications, positive attributes, expertise, integrity and independence of a Director and recommend to the Board a policy relating to the remuneration of Directors, Key Managerial Personnel (KMP), Senior Management Personnel and other employees.
- To formulate the criteria for evaluation of the performance of the Board of Directors, its Committees, Individual Directors and Independent Directors.
- To devise a policy on the diversity of the Board of Directors.
- To identify persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down by the Committee, and recommend their appointment, re-appointment and removal to the Board.
- To recommend to the Board the appointment, re-appointment, remuneration, terms and conditions of appointment, continuation and removal of Directors, Key Managerial Personnel and Senior Management Personnel.
- To recommend to the Board the remuneration, including salary, perquisites, allowances, incentives, retirement benefits, commission (where applicable)

and other benefits payable to the Executive Directors, Key Managerial Personnel and Senior Management Personnel, in accordance with the applicable laws and the Company's Remuneration Policy.

- To recommend to the Board the sitting fees, commission (where applicable) and other compensation payable to Non-Executive Directors and Independent Directors, in accordance with the applicable laws and shareholders' approvals, wherever required.
- To ensure that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors and Senior Management of the quality required to run the Company successfully, and that the relationship of remuneration to performance is clear and meets appropriate performance benchmarks.
- To determine and recommend the overall remuneration policy and other terms and conditions of employment of Directors, Key Managerial Personnel and Senior Management Personnel.
- To carry out the evaluation of the performance of every Director and review the implementation and effectiveness of the performance evaluation framework.
- To determine whether to extend or continue the term of appointment of an Independent Director on the basis of the report of performance evaluation and fulfilment of the applicable criteria under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- To review and ensure that the proposed and existing Directors satisfy the applicable eligibility, independence and other criteria prescribed under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws.
- To administer, supervise and perform such functions as are required under the Company's employee stock option/share-based benefit schemes and the provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, including such powers as may be delegated by the Board.
- To ensure that the removal of Directors, Key Managerial Personnel and Senior Management Personnel is carried out in accordance with the applicable provisions of law and the principles of natural justice.

- To perform such other duties, responsibilities and functions as may be assigned by the Board of Directors or as may be prescribed under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, or any other applicable law, statutory amendment or regulatory requirement from time to time.

Meetings and Attendance during the year

During the financial year ended March 31, 2026, the Committee met 5 (five) times i.e. on, April 21, 2025, August 04, 2025, August 27, 2025, October 01, 2025 and January 01, 2026.

The attendance of Committee members in these meetings is as under:

Name of the Member	No. of meetings attended
Mr. Karan Vir Bindra	5
Mr. Chandan Kumar Kaushal	5
Mrs. Priyanka Bansal	2
Ms. Shreya Grover	3

*Mrs. Priyanka Bansal was appointed as the member of the Committee and Ms. Shreya Grover ceased to be member w.e.f. August 27, 2025 pursuant to Reconstitution of the Nomination and Remuneration Committee.

Policy for selection and appointment of Directors

The Nomination and Remuneration Committee (N&R Committee/NRC) has adopted a policy which, inter alia, deals with the manner of selection of the Board of Directors, Senior Management and their compensation. This Policy is accordingly derived from the said Charter.

- The incumbent for the positions of Executive Directors and/or at Senior Management, shall be the persons of high integrity, possesses relevant expertise, experience and leadership qualities, required for the position.
- The Non-Executive Directors shall be of high integrity, with relevant expertise and experience so as to have the diverse Board with Directors having expertise in the fields of finance, banking, regulatory, taxation, law, governance and general management.
- In case of appointment of Independent Directors, the independent nature of the proposed appointee vis-a-vis the Company shall be ensured.
- The N&R Committee shall consider qualification, experience, expertise of the incumbent, and shall also ensure that such other criteria with regard to age and other qualification etc., as laid down under the Companies Act, 2013 or other applicable laws are fulfilled, before recommending to the Board, for their appointment as Directors.
- In case of re-appointment, the Board shall take into consideration, the performance evaluation of the Director and his/her engagement level.

Remuneration Policy

Company's Remuneration Policy is market led, based on the fundamental principles of payment for performance, for potential and for growth. It also takes into account the competitive circumstances of the business, so as to attract and retain quality talent and leverage performance significantly. The N&R Committee recommends the remuneration payable to the Executive Directors and Key Managerial Personnel, for approval by Board of Directors of the Company, subject to the approval of its Shareholders, wherever necessary. The Remuneration Policy is also available at the website of the Company, at <https://jeenasikho.com/wp-content/uploads/2026/08/NRC-Policy.pdf>

Evaluation of the Board and Directors

The Independent Directors play a key role in the decision-making process of the Board as they approve the overall strategy of the Company and oversee performance of the management. The Independent Directors are committed to act in the best interest of the Company and its stakeholders. The Independent Directors bring a wide range of experience, knowledge and judgment. Their wide knowledge of both, their field of expertise and boardroom practices brings in varied, unbiased, independent and experienced outlook. All Independent Directors have committed and allocated sufficient time to perform their duties effectively. All the Independent Directors of the Company have confirmed that they have registered themselves in the databank created for Independent Directors, well within the stipulated time frame.

The Nomination and Remuneration Committee (NRC) of the Board reassessed the framework, methodology and criteria for evaluating the performance of the Board as a whole, including Board Committee(s), as well as performance of each Director(s)/Chairman and confirmed that the existing evaluation parameters are in compliance with the requirements as per SEBI guidance note dated January 5, 2017 on Board evaluation. The existing parameters includes effectiveness of the Board and its committees, decision making process, Directors/Members participation, governance, independence, quality and content of agenda papers, team work, frequency of meetings, discussions at meetings, corporate culture, contribution, role of the Chairman and management of conflict of interest. Basis these parameters and guidance note on board evaluation issued by SEBI, the NRC had reviewed at length the performance of each Director individually and expressed satisfaction on the process of evaluation and the performance of each Director. The performance evaluation of the Board as a whole and its Committees, namely, Corporate Social Responsibility Committee and Risk Management Committee as well as the performance of each Director individually, including the Chairman was carried out by the entire Board of Directors. The performance evaluation of the Chairman and Executive Directors was carried out by the Independent Directors in their meeting held on January 01, 2026 and February 07, 2026. The Directors expressed their satisfaction with the evaluation process.

Policy on Board Diversity

The Nomination & Remuneration Committee has formulated a Board Diversity Policy to ensure an appropriate balance of skills, experience, knowledge, and perspectives on the Board.

The policy aims to promote diversity in areas such as professional expertise, industry experience, functional knowledge, and leadership capabilities, enabling the Board to effectively address strategic and operational challenges.

Director's Remuneration:

(i) Remuneration of Executive Directors

The Executive Directors are being paid remuneration as recommended by Nomination and Remuneration Committee and approved by the Board of Directors/Shareholders. The elements of the remuneration package of Executive Directors comprise salary, other benefits & allowances and post-retirement benefits. The same is decided by the Nomination and Remuneration Committee within the overall limits as approved by the Board/Shareholders. The annual increments of Executive Directors are linked to their performance & are reviewed by Nomination and Remuneration Committee. The notice period presently applicable to them is as per the Company policies. No severance fee is payable by the Company on termination of Executive Directors. The Whole Time Directors and Managing Director of the Company have been appointed by the Shareholders for a fixed tenure.

Details of remuneration paid to the Executive Directors during the year under review are as follows:

Particulars	Mr. Manish Grover	Mrs. Bhavna Grover	Ms. Shreya Grover
Designation	Managing Director (Executive Director)	Whole-time Director (Executive Director)	Whole-time Director (Executive Director)
Nature of Transaction	Remuneration	Remuneration	Remuneration
Remuneration Paid	₹ 2,40,00,000	₹ 1,80,00,000	₹ 7,00,000

(ii) Remuneration of Non-Executive Independent Directors

Though day-to-day management of the Company is delegated to its Executive Directors, the Non-Executive Independent Directors also contribute significantly for laying down the policies and providing guidelines for conduct of Company's business. Considering the need for the enlarged role and active participation/contribution of Non-Executive Independent Directors to achieve the growth in operations and profitability of the Company, it is appropriate that the services being rendered by them to the Company are recognized by it by way of payment of compensation, commensurate with their contributions, as permissible within the applicable regulations. The Company's Non-Executive Independent Directors between them have extensive entrepreneurial experience, and deep experience in the fields of financial sector regulation and supervision, secretarial, accounting, administration, and law enforcement etc. The Non-Executive Independent Directors both exercise effective oversight, and also guide the senior management team. Their experience and inputs have been invaluable. They also devote their valuable time in deliberating on the strategic and critical issues in the course of the Board and Committee meetings of the Company and give their valuable advice, suggestion and guidance to the management of the Company. The Company is making payment of Sitting fees payable to its Non-Executive Independent Directors in accordance with the provisions of the Companies Act, 2013 and SEBI LODR.

The Company has placed on its website, criteria for making payment to Non-Executive Independent Directors. During the Financial Year ended March 31, 2026, the Non-Executive Independent Directors have been paid, sitting fees for attending the Board meetings and committee meetings of the Company, the details of which are provided as follows:

Particulars	Mr. Karan Vir Bindra	Mrs. Priyanka Bansal	Mr. Chandan Kumar Kaushal
Designation	Independent Director	Independent Director	Independent Director
Nature of Transaction	Sitting Fees	Sitting Fees	Sitting Fees
Sitting Fees paid	₹ 1,56,000	₹ 2,20,000	₹ 6,50,000

The Non-Executive Independent Directors of the Company do not have any pecuniary relationships or transactions with the Company or its Directors, Senior Management, Subsidiary or Associate Companies, other than in the normal course of business.

Shares and Convertible Instruments held by Non-Executive Directors

Pursuant to Part C of Schedule V of the SEBI Listing Regulations, the number of shares and convertible instruments held by each of the Non-Executive Directors of the Company as on March 31, 2026 is set out below:

Sr. No.	Name of the Non-Executive Director	No. of Equity Shares held	No. of Convertible Instruments held
1.	Mr. Karan Vir Bindra (Independent Director)	Nil	Not Applicable
2.	Mr. Chandan Kumar Kaushal (Independent Director)	Nil	Not Applicable
3.	Mrs. Priyanka Bansal (Independent Director)	Nil	Not Applicable

As reflected in the shareholding pattern of the Company as on March 31, 2026, the category 'Directors and their relatives' (other than the Promoter Directors) holds Nil shares, and the Company has not issued any convertible instruments to its Non-Executive Directors.

(D) Stakeholders Relationship Committee

Composition

The Stakeholders Relationship Committee (SRC) currently comprises of three members, namely, Mr. Chandan Kumar Kaushal as Chairman, Mrs. Bhavna Grover and Mr. Manish Grover, as Members. One out of the three Members of the Committee, namely, Mr. Chandan Kumar Kaushal is the Independent Director and Mrs. Bhavna Grover and Mr. Manish Grover are Executive Directors.

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, acts as the Secretary to the Stakeholders Relationship Committee. She was appointed as the Company Secretary & Compliance Officer with effect from July 15, 2026, pursuant to the resignation of Mrs. Smita Chaturvedi, who ceased to hold the office of Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

Terms of Reference

- To approve requests for share transfers and transmissions;

- To approve the requests pertaining to remat of shares/ sub-division/consolidation/issue of renewed and duplicate share certificates etc.;
- To oversee all matters encompassing the Shareholders'/ Investors' related issues;
- Resolving the grievances of the security holders of the Company, including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/ duplicate certificates, general meetings etc.;
- Review of measures taken for effective exercise of voting rights by Shareholders;
- Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent; and
- Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the Shareholders of the Company.

Meetings and Attendance during the year

During the financial year ended March 31, 2026, the Committee met 2 (two) times. The dates of the meetings being October 01, 2025 and February 07, 2026.

The attendance of Committee members in these meetings is as under:

Name of the Member	No. of meetings attended
Mr. Chandan Kumar Kaushal	2
Mrs. Bhavna Grover	2
Mr. Manish Grover	2

Name and designation of Compliance Officer

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, is the Compliance Officer of the Company pursuant to Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. She was appointed with effect from July 15, 2026, pursuant to the resignation of Ms. Smita Chaturvedi, who ceased to be the Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

Details of queries/complaints received and resolved pertaining to Equity Shares of the Company during the year 2025-26:

Sl. No.	Particulars	Opening	Received	Disposed	Pending
1	Legal Cases before Consumer Forums	0	2	0	2
2	Letters from SEBI/Stock Exchange.	0	6	6	0
3	Status of applications lodged for public issue(s)	0	0	0	0
4	Non-receipt of dividend	0	1	1	0
5	Non-receipt of annual report	0	0	0	0
6	Non receipt of Refund order	0	0	0	0
7	Non-credit/receipt of shares in demat account	0	0	0	0
8	Non receipt of securities after transfer	0	0	0	0
9	Non receipt of call money notice	0	0	0	0
TOTAL		0	9	7	2

(E) Risk Management Committee

Composition

The Risk Management Committee of the Board comprises of three members i.e. Mr. Manish Grover (Managing Director) as Chairman, Mrs. Bhavna Grover (Whole Time Director) and Mrs. Priyanka Bansal (Independent Director), the other two Members of Committee.

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, acts as the Secretary to the Risk Management Committee. She was appointed as the Company Secretary & Compliance Officer with effect from July 15, 2026, pursuant to the resignation of Mrs. Smita Chaturvedi, who ceased to hold the office of Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

The policy aims to promote diversity in areas such as professional expertise, industry experience, functional knowledge, and leadership capabilities, enabling the Board to effectively address strategic and operational challenges.

Terms of reference

The terms of reference of the Risk Management Committee, inter-alia, include:

- Approve the enterprise-level Risk Management Policy of the Company and review/modify the same from time to time;
- Review the applicable regulatory and statutory requirements and monitor compliance therewith;
- Review and approve the framework and functional policies of the Company relating to identification, assessment and mitigation of enterprise, operational, financial, regulatory, ESG (Environmental, Social and Governance) and business-continuity risks;

- Review the Company's exposure to cyber-security risks and oversee the adequacy of information and cyber-security systems and controls, including business-continuity and disaster-recovery preparedness;
- Review the risk mitigation systems and internal control mechanisms put in place by the management for key operational and financial risks, including risks relating to supply chain, patient safety, quality, statutory compliance and regulatory approvals applicable to the healthcare and Ayurveda business of the Company;
- Review reports on internal audit findings pertaining to operational risk areas and monitor compliance with identified action points;
- Periodically review the Company's risk management framework and functional policies, at least once in two years, including by considering the changing industry dynamics and evolving complexity;
- Keep the Board of Directors informed about the nature and content of its discussions, recommendations and actions to be taken;
- Ensure appropriate mechanisms are in place for timely identification, assessment, monitoring and reporting of enterprise-wide risks, including fraud risk; and
- Any other matter involving risk to the assets, business, operations, financial position, reputation or continuity of the Company, or as may be required under Regulation 21 and Part D of Schedule II of the SEBI Listing Regulations.

Meetings and Attendance during the year

During the financial year ended March 31, 2026, the Committee met 2 (Two) times. The dates of the meetings being, November 06, 2025 and February 07, 2026.

The attendance record of Committee members in respect of the meetings so held is depicted in the table given below:

Sl. No.	Name of the Member	No. of meetings attended
1	Mr. Manish Grover	2
2	Mrs. Bhavna Grover	2
3	Mrs. Priyanka Bansal	2

(F) Corporate Social Responsibility (CSR) Committee

Composition

The Corporate Social Responsibility Committee comprises of three members, namely, Mr. Karan Vir Bindra (Independent Director) as the Chairman, Mr. Manish Grover (Managing Director) and Mrs. Bhavna Grover (Whole Time Director) as the other two members.

Ms. Priya Goyal (Membership No. A71180), Company Secretary & Compliance Officer, acts as the Secretary to the Corporate Social Responsibility Committee. She was appointed as the Company Secretary & Compliance Officer with effect from July 15, 2026, pursuant to the resignation of Mrs. Smita Chaturvedi, who ceased to hold the office of Company Secretary & Compliance Officer with effect from the close of business hours on July 14, 2026.

Terms of Reference

The terms of reference of the CSR Committee, inter-alia, include:

- To recommend to the Board, the CSR activity to be undertaken by the Company;
- To approve the expenditure to be incurred on the CSR activity;
- To oversee and review the effective implementation of the CSR activity; and
- To ensure compliance of all related applicable regulatory requirements.

Meetings and Attendance during the year

During the financial year ended March 31, 2026 the Committee met 2 (Two) times. The date of the meetings being May 16, 2025 and February 24, 2026.

Sl. No.	Name of the Member	No. of meetings attended
1	Mr. Karan Vir Bindra	2
2	Mr. Manish Grover	2
3	Mrs. Bhavna Grover	2

4. GENERAL BODY MEETINGS

(A) Location and time of last three Annual General Meetings (AGMs) and number of special resolutions passed thereat:

Year	Meeting	Location	Date	Time	Number of special resolutions passed
2024-25	Annual General Meeting	First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, Main Road, Sas Nagar, Punjab 140603	29 September, 2025	12:00 Noon	3
2023-24	Annual General Meeting	Shuddhi Ayurveda Panchkarma Hospital, Pind Devinagar, Hadbast No. 18 Tehsil, Derabassi Dist, Punjab 140507	28 August, 2024	12:00 Noon	2
2022-23	Annual General Meeting	Shuddhi Ayurveda Panchkarma Hospital, Pind Devinagar, Hadbast No. 18 Tehsil, Derabassi Dist, Punjab 140507	08 September, 2023	12:00 Noon	3

(B) Postal Ballot during the FY 2025-26

During the financial year 2025-26, the Company sought approval of its Members through Postal Ballot conducted by remote e-voting in accordance with the provisions of Section 110 of the Companies Act, 2013 read with the applicable Rules and MCA Circulars. The results of the Postal Ballot were declared on May 24, 2025.

The following Special Resolutions were passed by the Members with the requisite majority through Postal Ballot:

- Approval for sub-division/split of the existing equity shares of the Company from face value of ₹10/- each into equity shares of face value of ₹2/- each;
- Approval for migration of the Company's equity shares from the NSE Emerge Platform to the Main Board of National Stock Exchange of India Limited (NSE) and BSE Limited (BSE); and
- Appointment of Mrs. Priyanka Bansal (DIN: 09051665) as a Non-Executive Independent Director of the Company for a term of five consecutive years with effect from April 21, 2025.

5. MEANS OF COMMUNICATION

The Company has provided adequate and timely information to its member's, inter-alia, through the following means:

- Publication of financial Results: The quarterly/annual results of the Company are published in the leading newspapers viz. Business Standard (English and Punjab), Financial Express and (English), Nawanzamana (Punjabi).

- News, Release etc.: The Company has its own website <https://jeenasikho.com> and all vital information relating to the Company and its performance including financial results, earnings update, press releases pertaining to important developments, performance updates and corporate presentations etc. are regularly posted on the website.

- Presentation to institutional investors or analysts: The presentations made to the institutional investors or analysts, are uploaded on the website of the Company, and also sent to the Stock Exchange for dissemination.

- Management's Discussion and Analysis Report has been included in the Annual Report, which forms a part of the Annual Report.

6. GENERAL SHAREHOLDERS INFORMATION

(A) Company Registration Details

The Company is registered in the State of Punjab. The Corporate Identity Number (CIN) allotted to the Company by the Ministry of Corporate Affairs (MCA) is L52601PB2017PLCO46545

(B) Date, Time and Venue of AGM

The 9th AGM of the Company would be held on the day, date and time as mentioned in the Notice convening the said AGM. The Company is conducting AGM at First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, Main Road, Sas Nagar, Punjab 140603.

(C) Financial year

The financial year of the Company is a period of twelve months beginning on April 01, every calendar year and ending on March 31 the following calendar year.

(D) Dividend Payment Date

The board of directors has recommended a final dividend of ₹ 4.50/- per equity share having face value of ₹ 2/- each for the financial year 2025-26, subject to the approval of the shareholders in ensuing Annual General Meeting of the Company & shall be paid within 30 days from the date of Annual General Meeting.

(E) Dividend Policy

The declaration and payment of dividend will be recommended by the Board of Directors and approved by the Shareholders, at their discretion, subject to the provisions of the Articles of Association and the Act. The dividend, if any, will depend on several factors, including but not limited to growth plans, capital requirements and the available distributable surplus. This Policy is available on the

Company's website at https://jeenasikho.com/wp-content/uploads/2024/07/Dividend-Distribution-Policy_JSLL.pdf

(F) Date of Book Closure

The Record Date for the purpose of determining the Members eligible to receive dividend for the financial year 2025-26, is as mentioned in the Notice convening the 9th AGM of the Company.

(G) Listing on Stock Exchanges

The Company's shares are listed at the following stock exchanges:

Equity Shares

BSE Limited (BSE)

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

National Stock Exchange of India Ltd (NSE) "Exchange Plaza" C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051

Stock Code/Symbol/ISIN

The Company's Equity Shares are identified on the stock exchanges and depositories through the following codes/symbol:

Particulars	Details
BSE Scrip Code	544476
NSE Symbol	JSLL
ISIN (for Equity Shares in dematerialized form)	INEOJ5801029

The Company confirms that the annual listing fees for the financial year 2025-26 have been paid in full to both BSE Limited and the National Stock Exchange of India Limited within the prescribed timelines.

The Annual Custodial Fee as applicable for the financial year 2025-26 has been paid within the due dates to Central Depository Services Limited (CDSL) and National Securities Depository Limited (NSDL).

Market Price Data and Performance in comparison to Broad-based Indices

The monthly high and low market prices of the Company's Equity Shares traded on BSE Limited and the National Stock Exchange of India Limited during the financial year 2025-26, along with the corresponding closing values of the BSE Sensex/ NSE Nifty, are as under:

Month	BSE High (₹)	BSE Low (₹)	NSE High (₹)	NSE Low (₹)	BSE Sensex/NSE Nifty (Closing)
April 2025	Not Listed	Not Listed	2380	1850	2104.85 (NSE)
May 2025	Not Listed	Not Listed	2450.00	1880	2132.25 (NSE)
June 2025*	Not Listed	Not Listed	2348.95	400.25	426.4 (NSE)
July 2025	Not Listed	Not Listed	584	432.9	553.15 (NSE)
August 2025	747.95	516.5	748	510.3	707.75 (BSE) 708.15 (NSE)
September 2025	850	698.95	849.5	699.50	799.55 (BSE) 798.75 (NSE)
October 2025	837.95	717.35	839	717.15	743.8 (BSE) 742 (NSE)
November 2025	839.9	678.05	835	679.50	707.9 (BSE) 707.35 (NSE)
December 2025	760.00	661.75	760.00	661.25	680.60 (BSE) 680.65 (NSE)
January 2026	748.45	643.7	748.9	642.35	663.2 (BSE) 664.35 (NSE)
February 2026	809.45	605.5	809.00	606	609.8 (BSE) 608.65 (NSE)
March 2026	644.95	535.2	635	534.4	539.9 (BSE) 539.7 (NSE)

*It's updated with the verified monthly high/low price and index data obtained from the BSE and NSE websites.

W.e.f. from 12th June 2025 the company sub-divided/split the existing equity shares of the Company from face value of ₹ 10/- each into equity shares of face value of ₹ 2/- each

The performance of the Company's Equity Share price during the financial year 2025-26, as compared to the movement of the broad-based indices (BSE Sensex/NSE Nifty), indicates the relative trend of the Company's share price vis-à-vis the market.

(H) Details of securities suspended from trading

None of the Securities of the Company, listed on Stock Exchanges have ever been suspended from trading.

(I) Registrar and Transfer Agents

(i) For Equity Shares:

Skyline Financial Services Pvt. Limited

Office:-D-153A,1ST Floor, Okhla Industrial Area,

Phase -I New Delhi-110020

Email Id: info@Skylinerta.com

Contact: 011-40450193

SEBI Registration No.: INR000003241

Website: www.skylinerta.com

(J) Share Transfer System

The Board has delegated the authority for share transfers, transmissions, remat/demat of shares/sub-division/consolidation/issue of renewed and duplicate share certificates etc. to the Board constituted Stakeholders' Relationship Committee. For any such action request is to be made to the RTA, which after scrutinizing all such requests, forwards it for approval by Stakeholders' Relationship Committee.

(K)

(i) Distribution of shareholding as on March 31, 2026

Fully Paid up Equity Shares

Sl. No.	Category Amount	No. of Shareholders	% to total shareholders	No. of Shares	Amount (in ₹.)	% to Amount
1	1-5,000	24,591	94.93	75,11,589	1,50,23,178.00	6.04
2	5,001 - 10,000	660	2.55	23,61,135	47,22,270.00	1.90
3	10,001 - 20,000	351	1.35	26,11,269	52,22,538.00	2.10
4	20,001 - 30,000	85	0.33	10,44,112	20,88,224.00	0.84
5	30,001 - 40,000	51	0.20	8,90,216	17,80,432.00	0.72
6	40,001 - 50,000	23	0.09	5,24,003	10,48,006.00	0.42
7	50,001 - 1,00,000	63	0.24	23,38,049	46,76,098.00	1.88
8	1,00,001 & Above	81	0.31	10,70,20,357	21,40,40,714.00	86.10
Total:		25,905	100.00	12,43,00,730	24,86,01,460.00	100.00

(ii) Shareholding pattern as on March 31, 2026

Fully Paid up Equity Shares

Sr. No.	Description	No. of Shares	% holding
1	Promoters and Promoters Group	7,90,80,648	63.62
2	Resident Individuals	2,28,36,665	18.36
3	Foreign Portfolio Investors Category I	75,04,263	6.04
4	Bodies Corporate	1,07,63,211	8.66
5	Insurance Companies	0	0.00
6	Employee Benefit Trust/Employee Welfare Trust	0	0.00
7	Mutual Funds	1,36,032	0.11
8	Trusts	3,68,006	0.30
9	Foreign Portfolio Investors Category II	1,61,436	0.13
10	HUF	14,79,781	1.19

Fully Paid up Equity Shares (Contd.)

S. No.	Description	No. of Shares	% holding
11	Non Resident Indians	13,28,165	1.07
12	Directors and their relatives	0	0.00
13	Clearing Members	0	0.00
14	Alternate Investment Funds	4,30,149	0.35
15	NBFCs registered with RBI	0	0.00
16	Investor Education and Protection Fund (IEPF)	0	0.00
17	Firms	2,12,289	0.17
18	Escrow Account	85	0.00
Total		12,43,00,730	100.00

(L) Dematerialization of shares and liquidity

Equity Shares of the Company are traded under compulsory dematerialized mode and are available for trading under both the depositories i.e. NSDL and CDSL.

Mode of Shares	Number of Shares	% age
Physical	Nil	Nil
CDSL	1,87,79,028	15.11%
NSDL	10,55,21,702	84.89%
Total	12,43,00,730	100%

As on March 31, 2026, 100% Equity shares of the Company representing 12,43,00,730 Equity shares were held in dematerialized form.

(M) Outstanding GDRs/Convertible Instruments

- (i) **GDRs:** As on March 31, 2026, there is no outstanding GDR.
- (ii) **ESOPs:** As on March 31, 2026, an aggregate of 4,08,075 outstanding Employee Stock Options (ESOPs) were granted under the Company's ESOP scheme. These options, upon exercise, are convertible into an equivalent number of equity shares of the Company. Consequently, as and when such options are exercised, the paid-up share capital of the Company shall increase to the extent of the equity shares allotted pursuant to such exercise.
- (iii) **FCCBs:** As on 31st March, 2026, there are no Outstanding FCCBs

(N) Commodity price risk or foreign exchange risk and hedging activities

The Company does not have any exposure to commodity price risks. During FY 2025-26.

(O) Plant Locations

As on March 31, 2026, the Company has not established or operated any manufacturing facility or plant and is presently engaged in the trading of Ayurvedic products and rendering

of healthcare services. Accordingly, the Company does not have any manufacturing plant locations as on March 31, 2026.

(P) Address for Correspondence**(i) Registered Office:**

JEENA SIKHO LIFECARE LIMITED

SCO 11 First Floor, Kalgidhar Enclave,
Mohali, Zirakpur, Punjab, India, 140604

Tele: 01762-513185

Email: divyaupchar.zk@gmail.com

Website: <https://jeenasikho.com/investors/>

The Corporate Identity Number (CIN) allotted to the Company by the Ministry of Corporate Affairs (MCA) is L52601PB2017PLC046545

(ii) Corporate Office:

Not Applicable

(Q) Profiles of the directors seeking appointment/re-appointment have been captured in the Notice convening the 09th AGM of the Company.

(R) Credit Ratings and Change:

During the Financial Year 2025-26, no credit rating was obtained by the Company.

(S) Statutory Auditors

Total fees, for all services, paid by the Company and its subsidiaries, on a consolidated basis, to respective Statutory Auditors and other firms in the network entity of which the Statutory Auditors are a part, for the financial year 2025-26 amounted to ₹ 203.24 Lakhs.

(T) Particulars of Board

Changes in the Board During the Financial Year 2025-26, the following changes took place in the composition of the Board of Directors of the Company:

- The designation of Ms. Shreya Grover (DIN: 09199495) was changed from Non-Executive Director to Whole-Time Director of the Company for a period of five (5) years with effect from 27th August, 2025. The said change was approved by the Board of Directors at its meeting held on 27th August, 2025 and subsequently approved by the Members of the Company in the Annual General Meeting held on 29th September, 2025, in accordance with the provisions of the Companies Act, 2013.
- Mrs. Priyanka Bansal (DIN: 09051665) was appointed as an Additional Director under the category of Independent Non-Executive Director of the Company by the Board of Directors with effect from 21st April, 2025 for a first term of five consecutive years commencing from 21st April, 2025 up to 20th April, 2030 (both days inclusive).

The appointment of Mrs. Priyanka Bansal as an Independent Director was subsequently approved by the Members of the Company through a Postal Ballot resolution passed on 23rd May, 2025.

Subsequent to the close of the financial year, the Board of Directors at its meeting held on 15th July, 2026, based on the recommendation of the Nomination and Remuneration Committee, approved the following appointments, subject to the approval of the shareholders wherever applicable:

- Mr. Ajay Sharma (DIN: 07671350) was appointed as an Additional Director in the category of Non-Executive Independent Director. Further, his appointment as a Non-Executive Independent Director, not liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, was approved, subject to the approval of the shareholders.
- Mrs. Sapna Singh (DIN: 11812894) was appointed as an Additional Director in the category of Non-Executive Woman Independent Director. Further, her appointment as a Non-Executive Independent Director, not liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, was approved, subject to the approval of the shareholders.
- Dr. Ish Sharma (DIN: 11815526) was appointed as an Additional Director in the Executive category and designated as the Whole-Time Director and Key Managerial Personnel of the Company, liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, subject to the approval of the shareholders.

- Mr. Ankush Kaushal (DIN: 03308862) was appointed as an Additional Director in the Executive category and designated as the Whole-Time Director and Key Managerial Personnel of the Company, liable to retire by rotation, for a term of two (2) consecutive years commencing from 15th July, 2026 to 14th July, 2028, subject to the approval of the shareholders.

During the Financial Year 2025-26, the following changes took place in the Key Managerial Personnel (KMPs) of the Company:

During the year under review, Ms. Anshika Garg resigned from the position of Company Secretary & Compliance Officer of the Company with effect from 1st August, 2025.

Subsequently, Mrs. Smita Chaturvedi was appointed as the Company Secretary & Compliance Officer and designated as the Key Managerial Personnel of the Company with effect from 4th August, 2025.

Subsequent to the close of the financial year, Mrs. Smita Chaturvedi resigned from the position of Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 14th July, 2026. The Board of Directors, at its meeting held on 15th July, 2026, approved the appointment of Ms. Priya Goyal (ACS-71180) as the Company Secretary & Compliance Officer and designated her as the Key Managerial Personnel of the Company with effect from 15th July, 2026.

The Board of Directors, at its meeting held on 27th August, 2025, approved the appointment of Mr. Sahil Jain as the Chief Operating Officer (COO) of the Company with effect from 27th August, 2025. The Chief Operating Officer forms part of the Senior Management of the Company.

Except as stated above, there were no other changes in the Key Managerial Personnel of the Company during the year under review.

Further, there was no other change in management during FY 2025-26.

(U) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

Sr. No.	Particulars	Details
1	Number of complaints received during the financial year	0
2	Number of complaints disposed of during the financial year	0
3	Number of complaints pending as on end of the financial year	0

7. COMPLIANCE CERTIFICATE FROM THE PRACTICING COMPANY SECRETARY

A certificate from a Practicing Company Secretary M/s Rawal & Co., Company Secretaries, certifying the Company's compliance with the provisions of Corporate Governance as stipulated in Regulation 34(3) read with Schedule-V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to and forms a part of this Report.

8. SECRETARIAL AUDIT:

M/s. Ankur Singh & Associates, Practicing Company Secretaries, Delhi, has conducted a Secretarial Audit of the Company for the financial year 2025-26. Their Audit Report confirms that the Company has complied with the applicable provisions of the Act and the Rules made there under, its Memorandum and Articles of Association, Listing Regulations and the applicable SEBI Regulations. The Secretarial Audit Report forms part of the Board's Report.

9. OTHER DISCLOSURES:

(i) Subsidiary Companies:

During the year under review, Jeena Green Resources Private Limited was incorporated on 10th March, 2025 and became a subsidiary of the Company.

Further, the Company incorporated its wholly-owned subsidiary, Jeena Sikho International LLC, under the Sharjah Media City (Shams) Free Zone Authority, United Arab Emirates. The said wholly-owned subsidiary was successfully incorporated and was granted a business license to commence its operations under the name "Jeena Sikho International LLC" on 11th September, 2025.

Accordingly, both the aforesaid entities are considered subsidiaries of the Company for the financial year 2025-26. In compliance with the provisions of Section 129(3) of the Companies Act, 2013 read with Rule 5 of the Companies (Accounts) Rules, 2014, the requisite disclosures relating to the subsidiaries form part of the Consolidated Financial Statements and are annexed to the Board Report in the prescribed Form AOC-1.

Further, the Company does not have any Material Subsidiary within the meaning of the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, during the financial year under review.

(ii) Details of Non-Compliance

The Company has complied with the requirements of the Stock Exchanges, SEBI, and other statutory authorities in respect of capital market matters during the financial year 2025-26.

However, during the financial year 2025-26, the Company was levied penalties by the National Stock Exchange of India Limited (NSE) and BSE Limited aggregating to ₹11,800/- (Rupees Eleven Thousand Eight Hundred only), inclusive of GST, for non-compliance with Regulations 29(2) and 29(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has duly paid the said penalties to both the stock exchanges.

Further, there has been no material non-compliance with any of the requirements of the Corporate Governance Report as specified under Sub-Paragraphs (2) to (10) of Part C of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(iii) Related Party Transactions

The Company has a board approved policy on Related Party Transactions. The policy intends to ensure that proper reporting, approval and disclosure processes are in place for all related party transactions. Further, pursuant to notification of amendments to Listing Regulations, amongst other changes, the scope of related party transactions has been widened significantly and the said policy was amended to align it with all the applicable amendments. The updated policy is placed on the Company's website at https://jeenasikho.com/wp-content/uploads/2025/05/Revised-RPT_JSLL-1.pdf and is provided elsewhere in the annual report. There are no materially significant related party transactions entered into by the Company with its Promoters, Directors or Management, their subsidiaries, or relatives, etc. that may have potential conflict with the interests of the Company at large.

All transactions entered with related parties during the year ended 31st March, 2026 as mentioned under Companies Act, 2013 and Regulation 23 and 27(2)(b) of the Listing Obligations & Disclosures Regulations (LODR) were in the ordinary course of business and on arm's length pricing basis.

Further, as per Regulation 23(9) of the SEBI Listing Regulations, your Company has also filed the related party transactions as per the timelines specified under the said regulations.

Loans and advances in the nature of loans to firms/companies in which directors are interested, is disclosed along with other related party transactions, in the notes forming part of financial statements.

(iv) MD AND CFO Certification

- The Managing Director and CFO have issued certificate pursuant to the Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015, certifying that the financial statements do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.
- The Managing Director and the CFO have issued certificate pursuant to the provisions of Regulation 17(8) read with Part-B of Schedule-II of the SEBI LODR, certifying that the financial statements do not contain any materially untrue statement and these statements represent a true and fair view of the Company's affairs.

(v) Codes of the Company

(a) Code of Conduct and Ethics

The Company has laid down a Code of Conduct and Ethics (the "Code") for the Board Members and Senior Management personnel of the Company. The Code is available on the website of the Company at https://jeenasikho.com/wp-content/uploads/2023/12/1.-JSLL_Code_of_Conduct_Board_Senior_Management_Final.pdf

All Board Members and Senior Management personnel have affirmed compliance with the Code. A declaration signed by the Chief Executive Officer to this effect is enclosed at the end of this Report.

The Code seeks to ensure that the Board Members and Senior Management personnel observe a total commitment to their duties and responsibilities while ensuring a complete adherence with the applicable statutes along with business values and ethics.

(b) Code of Conduct for Prevention of Insider Trading

The Company has laid down a Code of Conduct for Prevention of Insider Trading, in accordance with the requirements of The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and other applicable laws, with a view to regulate trading in Securities of the Company by its directors, designated persons and employees.

The Company also maintains a structured digital database of persons or entities with whom the Unpublished Price Sensitive Information is shared.

(vi) Whistle Blower Policy

The Company is committed to adhere to the highest standards of ethical, moral and legal conduct of its business operations. To maintain these standards, the Company has implemented the Whistle Blower Policy ("the Policy"), to provide an avenue for employees to report matters without the risk of subsequent victimization, discrimination or disadvantage. The Policy applies to all employees working for the Company and its subsidiaries and no personnel have been denied access to the audit committee. Pursuant to the Policy, the whistle blowers can raise concerns relating to matters such as breach of Company's Code of Conduct, fraud, bribery, corruption, employee misconduct, illegality, misappropriation of Company's funds/assets etc. A whistle-blowing or reporting mechanism, as set out in the Policy, invites all employees to act responsibly to uphold the reputation of the Company and its subsidiaries. The Policy aims to ensure that serious concerns are properly raised and addressed and are recognized as an enabling factor in administering good governance practices. The details of the Whistle Blower Policy are available on the website of the Company (<https://jeenasikho.com/wp-content/uploads/2023/12/3.-Whistle-Blower-Policy.pdf>)

(vii) Strictures and penalties during the last three years

During the financial year 2025-26, the Company was levied penalties by the National Stock Exchange of India Limited (NSE) and BSE Limited aggregating to ₹11,800/- (Rupees Eleven Thousand Eight Hundred only), inclusive of GST, for non-compliance with Regulations 29(2) and 29(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has paid the said penalties to both the stock exchanges.

(viii) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements pursuant to SEBI (LODR) Regulations, 2015.

The Company has complied with all the mandatory requirements pursuant to SEBI (LODR) Regulations, 2015. The details of these compliances have been given in the relevant

sections of this Report. The status on compliance with the Non mandatory requirements are given in the next section of the Report.

10. DISCRETIONARY REQUIREMENTS

(A) Shareholders Rights

The Company would be getting its quarterly/half yearly and annual financial results published in leading newspapers namely Financial Express (English language newspaper) and Nawanzamana (Punjabi language newspaper) with wide circulation across the country and regularly update the same on its public domain website. In view of the same individual communication of quarterly/annual financial results to the Shareholders will not be made. Further, information pertaining to important developments in the Company shall be brought to the knowledge of the public at large and to the Shareholders of the Company in particular, through communications sent to the stock exchanges where the shares of the Company are listed, through press releases in leading newspapers and through regular uploads made on the Company website.

(B) Audit Qualification

The Auditors' Report on the audited annual accounts of the Company for the financial year ended 31st March, 2026 contains an unmodified opinion of the Statutory Auditors on the financial statements. Except as otherwise stated in the Auditors' Report attached to this Annual Report, the said Report does not contain any qualification, reservation, adverse remark or disclaimer. The Company continues to maintain appropriate accounting systems, internal controls and practices to ensure compliance with the applicable Accounting Standards and other relevant statutory requirements.

(C) Disclosure of non-acceptance of Committee recommendation by the Board

During the Financial Year 2025-26, the Board has accepted all the recommendations/submission of its' Committees.

(D) Reporting of Internal Auditor

The Internal Auditor of the Company reports to CFO and has direct access to the Audit Committee.

Except as set out above, the Company has not adopted the non-mandatory requirements as to any of the other matters recommended under Part E of Schedule II of Regulation 27(1) of SEBI (LODR) Regulations, 2015.

(E) Unclaimed Shares lying in Demat Suspense Account

Pursuant to Regulation 39(4) read with Schedule VI of the Listing Regulations, the Company reports that there are 85 unclaimed shares as on 31st March, 2026.

(F) Disclosure of certain types of agreements binding listed entities

There are no agreements that require disclosure under clause 5A of paragraph A of Part A of Schedule III of the SEBI Listing Regulations, 2015.

ANNUAL DECLARATION PURSUANT TO REGULATION 34(3) READ WITH SCHEDULE-V OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

As required under Regulation 34(3) read with Part D of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we, Manish Grover and Nanak Chand, the undersigned, in our respective capacities as the Managing Director and the Chief Financial Officer (CFO) of Jeena Sikho Lifecare Limited ("the Company"), hereby declare that all the Members of the Board of Directors and the Senior Management Personnel of the Company have affirmed compliance with the Company's Code of Conduct for the financial year ended March 31, 2026.

This declaration is made in compliance with the requirements of Regulation 34(3) read with Part D of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For and on behalf of
JEENA SIKHO LIFECARE LIMITED

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Nanak Chand
Chief Financial Officer (CFO)
PAN: AVMPC1378C

Date: 31.08.2026
Place: Zirakpur, Punjab

CERTIFICATION BY MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER (CFO)
(Pursuant to Regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
 The Board of Directors
Jeena Sikho Lifecare Limited
 CIN L52601PB2017PLCO46545
 SCO 11, First Floor, Kalgidhar Enclave,
 Mohali, Zirakpur, Punjab, India – 140604

We, the Undersigned, in our respective capacities as Managing Director ("MD") and Chief Financial Officer ("CFO") of Jeena Sikho Lifecare Limited ("the Company") hereby certify, to the best of our knowledge and belief, that:

1. The standalone and consolidated financial results of the Company for the quarter and financial year ended 31st March, 2026 ("Financial Results"), as placed before the Board of Directors, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.
2. The Financial Results have been prepared in accordance with the applicable accounting standards and other applicable requirements prescribed under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as applicable.
3. This certificate is issued for placing before the Board of Directors of the Company in compliance with the requirements of Regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For and on behalf of
JEENA SIKHO LIFECARE LIMITED

Sd/-
Manish Grover
 Managing Director
 DIN: 07557886

Sd/-
Nanak Chand
 Chief Financial Officer (CFO)
 PAN: AVMPIC378C

Date: 30.05.2026
Place: Zirakpur, Punjab

CERTIFICATION BY THE MANAGING DIRECTOR AND THE CHIEF FINANCIAL OFFICER (CFO) ON FINANCIAL STATEMENTS OF THE COMPANY

(Pursuant to Regulation 17(8) Read with Part-B of Schedule-II of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015)

To

The Board of Directors,
CIN L52601PB2017PLCO46545
Jeena Sikho Lifecare Limited.
SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur,
Punjab, India, 140604

As required by Regulation 17(8) read with Part-B of Schedule-II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, Manish Grover and Nanak Chand the undersigned, in our respective capacities as the Managing Director and the Chief Financial Officer (CFO) of Jeena Sikho Lifecare Limited ("the Company"), to the best of our knowledge and belief, hereby confirm to the Board that:

- A. We have reviewed financial statements and the cash flow statement for the year and that to the best of our knowledge and belief:
 - (1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (2) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- D. We have indicated to the auditors and the Audit committee that:
 - (1) There were no significant changes in internal control over financial reporting during the year;
 - (2) During the year, the Company has adopted Indian Accounting Standards (Ind AS) as applicable to the Company. Accordingly, the accounting policies have been revised/updated to align with the requirements of Ind AS. The resultant changes in accounting policies arising from such adoption, along with the applicable disclosures, have been appropriately disclosed in the Notes to the Financial Statements.
 - (3) There were no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For and on behalf of
JEENA SIKHO LIFECARE LIMITED

Sd/-
Manish Grover
Managing Director
DIN: 07557886

Sd/-
Nanak Chand
Chief Financial Officer (CFO)
PAN: AVMPIC1378C

Date: 30.05.2026
Place: Zirakpur, Punjab

CERTIFICATE REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

133

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

To,
The Members of
The Board of Directors,
CIN L52601PB2017PLCO46545
Jeena Sikho Lifecare Limited.
SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur,
Punjab, India, 140604

We have examined the compliance of conditions of Corporate Governance by Jeena Sikho Lifecare Limited ("the Company"), for the year ended March 31, 2026, as prescribed in Regulations 17 to 27, 46(2)(b) to (i) and (t) and para C, D and E of Schedule V of Chapter IV of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR).

We state that the compliance of conditions of Corporate Governance is the responsibility of the Company's management and, our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion, and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned SEBI LODR.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

This certificate is issued solely for the purposes of complying with the aforesaid Regulations and may not be suitable for any other purpose.

For Rawal & Co.
(Company Secretaries)
FRN: S2020UP717200

Vivek Rawal
Company Secretary
M. No.: 43231
CP No.: 22687
Peer Review No. 5722/2024

UDIN: AO43231H001242946
Date: 27.08.2026
Place: Gurugram

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTOR

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
The Board of Directors,
Jeena Sikho Lifecare Limited.
CIN L52601PB2017PLCO46545
SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur,
Punjab, India, 140604

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Jeena Sikho Lifecare Limited having CIN L52601PB2017PLCO46545 and having registered office at SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur, Punjab, India, 140604, India (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ended on 31st March, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs (MCA) or any such other Statutory Authority:

Sr. No.	Name of Director	DIN	Date of appointment in the Company*
1.	Mr. Manish Grover	07557886	25/08/2021
2.	Mrs. Bhavna Grover	07557913	25/08/2021
3.	Ms. Shreya Grover	09199495	12/06/2021
4.	Mr. Karan Vir Bindra	09283623	25/08/2021
5.	Mrs. Priyanka Bansal	09051665	21/04/2025
6.	Mr. Chandan Kumar Kaushal	10515819	29/04/2024

*the date of appointment is as per the MCA Portal.

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Rawal & Co.
(Company Secretaries)
FRN: S2020UP717200

Vivek Rawal
Company Secretary
M. No.: 43231
CP No.: 22687
Peer Review No. 5722/2024

UDIN: AO43231H001243001
Date: 27.08.2026
Place: Gurugram

Business Responsibility and Sustainability Report (BRSR)

SECTION A: GENERAL DISCLOSURES

I. Details of the Listed Entity

1.	Corporate Identity Number (CIN) of the Company	L52601PB2017PLC046545
2.	Name of the Company	JEENA SIKHO LIFECARE LIMITED
3.	Year of incorporation	5/29/2017
4.	Registered office address	SCO 11 FIRST FLOOR, KALGIDHAR ENCLAVE, Mohali, ZIRAKPUR, Punjab, India, 140604
5.	Corporate address	SCO 11 FIRST FLOOR, KALGIDHAR ENCLAVE, Mohali, ZIRAKPUR, Punjab, India, 140604
10.	Name of the Stock Exchange(s) where shares are listed	1. BSE Limited (BSE) 2. National Stock Exchange of India Limited (NSE)
11.	Paid-up Capital (H)	Rs. 24,86,01,460/-
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Name: Priya Goyal Email: Cs@jeenasikho.com Contact: +91 9878600875
13.	Reporting boundary- Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities that form a part of its consolidated financial statements, taken together)	Disclosures made in this report are on a Standalone basis
14.	Name of assurance provider	Not Applicable
15.	Type of assurance obtained	Not Applicable

II. Products/Services

16. Details of business activities (accounting for 90% of the turnover):

Description of Main Activity	Description of Business Activity	% of turnover
Trade	Retail Trading	51.87%
Hospital and Medical care	Other Hospital and Medical Care Activities	47.84%

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

Product/Service	NIC Code	% of Turnover of the entity
Retail Trading	4772	51.87%
Other Hospital and Medical Care Activities	8690	47.84%

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of Plants	Number of offices	Total
National	0	119	119
International	0	1	1

19. Markets served by the entity:

a. Number of Locations:

Location	Number
National (No. of States)	23
International (No. of Countries)	1

b. What is the contribution of exports as a percentage of the total turnover of the entity?

0.30%

c. A brief on types of customers

The Company's customer base comprises individual patients, retail consumers, and wellness seekers who avail Ayurvedic healthcare services and purchase Ayurvedic and wellness products. These offerings are delivered through the Company's network of hospitals, clinics, dealers, and franchisees, enabling wider access to traditional healthcare solutions.

iv. EMPLOYEES

20. Employees at the end of the Financial Year:

a. Employees/workers (including differently abled):

Particulars	Total (A)	Male		Female	
		No. (B)	% (B/A)	No. (C)	% (C/A)
Employees					
Permanent (D)	4,299	2,232	51.92%	2067	48.08%
Other than permanent (E)	1,247	863	69.21%	384	30.79%
Total employees (D + E)	5,546	3,095	55.81%	2451	44.19%
Workers					
Permanent (F)	NA	NA	NA	NA	NA
Other than permanent (G)	NA	NA	NA	NA	NA
Total workers (F + G)	NA	NA	NA	NA	NA

*The number of employees disclosed in the BRSR differs from the number of employees considered for the purpose of gratuity calculation. The number of employees considered for gratuity is based on the applicable eligibility criteria, wherein employees who resigned during the close of the financial year and were consequently not eligible for gratuity calculation have been excluded. Accordingly, the employee count considered for gratuity may differ from the employee count reported in the BRSR.

b. Differently abled Employees and workers:

Particulars	Total (A)	Male		Female	
		No. (B)	% (B/A)	No. (C)	% (C/A)
Differently abled employees					
Permanent (D)	Nil	Nil	Nil	Nil	Nil
Other than Permanent (E)	Nil	Nil	Nil	Nil	Nil
Total employees (D + E)	Nil	Nil	Nil	Nil	Nil
Differently abled Workers					
Permanent (F)	NA	NA	NA	NA	NA
Other than Permanent (G)	NA	NA	NA	NA	NA
Total workers (F + G)	NA	NA	NA	NA	NA

21. Participation/Inclusion/Representation of women:

Particulars	Total (A)	No. and percentage of Females	
		No. (B)	% (B/A)
Board of Directors	6	3	50%
Key Management Personnel	2	1	50%

22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

Particulars	FY 2025-26*			FY 2024-25			FY 2023-24		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	55.55%	57.29%	56.39%	54%	78%	66%	48%	72%	60%
Permanent Workers	NA	NA	NA	NA	NA	NA	NA	NA	NA

*Note: Turnover rates for FY 2023-24 and FY 2024-25, previously disclosed on a monthly basis, have been annualised and restated to ensure comparability with the annual turnover rate reported for FY 2025-26.

V. Holding, Subsidiary and Associate Companies (including Joint Ventures)

23. Names of holding/subsidiary/associate companies/joint ventures:

Name of the holding/subsidiary/associate companies/joint ventures (A)	Indicate whether holding/Subsidiary/Associate/Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
Jeena Green Resources Private Limited	Subsidiary	51%	No
Jeena Sikho International LLC	Wholly owned Subsidiary	100%	No

VI. CSR Details

24.

- Whether CSR is applicable as per Section 135 of the Companies Act, 2013: **Yes**
- Turnover (in Rs.): **8,01,34,64,032**
- Net worth (in Rs.): **4,67,40,05,000**

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)	FY 2025-26			FY 2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes Policies – Jeena Sikho	Nil	Nil	-	Nil	Nil	-
Shareholders	Yes Policies – Jeena Sikho	1	Nil	-	Nil	Nil	-
Investors (Other than shareholders)	Yes Policies – Jeena Sikho	Nil	Nil	-	Nil	Nil	-
Employees and workers	Yes Policies – Jeena Sikho	Nil	Nil	-	Nil	Nil	-
Customers	Yes Policies – Jeena Sikho	13,599	Nil	-	Nil	Nil	-
Value Chain Partners	Yes Policies – Jeena Sikho	Nil	Nil	-	Nil	Nil	-
Other: NGO	Yes Policies – Jeena Sikho	Nil	Nil	-	Nil	Nil	-

26. Overview of the entity's material responsible business conduct issues:

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same approach to adapt or mitigate the risk along-with its financial implications, as per the following format:

Sr. No.	Material Issue Identified	Risk/ Opportunity	Rationale for Identifying the Risk/ Opportunity	Approach to Adapt or Mitigate the Risk/ Leverage the Opportunity	Financial Implications of the Risk or Opportunity
1	Customer Health, Safety & Product Quality	Risk & Opportunity	As a healthcare and wellness company, product quality, safety and appropriate product information are important to maintaining customer and patient trust. Product quality issues, adverse customer experiences or non-compliance with applicable requirements may affect the Company's reputation and business performance, while consistent quality creates opportunities to strengthen customer confidence and retention.	As a healthcare and wellness company, product quality, safety and appropriate product information are important to maintaining customer and patient trust. Product quality issues, adverse customer experiences or non-compliance with applicable requirements may affect the Company's reputation and business performance, while consistent quality creates opportunities to strengthen customer confidence and retention. The Company focuses on quality control, product-related compliance, supplier evaluation, customer feedback and grievance redressal mechanisms, as applicable to its operations. The Company also seeks to provide appropriate product information and maintain relevant quality and safety practices across its operations.	Product quality or safety issues may result in product returns, customer claims, regulatory costs and reputational impact. Effective quality management supports customer retention, brand trust and sustainable revenue growth.
2	Digital Distribution, Product Availability & E-commerce	Risk & Opportunity	Digital and online distribution channels provide opportunities to expand customer reach and improve product accessibility. At the same time, dependence on digital platforms, logistics and inventory availability may expose the Company to risks relating to product availability, fulfilment, counterfeit products and unauthorised use of brand identity.	The Company monitors product availability, inventory and distribution requirements and engages with relevant marketplace, logistics and distribution partners. Where applicable, the Company monitors online product listings and takes appropriate measures to protect its products and brand.	Distribution disruptions, inventory shortages or unauthorised/ counterfeit products may affect sales and brand reputation. Effective digital distribution can support market reach, customer convenience and revenue growth.
3	Regulatory Compliance & Ethical Business Practices	Risk	The Company's healthcare, wellness and business operations are subject to applicable laws and regulatory requirements. Non-compliance may result in penalties, regulatory action, operational disruption and reputational risks.	The Company follows applicable legal and regulatory requirements and maintains relevant policies, internal controls and monitoring mechanisms to support compliance and ethical business conduct.	Non-compliance may result in penalties, legal costs, operational restrictions and reputational damage. Effective compliance practices help minimise regulatory and business risks.

26. Overview of the entity's material responsible business conduct issues: (Contd.)

Sr. No.	Material Issue Identified	Risk/ Opportunity	Rationale for Identifying the Risk/ Opportunity	Approach to Adapt or Mitigate the Risk/ Leverage the Opportunity	Financial Implications of the Risk or Opportunity
4	Customer Engagement & Brand Reputation	Opportunity & Risk	Customer trust, satisfaction and engagement are important to the Company's healthcare and wellness business. Changing customer expectations and negative customer experiences may affect brand perception, while effective customer engagement can strengthen loyalty and retention.	The Company focuses on customer service, addressing customer feedback and grievances, and maintaining communication channels to understand and respond to customer requirements.	Effective customer engagement may support customer retention, brand value and revenue growth, while unresolved customer concerns may result in loss of customers and reputational impact.
5	Digital Transformation, Cybersecurity & Data Privacy	Risk & Opportunity	Increasing use of digital systems and platforms across customer engagement and business operations creates opportunities for efficiency and accessibility, while cybersecurity incidents, system failures and unauthorised access may expose the Company to operational, financial and data privacy risks.	The Company focuses on appropriate IT controls, information security, data protection and access management practices, along with measures to maintain the availability and security of its digital systems.	Cybersecurity incidents or system disruptions may result in financial losses, regulatory implications, business interruption and reputational damage. Digitalisation may improve operational efficiency and scalability.
6	Access to Healthcare & Affordable Wellness Solutions	Opportunity & Risk	The Company's healthcare and wellness operations provide an opportunity to improve access to healthcare and wellness services and products, including for customers seeking affordable and accessible solutions. At the same time, changing consumer preferences and perceptions regarding different healthcare systems may affect adoption and demand.	The Company seeks to improve accessibility through its healthcare, wellness and service offerings and focuses on customer awareness, service quality and accessibility. The Company may also undertake initiatives to enhance awareness and understanding of its healthcare and wellness offerings.	Improved healthcare accessibility may expand the Company's customer base and support long-term revenue growth. Changes in customer preferences or lower adoption may adversely affect demand and business performance.
7	Research, Development & Innovation	Opportunity & Risk	Research, product development and innovation can support improvement in healthcare and wellness offerings, enhance customer value and strengthen the Company's competitiveness. Inadequate innovation or inability to respond to changing customer needs may affect long-term competitiveness.	The Company focuses on product and service improvement, innovation and relevant research and development activities, as applicable to its operations, to respond to evolving customer and market requirements.	Successful innovation can support new products/services, market expansion and revenue growth, while inadequate innovation may result in loss of market share and competitive disadvantage.

26. Overview of the entity's material responsible business conduct issues: (Contd.)

Sr. No.	Material Issue Identified	Risk/ Opportunity	Rationale for Identifying the Risk/ Opportunity	Approach to Adapt or Mitigate the Risk/ Leverage the Opportunity	Financial Implications of the Risk or Opportunity
8	Diversity, Equity & Inclusion	Opportunity & Risk	A diverse and inclusive workforce can support employee engagement, organisational effectiveness and a positive workplace culture. Gaps in equal opportunity or diversity may affect employee morale and retention.	The Company promotes equal employment opportunities and seeks to maintain a workplace based on fairness, dignity, respect and non-discrimination.	Effective diversity and inclusion practices can improve employee engagement and retention and support organisational performance.
9	Anti-Corruption, Anti-Bribery & Business Ethics	Risk	Corruption, bribery and unethical business practices may result in legal and regulatory consequences, financial losses and reputational damage, particularly for a company operating across multiple locations and stakeholder groups.	The Company maintains relevant policies and internal controls relating to ethical conduct, anti-bribery and anti-corruption, supported by employee awareness and grievance/whistle-blower mechanisms, as applicable.	Incidents of corruption or bribery may result in penalties, legal expenses, loss of business and reputational damage. Strong ethical practices support stakeholder confidence and business continuity.
10	Human Capital Development & Employee Welfare	Risk & Opportunity	Employees are critical to the delivery of healthcare, wellness and business operations. Employee turnover, skill gaps, inadequate training or insufficient employee engagement may affect operational efficiency and service quality.	The Company focuses on employee training and development, skill enhancement, employee engagement, workplace safety and employee welfare initiatives, as applicable.	Investment in employee development can improve productivity, retention and service quality. High employee turnover and skill gaps may increase recruitment and training costs and affect operational performance.
11	Corporate Governance, Ethics & Transparency	Risk & Opportunity	Effective governance, transparency and accountability are essential for maintaining stakeholder confidence and ensuring compliance with applicable legal and regulatory requirements. Weak governance practices may result in regulatory, financial and reputational risks.	The Company follows applicable governance requirements and maintains Board oversight, internal controls, statutory compliance mechanisms and relevant policies and procedures.	Governance failures may result in regulatory penalties, financial losses and reputational damage. Strong governance supports investor/stakeholder confidence and long-term value creation.
12	Climate Change, Energy & GHG Emissions	Risk & Opportunity	The Company's operations consume energy and generate greenhouse gas emissions. Increasing climate-related expectations, energy costs and regulatory requirements may create operational and compliance risks, while energy efficiency and renewable energy adoption can provide opportunities for resource and cost optimisation.	The Company monitors energy consumption and GHG emissions and seeks to improve energy efficiency and resource utilisation. Opportunities for renewable energy adoption and other emission-reduction measures may be evaluated based on operational feasibility.	Energy efficiency may reduce operating costs and resource consumption. Increasing energy prices, climate-related regulations or transition requirements may increase operating costs and compliance expenditure.

26. Overview of the entity's material responsible business conduct issues: (Contd.)

Sr. No.	Material Issue Identified	Risk/ Opportunity	Rationale for Identifying the Risk/ Opportunity	Approach to Adapt or Mitigate the Risk/ Leverage the Opportunity	Financial Implications of the Risk or Opportunity
13	Water Stewardship, Resource Efficiency & Waste Management	Risk & Opportunity	Water is an important resource for the Company's healthcare and operational activities. In addition, healthcare operations generate waste, including biomedical and other operational waste, requiring appropriate handling and disposal. Inefficient resource use or improper waste management may create environmental, operational and compliance risks.	The Company monitors water consumption and seeks to implement water conservation and efficiency measures, where feasible. Waste is managed through segregation, appropriate handling, recycling/recovery and disposal through authorised channels, in accordance with applicable requirements.	Efficient water and waste management may reduce resource and waste-management costs and associated environmental liabilities. Non-compliance may result in penalties, remediation costs and reputational impact.
14	Responsible Supply Chain & Sustainable Procurement	Risk & Opportunity	The Company's ability to maintain product quality, service continuity and operational resilience depends on reliable suppliers and service providers. Supply disruptions, quality issues or inadequate supplier practices may affect business operations.	The Company undertakes supplier/vendor evaluation and monitoring, as applicable, with focus on product/service quality, continuity and compliance requirements. Sustainability considerations may be incorporated into procurement practices where relevant.	Supply-chain disruptions may result in increased procurement costs, delays and loss of revenue. Effective supplier management supports operational continuity, quality and resilience.
15	Social Responsibility & Community Development	Opportunity	As a healthcare and wellness company, the Company has opportunities to contribute to community wellbeing through initiatives related to healthcare awareness, education and social development, including activities undertaken under its CSR programme, where applicable.	The Company undertakes CSR and community-oriented initiatives in accordance with applicable requirements and its identified social priorities.	Social initiatives can strengthen community relationships, stakeholder trust and the Company's reputation, while supporting long-term social value creation.
16	Occupational Health & Safety	Risk & Opportunity	Employees and personnel engaged across healthcare, operational and other activities may be exposed to workplace health and safety risks. Effective occupational health and safety practices are therefore important for employee wellbeing, business continuity and productivity.	The Company focuses on workplace safety practices, employee awareness and training, risk identification and appropriate safety measures across relevant operations, as applicable.	Workplace incidents may result in medical, compensation, legal and operational costs. Effective health and safety practices can reduce incidents, support productivity and improve employee retention.

[illegible]

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements. (Contd.)

Disclosure	P1	P2	P3	P4	P5	P6	P7	P8	P9
8. Details of the highest authority responsible for the implementation and oversight of the Business Responsibility policy (ies).	Name: Manish Grover, Designation: Managing Director DIN: 07557886								
9. Does the entity have a specified Committee of the Board/responsible for decision-making on sustainability-related issues? (Yes/No). If yes, provide details.	Yes, Mr. Manish Grover, Managing Director of the Company oversees and periodically review Business Responsibility and Sustainability Initiatives of the Company. The Company's CSR committee and Risk Management Committee is responsible for decision making on sustainability related issues.								

10. Details of Review of NGBRCs by the company:

Subject for Review	Indicate whether review was undertaken by Director/Committee of the Board/Any other Committee									Frequency (Annually/Half yearly/Quarterly/Any other-please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	All the policies are reviewed periodically or on a need basis by department heads, business heads, senior management personnel/respective committees and placed before the BOD as and when required. In the assessment, the efficacy of these policies is also reviewed and necessary changes to policies and procedures are implemented.																	
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	Departmental Heads/Directors/Committees of the Board. The Company complies with the applicable regulations. In case of any non-compliance, the Company investigates the issue, takes appropriate corrective measures, and undertakes necessary actions to rectify the same.																	

Disclosure	P1	P2	P3	P4	P5	P6	P7	P8	P9
11 Particulars Has the entity carried out independent assessment/evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency :	The policies are assessed on a Periodical basis. The Board of Directors and Senior Management review adherence to the stated policies within the organization. However, no independent assessment or external evaluation is currently conducted.								

12. If the answer to question (1) above is "No" i.e., not all Principles are covered by a policy, reasons to be stated

Disclosure	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the principles material to its business (Yes/No)	N.A.								
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/human and technical resources available for the task (Yes/No)									
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent, and Accountable

Essential Indicators

1. Percentage coverage by training and awareness programmers on any of the Principles during the financial year:

Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and its impact	% age of persons in respective category covered by the awareness programs
Board of Directors	7	Business Strategy, risk & updates of Laws	100%
Key Managerial Personnel	7	Health & Safety, Cyber security, POSH, Patient Safety, Occupational health & safety, internal control developing, updates of laws	100%
Employees other than BoD and KMPs	10	Health & Safety, POSH, Internal control implementation, Occupational Health & Safety, Soft Skill, Product Training, Grooming Training, Mindset Training, Skill Enhancement Training, Office Decorum Training, Fire Safety Training etc.	100%
Workers	NA	NA	100%

2. Details of fines/penalties/punishment/award/compounding fees/settlement amount paid in proceedings (by the entity or by directors/KMPs) with regulators/law enforcement agencies/judicial institutions, in the financial year, in the following format

Monetary					
Particulars	NGRBC Principle	Name of the regulatory/enforcement agencies/judicial institutions	Amount (In RS)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/Fine*	Principle - 1	National Stock Exchange of India Limited, BSE LIMITED	11,800/- Each	finer for non-compliance under Regulation 29(2)/29(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015	No
Settlement			N.A.	N.A.	N.A.
Compounding fee			N.A.	N.A.	N.A.

Non-Monetary				
Particulars	NGRBC Principle	Name of the regulatory/enforcement agencies/judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	None	N.A.	N.A.	N.A.
Punishment	None	N.A.	N.A.	N.A.

*During the financial year 2025-26, there were no instances of non-monetary fines, penalties, punishments, awards, compounding fees, or settlement amounts paid by the entity or its Directors/Key Managerial Personnel in any proceedings initiated by regulatory authorities, law enforcement agencies, or judicial institutions.

3. Of the instances disclosed in Question 2 above, details of the Appeal/Revision are preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory/enforcement agencies/judicial institutions
NA	NA

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web link to the policy.

Yes. The Company has a zero-tolerance approach towards bribery, corruption, and other unethical business practices. The Company's Code of Conduct and Anti-Bribery and Anti-Corruption Policy provide guidance to Directors, Senior Management Personnel, Functional Heads, and employees on maintaining high standards of integrity and ethical conduct and ensuring compliance with applicable anti-bribery and anti-corruption laws, rules, and regulations.

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/corruption:

Particulars	FY 2025-26	FY 2024-25
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	Nil

6. Details of complaints with regard to conflict of interest:

Particulars	FY 2025-26		FY 2024-25	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	Nil	-	Nil	-
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	Nil	-	Nil	-

7. Provide details of any corrective action taken or underway on issues related to fines/penalties/action taken by regulators/law enforcement agencies/judicial institutions, on cases of corruption and conflicts of interest:

No corrective actions were required, as there were no reported instances of fines, penalties, or actions imposed by regulatory authorities, law enforcement agencies, or judicial bodies related to corruption or conflicts of interest.

8. Number of days of accounts payables ((Accounts payable *365)/Cost of goods/services procured) in the following format:

Particulars	FY 2025-26	FY 2024-25
Number of days of accounts payables*	68	75

*Standard payment terms for trade payables are 15 days. Reported trade payable days, however, stand at approximately 68 days. This is largely on account of certain service creditors, such as advertising and media service providers, whose credit terms are considerably longer than the standard 15 days.

In addition, trade payable days for the current period have been computed on an average basis, whereas earlier periods used actual closing figures. This change in methodology may also account for part of the variation against the previous year.

9. Open-ness of business Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics	FY 2025-26	FY 2024-25
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	31.38%	-
	b. Number of trading houses where purchases are made from	514	-
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	61.06%	-
Concentration of Sales	a. Sales to dealers/distributors as % of total sales	3.52%	6.22%
	b. Number of dealers/distributors to whom sales are made	61	63
	c. Sales to top 10 dealers/distributors as % of total sales to dealers/distributors	44.20%	42.29%
Shares of RPTs in	a. Purchases (Purchases with related parties/Total Purchases)	0.06%	0%
	b. Sales (Sales to related parties/Total Sales)	0.55%	1.06%
	c. Loans & advances (Loans & advances given to related parties/Total loans & advances)	100%	0.00%
	d. Investments (Investments in related parties/Total Investments made)	0.84%	0.00%

Leadership Indicators

1. Awareness programs conducted for value chain partners on any of the Principles during the financial year:

Total number of awareness programmes held	Topics/principles covered in the training	% age of value chain partners covered (by the value of business done with such partners) under the awareness programmes
Nil	The Company intends to strengthen awareness and capacity-building initiatives for its value chain partners on relevant ESG principles in the coming years. Going forward, the Company aims to conduct structured awareness programmes covering applicable principles and sustainability-related topics and progressively enhance the coverage of its value chain partners based on the value of business conducted with such partners.	NA

2. Does the entity have processes in place to avoid/manage conflict of interests involving members of the Board?

Yes, directors do not participate in discussions or decisions at Board or Committee meetings where they have a personal interest in the matter. Additionally, employees and key stakeholders are required to disclose any potential conflicts of interest. Directors also regularly update their details concerning other directorships, committee roles, shareholdings, and associations.

PRINCIPLE 2: Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve environmental and Social Impacts of product and processes to total R&D and capex investments made by the entity, respectively:

Particulars	FY 2025-26	FY 2024-25	Details of improvements in environmental and social impacts
R&D	N.A	N.A	-
Capex	N.A	N.A	-

2. a. Does the entity have procedures in place for sustainable sourcing?

Yes. The Company has initiated efforts towards responsible and sustainable sourcing during the current reporting year. The Company is progressively incorporating environmental, social, ethical and governance (ESG) considerations into its procurement and supplier management processes, as applicable. These considerations may include compliance with applicable environmental and social standards, ethical business practices, human rights and labour standards, health and safety requirements, and applicable regulatory requirements.

The Company is in the process of strengthening its responsible sourcing framework and related monitoring mechanisms across its supply chain. As these practices are currently being progressively implemented and formalised, quantitative data regarding the proportion of inputs sourced sustainably is not presently available for the reporting period.

b. If yes, what percentage of inputs were sourced sustainably?

Accordingly, quantitative data on the percentage of inputs sourced sustainably is not available for the current reporting period.

3. Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

(a) Plastics (including packaging) – Yes	Yes, Plastic waste, including packaging materials generated during operations, is segregated at source and managed in accordance with the Company's waste management procedures and applicable regulatory requirements. Wherever feasible, plastic waste is sent to authorized recyclers to promote resource recovery and responsible disposal.
(b) E-waste – No	The Company does not currently have a formal product take-back or end-of-life reclamation programme. However, e-waste generated from the Company's operations is appropriately segregated, handled and handed over to authorised/registered e-waste recyclers, as applicable, for environmentally sound recycling and disposal in accordance with applicable regulatory requirements.
(c) Hazardous Waste – Yes	Hazardous waste is identified, segregated, stored, transported, and disposed of in accordance with applicable statutory requirements. The Company engages only authorized recyclers, treatment, storage, and disposal facilities (TSDFs), or other authorized agencies for the safe handling, recycling, treatment, or disposal of hazardous waste.
(d) Other Waste (General Waste) – Yes	General waste is segregated at source and disposed of through authorized municipal agencies or waste management service providers, in compliance with applicable environmental regulations. Wherever practicable, recyclable materials are recovered to minimize waste sent for disposal.

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes/No). No.

- If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards?
- If not, take steps to address the same.
- Not Applicable

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective/Assessments (LCA) for any of its products (for manufacturing industry) or for its Services (for service industry)? If yes, provide details in the following format?

NIC Code	Name of Product/Service	% of total turnover contributed	Boundary for which the life cycle perspective/Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link

N.A.

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products/services, as identified in the Life Cycle Perspective/Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same:

Name of product/service	Description of the risk/concern	Action taken

N.A.

3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).

Indicate input material

None

PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. Details of measures for the well-being of employees:

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent employees											
Male	2,232	Nil	Nil	Nil	Nil	-	-	Nil	Nil	Nil	Nil
Female	2,067	Nil	Nil	Nil	Nil	1,347	65.17%	Nil	Nil	Nil	Nil
Total	4,299	Nil	Nil	Nil	Nil	1,347	31.33%	Nil	Nil	Nil	Nil
Other than permanent employees											
Male	863	Nil	Nil	Nil	Nil	-	-	Nil	Nil	Nil	Nil
Female	384	Nil	Nil	Nil	Nil	-	-	Nil	Nil	Nil	Nil
Total	1,247	Nil	Nil	Nil	Nil	-	-	Nil	Nil	Nil	Nil

b. Details of measures for the well-being of workers:

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent workers											
Male	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Female	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Total	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Other than permanent workers											
Male	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Female	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Total	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format

Particulars	Current FY 2025-2026	Previous FY 2024-2025*
Cost incurred on well-being measures as a % of total revenue of the company	1.63%	0.17%

*Note: The percentage reported for the previous year has been revised in the current year's disclosure, as certain amounts were not considered in the previous year's calculation. The same have been appropriately included in the current year's calculation. Accordingly, the percentage for the previous year has changed.

2. Details of retirement benefits, for the Current Financial Year and Previous Financial Year.

Benefits	FY 2025-26			FY 2024-25		
	No. of employees covered as a % of total employees*	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees*	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	81%	Na	Yes	75.65%	Na	Yes
Gratuity	100%	Na	Yes	100%	Na	Yes
ESI	56%	Na	Yes	68.86%	Na	Yes
Other	Na	Na	Na	Na	Na	Na

*Note: Only permanent employee have been considered for the calculation.

3. Are the premises/offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes. The Company's offices and operational locations are equipped with facilities, wherever applicable, to support accessibility for differently abled employees in accordance with the provisions of the Rights of Persons with Disabilities Act, 2016. The Company remains committed to providing an inclusive, safe, and accessible workplace for all employees.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes. The Company has adopted an Equal Opportunity Policy in line with the provisions of the Rights of Persons with Disabilities Act, 2016, reaffirming its commitment to equal opportunity, non-discrimination, and an inclusive work environment.

Web-link: <https://jeenasikho.com/wp-content/uploads/2026/07/Equal-Opportunity-Disability-Inclusion-Policy-V3.0.pdf>

9. Details of performance and career development reviews of employees and worker:

Benefits	FY 2025-26			FY 2024-25		
	Total (A)	No. (B)	% (B/A)	Total (C)	No. (D)	% (D/C)
Employees						
Male	2,232	2,232	100%	1,938	1,938	100%
Female	2,067	2,067	100%	1,826	1,826	100%
Total	4,299	4,299	100%	3,764	3,764	100%
Workers						
Male	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA
Total	NA	NA	NA	NA	NA	NA

10. Health and safety management system:

a.	Whether an occupational health and safety management system has been implemented by the entity? If yes, the coverage such system?	Yes. Jeena Sikho Lifecare Limited has established policies, procedures and practices to promote occupational health and safety across its operations. The system covers employees at its hospitals, clinics and other operational facilities, with measures addressing workplace safety, healthcare-related occupational risks, emergency preparedness and safe working practices.
b.	What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?	The Company identifies and assesses work-related hazards through routine workplace monitoring, inspections, review of incidents and near-misses, and assessment of risks associated with healthcare and operational activities. Appropriate preventive and corrective measures are implemented based on the risks identified.
c.	Whether you have processes for workers to report work-related hazards and to remove themselves from such risks.	Yes. The Company provides mechanisms through which employees can report workplace hazards, safety concerns and incidents to the personnel concerned. Employees are encouraged to raise concerns through the established grievance and reporting mechanisms, enabling timely corrective and preventive action.
d.	Do the employees/workers of the entity have access to non-occupational medical and healthcare services?	Yes. Employees have access to healthcare services through the Company's healthcare facilities, as applicable, enabling them to seek medical assistance for non-occupational health concerns.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY 2025-26	FY 2024-25
Lost Time Injury Frequency Rate (LTIFR) (per one million- person hours worked)	Employees	Nil	Nil
	Workers	NA	NA
Total recordable work-related injuries	Employees	Nil	Nil
	Workers	NA	NA
No. of fatalities	Employees	Nil	Nil
	Workers	NA	NA
High consequence work-related injury or ill-health (excluding fatalities)	Employees	Nil	Nil
	Workers	NA	NA

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

Jeena Sikho Lifecare Limited takes various measures to ensure a safe and healthy workplace across its hospitals, clinics and other operational facilities. The Company implements workplace safety procedures and maintains appropriate fire safety systems, including fire safety equipment, emergency preparedness measures and periodic fire safety checks/audits, as applicable. Regular fire safety, emergency response and other safety training sessions, including CPR training and emergency mock drills, are conducted to enhance preparedness among employees. The Company also undertakes appropriate preventive and corrective measures to address identified health and safety risks and promote a safe working environment.

13. Number of Complaints on the following made by employees and workers.

Particulars	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	Nil	Nil	-	Nil	Nil	-
Health & Safety	Nil	Nil	-	Nil	Nil	-

14. Assessments for the year.

Particulars	Percentage of your plants and offices that were assessed (by entity or statutory authorities or third parties) (%)
Health and safety practices	100% (NABH)
Working Conditions	100% (NABH)

15. Provide details of any corrective action taken or under way to address safety-related incidents (if any) and on significant risks/

No significant safety-related incidents or material health and safety risks were reported during the reporting period. The Company continues to monitor workplace health and safety practices and working conditions across its operations and undertakes corrective and preventive measures, as required, based on identified risks, observations and assessments.

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of: (Y/N)?

A) Employees	No
B) Workers	NA

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners:

The Company encourages its value chain partners to comply with applicable statutory and regulatory requirements, including applicable requirements relating to statutory dues. Relevant compliance information may be considered, where available and applicable, based on the nature of the engagement and documentation provided by value chain partners.

3. Provide the number of employees/workers having suffered high consequence work-related injury/ill-health/fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment.

Particulars	Total no. of affected workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Employees	Nil	Nil	Nil	Nil
Workers	Nil	Nil	Nil	Nil

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment?

Yes

5. Details on assessment of value chain partners.

Particulars	% of value chain partners (by value of business done with such partners) that were assessed (%)
Health and safety practices	Nil; the Company requires all its value chain partners, including suppliers and contractors, to comply fully with applicable regulatory standards, including safety regulations and labor laws.
Working Conditions	

6. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from assessments of Health and safety practices and working conditions of value chain partners.

Not Applicable

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity.

Jeena Sikho Lifecare Limited is committed to fostering collaborative growth and creating value for all its stakeholders. The Company identifies key stakeholder groups based on their impact on the Company's operations and the extent to which the Company's activities may affect them. The stakeholder identification process considers factors such as their influence, responsibility, dependence, and relevance to the Company's business activities.

The Company's key stakeholders include patients/customers, shareholders and investors. The Company engages with these stakeholder groups through appropriate channels to understand their expectations, concerns, grievances, and suggestions. The inputs received through these engagements are considered in business planning, decision-making, and the Company's sustainability and social initiatives.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/Half yearly/Quarterly/ others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Investors & Shareholders	Yes	* Email, Newspaper, Website, Investor and Analyst Meetings/ Conferences * One-to-One Meetings (Physical and Virtual), * Earnings Call with Analysts and Investors * Annual General Meeting * Press Releases * Stock Exchange Filings	Quarterly/ Annually/Event Based	To ensure transparent and effective communication of business performance * To provide insights into Company's strategy and sustainability initiatives * To address investor/analyst queries and concerns * To ensure sound corporate governance mechanisms * To enhance Company reputation
Patients/ Customers	Yes	* Listening to patients posts via email, SMS, website, feedback App, social media platforms, verbal, patient feedback surveys, complaint box, etc. * Patient communication by the hospital: email, meetings/ telephonic/verbal	Others – ongoing	* Establishing an effective mechanism for promptly recognising and resolving concerns and complaints raised by patients and their attendants * Enhancing the provision of highquality healthcare services and safeguarding patient health and safety through thorough review, investigation, tracking and trend analysis of complaints * Ensuring immediate responses to patient and attendant complaints and grievances in realtime.

Leadership Indicators

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board?

Yes

2. Whether stakeholder consultation is used to support the identification and management of environmental, and social topics.

Yes

If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into the Policies and activities of the entity.

Yes. The Company undertakes stakeholder engagement and consultation, as appropriate, to understand relevant environmental and social concerns and expectations. Inputs received through stakeholder interactions are considered in the identification and management of relevant environmental and social topics and, where appropriate, are incorporated into the Company's policies, practices, and initiatives. The Company continues to strengthen its stakeholder engagement mechanisms to facilitate effective consideration of such inputs in its decision-making processes.

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/marginalized stakeholder groups.

The Company places high importance on resolving community issues and actively supports the well-being of underserved and vulnerable groups through its CSR programs.

PRINCIPLE 5: Businesses should respect and promote human rights

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Particulars	FY 2025-26			FY 2024-25		
	Total (A)	No. of employees/workers covered (B)	% (B/A)	Total (C)	No. of employees/workers covered (D)	% (D/C)
Employees						
Permanent	4,299	4,299	100%	3,764	3,764	100%
Other than permanent	1,247	0	0	1,000	0	0%
Total Employees	5,546	4,299	77.51%	4,764	3,764	79%
Workers						
Permanent	NA	NA	NA	NA	NA	NA
Other than permanent	NA	NA	NA	NA	NA	NA
Total Employees	NA	NA	NA	NA	NA	NA

2. Details of minimum wages paid to employees and workers, in the following format*:

Category	FY 2025-26					FY 2024-25				
	Total (A)	Equal to minimum wage		More than minimum wage		Total (D)	Equal to minimum wage		More than minimum wage	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
Permanent employees										
Male	2,232	1,120	50.18%	1112	49.82%	1,938	325	16.77%	1,613	83.23%
Female	2,067	1,413	68.36%	654	31.64%	1,826	545	29.85%	1,281	70.15%
Total	4,299	2,533	58.92%	1,766	41.08%	3,764	870	23.11%	2,894	76.89%
Other than permanent employees										
Male	863	863	100%	0	0	650	650	100%	0	0
Female	384	384	100%	0	0	350	350	100%	0	0
Total	1,247	1,247	100%	0	0	1,000	1,000	100%	0	0
Permanent Workers										
Male	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Other than permanent workers										
Male	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Female	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

*Note: The increase in the percentage of employees covered under the minimum wage category is primarily attributable to the increase in statutory minimum wage rates, along with changes in the employee mix due to replacement hiring during the year, resulting in a higher proportion of employees falling within the applicable minimum wage category

3. Details of remuneration/salary/wages

a. Median remuneration/wages:

Particulars	Male		Female	
	Number	Median remuneration/salary/wages of respective category	Number	Median remuneration/salary/wages of respective category
Board of Directors (BoD)*	1	2,40,00,000	2	93,50,000
Key managerial Personnel	1	31,50,000	1	2,97,581
Employees other than BoD and KMP**	2,230	2,04,572	2064	1,77,262

*Sitting fees paid to Non-Executive Independent Directors have not been considered in the remuneration disclosed for the Board of Directors.

**The employee count and median remuneration/wages(Annual Basis) disclosed for employees other than the BOD and KMP are based on employees eligible for the remuneration calculation and in active employment as at 31 March 2026.

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

Particulars	FY 2025-26	FY 2024-25
Gross wages paid to females as % of total wages	42.64%	43.93%

4. Do you have a focal point (Individual/Committee) responsible for addressing human rights impacts or issues caused or Contributed to by the business?

Yes. The Company has designated internal mechanisms, including the **Internal Committee constituted under the POSH framework and the grievance redressal mechanism**, to receive, address, and resolve concerns relating to workplace dignity, safety, and human rights.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

The Company is committed to upholding internationally recognized human rights and maintaining a workplace based on **dignity, equality, respect, and non-discrimination**. Grievances relating to human rights issues are addressed through the following mechanisms:

- **Whistleblower and Ethics Framework** – for reporting ethical concerns and potential violations.
- **Open-door and Reporting Mechanism** – enabling employees to raise concerns through appropriate channels.
- **POSH Internal Committee** – for addressing complaints relating to sexual harassment at the workplace.
- **Grievance Redressal Mechanism** – for receiving and resolving employee grievances.
- **Non-retaliation Assurance** – to encourage employees to report concerns without fear of retaliation.
- **Investigation and Resolution Process** – complaints are reviewed and investigated, as appropriate, and corrective action is taken where required.
- **Awareness and Training** – employees are sensitised on relevant policies, rights, responsibilities, and expected workplace conduct.
- **Escalation and Management Oversight** – significant or unresolved matters are escalated to the appropriate management for review and resolution.

6. Number of Complaints on the following made by employees and workers:

Category	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	Nil	Nil	-	Nil	Nil	-
Discrimination at workplace	Nil	Nil	-	Nil	Nil	-
Child Labour	Nil	Nil	-	Nil	Nil	-
Forced Labour/ Involuntary Labour	Nil	Nil	-	Nil	Nil	-
Wages	Nil	Nil	-	Nil	Nil	-
Other human rights related issues	Nil	Nil	-	Nil	Nil	-

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

Particulars	FY 2025-26	FY 2024-25
Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	Nil	Nil
Complaints on POSH as a % of female employees/workers Complaints on POSH upheld	Nil	Nil

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The Company has established a POSH Internal Committee and grievance redressal mechanism to provide appropriate channels for reporting and resolution of discrimination and harassment-related concerns. The Company is committed to maintaining confidentiality and ensuring that complaints are addressed through an appropriate investigation and resolution process, with protection against retaliation for raising concerns in good faith.

9. Do human rights requirements form part of your business agreements and contracts?

Yes. The Company recognises the importance of respecting human rights in its business operations and, where relevant, incorporates applicable human rights considerations into its business arrangements and contractual engagements. These considerations may include compliance with applicable labour laws, prohibition of child and forced labour, non-discrimination, prevention of sexual harassment, fair and lawful employment practices, and respect for fundamental human rights. The Company encourages its value chain partners and relevant business associates to adhere to applicable legal and ethical standards in these areas, as appropriate to the nature of their engagement.

10. Assessments for the year:

Particulars	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child Labour	The Company's human rights due-diligence approach includes periodic review of relevant policies and procedures, applicable legal and regulatory requirements, risk identification and assessment, employee awareness and training, compliance reviews, and evaluation of relevant value chain partners, as applicable. The Company's healthcare facilities are also subject to assessment and accreditation requirements under the National Accreditation Board for Hospitals & Healthcare Providers (NABH), which covers relevant aspects of patient care, employee practices, safety, ethical conduct and organisational processes. While separate site-level assessments specifically for child labour were not undertaken during the reporting period, these aspects are addressed through the Company's existing policies, processes, NABH-related assessment mechanisms, and compliance systems.
Forced/involuntary Labour	
Sexual harassment	
Discrimination at workplace	
Wages	

11. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from the assessments at Question above.

Based on the Company's existing human rights policies, compliance mechanisms, employee grievance channels, and due-diligence processes, no significant human rights risks or concerns requiring specific corrective action were identified during the reporting period. Accordingly, no specific corrective actions were required or initiated during the year. The Company will continue to monitor relevant human rights risks and undertake appropriate corrective measures, wherever required.

Leadership Indicators

1. Details of a business process being modified/introduced as a result of addressing human rights grievances/complaints:

Although no instances were observed that required modification of the existing process, we consistently monitor it to ensure we can address any potential need for change.

2. Details of the scope and coverage of any Human rights due diligence conducted:

The Company's human rights due-diligence process covers periodic review of relevant policies, risk assessments, compliance reviews, employee awareness and training, supplier evaluations, grievance redressal mechanisms, and corrective action measures, wherever required. The effectiveness of the human rights due-diligence framework is reviewed periodically, and necessary improvements are undertaken to address identified risks and align with applicable legal and regulatory requirements and recognized human rights principles. No such third-party due diligence was conducted.

3. Is the premise/office of the entity accessible to differently-abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes, The Company's hospitals, clinics, and other workplace facilities are designed to facilitate accessibility for differently-abled visitors and employees, wherever applicable. Accessible infrastructure such as ramps, level access points, and suitable entry/exit arrangements is provided at relevant locations to enable safe and convenient movement. The Company continues to assess and improve accessibility measures in line with applicable requirements under the Rights of Persons with Disabilities Act, 2016.

4. Details on assessment of value chain partners.

Particulars	% of value chain partners (by value of business done with such partners) that were assessed
Sexual harassment	The Company requires its vendors, suppliers, and value chain partners to comply with applicable labour laws, human rights requirements, ethical business practices, workplace safety requirements, and other relevant statutory obligations. Compliance with these requirements is assessed through contractual provisions, vendor onboarding and due-diligence processes, declarations, and relevant compliance documentation, as applicable. Accordingly, the above parameters are covered as part of the Company's value chain partner assessment and compliance process.
Discrimination at workplace	
Child Labour	
Forced/involuntary Labour	
Wages	

5. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from the assessments at Question above.

Not Applicable

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format.

Particulars	Unit	FY 2025-26	FY 2024-25
From Renewable Sources			
Total electricity consumption (A)	-	-	-
Total fuel consumption (B)	-	-	-
Energy consumption through other sources (C)	-	-	-
Total energy consumed from renewable sources (A+B+C)	-	-	-
From Non-Renewable Sources			
Total electricity consumption (D)	TJ	17.128	-
Total fuel consumption (E)	TJ	5.219	-
Energy consumption through other sources (F)	-	-	-
Total energy consumed from Non-renewable sources (D+E+F)	TJ	22.347	-
Total energy consumed (A+B+C+D+E+F)	TJ	22.347	-
Energy intensity per rupee of turnover (Total energy consumed/Revenue from operations)	TJ/Rs	0.00000002789 TJ/Rs	-
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed/Revenue from operations adjusted for PPP)	TJ/Rs	0.00000005674 TJ/Rs	-
Energy intensity in terms of physical output	-	-	-
Energy intensity (optional) – the relevant metric may be selected by the entity	-	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency. (Y/N) If yes, the name of the external agency. No.

Note: Electricity consumption has been calculated based on the electricity consumption details reflected in the invoices and supporting records provided by the Company, including the units recorded therein. The calculation has been undertaken based on the information and documentation provided by the Company for the respective reporting locations.

Note: Fuel consumption has been estimated based on the expenditure/amount details for petrol and diesel as reflected in the invoices and supporting records provided by the Company. The corresponding quantity in litres has been derived by dividing the reported expenditure by the applicable assumed/standard fuel price per litre, considered on a location-wise basis.

2. Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, Achieve, and Trade (PAT) Scheme of the Government of India? No.

If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any. Not Applicable

3. Provide details of the following disclosures related to water, in the following format.

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kilolitres)		
(i) Surface water	-	-
(ii) Ground water	-	-
(iii) Third-party water	121,442.1 KL	-
(iv) Seawater/desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kilolitres) (I + ii + iii + iv + v)	121,442.1 KL	-
Total volume of water consumption (in kilolitres)	121,442.1 KL	-
Water intensity per rupee of turnover (Water consumed/Revenue from operations)	0.000015155 KL/₹	-
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)	0.00030832 KL/₹	-
Water intensity in terms of physical output	-	-
Water intensity (optional) – the relevant metric may be selected by the entity	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No assessment or assurance has been conducted by an external agency.

4. Provide the following details related to water discharged:

Parameter	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kilolitres)		
(i) Surface water	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(ii) Groundwater	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(ii) Groundwater	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(iv) Seawater/desalinated water	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(v) Others (Municipal Waste)	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No assessment or assurance has been conducted by an external agency.

Note: Water consumption has been estimated using NBC (National Building Code) per-capita water demand norms applied to average OPD/IPD patient footfall and staff headcount, in the absence of branch-wise water metering

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

The Company has not implemented a Zero Liquid Discharge (ZLD) mechanism across its operations. However, it is committed to responsible water management and ensures compliance with applicable environmental regulations relating to water use and wastewater management. The Company continues to evaluate opportunities to enhance its water conservation and wastewater management practices wherever feasible.

6. Please provide details of air emissions (other than GHG emissions) by the entity

Parameter	Unit	FY 2025-26	FY 2024-25
NOx	Kg	-	-
SOx	Kg	-	-
Particulate matter (PM)	Kg	-	-
Persistent organic pollutants (POP)	-	-	-
Volatile organic compounds (VOC)	-	-	-
Hazardous air pollutants (HAP)	-	-	-
Others (Please specify)	Kg	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No assessment or assurance has been conducted by an external agency.

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format

Parameter	Please specify unit	FY 2025-26	FY 2024-25
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	385.01	-
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	3378.05	-
Total Scope 1 and Scope 2 emissions per rupee of turnover	-	0.0000004696 tCO₂e/Rs	-
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)	-	0.000009554 tCO ₂ e/Rs	-
Total Scope 1 and Scope 2 emission intensity in terms of physical output	-	-	-
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No assessment or assurance has been conducted by an external agency.

Note: GHG emissions have been calculated based on the available electricity and fuel consumption data provided by the Company. Emission factors have been applied to the respective activity data to estimate Scope 1 and Scope 2 GHG emissions. The calculation is based on the available information and covers only those locations for which relevant electricity and fuel consumption data was provided.

8. Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.

No. The Company has not undertaken any specific greenhouse gas (GHG) emission reduction initiatives during the reporting period. However, it remains committed to the efficient use of resources and will continue to evaluate opportunities to improve its environmental performance as part of its sustainability journey.9. Provide details related to waste management by the entity, in the following format.

9. Provide details related to waste management by the entity

Parameter	FY 2025-26	FY 2024-25
Total Waste generated (in metric tonnes)		
Plastic waste (A)	-	-
E-waste (B)	-	-
Bio-medical waste (C)	64.9	7.56
Construction and demolition waste (D)	-	-
Battery waste (E)	-	-
Radioactive waste (F)	-	-
Other Hazardous waste. Please specify, if any. (G) - Diesel Oil	-	91.20
Total (A + B + C + D + E + F + G + H)	64.9	-
Waste intensity per rupee of turnover	0.00000000810 tonnes/Rs	0.0000000194
Waste intensity per rupee of turnover adjusted Purchasing for Power Parity (PPP)	0.0000001647 tonnes/Rs	-
Waste intensity in terms of physical output	-	-
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tons)		
Category of waste	-	-
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total	-	-
For each category of waste generated, total waste disposed by nature of disposal method (in metric tons)		
Category of waste	-	-
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations (Hazardous waste/sludge sold to authorized vendor)	-	-
Total	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? If yes, name of the external agency.

No assessment or assurance has been conducted by an external agency.

Note: Waste data has been compiled based on the biomedical waste (BMW) data provided by the Company for the locations where data was available. The reported quantity represents the available site-wise BMW data and may not cover all operational locations of the Company due to non-availability of data for certain sites. No data was provided for other waste categories; therefore, only the available BMW data has been considered in this assessment.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce the usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

The Company follows appropriate waste management practices in accordance with applicable regulatory requirements and is committed to minimizing the environmental impact of its operations. Key practices include:

- Segregation of waste at source to facilitate appropriate handling and disposal.
- Collection and disposal of biomedical waste through authorized vendors in compliance with applicable regulations, wherever applicable.
- Segregation of general waste to promote responsible disposal and recycling, wherever feasible.

- Engagement of authorized waste management agencies for the collection, transportation, and disposal of waste, as applicable.

Periodic awareness and monitoring initiatives to encourage effective waste management and ensure regulatory compliance across its operations.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones, etc.) where environmental approvals/clearances are required, please specify details in the following format:

Location of operations/offices	Type of operations	Whether the conditions of environmental approval/clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
Nil		

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No)	Relevant Web link
Nil					

13. Is the entity compliant with the applicable environmental law/regulations/guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment Protection Act, and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Specify the law/regulation/guidelines which was not complied with	Provide details of the non-compliance	Any fines/penalties/action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
Nil			

Jeena Sikho Lifecare Limited seeks to comply with applicable environmental laws, rules, regulations and guidelines in force in India, as relevant to its operations. These may include, as applicable, the Water (Prevention and Control of Pollution) Act, 1974, the Air (Prevention and Control of Pollution) Act, 1981, the Environment (Protection) Act, 1986, and the rules and directions issued thereunder. Based on the information and confirmations available for the reporting period, no material instance of environmental non-compliance has been identified or reported in relation to the Company's operations. Accordingly, no material fines, penalties or regulatory actions arising from environmental non-compliance have been identified or reported during the reporting period.

Leadership Indicators

1. Water withdrawal, consumption, and discharge in areas of water stress (in kilolitres): For each facility/plant located in areas of water stress, provide the following information:

- (i) Name of the area
- (ii) Nature of operations
- (iii) Water withdrawal, consumption, and discharge in the following format:

Parameter	Please Specify Unit	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)			
Surface water	KL	0	0
Groundwater	KL	0	0
Third party water	KL	0	0
Seawater/desalinated water	KL	0	0
Others	KL	0	0
Total volume of water withdrawal (in kilolitres)	KL	0	0
Total volume of water consumption (in kilolitres)	KL	0	0

(iii) Water withdrawal, consumption, and discharge in the following format: (Contd.)

Parameter	Please Specify Unit	FY 2025-26	FY 2024-25
Water intensity per rupee of turnover (Water consumed/turnover)	KL	0	0
Water intensity (optional) – the relevant metric may be selected by the entity	KL	0	0
Water discharge by destination and level of treatment (in kilolitres)			
(i) Into Surface water	KL	0	0
– No treatment	KL	0	0
– With treatment – please specify level of treatment	KL	0	0
(ii) Into Groundwater	KL	0	0
– No treatment	KL	0	0
– With treatment – please specify level of treatment	KL	0	0
(iii) Into Seawater	KL	0	0
– No treatment	KL	0	0
– With treatment – please specify level of treatment	KL	0	0
(iv) third party water	KL	0	0
– No treatment	KL	0	0
– With treatment – please specify level of treatment	KL	0	0
(v) Others	KL	0	0
– No treatment	KL	0	0
– With treatment – please specify level of treatment	KL	0	0
Total water discharged (in kilolitres)	KL	0	0

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)

No independent assessment, evaluation, or assurance has been carried out by an external agency.

Note: The Company has not identified any operations located in water-stressed or water-scarcity areas during the current reporting period. Accordingly, the relevant quantitative information has not been reported.

2. Please provide details of total Scope 3 emissions & its intensity, in the following format: Whether total Scope 3 emissions & its intensity is applicable to the Company?

No

Parameter	Please Specify Unit	FY 2025-26	FY 2024-25
Total Scope 3 Emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	TCO ₂ e	-	-
Total Scope 3 Emissions per Rupee of Turnover	TCO ₂ e/₹ Crores	-	-
Total Scope 3 Emission Intensity (Optional) – The Relevant Metric May be Selected by the Entity	TCO ₂ e	-	-

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)

If yes, name of the external agency.

No independent assessment, evaluation, or assurance has been carried out by an external agency.

3. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

Not Applicable.

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions/effluent discharge/waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
-	-	-

5. Does the entity have a business continuity and disaster management plan?

Yes

Details of entity at which business continuity and disaster management plan is placed or weblink.

Yes. The Company has established business continuity and disaster management arrangements to support the continuity of critical operations and ensure the safety of employees, patients, visitors, and other stakeholders during emergencies and unforeseen events. The framework covers identification of potential operational risks, emergency response and escalation mechanisms, safety protocols, communication arrangements, and measures for restoration of critical activities. The Company periodically reviews and strengthens these arrangements based on operational requirements, identified risks, and applicable regulatory requirements. Relevant site-level emergency response and safety procedures are implemented, as applicable, to support preparedness and effective response to potential disruptions and emergencies.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

No significant adverse environmental impacts have been identified arising from the Company's value chain. As the Company operates in the Ayurveda healthcare sector, the majority of the waste generated comprises herbal and biodegradable materials used in therapies. The Company follows applicable waste management practices and regulatory requirements to ensure the safe handling and disposal of waste, thereby minimizing its environmental impact.

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

Nil

PRINCIPLE 7: BUSINESSES, WHEN ENGAGING IN INFLUENCING PUBLIC AND REGULATORY POLICY, SHOULD DO IN A MANNER THAT IS RESPONSIBLE AND TRANSPARENT

Essential Indicators

1. a. Number of affiliations with trade and industry chambers/associations: 2

b. List the top 10 trade and industry chambers/associations (determined based on the total members of such body) the entity is a member of/affiliated to.

Name of the trade and industry chambers/Associations	Reach of trade and industry chambers/associations (State/national)
NABH	National
Ayurveda Federation of India	National

2. Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities.

Name of authority	Brief of the case	Corrective action taken
No cases of issues related to anti- competitive conduct by the entity		

Leadership Indicators

1. Details of Public Policy Positions Advocated by the entity:

Public policy advocated	Method resorted for such advocacy	Whether information is available in public domain? (Yes/No)	Frequency of review by Board (Annually/ Half yearly/ Quarterly/ Others – please specify)	Web Link, if available
Nil				

PRINCIPLE 8: BUSINESSES SHOULD PROMOTE INCLUSIVE GROWTH AND EQUITABLE DEVELOPMENT

Essential Indicators

1. Details of social impact assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year

Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No)	Relevant Web link
NA					

2. Provide information on project(s) for which ongoing rehabilitation and resettlement (R&R) is being undertaken by your entity

Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In INR)
NA					

3. Describe the mechanisms to receive and redress grievances of the community

The Company has established a grievance redressal mechanism across its hospitals through dedicated reception/helpdesk facilities. Patients, attendants, and other members of the community can submit their concerns, feedback, or complaints in person at reception. The grievances are reviewed by the personnel concerned and are addressed promptly through the Company's internal grievance resolution process to ensure timely and satisfactory resolution.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers*

Parameter	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/small producers	100%	100%
Directly from within India	100%	100%

*Note: The input material sourcing percentages reported above correspond strictly to the procurement of raw materials, packaged goods, and ingredients for Ayurvedic and wellness products under the Retail Trading segment (NIC Code 4772, representing 51.87% of turnover). Operating consumables, including medicated oils and healthcare supplies utilized in Hospital and Medical Care activities (NIC Code 8690), have been excluded from this computation as they are treated as direct operational service consumables.

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/on contract basis) in the following locations, as % of total wage cost:

Parameter	FY 2025-26	FY 2024-25
Rural	–	–
Semi-urban	1.47%	2.61%
Urban	60.08%	56.95%
Metropolitan	38.45%	40.44%

*Note: Only permanent employees have been considered for the calculation.

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):

Corrective action taken
This section is not applicable since a Social Impact Assessment was not carried out in FY 2025-26.

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

The Company has not undertaken any CSR initiatives in government-designated aspirational districts during the reporting period; however, it has implemented CSR projects in other districts as part of its ongoing community development efforts.

3. a. Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized/vulnerable groups?

No, our Code of Conduct and Ethics Policy ensures that there is no discrimination of any kind in the supplier selection process, and equal opportunity is provided to all potential suppliers. We encourage collaboration with local suppliers or those located near our operational facilities. However, we have not explicitly included marginalized or vulnerable groups as part of our supplier qualification criteria.

b. From which marginalized/vulnerable groups do you procure?: Not Applicable

c. What percentage of total procurement (by value) does it constitute? Not Applicable

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge

Intellectual Property based on traditional knowledge	Owned/Acquired (Yes/No)	Benefit shared (Yes/No)	Basis of calculating benefit share
		N.A	

5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes where in usage of traditional knowledge is involved.

Brief of the Case	Corrective action taken
	Nil

6. Details of beneficiaries of CSR Projects:

The Company's CSR initiatives primarily benefit underprivileged and underserved communities, including children, students, youth, women, girls, and vulnerable households. Key beneficiary groups include students receiving education and skill-development support; women, including single mothers, widows and lactating mothers; children and adolescents receiving mental health support; and economically vulnerable families receiving food and nutrition assistance. The CSR programmes also support students from ITIs, government colleges and universities through technical skill development and industry-oriented training.

Thematic Area	No. of persons benefitted from CSR Projects*	% of beneficiaries from vulnerable and marginalized groups
Education & Skill Development: Enhancing access to education and technical training to empower individuals with knowledge and employable skills.	75,000+	
Social Welfare and Community Support: Supporting initiatives that uplift marginalized groups and promote inclusive development through trusted social organizations.	5,320+	100%
Community Infrastructure: Contributing to essential infrastructure like clean water and sanitation to improve community living standards.	NA	

*Note: In respect of CSR contributions made to various entities, it is difficult to ascertain the exact number of beneficiaries. Accordingly, the respective entities have provided the Company with an estimated number of beneficiaries, which has been considered for the purpose of this disclosure.

Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback

The Company has established a structured grievance redressal mechanism to receive and address grievances through multiple channels, including customer care helplines, email, website, hospitals/clinics, and social media platforms. Grievances received through these channels are recorded, monitored, and addressed within defined timelines. Significant or unresolved grievances are escalated to the appropriate management for review and timely resolution. The grievance redressal mechanism is periodically monitored to ensure effective and responsive resolution of stakeholder concerns.

2. Turnover of products and/services as a percentage of turnover from all products/service that carry information about:

The Company provides relevant information on environmental and social aspects associated with its Services/Products through appropriate Services/Products-related documentation, operational guidelines, customer communication, and other applicable channels. Information relating to responsible and safe use of Services/Products relevant environmental and social considerations, and appropriate management or disposal of materials/waste, wherever applicable, is communicated to relevant customers and stakeholders.

As a percentage to total turnover*	
Environmental and social parameters relevant to the product	100%
Safe and responsible usage	100%
Recycling and/or safe disposal	100%

*Note: The percentage of turnover has been calculated considering only those products and services to which the respective environmental and social parameters, safe and responsible usage, and recycling and/or safe disposal guidelines are applicable.

3. Number of consumer complaints

Category	FY 2025-26 (Current Financial Year)			FY 2024-25 (Previous Financial Year)		
	Received During the Year	Pending Resolution at End of Year	Remarks	Received During the Year	Pending Resolution at End of Year	Remarks
Data Privacy	0	0	-	128	5	-
Advertising	0	0	-	0	0	-
Cybersecurity	0	0	-	0	0	-
Delivery of Essential Services	3,254	0	-	3,850	0	-
Restrictive Trade Practises	0	0	-	0	0	-
Unfair Trade Practises	399	0	-	0	0	-
Other	9,946	0	-	8,650	20	-

4. Details of instances of product recalls on account of safety issues

	Number	Reasons for recall
Voluntary recalls	0	NA
Forced recalls	0	NA

5. Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.

Yes, The Company has established an Information Security and Data Privacy framework to safeguard confidential information and personal data. The framework covers key aspects such as access controls, data protection measures, cybersecurity monitoring, employee awareness and training, and periodic security reviews to identify and mitigate cyber security and data privacy risks. The Company is committed to maintaining the confidentiality, integrity, and security of stakeholder information in compliance with applicable laws and regulations.

web link: <https://jeenasikho.com/privacy-policy/>

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty/action taken by regulatory authorities on safety of products/services.

The Company periodically reviews customer complaints and feedback relating to advertising, delivery of essential services, and customer service, and implements appropriate corrective and preventive actions, wherever required. Employees are provided with regular training and guidance on responsible and transparent customer communication.

With respect to cyber security and customer data privacy, the Company continues to strengthen its controls through periodic system updates, monitoring, access controls, and employee awareness initiatives to mitigate identified risks.

During the reporting period, no instances of product recalls or penalties/actions by regulatory authorities relating to product/service safety were reported. Any significant customer or operational concerns identified are reviewed by the functions concerned and addressed through appropriate corrective actions.

7. Provide the following information related to data breaches:

a. Number of instances of data breaches

No instances of data breaches

b. Percentage of data breaches involving personally identifiable information of customers

0%

c. Impact, if any, of the data breaches

Not Applicable

Leadership Indicators

1. Channels/platforms where information on products and services of the entity can be accessed (provide web link, if available)

Information relating to the Company's products and services is made available to consumers through multiple channels, including the Company's website, online store, hospitals and clinics, customer care channels, and social media platforms.

Website: <https://jeenasikho.com/>

Online Store: <https://store.jeeenasikho.com/>

2. Steps were taken to inform and educate consumers about the safety and responsible usage of products and/or services:

The Company provides information and guidance to consumers on the safe and responsible use of its products and services through product labels containing usage instructions, dosage information and precautions. Consumers are also provided guidance through consultations with qualified Ayurvedic doctors and patient counselling. In addition, the Company undertakes health awareness initiatives through campaigns, webinars, blogs, and digital content to promote informed and responsible usage.

3. Mechanisms are in place to inform consumers of any risk of disruption/discontinuation of essential services.

In the event of any anticipated disruption or discontinuation of essential services, consumers are informed through appropriate communication channels, including SMS, telephone calls, email, website notifications, social media updates, and direct communication through hospitals and clinics. Wherever feasible, the Company also communicates alternative arrangements to minimise inconvenience to consumers.

4. a. Does the entity display product information on the product over and above what is mandated as per local laws?

Yes, In addition to information mandated under applicable laws, the Company provides relevant information such as ingredients, dosage/usage instructions, storage conditions, precautions, customer care details, and wellness-related guidance, as applicable to the product.

b. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products/services of the entity, significant locations of operation of the entity, or the entity as a whole?

Yes

The Company obtains consumer feedback through patient surveys, feedback forms, customer care interactions, and online reviews. The feedback received is reviewed to identify areas for improvement and enhance the quality of products and services.

Independent Auditor's Report

To the Members of Jeena Sikho Lifecare Limited

Report on the Audit of the Standalone Financial Statements

167

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

OPINION

1. We have audited the accompanying standalone financial statements of Jeena Sikho Lifecare Limited ('the Company'), which comprise the Standalone Balance Sheet as at 31 March 2026, the Standalone Statement of Profit and Loss (including Other Comprehensive Income), the Standalone Statement of Cash Flow and the Standalone Statement of Changes in Equity for the year then ended, and notes to the standalone financial statements, including material accounting policy information and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, and its profit (including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

BASIS FOR OPINION

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

KEY AUDIT MATTERS

5. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key audit matters	How our audit addressed the key audit matter
Revenue recognition: Refer Note 2(l) and Note 25 to the accompanying standalone financial statements for the material accounting policy information on revenue recognition and details of revenue recognised during the year. The Company earns revenue primarily from sale of ayurvedic products/medicines and providing ayurvedic healthcare services, which are sold/offered through a wide network of hospitals, clinics, day-care centers, e-commerce platforms, Company's own website, dealer/franchisee networks etc. across India. The Company recognises revenue from contracts with customers in accordance with Ind AS 115 – Revenue from Contracts with Customers and requires management to make certain judgements with respect to: - Identification of distinct/bundled performance obligations; - Assessment of the timing of transfer of control of goods/bundled services depending on the specific terms and conditions of the customer contracts; - Evaluation of principal versus agent relationship.	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of the process for revenue recognition and evaluated the appropriateness of accounting policy on revenue recognition in accordance with Ind AS 115. - Evaluated the design and tested the operating effectiveness of internal financial controls, around revenue recognition. - Selected samples of customer contracts/consent forms/franchise agreements as entered in current year and evaluated management's assessment with respect to identification of distinct/bundled performance obligations in such contracts, timing of transfer of control of goods/bundled services and evaluation of principal versus agent relationship as per the requirements of Ind AS 115. - Performed substantive testing, on a sample basis, on revenue transactions recorded during the year and those recorded during a specific period before and after year-end, by inspecting relevant supporting documents such as invoices, patient files, customer contracts, proof of delivery, to ensure transactions are recorded for the correct amount and in the correct period. Additionally, on a sample basis, traced sales recorded to related collection reports, cash deposit documents and bank statements.

5. We have determined the matters described below to be the key audit matters to be communicated in our report. (Contd.)

Key audit matters	How our audit addressed the key audit matter
Revenue serves as a key performance indicator for the Company and, in accordance with the requirements of the Standards on Auditing, revenue recognition is determined to be an area involving significant risk which requires significant auditor attention. Considering the significance of amount involved, volume of transactions, multiplicity of sales/service channels which also involves sales made through cash-and-carry model and significant management judgements involved, revenue recognition has been identified as a key audit matter in the current year audit.	- Conducted analytical procedures, such as variance analysis on revenue, to identify any unusual trends or items. - Evaluated the appropriateness and adequacy of related presentation and disclosures made in the standalone financial statements in accordance with applicable Ind AS.
Impairment assessment of goodwill Refer Note 2(h), Note 5 and Note 45 to the accompanying standalone financial statements for the material accounting policy information on impairment assessment of goodwill and related disclosures. As at 31 March 2026, the Company has a significant goodwill balance of ₹ 5,811.82 lakhs, arising from acquisition of ayurveda business from Oregon Life Private Limited in previous year. The Company has performed an annual impairment test of goodwill as required under Ind AS 36, Impairment of Assets ('Ind AS 36') by determining the recoverable value of Cash Generating Unit (CGU) i.e., Ayurvedic Healthcare Services segment, to which such goodwill is allocated, by calculating the value-in-use (determined using discounted cash flow ('DCF') model) and comparing it with the carrying amount of CGU, as on the reporting date. The impairment assessment involves significant management judgments and estimates, particularly in: - Identifying the appropriate CGUs or group of CGUs to whom goodwill is allocated; - Forecasting future cash flows of CGU; - Determining key assumptions such as revenue and profit growth rates, operating margins, terminal growth rates of the CGU to which it relates and discount rates; and - Estimating future capital expenditure. Considering the goodwill balance is material to the standalone financial statements and significant management judgements and estimates are involved in identification of CGU and impairment testing, impairment assessment of goodwill has been identified as a key audit matter for the current year audit.	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of management's process for annual impairment assessment, and assessed the appropriateness of the Company's accounting policy for impairment in accordance with Ind AS 36; - Evaluated the design and tested the operating effectiveness of internal financial controls implemented by the management over impairment assessment of goodwill and identification of the CGUs. - Evaluated management's assessment of identification of CGU i.e., Ayurvedic Healthcare Services segment to which goodwill is allocated, basis understanding of expected synergies arising from such business acquisition and level at which such goodwill is monitored for internal management purposes. - Obtained cash flow projections as considering in DCF model and assessed if these are in line with projections as approved by the Board of Directors of the Company. - Assessed the professional competence, objectivity, and capabilities of the valuation specialist engaged by the management. - Assessed the reasonableness of key assumptions used in the cash flow projections such as revenue and profit growth rates, operating margins and terminal growth rates based on our understanding of historical trends, current market conditions, future plans of the Company and also compared these assumptions with industry and economic forecasts. Also assessed the reasonableness of discount rate as considered by the management and performed sensitivity analysis on key assumptions. - Involved auditor's valuation specialists to assist in evaluating the appropriateness of the valuation methodology and the reasonableness of key assumptions used by management's expert while computing the recoverable amount. Evaluated the appropriateness and adequacy of related disclosures made in the standalone financial statements in accordance with applicable Ind AS.

5. We have determined the matters described below to be the key audit matters to be communicated in our report. (Contd.)

Key audit matters	How our audit addressed the key audit matter
Transition to Ind AS accounting framework: Refer Note 2(a) and 46 to the accompanying standalone financial statements for disclosures included in respect to transition to Ind AS. The Company's equity shares were migrated from the SME Emerge platform to the Main Board of both the National Stock Exchange of India Limited and BSE Limited on 11 August 2025. Accordingly, pursuant to the requirements of Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, the Company has prepared its financial statements for the year ended 31 March 2026 in accordance with Ind AS with 1 April 2024 being the transition date. This change in the financial reporting framework required an end-to-end evaluation of the potential impact on each item as included in the standalone financial statements including presentation thereof, additional notes and disclosures as per the requirements of Ind AS including specific first-time adoption related disclosures contained under Ind-AS 101, First-time Adoption of Indian Accounting Standards and required significant audit efforts. Further, such evaluation also required management to exercise significant judgments in selecting and applying appropriate accounting policies to various transactions and balances, including election of available options for transitioning to Ind AS for the transition date being 01 April 2024. The areas having a significant impact on account of transition involved the following standards, amongst others: - Ind AS 109, Financial Instruments - Ind AS 116, Leases Considering the significance of the impact of transition to Ind AS in current year's financial statements and the audit efforts required to test these transition adjustments, this matter has been identified as a key audit matter for the current year audit.	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of management's processes and controls for identification and assessment of impact on the standalone financial statements due to transition to Ind-AS. - Evaluated the appropriateness of accounting policies selected by the management on transition, considering the requirements of the applicable Ind AS. - Reviewed the implementation of exemptions availed and options elected by the Company for transitioning account balances as at 01 April 2024, in accordance with Ind-AS 101. - Assessed the appropriateness of impact of Ind AS transition and consequent reconciliations from previous GAAP to Ind AS framework as provided in Note 46 pursuant to the requirements of Ind AS 101. - Assessed the appropriateness of the adjustments made to the comparative financial information as at and for the year-ended 31 March 2025, which were previously prepared in IGAAP, to comply with Ind AS. - Evaluated the adequacy and appropriateness of disclosures in standalone financial statements, arising on adoption of Ind AS, in accordance with the requirements of applicable Ind-AS.

INFORMATION OTHER THAN THE STANDALONE FINANCIAL STATEMENTS AND AUDITOR'S REPORT THEREON

6. The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the standalone financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE STANDALONE FINANCIAL STATEMENTS

7. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS specified under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
8. In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
9. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE STANDALONE FINANCIAL STATEMENTS

10. Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.
11. As part of an audit in accordance with Standards on Auditing, specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those

risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
 - Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
12. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 13. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
 14. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report

because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

OTHER MATTER

15. The comparative financial information for the year ended 31 March 2025 and the transition date opening balance sheet as at 1 April 2024 prepared in accordance with Ind AS included in these standalone financial statements, are based on the previously issued statutory standalone financial statements for the year ended 31 March 2025 and 31 March 2024 respectively prepared in accordance with Accounting Standards prescribed under Section 133 of the Act, read with Companies (Accounting Standards) Rules, 2021 (as amended) which were audited by the predecessor auditor whose reports dated 16 May 2025 and 15 May 2024 respectively expressed unmodified opinion on those standalone financial statements, and have been adjusted for the differences in the accounting principles adopted by the Company on transition to Ind AS, which have been audited by us. Our opinion is not modified in respect of this matter.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

16. As required by section 197(16) of the Act, based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.
17. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act we give in the Annexure I a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
18. Further to our comments in Annexure I, as required by section 143(3) of the Act based on our audit, we report, to the extent applicable, that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements;
 - b) Except for the matters stated in paragraph 18(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) The standalone financial statements dealt with by this report are in agreement with the books of account;
 - d) In our opinion, the aforesaid standalone financial statements comply with Ind AS specified under section 133 of the Act;
 - e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors

is disqualified as on 31 March 2026 from being appointed as a director in terms of section 164(2) of the Act;

- f) The qualification relating to the maintenance of accounts and other matters connected therewith are as stated in paragraph 18(b) above on reporting under section 143(3)(b) of the Act and paragraph 18(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);
- g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company as on 31 March 2026 and the operating effectiveness of such controls, refer to our separate report in Annexure II wherein we have expressed an unmodified opinion; and
- h) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company, as detailed in note 42 to the standalone financial statements, has disclosed the impact of pending litigations on its financial position as at 31 March 2026;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2026;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended 31 March 2026;
 - iv.
 - a. The management has represented that, to the best of its knowledge and belief, other than as disclosed in note 47(h)(i) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Company to or in any persons or entities, including foreign entities ('the intermediaries'), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;
 - b. The management has represented that, to the best of its knowledge and belief, as disclosed in note 47(h)(ii) to the standalone financial statements, no funds have been received by the Company from any persons or entities, including foreign entities ('the Funding

Parties'), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

- c. Based on such audit procedures performed as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the management representations under sub-clauses (a) and (b) above contain any material misstatement.
- vi. As stated in Note 48 to the standalone financial statements and based on our examination which included test checks, except for instances mentioned below, the Company, in respect of financial year commencing on 1 April 2025, has used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with, other than the consequential impact of the exceptions given below. Furthermore, the audit trails, to the extent maintained in the prior year and other than the consequential impact of the exceptions given below, have been preserved by the Company as per the statutory requirements for record retention.

- v. The final dividend paid by the Company during the year ended 31 March 2026 in respect of such dividend declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

As stated in note 16 to the accompanying standalone financial statements, the Board of Directors of the Company have proposed final dividend for the year ended 31 March 2026 which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend.

Nature of exception noted	Details of Exception
Instances of accounting software for maintaining books of account which did not have a feature of recording audit trail (edit log) facility	The accounting software used for maintenance of certain inventory and revenue records of the Company did not have a feature of recording audit trail (edit log) facility during the period 1 April 2025 to 15 January 2026, at both application level and database level.
Instances of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated throughout the year for all relevant transactions recorded in the software	i) The audit trail feature was not enabled at the database level for an accounting software, to log any direct data changes, used for maintenance of certain inventory and revenue records by the Company during the period 16 January 2026 to 31 March 2026. ii) The audit trail feature was not enabled at the database level for an accounting software, to log any direct data changes, used for maintenance of Certain revenue and inventory records by the Company.
Instances of accounting software maintained by a third party where we are unable to comment on the audit trail feature at database level	The accounting software used for maintenance of certain revenue records is operated by a third-party software service provider. In the absence of any information on existence of audit trail (edit logs) for any direct changes made at the database level in the 'Independent Service Auditor's Assurance Report on the Description of Controls, their Design and Operating Effectiveness' ('Type 2 report' issued in accordance with ISAE 3402, Assurance Reports on Controls at a Service Organization), we are unable to comment on whether audit trail feature with respect to the database of the said software was enabled and operated throughout the year.

Nature of exception noted	Details of Exception
Instance of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated effectively during the reporting period	The accounting software used for maintenance of accounting records of certain branches of the Company did not capture the details of who made the changes for certain period during the year.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Sandeep Mehta

Partner

Membership No.: 099410

UDIN: 26099410HFFGBN4375

Place: Chandigarh**Date:** 30 May 2026

Annexure I

Referred to in paragraph 16 of the Independent Auditor's Report of even date to the members of Jeena Sikho Lifecare Limited on the standalone financial statements for the year ended 31 March 2026.

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, capital work-in-progress, and relevant details of right-of-use assets except for certain Furniture & fixtures, Office equipment, Computers and Electrical equipment at multiple locations with Gross Block and Net Block aggregating to ₹ 1,897 lacs and ₹ 738 lacs respectively, as at 31 March 2026, for which the details relating to quantity, description and purchase date have not been properly maintained by the Company.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) The Company has a regular programme of physical verification of its property, plant and equipment, Capital work-in-progress and relevant details of right-to-use assets. Under which the assets are physically verified in a phased manner over a period of Three Years, which in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this programme, certain property, plant and equipment capital work-in-progress and relevant details of right-of-use assets were verified during the year and no material discrepancies were noticed on such verification.
- (c) The title deeds of all the immovable properties held by the Company (other than properties
- where the Company is the lessee and the lease agreements are duly executed in favour of the lessee), disclosed in Note 3 to the standalone financial statements, are held in the name of the Company.
- (d) The Company has not revalued its property, plant and equipment including right-of-use assets or intangible assets during the year.
- (e) No proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended) and rules made thereunder.
- (ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year, except for goods-in-transit and inventory lying with third parties. In our opinion, the coverage and procedure of such verification by the management is appropriate and no discrepancies of 10% or more in the aggregate for each class of inventory were noticed as compared to book records. In respect of inventory lying with third parties, these have substantially been confirmed by the third parties and in respect of goods-in-transit, these have been confirmed from corresponding receipt and/or dispatch inventory records.
- (b) The Company has not been sanctioned working capital limits/working capital limits in excess of five crore rupees by banks or financial institutions on the basis of security of current assets at any point of time during the year. Accordingly, reporting under clause 3(ii)(b) of the Order is not applicable to the Company.
- (iii) The Company has not provided any guarantee or security to companies, firms, limited liability partnerships during the year. Further, the Company has made investments in, and granted unsecured loans to companies during the year, in respect of which:

- (a) The Company has provided loans to Subsidiaries during the year as per details given below:

Particulars	Loans (Amount in Lakhs INR)
Aggregate amount provided/granted during the year (₹ in lacs):	
- Subsidiaries	1,062.40
Balance outstanding as at balance sheet date (₹):	
- Subsidiaries	1,072.06

- (b) In our opinion, and according to the information and explanations given to us, the investments made, and terms and conditions of the grant of all loans are, prima facie, not prejudicial to the interest of the Company.
- (c) In respect of loans and advances in the nature of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments/receipts of principal and interest are regular.

- (d) There is no overdue amount in respect of loans granted to such companies.
- (e) The Company has not granted any loans or advances in the nature of loans which has fallen due during the year. Further, no fresh loans were granted to any party to settle the overdue loans/ advances in nature of loan that existed as at the beginning of the year.
- (f) The Company has not granted any loans or advances in the nature of loans, which are repayable on demand or without specifying any terms or period of repayment.
- (iv) The Company has not entered into any transaction covered under sections 185 and 186 of the Act. Accordingly, reporting under clause 3(iv) of the Order is not applicable to the Company.
- (v) In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits or there are no amounts which have been deemed to be deposits within the meaning of sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, reporting under clause 3(v) of the Order is not applicable to the Company.
- (vi) The Central Government has not specified maintenance of cost records under sub-section (1) of section 148 of the Act, in respect of Company's products/services/ business activities. Accordingly, reporting under clause 3(vi) of the Order is not applicable.
- (vii) (a) In our opinion and according to the information and explanations given to us, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, have generally been regularly deposited with the appropriate authorities by the Company, though there have been slight delays in a few cases. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, we report that there are no statutory dues referred in sub-clause (a) which have not been deposited with the appropriate authorities on account of any dispute except for the following:

Name of the statute	Nature of dues	Gross Amount (₹)	Amount paid under Protest (₹)	Period to which the amount relates	Forum where dispute is pending
Goods and Service Tax Act, 2017	Demand on Completion of search	5,07,98,832	Nil	FY 2018-19	Punjab and Haryana High Court

- (viii) According to the information and explanations given to us, we report that no transactions were surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961) which have not been previously recorded in the books of accounts.
- (ix) (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of its loans or borrowings or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us including confirmations received from banks, representation received from the management of the Company, and on the basis of our audit procedures, we report that the Company has not been declared a willful defaulter by any bank or financial institution or government or any government authority.
- (c) In our opinion and according to the information and explanations given to us, money raised by way of term loans were applied for the purposes for which these were obtained.
- (d) In our opinion and according to the information and explanations given to us, the Company has not raised any funds on short term basis during the year. Accordingly, reporting under clause 3(ix)(d) of the Order is not applicable to the Company.
- (e) In our opinion and according to the information and explanations given to us and on an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) In our opinion and according to the information and explanations given to us, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries.
- (x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments), during the year. Accordingly, reporting under clause 3(x)(a) of the Order is not applicable to the Company.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or (fully, partially or optionally) convertible debentures during the year. Accordingly, reporting under clause 3(x)(b) of the Order is not applicable to the Company.

- (xi) (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no fraud on the Company has been noticed or reported during the period covered by our audit.
- (b) According to the information and explanations given to us including the representation made to us by the management of the Company, no report under sub-section 12 of section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014, with the Central Government for the period covered by our audit.
- (c) According to the information and explanations given to us including the representation made to us by the management of the Company, there are no whistle-blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it. Accordingly, reporting under clause 3(xii) of the Order is not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions entered into by the Company with the related parties are in compliance with sections 177 and 188 of the Act, where applicable. Further, the details of such related party transactions have been disclosed in the standalone financial statements, as required under Indian Accounting Standard (Ind AS) 24, Related Party Disclosures specified in Companies (Indian Accounting Standards) Rules 2015 as prescribed under section 133 of the Act.
- (xiv) (a) In our opinion and according to the information and explanations given to us, the Company has an internal audit system which is commensurate with the size and nature of its business as required under the provisions of section 138 of the Act.
- (b) We have considered the reports issued by the Internal Auditors of the Company till date for the period under audit.
- (xv) According to the information and explanation given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, reporting under clause 3(xv) of the Order with respect to compliance with the provisions of section 192 of the Act are not applicable to the Company.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, reporting under clauses 3(xvi)(a), (b) (c) and (d) of the Order are not applicable to the Company.
- (xvii) The Company has not incurred any cash losses in the current financial year as well as the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditors during the year and based on the information and explanations given to us by the management and the response received by us pursuant to our communication with the outgoing auditors, there have been no issues, objections or concerns raised by the outgoing auditors.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information in the standalone financial statements, our knowledge of the plans of the Board of Directors and management and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
- (xx) According to the information and explanations given to us, the Company does not have any unspent amounts towards Corporate Social Responsibility in respect of any ongoing or other than ongoing project as at the end of the financial year. Accordingly, reporting under clause 3(xx) of the Order is not applicable to the Company.
- (xxi) The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

For Walker Chandio & Co LLP
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410
UDIN: 26099410HFFGBN4375

Place: Chandigarh
Date: 30 May 2026

Annexure II

Independent Auditor's Report on the internal financial controls with reference to the standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the standalone financial statements of Jeena Sikho Lifecare Limited ('the Company') as at and for the year ended 31 March 2026, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR INTERNAL FINANCIAL CONTROLS

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on internal financial controls with respect to financial statements criteria established by the Company considering the essential components of internal financial controls stated in Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('The Guidance Note') issued by the Institute of Chartered Accountants of India (the 'ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY FOR THE AUDIT OF THE INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India ('ICAI') prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements

includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

MEANING OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

OPINION

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2026, based on internal financial controls with respect to financial statements criteria established by the Company considering the essential components of internal financial controls stated in Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('The Guidance Note') issued by ICAI.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Sandeep Mehta

Partner

Membership No.: 099410

UDIN: 26099410HFFGBN4375

Place: Chandigarh**Date:** 30 May 2026

Standalone Balance Sheet

As at 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
ASSETS				
Non-current assets				
Property, plant and equipment	3	11,700.61	9,234.42	6,682.52
Capital work-in-progress	3A	191.56	1,123.31	349.84
Right-of-use assets	4	11,404.12	10,026.65	5,809.27
Goodwill	5	5,811.82	5,811.82	-
Other intangible assets	6	260.15	232.65	2.13
Intangible assets under development	6A	79.45	224.28	43.68
Financial assets				
i) Investments	7A	1,487.54	64.00	64.00
ii) Loans	8	1,045.66	-	-
iii) Other financial assets	9	1,173.81	999.83	480.23
Deferred tax assets (net)	15	1,025.51	584.19	172.16
Other non-current assets	10	98.73	95.90	-
Total non-current assets		34,278.96	28,397.05	13,603.83
Current assets				
Inventories	11	2,017.12	1,154.58	718.87
Financial assets				
i) Investments	7B	9,512.24	291.61	369.69
ii) Trade receivables	12	6,992.91	8,496.14	3,383.02
iii) Cash and cash equivalents	13	1,515.62	2,297.87	2,531.47
iv) Other bank balances	14	9,245.08	-	3,669.28
v) Loans	8	26.40	312.00	812.00
vi) Other financial assets	9	2,269.20	68.97	93.18
Other current assets	10	1,453.99	876.62	2,040.61
Total current assets		33,032.56	13,497.79	13,618.12
Total assets		67,311.52	41,894.84	27,221.95
EQUITY AND LIABILITIES				
Equity				
Equity share capital	16	2,486.01	2,486.01	2,486.01
Other equity	17	44,254.04	23,148.27	16,106.72
Total equity		46,740.05	25,634.28	18,592.73
LIABILITIES				
Non-current liabilities				
Financial liabilities				
i) Borrowings	18	26.50	42.92	32.16
ii) Lease liabilities	19	9,548.25	8,513.08	4,780.78
iii) Others financial liabilities	20	80.85	-	-
Provisions	21	562.52	369.31	257.95
Other non-current liabilities	23	12.49	-	-
Total non-current liabilities		10,230.61	8,925.31	5,070.89
Current liabilities				
Financial liabilities				
i) Borrowings	18	16.42	1,030.80	22.00
ii) Lease liabilities	19	3,136.09	2,106.99	931.94
iii) Trade payables	24			
a. total outstanding dues of micro enterprises and small enterprises		617.33	238.29	35.45
b. total outstanding dues of creditors other than micro enterprises and small enterprises		1,545.03	1,336.51	782.39
iv) Others financial liabilities	20	2,488.46	1,360.26	867.37
Other current liabilities	23	1,645.01	1,096.46	636.65
Provisions	21	77.63	28.66	16.50
Current tax liabilities	22	814.89	137.28	266.03
Total current liabilities		10,340.86	7,335.25	3,558.33
Total liabilities		20,571.47	16,260.56	8,629.22
Total equity and liabilities		67,311.52	41,894.84	27,221.95

The accompanying notes are an integral part of the standalone financial statements (1-49)

This is the standalone balance sheet referred to in our report of even date

For Walker Chandio & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Nanak Chand
Chief Financial Officer

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Bhavna Grover
Whole Time Director
DIN: 07557913

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Standalone Statement of Profit and Loss

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	25	80,134.64	46,907.19
Other income	26	865.89	673.54
Total income		81,000.53	47,580.73
Expenses			
Purchases of stock-in-trade and consumables	27	10,011.39	5,857.99
Changes in inventories of stock in trade and consumables	28	(862.53)	(435.71)
Employee benefits expense	29	14,840.48	10,074.28
Finance costs	30	1,283.35	1,065.49
Depreciation and amortization expense	31	4,757.82	2,910.54
Other expenses	32	21,182.55	17,350.38
Total expenses		51,213.06	36,822.97
Profit before tax		29,787.47	10,757.76
Tax expenses:			
Current tax	33	8,017.00	3,153.33
Adjustment of tax relating to earlier years		14.10	21.54
Deferred tax	33	(461.20)	(411.44)
Total tax expense		7,569.90	2,763.43
Profit for the year after tax		22,217.57	7,994.33
Other comprehensive income			
(i) Item that will not be reclassified to profit or loss in subsequent years			
- Remeasurement of post employment benefit obligation		79.01	(2.34)
- Income tax relating to items that will not be reclassified to profit or loss in subsequent years		(19.88)	0.59
Total other comprehensive income for the year		59.13	(1.75)
Total comprehensive income for the year		22,276.70	7,992.58
Earnings per equity share (INR)			
Basic	34	17.87	6.43
Diluted	34	17.85	6.42
The accompanying notes are an integral part of the standalone financial statements		(1-49)	
This is the standalone statement of profit and loss referred to in our report of even date			

For Walker Chandiok & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Bhavna Grover
Whole Time Director
DIN: 07557913

Nanak Chand
Chief Financial Officer

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Standalone Statement of Cash Flows

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
A. Cash flow from operating activities		
Profit before tax	29,787.47	10,757.76
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation and amortization expense	4,757.82	2,910.54
Finance cost	1,268.68	933.95
Share based payment expense	196.38	88.14
Allowance for expected credit loss	598.09	650.97
Gain on investments measured at fair value through profit and Loss	(465.85)	23.07
Gain on sale of investment (net)	(5.91)	(100.95)
Loss/(gain) on sale of property, plant and equipment (net)	21.58	(233.36)
Fixed assets written off	34.33	-
Amounts written off	-	115.03
Deferred franchise deposit income on security deposits	(96.79)	-
Interest income	(259.05)	(271.67)
Gain on termination of lease	(4.33)	-
Operating profit before working capital changes and other adjustments	35,832.42	14,873.48
Working capital adjustments:		
Change in inventories	(862.54)	(397.75)
Change in trade receivables	905.14	(5,234.68)
Change in financial assets	(4,416.04)	(384.03)
Change in other assets	(588.41)	1,140.51
Change in trade payable	579.09	730.09
Change in other financial liabilities	1,220.85	471.18
Change in other liabilities	561.04	434.09
Change in provisions	321.19	121.04
Cash generated from operating activities post working capital changes	33,552.74	11,753.93
Income tax paid	(7,353.49)	(3,303.62)
Net cash generated from operating activities (A)	26,199.25	8,450.31
B. Cash flow from investing activities		
Purchase of property, plant and equipment, intangible assets and intangible assets under development	(3,262.18)	(4,233.38)
Proceeds from sale of property, plant and equipment	139.94	323.04
Payment of initial direct costs towards leases acquired	(24.89)	-
Payment on acquisition of business	-	(6,915.70)
Investments in equity instruments	(1,423.54)	-
Investments in mutual funds	(10,957.46)	(1,417.22)
Proceeds from sale of investments in mutual funds	2,208.59	1,573.18
Loans given to related parties and others	(1,062.55)	(105.41)
Proceeds from repayment of loans	312.00	653.56
(Investments in bank deposits)/Proceeds on maturity of bank deposits (net)	(7,223.46)	3,371.14
Interest received	184.79	302.64
Net cash used in investing activities (B)	(21,108.76)	(6,448.15)
C. Cash flow from financing activities		
Proceeds from long-term borrowings	-	41.71
Repayment of long-term borrowings	(30.40)	(22.34)
Proceeds from short-term borrowings	-	1,000.00
Repayment of short term borrowings	(1,000.00)	-
Dividend paid	(1,367.31)	(1,039.16)
Payment of principal portion of lease liabilities	(2,214.42)	(1,291.87)
Payment of interest portion of lease liabilities	(1,255.78)	(930.59)
Interest paid	(4.83)	(3.17)
Net cash used in financing activities (C)	(5,872.74)	(2,245.42)
Net decrease in cash and cash equivalents (A+B+C)	(782.25)	(243.26)
Cash and cash equivalents acquired as part of acquisition of business	-	9.66
Cash and cash equivalents at the beginning of the year	2,297.87	2,531.47
Cash and cash equivalents at the end of the year (refer note 13)	1,515.62	2,297.87

Standalone Statement of Cash Flows (Contd.)

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Reconciliation of cash and cash equivalents as per the Statement of Cash Flows

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash and cash equivalents as per above comprises of the following		
- Current account	818.12	1,754.75
- Deposit account	495.00	-
- Cash on hand	202.50	543.12
Balance as per statement of cash flow	1,515.62	2,297.87

The Statement of Cash flows has been prepared under 'Indirect method' as set out in Ind AS - 7 'Statement of Cash Flows'.

(a) Reconciliation of financial liabilities arising from financing activities:

Particulars	Share Capital	Borrowings	Lease liabilities
Balance as at 01 April 2024	2,486.01	54.16	5,712.72
Cash flows:			
Proceeds from borrowings	-	1,041.71	-
Repayment of borrowings	-	(22.34)	-
Repayment of lease liabilities	-	-	(2,222.46)
Interest paid	-	(3.17)	-
Other non-cash changes:			
Additions for new leases	-	-	6,199.22
Interest on borrowings	-	3.36	-
Interest on lease liabilities	-	-	930.59
Balance as at 31 March 2025	2,486.01	1,073.72	10,620.07
Cash flows:			
Repayment of borrowings	-	(1,030.40)	-
Repayment of lease liabilities	-	-	(3,470.20)
Interest paid	-	(4.83)	-
Other non-cash changes			
Additions for new leases	-	-	4,331.93
Deletion of leases	-	-	(53.24)
Interest on borrowings	-	4.43	-
Interest on lease liabilities	-	-	1,255.78
Balance as at 31 March 2026	2,486.01	42.92	12,684.34

The accompanying notes are an integral part of the standalone financial statements (1-49)

This is the standalone statement of cash flows referred to in our report of even date

For Walker Chandio & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Bhavna Grover
Whole Time Director
DIN: 07557913

Nanak Chand
Chief Financial Officer

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Standalone Statement of Changes in Equity

For the year ended 31 March 2026

CIN: L52601PB2017PLCO46545

(All amounts are in INR Lakhs except otherwise stated)

A. EQUITY SHARE CAPITAL

Particulars	Number of shares	Amount
Equity shares of INR 10 each issued, subscribed and fully paid		
As at 01 April 2024	2,48,60,146	2,486.01
Changes in equity share capital during the year	-	-
As at 31 March 2025	2,48,60,146	2,486.01
Changes in equity share capital during the year*	9,94,40,584	-
As at 31 March 2026	12,43,00,730	2,486.01

*On 12 June 2025, the Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each, fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

Refer note no 16 for details

B. OTHER EQUITY

Particulars	Reserves and Surplus			Total other equity
	Security premium (Refer Note 17.1)	Retained earnings (Refer Note 17.2)	Share options outstanding account (Refer Note 17.3)	
As at 01 April 2024	5,330.79	10,774.85	1.08	16,106.72
Profit for the year	-	7,994.33	-	7,994.33
Other comprehensive loss for the year, net of income tax*	-	(1.75)	-	(1.75)
Transaction with owners in their capacity as owners				
Employee stock option expense (Refer note 37)	-	-	88.14	88.14
Dividend paid	-	(1,039.17)	-	(1,039.17)
As at 31 March 2025	5,330.79	17,728.26	89.22	23,148.27
Profit for the year	-	22,217.57	-	22,217.57
Other comprehensive income for the year, net of income tax*	-	59.13	-	59.13
Transaction with owners in their capacity as owners				
Employee stock option expense (Refer note 37)	-	-	196.38	196.38
Dividend paid	-	(1,367.31)	-	(1,367.31)
As at 31 March 2026	5,330.79	38,637.65	285.60	44,254.04

*Other comprehensive income/(loss) includes remeasurement of post employment benefit obligation (net of tax).

This is the standalone statement of changes in equity referred to in our report of even date

As per our report of even date attached

For Walker Chandiok & Co. LLP

Chartered Accountants

Firm's registration No.: 001076N/N500013

Sandeep Mehta

Partner

Membership No.: 099410

Manish Grover

Managing Director

DIN: 07557886

Nanak Chand
Chief Financial Officer

For and on behalf of the Board of Directors

Jeena Sikho Lifecare Limited

Bhavna Grover

Whole Time Director

DIN: 07557913

Smita Chaturvedi
Company Secretary

M.No.: A48303

Place: Zirakpur, Punjab

Date: 30 May 2026

Place: Zirakpur, Punjab

Date: 30 May 2026

Notes to the Standalone Financial Statements

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

1. CORPORATE INFORMATION

Jeena Sikho Lifecare Limited is a public Company domiciled in India having registered address at SCO 11 FIRST FLOOR, KALGIDHAR ENCLAVE, Mohali, ZIRAKPUR, Punjab, India, 140604 and is incorporated on 29 May 2017 under the provisions of the Companies Act applicable in India. The Company has its primary listings on BSE Limited and National Stock Exchange of India Limited

The Company's primary business is to provide healthcare services, offering a range of traditional and natural remedies to promote overall wellness. The company's products and services cater to various health needs, from detoxification and digestion to wellness supplements and beauty care. With a strong focus on holistic health, Jeena Sikho aims to provide comprehensive Ayurvedic solutions to individuals and families.

2. BASIS OF PREPARATION AND SUMMARY OF MATERIAL ACCOUNTING POLICIES

This note provides a list of the material accounting policies adopted in the preparation of these standalone financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of preparation

These standalone financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs pursuant to section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The standalone financial statements are prepared in INR, which is the functional currency and all values are rounded off to nearest lakhs (INR 100000), except otherwise indicated.

These Ind AS standalone financial statements for the year ended 31 March 2026 were approved for issue by the Board of Directors on 30 May 2026.

These financial statements for the year ended 31 March 2026 are the first financial statements prepared by the Company as per Ind AS. For all periods upto and including the year ended 31 March 2025, the Company prepared its financial statements in accordance with the accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (hereinafter referred to as 'Previous GAAP') used for its statutory reporting requirement in India immediately before adopting Ind AS. The opening balance sheet at the beginning of the comparative year have been restated in accordance with Ind AS for comparative information. Reconciliations and explanations of the effect of the transition from Previous GAAP to Ind AS on the Company's Balance Sheet, Statement of Profit and Loss and Statement of Cash Flows are provided in note 46.

(b) Basis of measurement

The standalone financial statements have been prepared on accrual and going concern basis under historical cost convention except for certain financial assets and financial liabilities that are measured at fair value or amortized cost, defined benefit obligations and share based payments.

(c) Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible to/by the Company.

All assets and liabilities for which fair value is measured or disclosed in the standalone financial statements are categorized within fair value hierarchy, described as follows, based on the lowest level of input that is significant to the fair value measurement as a whole:

Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the standalone financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

(d) Critical accounting estimates and judgements

The preparation of standalone financial statements in conformity with Ind AS requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities at the end

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

of the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods. Changes in estimates are reflected in the standalone financial statements in the period in which changes are made and if material, their effects are disclosed in the notes to the standalone financial statements.

Significant management judgements

Recognition of deferred tax assets – The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the Company's future taxable income against which the deferred tax assets can be utilized.

Evaluation of indicators for impairment of assets – The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.

Contingent liabilities – At each balance sheet date basis the management judgment, changes in facts and legal aspects, the Company assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.

Leases – Judgment required to ascertain lease classification, lease term, incremental borrowing rate, lease and non-lease component, and impairment of ROU.

Significant estimates

Defined benefit obligation (DBO) – Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

Allowance for expected credit losses – The allowance for doubtful debts reflects management's estimate of losses inherent in its credit portfolio. This allowance is based on Company's estimate of the losses to be incurred, which derives from past experience with similar receivables, current and historical past due amounts, write-offs and collections, the careful monitoring of portfolio credit quality and current and projected economic and market conditions. Should the present economic and financial situation persist or even worsen, there could be a further deterioration in the financial situation of the Company's debtors compared to that already taken into consideration in calculating the allowances recognised in the financial statements.

Share based payments – Measurement of share-based payments; measurement of financial guarantee contracts, provisions and contingent liabilities.

Inventory obsolescence & Valuation – Inventories are carried at the lower of cost and net realisable value. The estimation of net realisable value and provision for obsolescence involves significant judgment, including assessment of demand, market conditions, and inventory ageing. Appropriate provisions are made for slow-moving and obsolete inventories based on management's estimates.

Useful life of Fixed assets – Useful lives of property, plant and equipment are determined based on management's estimate of expected usage, wear and tear, and technological obsolescence, in line with Schedule II. These estimates are reviewed annually and revised prospectively, where necessary.

Fair valuation of investments – Investments measured at fair value involve the use of valuation techniques and significant estimates, particularly where market quotes are not available. Key assumptions include cash flow projections, discount rates, and market comparables. Changes in these assumptions may materially impact the fair value of such investments.

Recoverability of goodwill – Goodwill is tested annually for impairment based on the recoverable amount of the underlying CGU. The assessment involves significant estimates, including projected cash flows, growth rates, and discount rates. Changes in these assumptions may materially impact the carrying value of goodwill.

Probability of exercise of ESOP – The estimation of ESOP expense involves judgment in assessing the probability of vesting and exercise, based on assumptions such as employee attrition and historical trends. These estimates are reviewed periodically and revised prospectively.

There are no assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year except for as disclosed in these standalone financial statements.

(e) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realized within twelve months after the reporting period; or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

All other assets are classified as non-current.

A liability is treated as current when it is:

- Expected to be settled in normal operating cycle;
- Held primarily for the purpose of trading;
- Due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

Current liabilities include the current portion of non-current financial liabilities. All other liabilities are classified as non-current.

Deferred tax assets/liabilities are classified as non-current assets/liabilities.

Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realization/settlement in cash and cash equivalents. The companies have identified twelve months as their operating cycle for classification of their current assets and liabilities.

(f) Property, plant equipment

Recognition and measurement

Items of property, plant and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses, if any.

The cost of an item of property, plant and equipment comprises its purchase price and non-refundable purchase taxes, after deducting trade discounts and rebates any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other cost directly attributable to bringing the item to working condition for its intended use.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the standalone Statement of profit and loss when such asset is derecognised.

Subsequent cost

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that the future economic benefits associated with expenditure will flow to the Company and the cost of

the item can be measured reliably. All other subsequent costs are charged to standalone Statement of profit and loss at the time of incurrence.

Depreciation

Depreciation is calculated on cost of items of property, plant and equipment less their estimated residual value over the estimated useful lives using the straight-line method and is generally recognised in the standalone statement of profit and loss. Depreciation on items of property, plant and equipment of Company is provided as per Schedule II of the Companies Act, 2013 except in cases where expected useful life of the assets are different from the corresponding life prescribed as under and the Company based upon the nature of asset, the operating condition of the asset, the estimated usage of the asset, past history of replacement and anticipated technological changes, believes that this is the best estimate on the basis of actual realization.

Depreciation on other items of property, plant and equipment of Company is provided as per Part C of Schedule II of the Companies Act, 2013:

Block of asset	Useful Life (in years)
Building	30
Furniture and Fixtures	10
Motor vehicles	8
Office Equipment	5
Computers	3
Leasehold improvements	Over the lease term

Depreciation method, useful lives and residual values are reviewed by management at each reporting date and adjusted prospectively, as appropriate.

Depreciation on additions/disposals is provided on pro-rata basis i.e. from (upto) the date on which asset is ready to use/disposed of.

The residual values, useful lives and methods of depreciation of property plant and equipment are reviewed by management at each reporting date and adjusted prospectively, as appropriate.

During disposal of property, plant and equipment, any profit earned/loss sustained towards excess/shortfall of sale value vis-a-vis carrying cost of assets is accounted for in Standalone Statement of Profit and Loss.

(g) Capital work-in-progress and Intangible Assets under development:

Capital work-in-progress and intangible assets under development represent expenditure incurred in respect of capital projects/intangible assets under development and are carried at cost. Cost comprises purchase cost, related acquisition expenses, development/construction costs, borrowing costs and other direct expenditure.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(h) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost and recognised only if it is probable that the expected future economic benefits that are attributable to the asset will flow to the Company and the cost of assets can be measured reliably. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates.

The amortisation expense on intangible assets with finite lives is recognised in the standalone statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Amortization of intangible assets such as software is computed on a straight-line basis, at the rates representing estimated useful life of up to 5 years:

Block of asset	Useful Life (in years)
Softwares	5
Non-compete fee	4
Empanelment	1.93

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the standalone statement of profit or loss when the asset is derecognised.

Goodwill

Goodwill arising on acquisition of a business represents the excess of the consideration transferred over the Company's

interest in the net fair value of identifiable assets acquired and liabilities assumed at the date of acquisition, in accordance with Ind AS 103 – Business Combinations.

Goodwill is recognised as an intangible asset and is subsequently measured at cost less accumulated impairment losses. In accordance with Ind AS 38 and Ind AS 36, goodwill is not amortised but is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate potential impairment.

For the purpose of impairment testing, goodwill is allocated to the respective cash-generating units ("CGUs") or groups of CGUs that are expected to benefit from the synergies of the acquisition. Goodwill is allocated to the relevant CGUs within the Company's operating segments, representing the lowest level at which goodwill is monitored for internal management purposes.

The recoverable amount of each CGU to which goodwill is allocated is determined as the higher of its value in use and fair value less costs of disposal.

Value in use is based on discounted cash flow projections derived from management-approved budgets and forecasts, covering a defined projection period. These projections involve significant estimates and assumptions, including revenue growth rates, operating margins, patient footfall, expected capacity utilisation, and discount rates reflecting the time value of money and risks specific to the CGU.

Key assumptions are reviewed periodically and are based on management's best estimate of future economic and operating conditions.

Any impairment loss, being the excess of the carrying amount of the CGU over its recoverable amount, is first allocated to reduce the carrying amount of goodwill. Such impairment losses are recognised in the Statement of Profit and Loss.

(i) Leases

The Company as lessee

The Company enters into an arrangement for lease of buildings. Such arrangements are generally for a fixed period but may have extension or termination options. In accordance with Ind AS 116 – Leases, at inception of the contract, the Company assesses whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to control the use an asset (the underlying asset) for a period of time in exchange for consideration'.

To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- The contract involves the use of an identified asset – this may be specified explicitly or implicitly, and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified;

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- The Company has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and
- The Company assesses whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use. At inception or on reassessment of a contract that contains a lease component, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of buildings in which it is a lessee, the Company has elected not to separate non-lease components and account for the lease and non-lease components as a single lease component.

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Measurement and recognition of leases as a lessee

The Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Company is reasonably certain not to terminate early.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in Statement of profit and loss if the carrying amount of the right-of-use asset has been reduced to zero, as the case may be.

The Company presents right-of-use assets that do not meet the definition of investment property on the face of balance sheet below 'property, plant and equipment' and lease liabilities under 'financial liabilities' in the balance sheet.

The Company has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognizing a right-of-use asset and lease liability, the payments in relation to these are recognized as an expense in standalone statement of profit and loss on a straight-line basis over the lease term.

(j) Share based payment

Certain employees of the Company receive part of their remuneration in the form of share-based payment transactions, whereby employees render services in exchange for shares or rights over shares ('equity-settled transactions').

The fair value on grant date of equity-settled share-based payment arrangements granted to eligible employees of the Company under the Employee Stock Option Plan ('ESOP') is recognised as employee stock option plan expenses in the Statement of profit and loss, in relation to options granted to employees of the Company (over the vesting period of the awards), with a corresponding increase in other equity. The total amount to be expensed is determined by reference to the fair value of the options determined under Black-Scholes model.

The amount recognised as an expense reflects the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

The increase in equity recognised in connection with a share-based payment transaction is presented in the "Employee stock options outstanding account", as separate component in other equity. At the end of each period, the Company revises its estimates of the number of options that are expected to be vested based on the non-market performance conditions at the vesting date.

If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

expected to vest. Upon exercise of share options, the proceeds received, net of any directly attributable transaction costs, are allocated to share capital up to the nominal (or par) value of the shares issued with any excess being recorded as share premium.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(k) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Recognition and initial measurement

Trade receivables and debt instruments are initially recognised when they are originated. All other financial assets are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with Ind AS 115, all financial assets are initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are attributable to its acquisition or issue.

Classification

For the purpose of initial recognition, the Company classifies its financial assets in following categories:

- Financial assets measured at amortised cost;
- Financial assets measured at fair value through other comprehensive income (FVTOCI); and
- Financial assets measured at fair value through profit and loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at the amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- The financial asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate ('EIR') method.

A financial asset being 'debt instrument' is measured at the FVTOCI if both of the following criteria are met:

- The asset is held within the business model, whose objective is achieved both by collecting contractual cash flows and selling the financial assets, and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are SPPI on the principal amount outstanding.

On initial recognition of an equity instrument that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirement to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces as accounting mismatch that would otherwise arise.

Investment in equity instruments of subsidiaries

Investments in equity instruments of subsidiaries are accounted for at cost in accordance with Ind AS 27 'Separate Financial Statements'.

Investments in mutual funds

Investments in mutual funds are measured at FVTPL.

Measured at Amortized Cost

Financial assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows that are solely payments of principal and interest, are subsequently measured at amortized cost using the EIR method less impairment, if any. The amortization of EIR and loss arising from impairment, if any, is recognized in the Standalone Statement of Profit and Loss.

Measured at Fair Value through other Comprehensive Income

Financial assets that are held within a business model whose objective is achieved by both, selling financial assets and collecting contractual cash flows that are solely payments of principal and interest, are subsequently measured at FVTOCI. Fair value movements are recognized in the other comprehensive income ('OCI'). Interest income measured using the EIR method and impairment losses, if any are recognized in the Standalone Statement of Profit and Loss. On de-recognition, cumulative gain or loss previously recognized in OCI is reclassified from the equity to 'other income' in the Standalone Statement of Profit and Loss.

Measured at Fair Value through Profit or Loss

A financial asset not classified as either amortized cost or FVTOCI, is classified as FVTPL. Such financial assets are

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

measured at fair value with all changes in fair value, including interest income and dividend income, if any, recognized as 'other income' in the Standalone Statement of Profit and Loss.

Subsequent measurement

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses, if any. Interest income and impairment are recognised in the Statement of profit and loss.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognised in the Statement of profit and loss.

Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any gain or loss on derecognition is recognised in the standalone Statement of profit and loss.

Impairment of financial assets (other than at fair value)

The Company recognises loss allowances using the Expected Credit Loss (ECL) model for financial assets that are not measured at fair value through profit or loss.

For trade receivables that do not contain a significant financing component, the Company applies the simplified approach prescribed under Ind AS 109 and recognises loss allowances at an amount equal to lifetime ECL. Lifetime ECL represents the expected credit losses resulting from all possible default events over the expected life of the financial asset.

The Company measures lifetime ECL for trade receivables using a provision matrix, which is based on historical credit loss experience, adjusted for current conditions and forward looking information such as changes in economic conditions, customer-specific factors, and industry trends. The assessment considers factors including ageing of receivables, past default patterns, credit risk characteristics of customers, and reasonable and supportable forecasts of future economic conditions.

For all other financial assets, expected credit losses are measured at an amount equal to 12 month ECL, unless there has been a significant increase in credit risk, since initial recognition, in which case loss allowances are measured at lifetime ECL. In assessing whether credit risk has increased significantly, the Company considers quantitative and qualitative factors, including changes in credit ratings, adverse business or economic conditions, and past due status.

The changes (incremental or reversal) in loss allowance computed using the ECL model are recognised as an impairment gain or loss in the standalone Statement of Profit and Loss.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

Financial liabilities

Recognition and initial measurement

All financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument. All financial liabilities are initially measured at fair value minus, for an item not at fair value through profit and loss, transaction costs that are attributable to the liability.

Classification and subsequent measurement

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit and loss.

Financial liabilities other than classified as FVTPL, are subsequently measured at amortised cost using the effective interest method. Interest expenses are recognised in profit and loss. Any gain or loss on derecognition is also recognised in profit and loss.

Derecognition

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled or expired. The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in the standalone Statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount presented in the Balance Sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the assets and settle the liabilities simultaneously.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(I) Revenue recognition

Revenue from contracts with customers

Revenue from contracts with customers is recognised in accordance with Ind AS 115, when control of the promised goods or services is transferred to the customer, at an amount that reflects the consideration to which the Company expects to be entitled in exchange for such goods or services.

The Company assesses its performance obligations in each contract and recognises revenue when (or as) such performance obligations are satisfied. Control is considered to be transferred when the customer obtains the ability to direct the use of and substantially all of the remaining benefits from the goods or services.

Further, the Company evaluates whether it is acting as a principal or an agent in its revenue arrangements. The Company has generally concluded that it is acting as a principal, as it typically controls the specified goods or services prior to their transfer to the customer and is primarily responsible for fulfilling the promise to provide such goods or services.

Sale of products

In respect of sale of fast-growing Ayurvedic products where the performance obligation is satisfied at a point in time, revenue is recognised when the control of goods is transferred to the customer as per the terms & conditions of the contract. Revenue from the sale of goods is measured at the transaction price received or receivable, net of returns and allowances, trade discounts and volume rebates.

The Company considers whether there are other promises in the contract that are separate performance obligations to which a portion of the transaction price needs to be allocated.

For each performance obligation identified, the Company recognizes revenue as and when it satisfies the performance obligation at a point in time.

Sale of services

The healthcare services income includes revenue generated from in-patient services, panchakarma therapies, 72-hour health camps, home based health care services, out-patient services and day care, dietary support and nutrition guidance and comprehensive patient support anytime, anywhere.

Revenue is recognised when each performance obligation is satisfied over a period of time when inpatient/outpatients has received the service.

Other operating revenue

Revenue from testing services provided under the agreement with Chandan Healthcare Limited is recognised in accordance with Ind AS 115, when the performance obligation is satisfied.

The Company provides diagnostic and testing services to patients, and revenue is recognised at a point in time, i.e., upon completion of the testing services and issuance of test results, when control of the service is transferred to the customer.

Further, the Company has entered into an arrangement with its related party, Shuddhi Lifecare Private Limited ("SLPL"), whereby SLPL is permitted to use the Company's branding and marketing collateral, including promotional materials and related intellectual property.

Revenue from such arrangements is royalty income and is recognised in accordance with Ind AS 115 over the period to which it relates, based on the underlying sales made by SLPL as per the agreed terms. The consideration is determined as a percentage of sales of goods and services undertaken by SLPL.

Such income is considered ancillary to the main business operations of the Company and is recognised on an accrual basis in line with the substance of the contractual arrangement.

Contract liability of loyalty points

Loyalty points granted to customers are treated as a separate performance obligation under Ind AS 115, as they provide a material right for future purchases. Accordingly, a portion of the transaction price is allocated to such points based on their relative standalone selling price and is deferred as a contract liability until redemption or expiry. Revenue is recognised net of such incentives, reflecting the effective discount provided to customers.

Interest income

For all debt instruments measured either at amortized cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortized cost of the financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument but does not consider the expected credit losses. Interest income is included in other income in the standalone statement of profit and loss.

Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the company perform by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the company have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the company transfer goods or services to the customer, a contract liability is recognised when the payment is made, or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the company perform under the contract.

Trade receivables

A receivable represents the right of entities forming part of company to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in financial instruments – initial recognition and subsequent measurement.

(m) Foreign currency

The Company's standalone financial statement are presented in Indian Rupees (INR), which is the company's functional currency. Functional currency is the currency of the primary economic environment in which a Company operates and is normally the currency in which the Company primarily generates and expends cash.

Transactions in foreign currencies are initially recorded by the Company at the functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognised in standalone statement of profit and loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of gain or loss on change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income or standalone statement of profit and loss are also recognised in other comprehensive income or standalone statement of profit and loss, respectively).

(n) Employee benefits

Short-term employee benefits

Employee benefit liabilities such as salaries, wages and bonus, etc. that are expected to be settled wholly within twelve months after the end of the reporting period in which the employees render the related service are recognised in respect of employee's services up to the end of the reporting period and are measured at an undiscounted amount expected to be paid when the liabilities are settled.

Post-employment benefit plans

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Company pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Payments to defined contribution plans are recognised as an expense when employees have rendered service entitling them to the contributions.

Defined benefit plans

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment, of an amount based on the respective employee's salary and the tenure of employment.

The liability recognised in the Balance Sheet in respect of defined benefit gratuity plan is the present value of the defined benefit obligation at the end of the reporting period. The defined benefit obligation is calculated by actuary using the projected unit credit method.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation. This cost and other costs are included in employee benefits expense in the Statement of profit and loss.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in other comprehensive income and transferred to retained earnings.

Changes in the present value of the defined benefit obligation resulting from settlement or curtailments are recognised immediately in Statement of profit and loss as past service cost.

The Company's net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date. Where Company has the unconditional legal and contractual right to defer the settlement for a period beyond 12 months, the same is presented as non-current liability.

The Company recognizes termination benefit as a liability and an expense when the Company has a present obligation as a result of past event, it is probable that an outflow of

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

If the termination benefits fall due more than 12 months after the balance sheet date, they are measured at present value of future cash flows using the discount rate determined by reference to market yields at the balance sheet date on government bonds.

The interest is calculated by applying the discount rate to the net defined benefit liability. The Company recognizes the following changes in the net defined benefit obligation as an expense in the standalone Statement of Profit and Loss:

- Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- Interest expense.

Other short-term employee benefits

Compensated absences

The Company's net obligation in respect of compensated absences is the amount of benefit to be settled in future, that employees have earned in return for their service in the current and previous years. The benefit is discounted to determine its present value. The obligation is measured on the basis of an actuarial valuation using the projected unit credit method. Remeasurements are recognised in Statement of profit and loss in the period in which they arise.

(o) Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the standalone statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources would be required to settle the obligation, the provision is reversed.

(p) Contingent assets/liabilities

Contingent liabilities are possible obligations that arise from past events and whose existence will only be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote.

Contingent assets are not recognised. However, when realization of income is virtually certain, then the related asset is no longer a contingent asset, and is recognised as an asset.

(q) Income taxes

Income tax expense comprises of current tax and deferred tax. It is recognised in the profit or loss except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any relating to income taxes. It is measured using tax rates enacted for the relevant reporting period.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis.

Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is also recognised in respect of carried forward losses and tax credits. Deferred tax is not recognised for temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that effects neither accounting not taxable profit or loss at the time of the transaction.

Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/reduced to the extent that it is probable/no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and deferred tax liabilities are offset only if there is a legally enforceable right to offset current tax liabilities and assets levied by the same tax authorities.

(r) Earnings per share

The Company presents basic and diluted earnings per share (EPS) data for its equity shares. Basic EPS is calculated by dividing the standalone Statement of profit and loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the year. Diluted EPS is determined by adjusting standalone Statement of profit and loss attributable to equity shareholders and the weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares, which comprise share options granted to employees.

The number of equity shares and potentially dilutive equity shares are adjusted retrospectively for all periods presented for any share splits and bonus shares issues including for changes effected prior to the approval of the standalone financial statements by the Board of Directors.

(s) Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the standalone statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above.

(t) Segment reporting

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. All operating segments' operating results are regularly reviewed by the Company's chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance. The Company's chief executive officer is the chief operating decision maker.

(u) Impairment of non-financial assets

The company assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets.

Impairment loss is recognised when the carrying amount of an asset exceeds recoverable amount and the asset is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year.

To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, company extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country or countries in which the entity operates, or for the market in which the asset is used.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the standalone statement of profit and loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

(v) Inventories

Inventories are valued at the lower of cost and net realizable value in accordance with the provisions of IND AS 2.

Inventories comprise medicines, healthcare products, and consumables used in providing Panchkarma and other therapies/treatment services, as well as goods held for sale.

Inventories are valued at the lower of cost and net realisable value, in accordance with Ind AS 2. Cost includes purchase price, duties and taxes (net of recoverable taxes), freight, and other costs incurred in bringing the inventories to their present location and condition. Cost is determined using the First-In-First-Out method.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Medicines and other items held for sale are recognised as inventory and expensed to cost of goods sold upon sale.

Consumables used in rendering panchkarma, and related services are recognised as expenses in the period in which such services are provided, based on actual consumption.

Net realisable value is estimated based on the expected selling price in the ordinary course of business, less estimated costs necessary to make the sale. The Company evaluates inventories at each reporting date for obsolescence, expiry, and slow-moving items, particularly for medicines with limited shelf life, and provides for diminution in value, where necessary.

(w) Events occurring after the Balance Sheet date

Impact of events occurring after the balance sheet date that provide additional information materially affecting the determination of the amounts relating to conditions existing at the balance sheet date are adjusted to respective assets and liabilities.

(x) New and amended standards adopted by the Company

The Company applied for the first-time certain standards and amendments, which are effective for annual periods beginning on or after 1 April 2025. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

The Ministry of Corporate Affairs ("MCA") notifies amendments to Indian Accounting Standards ('Ind AS') from time to time under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015.

Standards and amendments effective for the year ended 31 March 2026 The following amendments became effective for annual reporting periods beginning on or after 1 April 2025 and have been applied by the Company where relevant.

Amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates

The amendments prescribe accounting and disclosure requirements in situations where a currency is not exchangeable, including guidance on estimating the spot exchange rate when exchangeability is lacking and related disclosures.

Amendments to Ind AS 1 – Presentation of Financial Statements

These amendments clarify the principles for classification of liabilities as current or non-current, particularly in relation to the assessment of the right to defer settlement and the impact of covenants.

Amendments to Ind AS 12 – Income Taxes

The amendments introduce a temporary exception from the recognition of deferred tax assets and liabilities arising from the OECD's Pillar Two global minimum tax regime and prescribe additional disclosures relating to exposure to such taxes.

Amendments to Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures

These amendments introduce enhanced disclosure requirements for supplier finance arrangements.

Ind AS 19 – Employee Benefits and Labour Codes

During the year, the Government of India implemented the Code on Wages, 2019; the Code on Social Security, 2020; The Industrial Relations Code, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 with effect from 21 November 2025.

The Company has evaluated the impact of the above amendments and concluded that they do not have any material impact on the Company's financial statements for the year ended 31 March 2026, considering the nature and extent of the Company's operations.

Standards issued but not yet effective Ind AS 1 – Presentation of Financial Statements.

If covenant breach occurs on or before the reporting date and the liability becomes payable on demand, it must be classified as current, even if the lender subsequently agrees not to demand repayment. It is classified as current because, at the reporting date, the entity does not have the right to defer settlement for at least 12 months. However, if the lender has already provided by the reporting date, a grace period extending at least 12 months beyond that date, during which the breach can be rectified and repayment cannot be demanded, the liability is classified as non-current. This amendment is to be applied retrospectively for annual reporting periods beginning on or after 1 April 2026, in accordance with Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3. PROPERTY, PLANT AND EQUIPMENT

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Freehold land	1,624.76	1,618.98	1,708.16
Building	2,408.79	2,612.88	2,255.53
Furniture and fixtures	1,369.73	1,276.38	493.19
Office equipment	1,573.29	1,201.71	458.40
Leasehold Improvements	3,668.11	1,833.48	1,321.36
Motor Vehicles	1,055.93	691.00	445.88
	11,700.61	9,234.42	6,682.52

Particulars	Freehold land	Building	Furniture and fixtures	Office equipment	Leasehold Improvements	Motor Vehicles	Total
Gross carrying value at cost:							
As at 01 April 2024*	1,708.16	2,391.99	1,850.25	1,693.83	-	555.84	8,200.07
Reclassifications	-	-	(977.55)	(343.81)	1,321.36	-	-
Balance as at 01 April 2024 post reclassification	1,708.16	2,391.99	872.70	1,350.02	1,321.36	555.84	8,200.07
Additions	-	439.43	1,348.59	1,119.31	-	319.24	3,226.57
Disposals	(89.18)	-	-	(10.03)	-	-	(99.21)
Acquisition of business (Refer note 45 for details of acquisition of business.)	-	-	63.14	52.03	-	17.04	132.21
Reclassifications	-	-	(772.51)	(332.34)	1,104.84	-	-
As at 31 March 2025	1,618.98	2,831.42	1,511.93	2,178.99	2,426.21	892.12	11,459.64
Additions	43.73	-	266.66	796.52	2,602.64	549.20	4,258.74
Disposals	(37.95)	(127.58)	-	(10.25)	-	(76.21)	(251.99)
As at 31 March 2026	1,624.76	2,703.84	1,778.59	2,965.25	5,028.84	1,365.10	15,466.39
Accumulated depreciation:							
As at 01 April 2024*	-	136.46	379.51	891.62	-	109.96	1,517.55
Reclassifications	-	-	(224.25)	(131.80)	356.05	-	-
Balance as at 01 April 2024 post reclassification	-	136.46	155.26	759.82	356.05	109.96	1,517.55

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3. PROPERTY, PLANT AND EQUIPMENT (Contd.)

Particulars	Freehold land	Building	Furniture and fixtures	Office equipment	Leasehold Improvements	Motor Vehicles	Total
Charge for the year	-	82.08	223.11	320.85	-	91.16	717.20
Disposals	-	-	-	(9.53)	-	-	(9.53)
Reclassifications	-	-	(142.82)	(93.86)	236.68	-	-
As at 31 March 2025	-	218.54	235.55	977.28	592.73	201.12	2,225.22
Charge for the year	-	89.39	173.31	420.15	768.01	145.83	1,596.70
Disposals	-	(12.89)	-	(5.48)	-	(37.78)	(56.14)
As at 31 March 2026	-	295.05	408.86	1,391.96	1,360.74	309.17	3,765.77
Net carrying value:				-			
As at 01 April 2024*	1,708.16	2,255.53	493.19	458.40	1,321.36	445.88	6,682.52
As at 31 March 2025	1,618.98	2,612.88	1,276.38	1,201.71	1,833.48	691.00	9,234.42
As at 31 March 2026	1,624.76	2,408.79	1,369.73	1,573.29	3,668.11	1,055.93	11,700.61

*Represents deemed cost on the date of transition to Ind AS (i.e. 01 April 2024) for financial statements. Gross carrying value and accumulated depreciation from the previous GAAP have been disclosed for the purpose of better understanding of the original cost of assets.

- (i) The Company does not have assets pledged as security.
- (ii) Depreciation of property, plant and equipment has been presented in Note 31 i.e. Depreciation and amortisation expense.
- (iii) The title deeds of the immovable properties are held in the name of entities included in Company, covered under the Act.
- (iv) The depreciation expense for the year includes depreciation on the assets acquired as a part of business combination. (Refer note 45)
- (v) The Company has reclassified certain assets from "Furniture and Fixtures" and "Office Equipment" to "Leasehold Improvements" in order to better reflect the nature and use of such assets. This reclassification has been made as at the transition date (1 April 2024) and has been consistently applied for the comparative period ended 31 March 2025. The reclassification does not have any impact on the total carrying value of property, plant and equipment, profit for the period, or equity, as it represents only a change in presentation.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3A. Capital work-in-progress

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Capital work-in-progress	191.56	1,123.31	349.84
	191.56	1,123.31	349.84

Reconciliation of Capital work in progress:

Particulars	Amount
As at 01 April 2024	349.84
Addition during the year	1,119.55
Capitalisations	(346.08)
As at 31 March 2025	1,123.31
Addition during the year	1,530.47
Capitalisations	(2,462.22)
As at 31 March 2026	191.56
Net carrying value:	
As at 01 April 2024	349.84
As at 31 March 2025	1,123.31
As at 31 March 2026	191.56

Capital Work in progress ageing schedule

Capital work in progress	As at 31 March 2026				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	171.88	19.68	-	-	191.56
Projects temporarily suspended	-	-	-	-	-

Capital work in progress	As at 31 March 2025				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	1,119.55	3.76	-	-	1,123.31
Projects temporarily suspended	-	-	-	-	-

Capital work in progress	As at 01 April 2024				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	237.16	112.68	-	-	349.84
Projects temporarily suspended	-	-	-	-	-

Note:

No project has been identified whose completion is overdue versus original plan and which have exceeded their original budget.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

4. RIGHT-OF-USE ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Buildings	11,404.12	10,026.65	5,809.27
	11,404.12	10,026.65	5,809.27

Particulars	Amount
Gross carrying value:	
As at 01 April 2024	5,809.27
Additions	6,355.04
As at 31 March 2025	12,164.31
Additions	4,442.22
Disposals	(77.29)
As at 31 March 2026	16,529.24
Accumulated depreciation:	
As at 01 April 2024	-
Charge for the year	2,137.66
As at 31 March 2025	2,137.66
Charge for the year	3,015.38
Disposals	(27.92)
As at 31 March 2026	5,125.12
Net carrying value:	
As at 01 April 2024	5,809.27
As at 31 March 2025	10,026.65
As at 31 March 2026	11,404.12

Note:

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the standalone Statement of Profit and Loss.

5. GOODWILL

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Goodwill on acquisition of business	5,811.82	5,811.82	-
	5,811.82	5,811.82	-

Refer note 45 for details of acquisition of business.

There has been restatement of goodwill on account of transition from previous GAAP to IND AS.

Refer note 46 for restatement of goodwill from IGAAP.

Note - Impairment tests for goodwill:

The Company tests cash-generating units with goodwill annually for impairment, or more frequently if there is an indication that a cash-generating unit to which goodwill has been allocated may be impaired. The recoverable amount of a cash generating unit is the higher of the cash-generating unit's fair value less cost of disposal ('FVLCD') and its value-in-use.

For the purpose of annual impairment testing, goodwill is allocated to the operating segments expected to benefit from the synergies of the business combinations in which the goodwill arises as set out below, and is compared to its recoverable value:

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The carrying amount of goodwill is attributable to the following CGU/group of CGUs:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Ayurvedic Healthcare Segment	19,102.50	-	-
Total	19,102.50	-	-

Calculation of the value-in-use is based on cash flow projections on reasonable and supportable assumptions that represent economic conditions that will exist over the remaining useful life of the assets, approved by the management, but shall exclude any estimated future cash inflows or outflows expected to arise from future restructurings or from improving or enhancing asset performance.

As at 31 March 2026, the Company held goodwill of ₹ 5,811.82 lakhs attributable to identified Cash Generating Units (CGUs) resulting from the acquisition of business of Oregano Life Private Limited. Refer Note 45 for further details.

For CGU/Group of CGU's containing goodwill at the core business level, management conducts impairment assessment and compares the carrying amount of such CGU/Group of CGU's with its recoverable amount. Recoverable amount is value in use of the CGU/Group of CGU's computed based upon discounted cash flow projections for 5 years. The key assumptions used for computation of value in use are the growth rate and discount rate as specified below. The key assumptions have been determined based on management's calculations after considering, past experiences and other available internal information and are consistent with external sources of information to the extent applicable.

Growth rates:

Projections are based on the budgets/forecasts using a steady growth rate for subsequent years. In current scenario, terminal growth rate of 4% has been derived to offset inflation, basis past industry trend analysis.

Discount rates:

The discount rates reflect appropriate adjustments relating to market risk and specific risk factors of each segment. While calculating value in use discount rate of 13.55% has been considered.

Cash flow assumptions:

The management assumed that the business will be operated prudently and that the company shall continue to operate and that there are no unforeseen adverse changes in the economic conditions affecting the business, the market, or the industry.

Key assumptions:

Key assumptions include revenue and cost synergies over the forecast period for 5 years.

Recoverable Amount:

The recoverable amount of 'Ayurvedic Healthcare Segment' is ₹ 1,78,802 lakhs which is based on value in use.

Impairment:

For CGUs/Group of CGUs containing goodwill, the impairment assessment, taking into account above assumptions, did not result in any impairment loss and the management believes that any reasonably possible change in the key assumptions would not cause the carrying amount to exceed the recoverable amount of the said CGUs/Group of CGUs.

6. OTHER INTANGIBLE ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Softwares	140.73	2.67	2.13
Government Empanelment	34.22	110.83	-
Non-compete fees	85.20	119.15	-
	260.15	232.65	2.13

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

6. OTHER INTANGIBLE ASSETS (Contd.)

Particulars	Softwares	Government Empanelment	Non-compete fees	Amount
Gross carrying value at cost:				
As at 01 April 2024*	37.91	-	-	37.91
Additions	2.00			2.00
Acquisition [^]	-	148.40	135.80	284.20
Disposals/adjustments	-	-	-	-
As at 31 March 2025	39.91	148.40	135.80	324.11
Additions	173.24	-	-	173.24
Disposals/adjustments	-	-	-	-
As at 31 March 2026	213.15	148.40	135.80	497.35
Accumulated amortisation:				
As at 01 April 2024*	35.78	-	-	35.78
Amortisation expense	1.46	37.57	16.65	55.68
Disposals/adjustments	-	-	-	-
As at 31 March 2025	37.24	37.57	16.65	91.46
Amortisation expense	35.18	76.61	33.95	145.74
Disposals/adjustments	-	-	-	-
As at 31 March 2026	72.42	114.18	50.60	237.20
Net carrying value:				
As at 01 April 2024*	2.13	-	-	2.13
As at 31 March 2025	2.67	110.83	119.15	232.65
As at 31 March 2026	140.73	34.22	85.20	260.15

*Represents deemed cost on the date of transition to Ind AS (i.e. 01 April 2024) for financial statements. Gross block and accumulated amortisation from the previous GAAP have been disclosed for the purpose of better understanding of the original cost of assets.

[^]As a part of acquisition of the operations of Oregano Life Private Limited, the Company has acquired identifiable intangible assets namely, non-compete fees and government empanelment, along with other assets and liabilities, for a consideration agreed between the parties.

Refer note 45 for further details.

Amortisation of intangible assets has been presented in note 31, Depreciation and amortisation expense.

6A. INTANGIBLE ASSET UNDER DEVELOPMENT

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Intangible asset under development	79.45	224.28	43.68
Intangible asset under development	79.45	224.28	43.68

Reconciliation of Intangible asset under development:

Particulars	Amount
As at 01 April 2024	43.68
Addition during the year	180.60
Disposals	-
Capitalisations	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Reconciliation of Intangible asset under development: (Contd.)

Particulars	Amount
As at 31 March 2025	224.28
Addition during the year	79.45
Disposals	-
Adjustments*	(48.37)
Capitalisations	(175.91)
As at 31 March 2026	79.45

*Amount of ₹ 48.37 lakhs has been written off during the year

Intangible asset under development ageing schedule:

As at 31 March 2026

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	79.45	-	-	-	79.45
- Projects temporarily suspended	-	-	-	-	-
Total	79.45	-	-	-	79.45

As at 31 March 2025

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	180.60	43.68	-	-	224.28
- Projects temporarily suspended	-	-	-	-	-
Total	180.60	43.68	-	-	224.28

As at 01 April 2024

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	43.68	-	-	-	43.68
- Projects temporarily suspended	-	-	-	-	-
Total	43.68	-	-	-	43.68

There are no 'Intangible assets under development' whose completion is overdue or has exceeded its cost compared to its original plan.

7A. INVESTMENTS

Non-current investments

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
(a) Investment in LLP (Unquoted, at cost)*			
Dupon Clean Biofuel LLP (5% partnership share)			
Fixed capital	5.00	5.00	5.00
Floating capital	59.00	59.00	59.00

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Non-current investments (Contd.)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
(b) Investment in unquoted equity instruments of subsidiaries – at cost, fully paid up[^]			
Jeena Green Resources Private Ltd (25,500 equity shares of face value ₹ 10 per share) (51% stake)	2.55	-	-
Jeena Sikho International LLC–Dubai (100 equity shares of face value AED 1000 per share)**	25.45	-	-
(c) Investments in warrants (Convertible into equity shares) – Unquoted, at FVTPL			
Chandan Healthcare Limited*	1,395.54	-	-
Total non-current investments	1,487.54	64.00	64.00
Aggregate amount of quoted investments and market value thereof	-	-	-
Aggregate amount of unquoted investments	1,487.54	64.00	64.00
Aggregate amount of impairment in the value of investments	-	-	-

#Details of LLP

Particulars	Dupon Clean Biofuel LLP
Name of LLP	
Date of LLP Agreement	05.12.2022
Total capital	1,00,00,000
Partners details and their profitability ratio	
Dugar Growth Fund Private Limited	5%
Nitin Jain	30%
Paramjeet Singh Sehra	10%
Sucha Singh Sehra	20%
Manish Grover	30%
Jeena Sikho Lifecare Limited	5%

[^]Refer note 39 for further details.

^{**}During the current financial year ending 31 March 2026, the Company has incorporated a new wholly owned subsidiary, Jeena Sikho International LLC in Sharjah Media City, UAE, on 11 September 2025.

***On 03rd February 2026, the Company has been allotted 18,00,000 Fully Convertible Warrants ("Warrants") of Chandan Healthcare Limited on a preferential basis. Following are the terms of allotment:**

Number of Warrants allotted	18,00,000
Issue Price per Warrant	₹ 234 (includes face value + premium)
Total Warrant Issue Value	₹ 42,12,00,000
Amount Paid Upfront (25%)	₹ 10,53,00,000 (Paid on 02/02/2026)
Balance Amount Payable (75%)	₹ 31,59,00,000
Conversion Right and Period	Each Warrant is convertible into one Equity Share of the face value of ₹ 10 each at a premium of ₹ 224 per share within 18 month from the date of allotment

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7B. CURRENT INVESTMENTS

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	No. of units	Amount	No. of units	Amount	No. of units	Amount
Non-trade investments						
Investments in equity instruments (Quoted, carried at FVTPL)						
Axis Bank Ltd	605.00	7.03	455.00	5.01	229.00	2.40
Bharat Electronics Ltd	898.00	3.60	369.00	1.11	-	-
Bharti Airtel Ltd	583.00	10.39	308.00	5.34	182.00	2.24
Britannia Industries Ltd	62.00	3.36	35.00	1.73	21.00	1.03
Central Depository Services (India) Limited Eq	328.00	3.67	-	-	-	-
Cipla Ltd	291.00	3.56	151.00	2.18	-	-
Dr Reddys Laboratories Ltd	329.00	4.13	155.00	1.77	-	-
Eternal Ltd	694.00	1.59	2,119.00	4.27	-	-
Hcl Technologies Ltd	212.00	2.84	78.00	1.24	52.00	0.80
HDFC Bank Ltd	2,767.00	20.24	679.00	12.41	507.00	7.34
HDFC Life Insurance Company Ltd	422.00	2.49	139.00	0.95	105.00	0.67
ICICI Bank Ltd	1,544.00	18.62	657.00	8.86	356.00	3.89
Infosys Ltd	795.00	9.94	356.00	5.59	257.00	3.85
Interglobe Aviation Ltd	131.00	5.17	-	-	-	-
Kotak Mahindra Bank Ltd	1,520.00	5.37	192.00	4.17	163.00	2.91
Larsen & Toubro Ltd	240.00	8.41	119.00	4.16	61.00	2.30
Mahindra & Mahindra Ltd	236.00	6.97	98.00	2.61	56.00	1.08
Reliance Industries Ltd	1,225.00	16.46	615.00	7.84	194.00	5.77
Samvardhana Motherson International Ltd	3,889.00	4.09	-	-	-	-
Share India Securities Ltd	3,663.00	4.30	-	-	-	-
Star Cement Ltd	1,976.00	4.02	-	-	-	-
State Bank Of India	793.00	7.77	527.00	4.07	415.00	3.12
Tata Steel Ltd	2,636.00	5.06	1,338.00	2.06	847.00	1.32
Tata Teleservices (Maharashtra) Ltd	12,398.00	3.89	-	-	-	-
Tribhovandas Bhimji Zaveri Ltd	2,243.00	2.50	-	-	-	-
Tata Consultancy Services Ltd	-	-	157.00	5.66	96.00	3.72
Tata Motors Ltd	-	-	395.00	2.66	-	-
Central Depository Services (India) Limited	-	-	182.00	2.22	-	-
Capital Small Finance Bank Ltd	-	-	738.00	1.92	-	-
Cipla Ltd-Equity Shares ₹ 2/- After Subdivision	-	-	-	-	62.00	0.93
Divi's Laboratories Ltd	-	-	-	-	35.00	1.21
Dr Reddys Laboratories Ltd-Equity Shares Of ₹ 5/- Each	-	-	-	-	23.00	1.42
Eicher Motors Ltd	-	-	-	-	28.00	1.13
Hero Motocorp Ltd	-	-	-	-	34.00	1.61
One 97 Communications Ltd	-	-	-	-	811.00	3.27
SBI Cards And Payment Services Ltd	-	-	-	-	318.00	2.17
Zomato Ltd	-	-	-	-	1,054.00	1.92
Mutual Funds investment (Quoted, carried at FVTPL)						
ICICI Prudential Nifty Financial Services Exbank ETF	18,854.00	10.86	-	-	-	-
ICICI Prudential Nifty Alpha Low Volatility 30 Etf	-	-	33,146.00	8.76	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7B. CURRENT INVESTMENTS (Contd.)

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	No. of units	Amount	No. of units	Amount	No. of units	Amount
ICICI Prudential Nifty 200 Momentum 30 ETF	-	-	-	-	18,595.00	4.74
Bandhan Sterling	-	-	-	-	2,34,004.96	308.89
ICICI Prudential Saving fund	-	-	36,636.78	195.00	-	-
Edelweiss Multi Asset Allocation Fund – Regular Plan Growth	17,15,386.07	208.53	-	-	-	-
ICICI- 1525 Savings Fund Growth	73,558.13	418.56	-	-	-	-
ICICI- 1525 Savings Fund Growth	91,988.39	523.43	-	-	-	-
ICICI- 1525 Savings Fund Growth	73,529.24	418.40	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	4,45,809.19	100.84	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	17,77,688.89	402.11	-	-	-	-
Kotak Saving Funds – Growth	16,20,848.40	207.35	-	-	-	-
ICICI- Prudential Balanced Advantage Fund	1,35,936.65	97.59	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	22,18,167.71	501.75	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	8,83,738.40	199.90	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	17,61,250.56	398.39	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	13,06,554.88	295.54	-	-	-	-
ICICI- EDWRG/Prudential Balanced Advantage Fund	2,70,220.24	193.99	-	-	-	-
ICICI- EDWRG/Prudential Balanced Advantage Fund	3,95,053.27	283.61	-	-	-	-
Kotak Arbitrage Fund Growth	10,60,743.89	415.30	-	-	-	-
Kotak Saving Fund	13,94,588.27	624.31	-	-	-	-
Kotak Saving Fund	6,96,767.77	311.92	-	-	-	-
Kotak Saving Fund	3,47,878.88	155.73	-	-	-	-
Kotak Saving Fund	11,58,741.64	518.73	-	-	-	-
Kotak Saving Fund	4,62,921.60	207.24	-	-	-	-
Kotak Saving Fund	4,62,061.69	206.85	-	-	-	-
Kotak Saving Fund	6,85,883.81	307.05	-	-	-	-
Kotak Equity Savings Fund	3,71,931.87	96.31	-	-	-	-
Kotak Equity Savings Fund	3,71,713.43	96.26	-	-	-	-
Kotak Equity Savings Fund	7,39,446.65	191.49	-	-	-	-
Bandhan Money Market Fund	17,06,472.98	719.20	-	-	-	-
DSP Equity Saving Fund Growth	11,44,002.84	248.04	-	-	-	-
DSP Equity Saving Fund Growth	11,43,322.67	247.90	-	-	-	-
DSP Equity Saving Fund Growth	11,41,651.83	247.53	-	-	-	-
DSP Equity Saving Fund Growth	11,42,225.63	247.66	-	-	-	-
DSP Equity Saving Fund Growth	9,17,090.85	198.84	-	-	-	-
HDFC Focused Fund Growth	21,846.80	45.57	-	-	-	-
Total current investments	2,77,98,357.07	9,512.24	79,644.78	291.61	2,58,505.96	369.69
Total investments						
Aggregate amount of quoted investments and market value thereof	-	9,512.24	-	291.61	-	369.69
Aggregate amount of unquoted investments	-	-	-	-	-	-
Aggregate amount of impairment in the value of investments	-	-	-	-	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

8. LOANS, AT AMORTISED COST

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non – current			
(unsecured and considered good)			
Loans to related parties (Refer note a (ii) below)	1,045.66	-	-
	1,045.66	-	-
Current			
(unsecured and considered good)			
Loans to related parties (Refer note a (i), (ii) and (iii) below)	26.40	212.00	412.00
Other loans	-	100.00	400.00
	26.40	312.00	812.00

- a. i) The Company has granted loan to its subsidiary, Jeena Green Resources Private Limited, in two tranches, i.e., ₹ 5 lakhs (disbursed on 29 July 2025) and ₹ 20 lakhs (disbursed on 22 August 2025), carrying an interest rate of 10% p.a. payable annually for the purpose of business expansion and growth of its operations. The loan is for a period of 1 year commencing from 22 August 2025 and ending on 21 August 2026, unless extended or terminated earlier in accordance with the terms of the agreement. Interest amounting to ₹ 1.40 lakhs has been accrued on the said loan up to the reporting date. The said loan is repayable after 1 year structured as a bullet repayment.
- ii) The Company has granted loan to Jeena Sikho International LLC (wholly owned subsidiary) of AED 7.5 million @8.5% p.a. for the purpose of business expansion and growth of its operations. The loan shall be disbursed in 2 tranches. As at 31 March 2026, AED 4 million (₹ 1037.55 lakhs) has been granted by the Company. The loan is provided for a period of 5 years from the date of first disbursement. Interest amounting to ₹ 14.73 lakhs is accrued on the above loan and net foreign exchange loss recognised in statement of profit and loss amounted to ₹ 6.62 lakhs. The said loan along with interest accrued is repayable within 5 years structured as a bullet repayment.
- iii) The Company had granted a loan of ₹ 212 lakhs @10% p.a. repayable on demand, to Shuddhi Green Charcoal Private Limited, comprising ₹ 139 lakhs disbursed during the financial year ended 31 March 2022 and ₹ 73 lakhs disbursed during the financial year ended 31 March 2023 to support the borrower's working capital requirements and expansion of its operational capabilities. The loan has been fully repaid during the current financial year.

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Amount outstanding	Percentage to the total loans and advances in the nature of loans	Amount outstanding	Percentage to the total loans and advances in the nature of loans	Amount outstanding	Percentage to the total loans and advances in the nature of loans
a) amounts repayable on demand						
- Promoters	-	-	-	-	-	-
- Directors	-	-	-	-	-	-
- Key managerial personnel	-	-	-	-	-	-
- Other related parties	-	0%	212.00	68%	412.00	51%
b) without specifying any terms or period of repayment						
- Promoters	-	-	-	-	-	-
- Directors	-	-	-	-	-	-
- Key managerial personnel	-	-	-	-	-	-
- Other related parties	-	-	-	-	-	-
Total	-	0.00%	212.00	67.95%	412.00	51%

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

9. OTHER FINANCIAL ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
(Unsecured and considered good)			
Financial assets carried at amortised cost			
Security deposits given to third parties	930.94	717.39	480.23
Bank deposits with remaining maturity of more than 12 months*	242.87	282.44	-
	1,173.81	999.83	480.23
Current			
(Unsecured and considered good)			
Financial assets carried at amortised cost			
Interest accrued on deposits with banks	40.15	53.27	93.18
Bank deposits with remaining maturity of less than 12 months*	2,076.89	15.70	-
Other receivables**	152.16	-	-
	2,269.20	68.97	93.18

*As at 31 March 2026 deposits amounting to ₹ 113.50 lakhs (31 March 2025: ₹ 150.75 lakhs and 01 April 2024: ₹ Nil) have been kept against bank guarantee provided to various government authorities for empanelment of Company's Ayurvedic Treatments Centres. As at 31 March 2026, deposits amounting to ₹ 11.25 lakhs are marked against CC-lien (31 March 2025: ₹ 11.25 lakhs and 01 April 2024: ₹ Nil).

**Other receivables relates to non-interest bearing amount receivable against the transfer of fixed assets.

10. OTHER ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Prepaid expenses	34.51	23.45	-
Capital advances	64.22	72.45	-
	98.73	95.90	-
Current			
Prepaid expenses	228.16	239.69	92.14
Advances to vendors	977.35	509.20	1,688.77
Balances with government authorities	207.39	60.82	36.26
Others	41.09	66.91	223.44
	1,453.99	876.62	2,040.61

11. INVENTORIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Stock in trade and consumables*	2,017.12	1,154.58	718.87
	2,017.12	1,154.58	718.87

*It includes medicine inventory costing ₹ 12.18 lakhs as at 31 March 2026 (31 March 2025: ₹ Nil; 01 April 2024: Nil) which is in transit.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

12. TRADE RECEIVABLES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Secured, considered good	-	-	-
Unsecured, considered good (refer note (iii) below)	8,539.24	10,038.07	4,273.98
Credit impaired	-	-	-
Total	8,539.24	10,038.07	4,273.98
Less: Allowance for expected credit loss	(1,546.33)	(1,541.93)	(890.96)
	6,992.91	8,496.14	3,383.02

As at 31 March 2026

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	489.84	1,578.14	1,192.63	3,611.73	705.15	961.75	8,539.24
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	8,539.24

As at 31 March 2025

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	69.56	6,609.24	1,294.22	987.84	990.59	86.62	10,038.07
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	10,038.07

As at 01 April 2024

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	-	2,227.80	588.64	1,427.71	12.97	16.86	4,273.98
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

As at 01 April 2024 (Contd.)

Particulars	Outstanding for following periods from the date of transaction						Total
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	4,273.98

Notes:

- There are no disputed trade receivables.
- The arrangements do not contain any significant financing component or variable consideration, and the credit period is not fixed.
- Refer note 46 for reclassifications made during the year.
- All the Trade receivables of the Company are non interest bearing
- The Company's trade receivables as at the reporting date largely comprise of amounts due from various government panels/authorities. These receivables largely represent claims raised for services rendered to patients covered under such government schemes.
- Refer note 40 for details of the Company's credit risk policy and exposure.
- Trade receivables outstanding from related party ₹ 67.55 lakhs (31 March 2025: 6.04 and 01 April 2024: 270.41) (refer note 39)

13. CASH AND CASH EQUIVALENTS*

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balances with banks			
- In current account	818.12	1,754.75	1,707.38
- in deposit account	495.00	-	500.00
Cash in hand	202.50	543.12	324.09
	1,515.62	2,297.87	2,531.47

*There are no restrictions or specific conditions attached to the utilisation of the Company's cash and cash equivalents.

14. OTHER BANK BALANCES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Bank deposits with original maturity of more than three months but less than twelve months*	9,245.08	-	3,669.28
	9,245.08	-	3,669.28

*As at 31 March 2026 deposits amounting to ₹ Nil (31 March 2025: ₹ Nil and 01 April 2024: ₹ 215.23 lakhs) have been kept against bank guarantee provided to various government authorities for empanelment of Company's Ayurvedic Treatments Centres. The Company do not have any other margin money with banks except as disclosed in Note 9 above.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

15. DEFERRED TAX ASSETS (NET)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Deferred tax assets in relation to:			
Provision for post retirement benefits and other employee benefits (including bonus)	384.91	100.16	69.07
Impact of lease liability	3,192.40	2,672.86	1,437.78
Security deposits for leases	63.68	55.30	24.30
Allowance for expected credit loss	389.18	375.49	185.11
Intangible assets on account of business combination	32.24	13.65	-
Total	4,062.41	3,217.46	1,716.26
Deferred tax liabilities in relation to:			
Property, Plant and Equipment and other intangible assets	31.58	110.61	77.07
Fair value of FVTPL financial instruments	114.46	(0.85)	4.95
Security deposits from dealers	20.67	-	-
Impact of right of use asset	2,870.19	2,523.51	1,462.08
Total	3,036.90	2,633.27	1,544.10
Deferred tax assets (net)	1,025.51	584.19	172.16

(a) Movement in deferred tax liabilities/(asset) for the year ended 31 March 2026 is as follows:

Particulars	As at 01 April 2025	Recognised in statement of profit or loss	Recognised in other comprehensive Income	As at 31 March 2026
Deferred tax assets in relation to:				
Provision for post retirement benefits and other employee benefits (including bonus)	100.16	304.63	(19.88)	384.91
Impact of lease liability	2,672.86	519.54	-	3,192.40
Security deposits for leases	55.30	8.38	-	63.68
Allowance for expected credit loss	375.49	13.69	-	389.18
Intangible assets on account of business combination	13.65	18.59	-	32.24
Total	3,217.46	864.83	(19.88)	4,062.41
Deferred tax liabilities in relation to:				
Property, Plant and Equipment and other intangible assets	110.61	(79.03)	-	31.58
Fair value of FVTPL financial instruments	(0.85)	115.31	-	114.46
Security deposits from dealers	-	20.67	-	20.67
Impact of right of use asset	2,523.51	346.68	-	2,870.19
Total	2,633.27	403.63	-	3,036.90
Deferred tax assets (net)	584.19	461.20	(19.88)	1,025.51

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(b) Movement in deferred tax liabilities/(asset) for the year ended 31 March 2025 is as follows:

Particulars	As at 01 April 2024	Recognised in statement of profit or loss	Recognised in other comprehensive Income	As at 31 March 2025
Deferred tax assets in relation to:				
Provision for post retirement benefits and other employee benefits	69.07	30.50	0.59	100.16
Impact of lease liability	1,437.78	1,235.08	-	2,672.86
Security deposits for leases	24.30	31.00	-	55.30
Allowance for expected credit loss	185.11	190.38	-	375.49
Intangible assets on account of business combination	-	13.65	-	13.65
Total	1,716.26	1,500.61	0.59	3,217.46
Deferred tax liabilities in relation to:				
Property, Plant and Equipment and other intangible assets	77.07	33.54	-	110.61
Fair value of FVTPL Financial instruments	4.95	(5.80)	-	(0.85)
Impact of right of use asset	1,462.08	1,061.43	-	2,523.51
Total	1,544.10	1,089.17	-	2,633.27
Deferred tax assets (net)	172.16	411.44	0.59	584.19

16. EQUITY SHARE CAPITAL

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Authorised share capital			
12,50,00,000 (31 March 2025: 2,50,00,000 and 01 April 2024: 2,50,00,000) equity shares of face value ₹ 2 each (31 March 2025 and 01 April 2024: ₹ 10 each)	2,500.00	2,500.00	2,500.00
Issued, subscribed and fully paid-up			
12,43,00,730 (31 March 2025: 2,48,60,146 and 01 April 2024: 2,48,60,146) equity shares of face value ₹ 2 each fully paid-up (31 March 2025 and 01 April 2024: ₹ 10 each)	2,486.01	2,486.01	2,486.01
Total equity share capital	2,486.01	2,486.01	2,486.01

Notes:

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the year:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Number	Amount	Number	Amount	Number	Amount
Equity shares outstanding at the beginning of the year	2,48,60,146	2,486.01	2,48,60,146	2,486.01	2,48,60,146	2,486.01
Add: Subdivision of equity shares of ₹ 10 each to ₹ 2 each*	9,94,40,584	-	-	-	-	-
Equity shares outstanding at the end of the year	12,43,00,730	2,486.01	2,48,60,146	2,486.01	2,48,60,146	2,486.01

* On 12 June 2025, the Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each, fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(ii) Terms and rights attached to equity shares

The Company has only one class of Equity Shares having a par value of ₹ 2 per share. (31 March 2025 and 01 April 2024: ₹ 10 per share). Each holder of Equity Shares is entitled to one vote per share. In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

In the year ended 31 March 2022, the Company had issued bonus shares totalling to 1,00,00,080 equity shares on 25 August 2021 (90 equity shares for every one share held) and 1,10,48,954 equity shares on 03 November 2023 (4 equity shares for every 5 share held).

On 12 June 2025, the Holding Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each, fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

The board of directors in their meeting held on 16 May 2025 has recommended a dividend of ₹ 5.47 (before share split) of the face value of ₹ 10 each for the FY 2024-25, ₹ 1.10 (post share split) of face value of ₹ 2 each was approved by the shareholders in the Annual General Meeting of the Company dated 29 September 2025. The same has been paid during the year.

The board of directors of the Company at its meeting held on 30 May 2026, has recommended a final dividend of ₹ 4.50 per equity share to the shareholders of the Company for the year ended 31 March 2026, subject to the approval of the shareholders in the forthcoming Annual General Meeting.

(iii) Details of share holding more than 5 percent shares in the company:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Numbers	% holding	Numbers	% holding	Numbers	% holding
Manish Grover	7,86,41,190	63.27%	1,57,28,328	63.27%	1,66,52,448	66.98%
Sixteenth Street Asian Gems Fund	70,33,050	5.66%	14,06,610	5.66%	-	0.00%
Oregano Life Private Limited	46,85,708	3.77%	14,43,045	5.80%	15,04,245	6.05%
	9,03,59,948	72.70%	1,85,77,983	74.73%	1,81,56,693	73.03%

(v) Equity shareholding of Promoters

As at 31 March 2026

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	7,86,41,190	63.27%	0.00%
Bhavna Grover	2,43,000	0.20%	0.00%

As at 31 March 2025

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	1,57,28,238	63.27%	(3.71%)
Bhavna Grover	48,600	0.20%	(0.57%)

As at 01 April 2024

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	1,66,52,448	66.98%	-
Bhavna Grover	1,92,600	0.77%	-

[^]The change in the number of shares held by the promoters as at 31 March 2026 represents the change due to share split as explained in note 16(ii)

Promoter for the purpose of this disclosure means promoter as defined under section 2(69) of Companies Act, 2013.

(vi) The Company has not bought back any shares and neither issued any shares for consideration other than cash.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

17. OTHER EQUITY

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Securities premium	5,330.79	5,330.79	5,330.79
Retained earnings	38,637.65	17,728.26	10,774.85
Employee Stock Options Outstanding Account	285.60	89.22	1.08
	44,254.04	23,148.27	16,106.72

17.1 Securities premium

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	5,330.79	5,330.79	5,330.79
Balance at the end of the year	5,330.79	5,330.79	5,330.79

Note: This reserve represents the premium on issue of shares and can be utilised in accordance with the provisions of the Companies Act, 2013.

17.2 Retained earnings*

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	17,728.26	10,774.85	10,774.85
Profit for the year	22,217.57	7,994.33	-
Other comprehensive income	59.13	(1.75)	-
Dividend paid	(1,367.31)	(1,039.17)	-
Balance at the end of the year	38,637.65	17,728.26	10,774.85

Note: Retained earnings are created from the net profit/(loss) of the Company after all distributions and transfers to other reserves, etc.

17.3 Share options outstanding account

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	89.22	1.08	1.08
Employee stock option expense*	196.38	88.14	-
Balance at the end of the year	285.60	89.22	1.08

Notes:

*(i) Refer note 37 for further details of employee stock option expense.

(ii) The share based payment reserve represents the value of equity settled share based payment transaction with employees. The amounts recorded in share based payment reserves are transferred to share capital and share premium (excess of fair value) upon exercise of stock options by employees.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

18. BORROWINGS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
(Secured, at amortised cost)			
From banks			
Vehicle loans*	26.50	42.92	32.16
	26.50	42.92	32.16

*Vehicle loan from Banks is for a total of three vehicles (Loan from HDFC Bank and Axis Bank). The loans are secured by hypothecation of the vehicles. These vehicle loans carries an interest rate from 8.74% to 9.12% p.a. (31 March 2025 and 01 April 2024: 8.74% p.a. to 9.12% p.a.). The loans are repayable in 5 years EMI. The details for the repayment terms and other factors are listed below:

- Outstanding vehicle loan 1:** Repayable in equated monthly instalments of ₹ 0.28 lakhs over the period from 05 April 2022 to 05 March 2026.
- Outstanding vehicle loan 2:** Repayable in equated monthly instalments of ₹ 1.78 lakhs over the period from 07 September 2021 to 07 August 2026.
- Outstanding vehicle loan 3:** Repayable in equated monthly instalments of ₹ 0.86 lakhs over the period from 05 March 2025 to 05 February 2030.

Note: There are no covenants related to the above loans payable.

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current			
(Secured, at amortised cost)			
Current maturities of long term borrowing	16.42	30.80	22.00
(Unsecured, at amortised cost)			
Unsecured loans*	–	1,000.00	–
	16.42	1,030.80	22.00

*It represents interest free demand loan taken from the director which has been repaid during the year. Refer note 39 for further details

19. LEASE LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Lease obligations	9,548.25	8,513.08	4,780.78
	9,548.25	8,513.08	4,780.78
Current			
Lease obligations	3,136.09	2,106.99	931.94
	3,136.09	2,106.99	931.94

Refer note 36 Leases for lease liability movement.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

20. OTHER FINANCIAL LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current	80.85	-	-
Trade/security deposits from vendors and others	80.85	-	-
Current			
Capital creditors	106.70	21.71	-
Trade/security deposits from vendors and others	329.73	488.61	340.41
Employee related payable	2,049.24	847.61	525.68
Dividend payable	2.79	2.33	1.28
	2,488.46	1,360.26	867.37

21. PROVISIONS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Provision for employee benefits			
Provision for gratuity (refer note 38)	562.52	369.31	257.95
	562.52	369.31	257.95
Current			
Provision for employee benefits			
Provision for compensated absences (refer note 38)	33.79	-	-
Provision for gratuity (refer note 38)	43.84	28.66	16.50
	77.63	28.66	16.50

22. CURRENT TAX LIABILITIES (NET)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Provision for income tax (net of advance tax)	814.89	137.28	266.03
	814.89	137.28	266.03

23. OTHER LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Deferred revenue*	12.49	-	-
	12.49	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

23. OTHER LIABILITIES (Contd.)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current			
Revenue received in advance	1,219.13	673.47	366.60
Statutory liabilities	293.83	329.70	270.05
Deferred revenue*	7.13	-	-
Contract liability – loyalty points	124.92	-	-
Others**	-	93.29	-
	1,645.01	1,096.46	636.65

*It represents the unamortized portion of non-refundable security deposits received from franchisees/dealers.

**It represents the amount payable to the Rajasthan Government Health Scheme (government panel) against the notice received and the same has been paid during the year.

24. TRADE PAYABLES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
i. total outstanding dues of micro enterprises and small enterprises (refer note below)	617.33	238.29	35.45
ii. total outstanding dues of creditors other than micro enterprises and small enterprises	1,545.03	1,336.51	782.39
	2,162.36	1,574.80	817.84
Disclosures under Micro, Small and Medium Enterprises Development (MSMED) Act, 2006:			
i) Principal amount due to suppliers under MSMED Act	608.86	238.29	35.45
ii) Interest due on unpaid principal amount to MSME suppliers	8.47	-	-
iii) the amount of interest paid by the buyer under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-	-
iv) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006)	-	-	-
v) The amount of interest accrued and remaining unpaid at the end of accounting year	-	-	-
vi) The amount of further interest remaining due and payable even in the succeeding year, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23 of MSMED Act 2006	-	-	-
vii) Interest accrued and remaining unpaid at the end of the accounting year	-	-	-
	617.33	238.29	35.45

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(b) Trade payables ageing is as follows: **

Particulars	As at 31 March 2026					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	594.11	18.34	4.88	-	617.33
(ii) Others	946.72	567.09	27.55	3.56	0.10	1,545.03
Total	946.72	1,161.20	45.89	8.44	0.10	2,162.36

Particulars	As at 31 March 2025					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	238.28	-	-	-	238.28
(ii) Others	646.92	635.53	50.25	3.79	-	1,336.52
Total	646.92	873.81	50.25	3.79	-	1,574.80

Particulars	As at 01 April 2024					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	35.45				35.45
(ii) Others	372.08	340.16	54.37	2.15	13.64	782.39
Total	372.08	375.61	54.37	2.15	13.64	817.84

*Includes unbilled payables of ₹ 22.34 lakhs (31 March 2025: ₹ 18.91 lakhs; 01 April 2024 ₹ 11.12 lakhs)

**The Company doesn't have any disputed outstanding balance as at 31 March 2026, 31 March 2025 and 01 April 2024.

Refer Note 46 for the reclassification/regrouping made during the year.

25. REVENUE FROM OPERATIONS

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of products	41,567.53	21,535.59
Sale of services	38,340.37	25,371.60
Other operating revenues		
Royalty*	53.18	-
Deferred franchise deposit income	96.79	-
Others**	76.77	-
Revenue from operations	80,134.64	46,907.19

*It represents the royalty income transaction with the related party. Refer Note 39 for further details.

**It represents the revenue share income on account of diagnostic services rendered by Chandan Healthcare Limited to the patients referred by the Company.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Notes:

(a) Disaggregated revenue information

The company has performed disaggregated analysis of revenue considering the nature, amount, timing and uncertainty of revenue, this includes disclosure of revenue by geography and timing of recognition.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue by nature		
Ayurvedic products/medicines	41,567.53	21,535.59
Ayurvedic healthcare services	38,340.37	25,371.60
Total	79,907.90	46,907.19
Revenue by geography		
Domestic	79,888.50	46,800.67
Export	246.14	106.52
Total	80,134.64	46,907.19
Revenue by time		
Revenue recognised at point in time	41,697.48	21,535.59
Revenue recognised over time	38,437.16	25,371.60
Total	80,134.64	46,907.19

(b) Assets and liabilities related to contracts with customers

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Trade receivables (Asset)	6,992.91	8,496.14
Total contract assets	6,992.91	8,496.14
Revenue received in advance (Liability)	1,219.13	673.47
Contract liability – loyalty points* (Liability)	124.92	-
Total contract liabilities	1,344.05	673.47

*The Company has started giving loyalty points to the end consumers from the current financial year ending 31 March 2026.

(c) Reconciliation of contract liabilities recognised in the Balance Sheet

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening balance	673.47	366.60
Revenue received in advance and loyalty points earned during the year	2,068.83	673.47
Revenue billed/redemption/lapsed during the year	(1,398.25)	(366.60)
Closing balance	1,344.05	673.47

(d) Reconciling the amount of revenue recognised in the statement of profit and loss with the contracted price

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Contract price	80,641.76	46,907.19
Less:		
Discounts, Rebates, Credits etc.	(507.12)	-
Revenue from operations	80,134.64	46,907.19

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(e) The following aggregated amounts of transaction prices relate to the performance obligations from existing contracts that are unsatisfied or partially unsatisfied:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue expected to be recognised	1,219.13	673.47

(f) No single external customer represents 10% or more of the Company's total revenue.

26. OTHER INCOME

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest income		
Interest income earned on:		
– bank deposits (at amortised cost)	165.48	200.13
– financial assets (at amortised cost)	93.57	71.54
	259.05	271.67
Other income		
Fair value gain on financial instruments at fair value through profit or loss	465.85	–
Gain on sale of property, plant and equipment (net)	–	233.36
Gain on sale of investment (net)	5.91	100.95
Miscellaneous income*	135.08	67.56
	606.84	401.87
Total other income	865.89	673.54

*It significantly comprises income on account of rent, gain on termination of leases, referral incentives and advance from customers being written off.

27. PURCHASES OF STOCK IN TRADE AND CONSUMABLES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchases of stock in trade and consumables*	10,011.39	5,857.99
Total	10,011.39	5,857.99

*Refer note 32.2 below for the details of food and kitchen expenses included in the consumables in the current year.

28. CHANGES IN INVENTORIES OF STOCK IN TRADE AND CONSUMABLES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening Stock:		
Stock in trade and consumables	1,154.58	718.87
	1,154.58	718.87
Closing Stock:		
Stock in trade and consumables	2,017.12	1,154.58
	2,017.12	1,154.58
Net increase	(862.53)	(435.71)

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

29. EMPLOYEE BENEFITS EXPENSE

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Salaries and wages	13,514.56	9,316.15
Contribution to provident and other funds (refer note 38)	701.24	467.62
Defined benefit plan expense (refer note 38)	296.53	122.08
Share based payments to employees (refer note 37)	196.38	88.14
Staff welfare expenses	131.77	80.29
Total employee benefits expense	14,840.48	10,074.28

30. FINANCE COSTS

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest expense on borrowings- financial liability measured at amortised cost	4.43	3.36
Interest expense on financial liabilities at amortised cost	14.67	84.30
Interest on lease liabilities	1,255.78	930.59
Other finance costs	8.47	47.24
Total finance costs	1,283.35	1,065.49

31. DEPRECIATION AND AMORTISATION EXPENSE

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation of property, plant and equipment (refer note 3)	1,596.70	717.20
Amortisation of intangible assets (refer note 6)	145.74	55.68
Depreciation of right-of-use assets (refer note 4)	3,015.38	2,137.66
Total depreciation and amortisation expense	4,757.82	2,910.54

32. OTHER EXPENSES[#]

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Electricity charges	1,041.17	862.81
Telephone and communication expenses	106.34	111.08
Rent expense (variable and short term leases)	1,658.56	960.43
Repair and maintenance	501.05	482.62
Rates and taxes	268.69	238.40
Office and operational expenses	1,146.62	878.61
Postage and courier	949.98	388.31
Travelling and conveyance	662.65	515.53
Printing and stationery	227.39	139.60
Freight cartage and other distribution cost	91.97	46.65

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

32. OTHER EXPENSES[#] (Contd.)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Platform fees and franchisee (agent) service commission	130.25	453.80
CSR expenditure (refer note 43)	170.00	101.64
Legal and professional expenses	1,168.63	981.79
Payments to auditors (refer note 32.1 below)	200.74	14.62
Advertising and sales promotion expenses	6,269.65	5,801.20
Security expenses	2,581.95	1,511.48
Advances/loans written off	184.24	115.03
Software and computer expenses	382.31	143.39
Input tax credit written off	1,192.60	936.17
Bank charges	104.57	-
Allowance for expected credit loss	598.09	650.97
Call centre expenses	734.48	652.02
Uniform charges	51.31	40.52
Food & kitchen expenses (refer note 32.2 below)	66.19	576.50
Business support services	333.65	426.60
Loss on sale of property, plant and equipment (net)	21.58	-
Write off of property, plant and equipment (net)	34.33	-
Miscellaneous expenses ^{**}	303.56	320.61
Total other expenses	21,182.55	17,350.38

Note: 32.1 Payments to the auditors (excluding goods and services tax wherever applicable)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
As auditors		
- Statutory audit fees [*]	188.00	12.00
- Tax audit fees [^]	2.50	2.00
- Out of pocket expenses	5.99	0.62
- Other services	4.25	-
	200.74	14.62

Note: 32.2 The food and kitchen expenses pertaining to the hospitals, clinics and day care centres for the current year has been considered as a part of consumables and since the bifurcation of the expense for the previous year was not available, therefore, the same has been considered as a part of other expenses.

^{*}Current year expense includes ₹ 11 lakhs pertaining to the predecessor auditor.

[^]It relates to tax audit fees pertaining to predecessor auditor.

^{**}It majorly comprises of insurance charges, annual maintainence expenses, call centre expenses, cleaning expenses, fair value loss on financial instruments etc.

[#]Previous year expenses have been regrouped wherever necessary.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

33. INCOME TAXES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Income tax recognised in the statement of profit and loss		
Current tax		
In respect of the current year	8,017.00	3,153.33
In respect of the previous year	14.10	21.54
	8,031.10	3,174.87
Deferred tax		
In respect of the current year	(461.20)	(411.44)
	(461.20)	(411.44)
Total income tax expense recognised in the current year	7,569.90	2,763.43
The Income tax expense for the year can be reconciled to the accounting profit as follows:		
Profit before tax	29,787.47	10,757.76
Statutory income tax rate (as per Indian Income Tax Act 1961)	25.17%	25.17%
Income tax expense at statutory income tax rate	7,496.91	2,707.51
Excess of depreciation as per books over income tax	-	-
Effect of expenses that are not deductible in determining taxable profit	53.23	28.50
Others	19.76	27.42
	7,569.90	2,763.43

34. EARNINGS PER SHARE

Basic earnings per share amount is calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share amount is calculated by dividing the profit for the year attributable to equity holder by the weighted average number of equity shares outstanding during the year plus the weighted average number of equity shares that would be issued on conversion of all dilutive potential equity shares into equity shares.

The following reflects the income and share data used in the basic and diluted EPS computations:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit attributable to equity holder of the Company (A)	22,217.57	7,994.33
Number of equity shares as at 31 March 2026	12,43,00,730	2,48,60,146
Face value per share (INR)	2	10
Weighted average number of equity shares used for computing:		
Basic EPS (B)	12,43,00,730	12,43,00,730
Effect of dilutive shares (on account of ESOPs)	1,73,877	1,27,034
Diluted EPS (C)	12,44,74,607	12,44,27,764
Basic EPS (A/B)*	17.87	6.43
Diluted EPS (A/C)*	17.85	6.42

*Earnings per share is computed after giving effect to 1:5 stock split effective June 12, 2025 for all the periods presented. Accordingly, the number of equity shares for the year ended 31 March 2025 has been restated retrospectively for the purpose of EPS calculation. Refer Note 16 of these financial statements for further details regarding such stock split.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

35. SEGMENT REPORTING

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Company. The CODM is considered to be the one who makes strategic decisions and is responsible for allocating resources and assessing the financial performance of the operating segments. Information reported to the CODM for the purposes of resource allocation and assessment of segment performance focuses on the types of goods delivered or services rendered.

With regard to the segment reporting, the Company has identified the following operating and reportable segments:

- (a) Ayurvedic products/medicines
- (b) Ayurvedic healthcare services
- (c) Others

The Company has disclosed this Segment Reporting in Financial Statements as per Ind AS 108.

The Company's CODM does not review assets and liabilities for each operating segment separately, hence segment information relating to the total assets and liabilities has not been furnished.

Particulars	Year ending 31 March 2026				
	Ayurvedic products/medicines	Ayurvedic healthcare services	Others	Unallocable	Total
Segment Revenue					
Domestic	41,321.39	38,340.37	226.74	-	79,888.50
Export	246.14	-	-	-	246.14
Revenue from operations	41,567.53	38,340.37	226.74	-	80,134.64
Add: Other income					
Other income	-	-	-	865.89	865.89
Less: Expenses					
Purchases of stock-in-trade and consumables	6,186.06	3,825.33	-	-	10,011.39
Changes in inventories of stock in trade and consumables	(746.89)	(115.64)	-	-	(862.53)
Employee benefits expense	6,708.71	6,187.87	-	1,943.90	14,840.48
Finance costs	-	-	-	1,283.35	1,283.35
Depreciation and amortization expense	2,474.98	2,282.84	-	-	4,757.82
Other expenses	10,470.48	10,511.33	-	200.74	21,182.55
Segment results	16,474.19	15,648.64	226.74	(2,562.10)	29,787.47
Tax expense	-	-	-	-	7,569.90
Profit after tax	-	-	-	-	22,217.57

Particulars	Year ending 31 March 2025				
	Ayurvedic products/medicines	Ayurvedic healthcare services	Others	Unallocable	Total
Segment Revenue					
Domestic	21,429.07	25,371.60	-	-	46,800.67
Export	106.52	-	-	-	106.52
Revenue from operations	21,535.59	25,371.60	-	-	46,907.19

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(Contd.)

Particulars	Year ending 31 March 2025				Total
	Ayurvedic products/ medicines	Ayurvedic healthcare services	Others	Unallocable	
Add: Other income					
Other income	-	-	-	673.54	673.54
Less: Expenses					
Purchases of stock-in-trade and consumables	3,561.90	2,296.09	-	-	5,857.99
Changes in inventories of stock in trade and consumables	(435.71)	-	-	-	(435.71)
Employee benefits expense	4,025.24	4,742.23	-	1,306.81	10,074.28
Finance costs	-	-	-	1,065.49	1,065.49
Depreciation and amortization expense	1,336.26	1,574.28	-	-	2,910.54
Other expenses	8,035.69	9,300.07	-	14.62	17,350.38
Segment results	5,012.21	7,458.93	-	(1,713.38)	10,757.76
Tax expense	-	-	-	-	2,763.43
Profit after tax	-	-	-	-	7994.33

Note:

(i) No single external customer represents 10% or more of the Company's total revenue for the year ended 31 March 2026 and 31 March 2025.

(ii) There is no inter-segment revenue for the year ended 31 March 2026 and 31 March 2025.

(iii) There is no non current asset other than financial instruments which is located outside India.

36. LEASES

The Company has leases for buildings. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Company classifies its right-of-use assets in a consistent manner to its property, plant and equipment.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the lease liability. The lease payments are discounted using incremental borrowing rate of the Company, being the rate the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar environment with similar terms, security and conditions. The average remaining lease term is 2.8 years (31 March 2025: 3.8 years).

Following is the carrying value of lease liabilities:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current lease liabilities (refer note 19)	3,136.09	2,106.99	931.94
Non-current lease liabilities (refer note 19)	9,548.25	8,513.08	4,780.78

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Following is the movement of lease liabilities:

Particulars	Amount
Balance as at 01 April 2024	5,712.72
Additions during the year	6,199.22
Finance cost accrued during the year	930.59
Payment of lease liabilities	(2,222.46)
Balance as at 31 March 2025	10,620.07
Additions during the year	4,331.93
Finance cost accrued during the year	1,255.78
Termination during the year	(53.24)
Payment of lease liabilities	(3,470.20)
Balance as at 31 March 2026	12,684.34

Following amounts has been recognised in the statement of profit or loss:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation of right-of-use assets (refer note 4)	3,015.38	2,137.66
Interest on lease liabilities included in interest expenses (refer note 30)	1,255.78	930.59
Expenses relating to short-term leases (refer note 32)	1,628.56	960.43
Expenses related to variable lease payments	30.00	-

Total cash outflows of the leases for the year ended is ₹ 5,128.76 lakhs including payments relating to short-term leases ₹ 1,628.56 lakhs and expenses related to variable lease payments ₹ 30 lakhs. Further for the year ended 31 March 2025 the cash outflows of the leases was ₹ 3,182.90 lakhs including payments relating to short-term leases ₹ 960.43 lakhs.

Nature of the Company's leasing activities by type of right-of-use-asset recognized on balance sheet date:

Particulars	As at 31 March 2026	As at 31 March 2025
Number of right-of-used assets leased	100	69
Range of remaining lease term	0.18 to 10.18 years	0.05 to 11.18 years
Average of remaining lease term	2.8 years	3.8 years
No. of lease with extension options (where management is certain to exercise the extension option)	3	1
No. of lease with option to purchase	-	-
No. of lease with variable payments linked to an index	-	-
No. of lease with termination option	94	62

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

37. SHARE BASED PAYMENT

I a. Description of share based payment arrangements- Employee Stock Option Scheme 2024

The Jeena Sikho Employee Stock Option Scheme 2024 has been adopted by the Board of Directors on 27 February 2024, read with the Special Resolution passed by the Members of the Company on 27 February 2024 and shall be deemed to come into force with effect from 27 February 2024 being the date of approval by the Members. Pursuant to this, the Company granted options to eligible employees at an exercise price of ₹10 per option on 28 March 2024 i.e. the grant date of the employee stock option. Each option is convertible into one Equity Share of the Company upon vesting subject to the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the terms and conditions of the scheme.

The maximum number of shares that may be issued pursuant to exercise of options granted to the participants under this Scheme shall not exceed 6,50,000 post split (1,30,000 pre split) shares of the Company. Subject to applicable laws, the Company reserves the right to increase or reduce such number of shares as it deems fit.

The maximum number of the shares that may be issued pursuant to the grant of the options to each grantee under ESOS 2024 shall be 100,000 (20,000 pre split) provided that maximum number of shares with respect to which options may be granted to a single employee shall not exceed 1% of the issued capital of the Company at any point of time.

The terms and conditions of the grant as per the plan are as under:

A. Vesting period

Vesting of the options shall take place as per the following schedule:

- 25% of options shall vest at the end of a period of 2.5 years from date of grant
- 75% of options shall vest at the end of a period of 5 years from date of grant

B. Exercise period

The exercise period shall commence from the date of vesting and shall close on the expiry of one year from the last vesting date (i.e., vesting date of the second tranche) for the respective grant of option. The employee shall have a right to exercise all the option vested in him within the exercise period.

Further, during the current financial year, the Company's equity shares were sub-divided (split) in the ratio of 1:5, whereby one equity share of face value ₹10 each was split into five equity shares of face value ₹2 each.

Consequent to the above sub-division and in accordance with the terms of the ESOP Scheme and the principles of Ind AS 102, the ESOPs outstanding were proportionately adjusted.

Accordingly, the number of stock options outstanding was increased, and exercise price per option was reduced proportionately, so as to preserve the economic value of the options granted to employees.

The adjustment did not result in any change in the total fair value of the stock options outstanding and, accordingly, no incremental compensation cost has been recognised due to the share split.

Vesting of options will take place in the following manner:

Tranche	Vesting date	Option to be Vested (as a % of total Granted Options)
1	Date being the date immediately after the date of expiry of two and half (2.5) years from the date of acceptance of the Options Granted to such Participant	25%
2	Date being the date immediately after the date of expiry of five (5) years from the date of acceptance of the Options Granted to such Participant	75%

Set out below is a summary of options granted under the ESOP Scheme 2024:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options
Opening balance	10.00	50,625.00	10.00	60,275.00	10.00	60,275
Adjustment due to share split	2.00	2,02,500.00	-	-	-	-
Granted during the year	-	-	-	-	-	-
Cancelled during the year	2.00	(18,500.00)	-	-	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Set out below is a summary of options granted under the ESOP Scheme 2024: (Contd.)

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options
Forfeited during the year	2.00	(39,250.00)	10.00	(9,650.00)	-	-
Adjustment for issue of bonus shares and sub-division of equity shares	-	-	-	-	-	-
Closing balance	2.00	1,95,375.00	10.00	50,625.00	10.00	60,275

Share options outstanding at the end of the year has following exercise prices and remaining contractual life:

Tranche	Grant date	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
		Exercise price*	Share options**	Remaining contractual life	Exercise price	Share options	Remaining contractual life	Exercise price	Share options	Remaining contractual life
1	28-Mar-24	2.00	48,843.75	181 days	10.00	12,656.25	546 days	10.00	15,068.75	910 days
2	28-Mar-24	2.00	1,46,531.25	1093 days	10.00	37,968.75	1458 days	10.00	45,206.25	1822 days

*The exercise price of the ESOPs has been adjusted from ₹ 10 to ₹ 2 pursuant to the share split during the current year.

**The number of share options has increased pursuant to the share split undertaken during the current year.

b. Measurement of fair values

The fair values are measured based on the Black-Scholes-Merton model. The fair value of the options and inputs used in the measurement of the grant date and measurement date fair values of the equity-settled share based payments are as follows:

Tranche	Options granted on	Fair value per Option at grant date (in INR)*	Share price at grant date (in INR)**	Exercise price (in INR)	Expected volatility	Expected life (in years)^	Expected dividend yield	Risk-free interest rate
1	28-Mar-24	825.04	841.65	2.00	50.00%	4.25	0.25%	6.35%
2	28-Mar-24	823.01	841.65	2.00	50.00%	5.50	0.25%	6.38%

*Fair value per option at the grant date has been considered without giving effect to the share split undertaken during the current year.

**Share price at the grant date has been considered without giving effect to the share split undertaken during the current year.

^It has been computed by taking into account the vesting period along with the median of the exercise period for the respective tranches.

II a. Description of share based payment arrangements- Employee Stock Option Scheme 2025

The Jeena Sikho Employee Stock Option Scheme 2025 has been adopted by the Board of Directors on 29 September 2025, read with the Special Resolution passed by the Members of the Company on 29 September 2025 and shall be deemed to come into force with effect from 29 September 2025 being the date of approval by the Members. Pursuant to this, the Company granted options to eligible employees at an exercise price of ₹2 per option on 01 January 2026 and 25 March 2026 i.e. the grant date of the employee stock option as explained in note 37(II b). Each option is convertible into one Equity Share of the Company upon vesting subject to the Securities and Exchange Board of India (Share Based

Employee Benefits and Sweat Equity) Regulations, 2021 and the terms and conditions of the scheme.

The maximum number of shares that may be issued pursuant to exercise of options granted to the participants under this Scheme shall not exceed 2,50,000 shares of the Company. Subject to applicable laws, the Company reserves the right to increase or reduce such number of shares as it deems fit.

The maximum number of the shares that may be issued pursuant to the grant of the options to each grantee under ESOS 2025 shall be 25,000 provided that maximum number of shares with respect to which options may be granted to a single employee shall not exceed 1% of the issued capital of the Company at any point of time.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The terms and conditions of the grant as per the plan are as under:

A. Vesting period

Vesting of the options shall take place as per the following schedule:

- 20% of options shall vest at the end of a period of 1 year from date of grant
- 30% of options shall vest at the end of a period of 2 years from date of grant
- 50% of options shall vest at the end of a period of 3 years from date of grant

B. Exercise period

The exercise period shall commence from the date of vesting and shall close on the expiry of one year from the last vesting date (i.e., vesting date of the third tranche) for the respective grant of option. The employee shall have a right to exercise all the option vested in him within the exercise period.

Vesting of options will take place in the following manner:

Tranche	Vesting date	Option to be Vested (as a % of total Granted Options)
1	Date being the date immediately after the date of expiry of One (1) year from the date of acceptance of the Options Granted to such Participant	20%
2	Date being the date immediately after the date of expiry of Two (2) years from the date of acceptance of the Options Granted to such Participant	30%
3	Date being the date immediately after the date of expiry of Three (3) years from the date of acceptance of the Options Granted to such Participant	50%

Set out below is a summary of options granted under the ESOP Scheme 2025:

Particulars	As at 31 March 2026	
	Weighted average exercise price per share option (INR)	Number of options
Opening balance	-	-
Granted during the year	2.00	2,18,775.00
Forfeited/expired during the year	2.00	(6,075.00)
Closing balance	2.00	2,12,700.00

Share options outstanding at the end of the year has following exercise prices and remaining contractual life:

Tranche	Grant date	As at 31 March 2026		
		Exercise price	Share options	Remaining contractual life
1	1-Jan-26	2.00	37,540.00	276 days
2	1-Jan-26	2.00	56,310.00	641 days
3	1-Jan-26	2.00	93,850.00	1007 days
4	25-Mar-26	2.00	5,000.00	359 days
5	25-Mar-26	2.00	7,500.00	725 days
6	25-Mar-26	2.00	12,500.00	1090 days

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

b. Measurement of fair values

The fair values are measured based on the Black-Scholes-Merton model. The fair value of the options and inputs used in the measurement of the grant date and measurement date fair values of the equity-settled share based payments are as follows:

Tranche	Options granted on	Fair value per Option at grant date (in INR)	Share price at grant date (in INR)	Exercise price (in INR)	Expected volatility	Expected life (in years)	Expected dividend yield	Risk-free interest rate
1	1-Jan-26	673.74	682.20	2.00	50.00%	2.50	0.40%	5.69%
2	1-Jan-26	672.45	682.20	2.00	55.00%	3.00	0.40%	5.78%
3	1-Jan-26	671.17	682.20	2.00	55.00%	3.50	0.40%	5.86%
4	25-Mar-26	586.05	594.50	2.00	50.00%	2.50	0.45%	5.84%
5	25-Mar-26	584.77	594.50	2.00	50.00%	3.00	0.45%	5.93%
6	25-Mar-26	583.49	594.50	2.00	55.00%	3.50	0.45%	6.02%

III. Effect of employee stock option schemes on the statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Employee stock option reserve	196.38	88.14
Total Carrying amount of liabilities	196.38	88.14

IV. Effect of employee stock option schemes on the balance sheet

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Employee stock option scheme expense	285.60	89.22	1.08
Total expense on share based payments	285.60	89.22	1.08

V. The underlying expected volatility was determined by reference to historical data of the Company's shares over a period of time since its floatation on the National Stock Exchange. No special features inherent to the options granted were incorporated into measurement of fair value.

38. EMPLOYEE BENEFITS

The Company has adopted Indian Accounting Standard (Ind AS) - 19 on Employee Benefits as under:

38.1 Defined contribution plans

Provident fund

In accordance with the Employee's Provident Fund and Miscellaneous Provisions Act, 1952, eligible employees of the Company are entitled to receive benefits in respect of provident fund, a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the covered employees' salary. The contributions, as specified under the law, are made to the employee provident fund organization (EPFO).

The total expenses recognised in the statement of profit and loss during the year on account of defined contribution plans amounted to ₹ 701.24 Lakhs (31 March 2025: ₹ 467.62 Lakhs).

38.2 Defined obligation plans

Gratuity

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 26 days salary payable for each completed year of service. Vesting occurs upon completion of five years/one year (one year in case of fixed term employees) of service. The Company does not make any contributions to gratuity funds and the plan is unfunded. The Company follows Ind AS 19 'Employee Benefits' and uses Projected Unit Credit Method to value defined benefit obligations.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The defined benefit plans expose the Company to a number of actuarial risks as below:

- Interest risk:** A decrease in the bond interest rate will increase the plan liability.
- Salary risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.
- Longevity risk:** The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants. An increase in the life expectancy of the plan participants will increase the plan's liability.

The following table sets out the amounts recognised in the financial statements in respect of retiring gratuity plan:

Grant date	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Current	Non-current	Current	Non-current	Current	Non-current
Gratuity	43.84	562.52	28.66	369.31	16.50	257.95
Total	43.84	562.52	28.66	369.31	16.50	257.95

Disclosure of gratuity

(i). Amount recognised in the statement of profit and loss is as under:

Description	During the year ended 31 March 2026"	During the year ended 31 March 2025
Current service cost	146.16	102.92
Past service cost	124.86	-
Interest cost	25.51	19.16
Net impact on profit (before tax)	296.53	122.08
Actuarial loss/(gain) recognised during the year	(79.01)	2.34
Amount recognised in total comprehensive income	217.52	124.42

(ii). Reconciliation of the present value of obligation:

Description	For the year ended 31 March 2026	For the year ended 31 March 2025
Present value of defined benefit obligation as at the beginning of the year	397.98	274.45
Current service cost	146.16	102.92
Transfer in obligation	-	0.14
Interest cost	25.51	19.16
Past service cost	124.86	-
Benefits paid	(9.14)	(1.03)
Actuarial (gain)/loss (refer note iv)	(79.01)	2.34
Present value of defined benefit obligation as at the end of the year	606.36	397.98

(iii). Breakup of actuarial (gain)/loss:

Description	For the year ended 31 March 2026	For the year ended 31 March 2025
Actuarial (gain)/loss from change in financial assumption	(26.79)	17.01
Actuarial (gain)/loss from change in demographic assumption	-	(5.58)
Actuarial (gain)/loss from experience adjustment	(52.22)	(9.09)
Total actuarial (gain)/loss	(79.01)	2.34

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(iv). Actuarial assumptions

Description	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 01 April 2024
Discount rate (Per annum)	7.20%	6.65%	7.20%
Salary growth (per annum)	10.00%	10.00%	10.00%
Withdrawal rate	11.55% to 41.55%	11.55% to 41.55%	10.20% to 40.98%

(v). Sensitivity analysis for gratuity liability

Description	31 March 2026	31 March 2025
Impact of change in discount rate		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	(3.74%)	(3.90%)
- Impact due to decrease of 0.5 %	4.00%	4.18%
Impact of change in salary escalation		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	2.91%	3.12%
- Impact due to decrease of 0.5 %	(2.89%)	(3.05%)
Impact of change in withdrawal rates		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	(4.77%)	(5.07%)
- Impact due to decrease of 0.5 %	5.23%	5.74%

The above sensitivity analysis is based on a change an assumption while holding all other assumptions constant. In practice, this is unlikely to occur and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting year) has been applied which was applied while calculating the defined benefit obligation liability recognised in the balance sheet.

Note: Sensitivity due to mortality is not material and hence impact of change due to these not calculated.

(vi). Expected Maturity profile of defined benefit payment plan in future years:

Description	31 March 2026	31 March 2025
Within next 12 months (next annual reporting year)	43.84	28.66
Between 1-5 years	231.51	146.16
Beyond 5 years	298.16	181.05
Total	573.51	355.88

(vii). The best estimated expense for the next year ending 31 March 2027 is INR 223.31 lakhs.

(viii). The weighted average duration of defined benefit obligation at the end of reporting year is 6.65 years (31 March 2025: 6.7 years and 01 April 2024: 7.39 years).

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

38.3 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes viz Code on Wages, 2019, Industrial Relations Code, 2020, Code on Social Security, 2020, and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as 'the New Labour Codes'). The New Labour Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. Basis the Company's assessment, the estimated incremental impact amounting to ₹ 124.86 lacs has been recognized in the standalone statement of Profit and Loss for the year ended 31 March 2026. The Company continues to monitor the finalization of Central/State rules and clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect on the basis of such developments as needed.

38.4 Other short term benefits

Compensated absences

Employee benefit expenses for the year is 33.79 lacs (31 March 2025: Nil) towards compensated absences which has been recognised in the statement of profit and loss. Provision for compensated absences as on 31 march 2026 33.79 lacs (31 March 2025: Nil).

39. RELATED PARTY DISCLOSURES

(I) Relationship with related parties:

Description of relationship	Names of related parties
(a). Subsidiaries:	Jeena Green Resources Private Limited
	Jeena Sikho International LLC (wholly owned)
(b). Directors and/or Key management personnel (KMP):	Manish Grover (Managing Director)
	Bhavna Grover (Whole-time Director)
	Shreya Grover (Whole-time Director) (redesignation w.e.f 27August2025)
	Karan Vir Bindra (Non-Executive Independent Director)
	Priyanka Bansal (Non-Executive Independent Director) (w.e.f 21 April 2025)
	Chandan Kumar Kaushal (Non-Executive Independent Director) (w.e.f 29 April 2024)
	Nanak Chand (Chief Financial Officer)
	Smita Chaturvedi (Company Secretary) (w.e.f 04 August 2025)
(c). Relatives of KMP:	Anshika Garg (Company Secretary) (till 01 August 2025)
	Akansha Jain (Sister of KMP)
(d). Entities in which Directors/ KMP/Close members of KMP can exercise significant influence:	Ashish Grover (Brother of KMP)
	Manish Grover HUF
	Shuddhi Lifecare Private Limited (formerly Divya Upchar Sansthan)
	Shuddhi Green Charcoal Private Limited
	Dupon Clean Biofuels LLP

Note: The list of related parties disclosed includes only those entities with whom transactions were carried out by the Company during the current year and previous year.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Details of related party transactions during the year ended 31 March 2026 and 31 March 2025:

Particulars	For the year ended 31 March 2026				For the year ended 31 March 2025			
	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
1 Short-term employee benefits								
- Managerial remuneration[^]								
Manish Grover	-	240.00	-	-	-	240.00	-	-
Bhavna Grover	-	180.00	-	-	-	180.00	-	-
Shreya Grover	-	7.00	-	-	-	-	-	-
2 Sitting fees paid to independent director								
Karan Vir Bindra	-	1.56	-	-	-	-	-	-
Priyanka Bansal	-	2.20	-	-	-	-	-	-
Chandan Kumar Kaushal	-	6.50	-	-	-	-	-	-
3 Short-term employee benefits								
- Salary paid[^]								
Nanak Chand	-	31.50	-	-	-	19.85	-	-
Smita Chaturvedi	-	2.00	-	-	-	-	-	-
Akansha Jain	-	-	28.50	-	-	-	21.00	-
Ashish Grover	-	-	19.60	-	-	-	16.50	-
Anshika Garg	-	1.00	-	-	-	3.00	-	-
4 Share based payments to KMP								
Nanak Chand	-	2.40	-	-	-	1.44	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Details of related party transactions during the year ended 31 March 2026 and 31 March 2025: (Contd.)

Particulars	For the year ended 31 March 2026				For the year ended 31 March 2025			
	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
5 Sale of goods								
Shuddhi Lifecare Private Limited	-	-	-	438.46	-	-	-	498.14
6 Sale of fixed assets								
Shuddhi Lifecare Private Limited	-	-	-	0.33	-	-	-	-
Jeena Green Resource Private Limited	128.95	-	-	-	-	-	-	-
7 Rent income								
Shuddhi Lifecare Private Limited	-	-	-	3.72	-	-	-	12.18
8 Rent paid								
Manish Grover	-	3.00	-	-	-	11.00	-	-
Manish Grover (HUF)	-	-	-	6.00	-	-	-	6.00
9 Purchases								
Jeena Green Resources Private Limited	5.78	-	-	-	-	-	-	-
10 Loans recovered								
Shuddhi Lifecare Private Limited	-	-	-	-	-	-	-	212.53
Shuddhi Green Charcoal Private Limited	-	-	-	212.00	-	-	-	-
11 Loans and advances given								
Jeena Green Resources Private Limited	25.00	-	-	-	-	-	-	-
Jeena Sikho International LLC	1,037.40	-	-	-	-	-	-	-

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Details of related party transactions during the year ended 31 March 2026 and 31 March 2025: (Contd.)

Particulars	For the year ended 31 March 2026				For the year ended 31 March 2025			
	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
12 Interest received								
Shuddhi Green Charcoal Private Limited	-	-	-	21.20	-	-	-	-
13 Accrued interest income								
Jeena Green Resources Private Limited	1.55	-	-	-	-	-	-	-
Jeena Sikho International LLC	14.88	-	-	-	-	-	-	-
14 Unsecured loans received/ (repaid) - net								
Manish Grover	-	(1,000.00)	-	-	-	1,000.00	-	-
15 Equity investment								
Jeena Green Resources Private Limited	2.55	-	-	-	-	-	-	-
Jeena Sikho International LLC	25.45	-	-	-	-	-	-	-
16 Royalty income								
Shuddhi Lifecare Private Limited	-	-	-	53.18	-	-	-	-

Note: There is no allowance for receivables in relation to any outstanding balances, and no loss allowance has been recognised during the year in respect of receivables due from related parties.

^ Doesn't include the provision made for gratuity and compensated absences, as they are determined on actuarial basis for the Company as a whole.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(III) Balances outstanding as at 31 March 2026, 31 March 2025 and 01 April 2024:

Particulars	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024					
	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
1	Salary, allowances, bonus and imprest payable/(receivable)											
	Manish Grover	-	38.67	-	-	-	(25.79)	-	-	(129.66)	-	-
	Bhavna Grover	-	6.86	-	-	-	13.64	-	-	(39.23)	-	-
	Akansha Jain	-	-	2.78	-	-	-	-	-	-	-	-
	Nanak Chand	-	2.79	-	-	-	-	-	-	-	-	-
	Smita Chaturvedi	-	0.25	-	-	-	-	-	-	-	-	-
	Shreya Grover	-	1.00	-	-	-	-	-	-	-	-	-
	Ashish Grover	-	-	1.31	-	-	-	-	-	-	-	-
2	Sitting fees											
	Chandan Kumar Kaushal	-	0.45	-	-	-	-	-	-	-	-	-
3	Expenses payable (rent)											
	Manish Grover (HUF)	-	-	-	0.49	-	-	-	2.45	-	-	0.45
4	Trade receivable (refer note 12)											
	Shuddhi Lifecare Private Limited	-	-	-	67.55	-	-	-	6.04	-	-	270.41
5	Loans receivable (refer note 8)											
	Jeena Green Resources Private Limited	25.00	-	-	-	-	-	-	-	-	-	-
	Jeena Sikho International LLC	1,030.78	-	-	-	-	-	-	-	-	-	-
	Shuddhi Lifecare Private Limited	-	-	-	-	-	-	-	-	-	-	204.49
	Shuddhi Green Charcoal Private Limited	-	-	-	-	-	-	-	212.00	-	-	212.00

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(III) Balances outstanding as at 31 March 2026, 31 March 2025 and 01 April 2024: (Contd.)

Particulars	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	Subsidiaries	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	
6 Interest accrued (refer note 8)									
Jeena Green Resources Private Limited	1.55	-	-	-	-	-	-	-	
Jeena Sikho International LLC	14.88	-	-	-	-	-	-	-	
7 Borrowings outstanding (refer note 18)									
Manish Grover	-	-	-	-	-	1,000.00	-	-	
8 Equity investment (refer note 7)									
Jeena Green Resource Private Limited	2.55	-	-	-	-	-	-	-	
Jeena Sikho International LLC	25.45	-	-	-	-	-	-	-	
Dupon Clean Biofuels LLP (fixed plus floating capital)	-	-	-	64.00	-	-	-	64.00	
9 Other receivables (refer note 9)									
Jeena Green Resource Private Limited	152.16	-	-	-	-	-	-	-	

Note: Unless otherwise stated, all related party transactions have been entered on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and settlement occurs in cash.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

40. FAIR VALUE MEASUREMENTS

A) Financial instruments and Risk Management

The accounting classification of each category of financial instruments, their carrying values and fair values are set out below:

Particulars	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost
Financial assets									
Investments*	10,971.78	-	-	355.61	-	-	433.69	-	-
Trade receivables	-	-	6,992.91	-	-	8,496.14	-	-	3,383.02
Cash and cash equivalents	-	-	1,515.62	-	-	2,297.87	-	-	2,531.47
Other bank balances	-	-	9,245.08	-	-	-	-	-	3,669.28
Loans	-	-	1,072.06	-	-	312.00	-	-	812.00
Other financial assets	-	-	3,443.01	-	-	1,068.80	-	-	573.41
Total	10,971.78	-	22,268.68	355.61	-	12,174.81	433.69	-	10,969.18
Borrowings	-	-	42.92	-	-	1,073.72	-	-	54.16
Lease liabilities	-	-	12,684.34	-	-	10,620.07	-	-	5,712.72
Trade payables	-	-	2,162.36	-	-	1,574.80	-	-	817.84
Other financial liabilities	-	-	2,569.31	-	-	1,360.26	-	-	867.37
Total	-	-	17,458.93	-	-	14,628.85	-	-	7,452.09

*Investment in equity instruments of subsidiaries have been accounted under Ind-AS 27 and hence, not presented here.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

i) Fair value hierarchy

a. Financial assets and financial liabilities measured at fair value in the balance sheet are divided into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices in an active market. This includes listed equity instruments, traded debentures and mutual funds that have quoted price/declared NAV. The fair value of all equity instruments (including debentures) which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2: Level 2 hierarchy includes financial instruments that are not traded in an active market (for example, traded bonds/debentures, over the counter derivatives). The fair value in this hierarchy is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data. Financial instruments such as unlisted equity shares, loans are included in this hierarchy.

Financial assets and liabilities measured at fair value – recurring fair value measurements

As at 31 March 2026	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds– measured at fair value through profit and loss				
– Quoted	9,512.24	–	–	9,512.24
Investment in share warrants– unquoted measured at fair value through profit and loss	–	1,395.54	–	1,395.54
Investment in Dupon Clean Biofuel LLP	–	–	64.00	64.00
Total				10,972

As at 31 March 2025	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds– measured at fair value through profit and loss				
– Quoted	291.61	–	–	291.61
Investment in Dupon Clean Biofuel LLP	–	–	64.00	64.00
Total				355.61

As at 01 April 2024	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds– measured at fair value through profit and loss				
– Quoted	369.69	–	–	369.69
Investment in Dupon Clean Biofuel LLP	–	–	64.00	64.00
Total				433.69

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Valuation process and technique used to determine fair value

For level 1 instruments:

The fair value of investments in mutual fund units is based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at each reported balance sheet date. NAV represents the price at which the issuer will issue further units of mutual fund and the price at which issuers will redeem such units from the investors.

For level 2 instruments:

The Company has classified outstanding warrants within Level 2 of the fair value hierarchy, as the valuation is based on observable market inputs other than quoted prices included within Level 1. The fair value of warrants is determined using a Black-Scholes option pricing model valuation technique which incorporates observable inputs. The valuation of warrants is performed at each reporting date to reflect current market conditions, using internally developed valuation models, which are reviewed and validated by management and based on inputs that are primarily observable in the market, with limited use of judgment.

For level 3 instruments:

Investments in LLP (classified under Level 3 of fair value hierarchy) do not carry significant credit risk exposure, as these represent equity/ownership interests rather than contractual financial assets and accordingly, no expected credit loss assessment is required for such investments. Since the LLP is yet to commence operations and no material events have occurred, cost is considered a reasonable approximation of fair value.

b. Fair value of financial assets and liabilities measured at amortised cost:

The carrying amounts of trade receivables, trade payables, cash and cash equivalents, bank balances, loans, other current financial assets and liabilities are considered to be the same as their fair values, due to their short-term nature.

The management believes that the current rate of interest on the loans are in close approximation from market rates applicable to the Company. Therefore, the management estimates that the fair value of these borrowings are approximate to their respective carrying values.

iii) Financial risk management

The Company's activities expose it to market risk, liquidity risk and credit risk. The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

Risk	Exposure arising from	Measurement	Management
Credit risk	Cash and cash equivalents, trade receivables, financial assets measured at amortised cost, loans, other bank balances	Ageing analysis	Bank deposits, diversification of asset base, credit limits and collateral.
Liquidity risk	Borrowings and other liabilities	Rolling cash flow forecasts	Availability of committed credit lines and borrowing facilities
Market risk – interest rate risk	Borrowings at variable rates	Sensitivity analysis	Negotiation of terms that reflect the market factors
Market risk – foreign currency risk	Recognised financial liabilities not denominated in Indian rupee (INR)	Sensitivity analysis	Monitoring of exposure levels at regular intervals
Market risk – price risk	Investment in Mutual funds	Sensitivity analysis	Portfolio Diversification

a. Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Company. The Company is exposed to this risk for various financial instruments, for example by granting loans and receivables to customers, placing deposits, etc. The Company's maximum exposure to credit risk is limited to the carrying amount of following types of financial assets.

- cash and cash equivalents,
- trade receivables,
- loans and advances,
- investments,
- other bank balances, and
- other financial assets

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The maximum exposure to credit risks is represented by the total carrying amount of these financial assets in the balance sheet are as follows:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Loans (current and non current)	1,072.06	312.00	812.00
Investments	10,971.78	355.61	433.69
Trade receivables	6,992.91	8,496.14	3,383.02
Cash and cash equivalents	1,515.62	2,297.87	2,531.47
Other bank balances	9,245.08	-	3,669.28
Other financial assets (current and non current)	3,443.01	1,068.80	573.41

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers, loans.

Credit risk on cash and cash equivalents is limited as the Company generally invests in deposits with banks with high credit ratings assigned by domestic credit rating agencies. While cash and cash equivalents are also subject to the impairment requirements of Ind AS 109, the identified impairment loss was immaterial.

The Company has investments in mutual funds which are measured at fair value through profit and loss (FVTPL), investments in subsidiaries measured at cost and investment in LLP for which cost is considered a reasonable approximation of fair value since the LLP is yet to commence operations and no material events have occurred. The management considers all these investments to have low credit risk.

The maximum exposure to the credit risk at the reporting date is primarily from trade receivables. Trade receivables are unsecured and are derived from revenue earned from customers primarily located in India. For these trade receivables, the Company does not presume significant increase in credit risk when financial assets are past 30 days but monitor the recoverability on case to case basis. The Company does monitor the economic environment in which it operates.

The Company considers the probability of default upon initial recognition of loan and whether there has been a significant

increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares the risk of a default occurring on the loan as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable and supportive forward-looking information. Especially the following indicators are incorporated:

- actual or expected significant adverse changes in business, financial or economic conditions that are expected to cause a significant change to the borrower's ability to meet its obligations.
- actual or expected significant changes in the operating results of the borrower.

Credit risk has always been managed by the Company through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. Credit risk in security deposits (other financial assets) is considered to be low as they form part of other commercial arrangements such as leases, therefore security deposit are impaired only when there is objective evidence of impairment. On account of adoption of Ind AS 109, the Company uses expected credit loss (ECL) model to assess the impairment loss or gain. The Company uses a provision matrix to compute the expected credit loss allowance for trade receivables. The provision matrix takes into account available external and internal credit risk factors such as Company's historical experience for customers.

Refer note 12 for bifurcation of trade receivables.

Changes in the loss allowance in respect of trade receivables	For the year ended 31 March 2026	For the year ended 31 March 2025
Balance at the beginning of the year	1,541.93	890.96
Provision for expected credit losses recognised during the year	598.09	650.97
Provision for expected credit losses utilised during the year	(593.69)	-
Balance at the end of the year	1,546.33	1,541.93

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Expected credit loss for trade receivables under simplified approach

Particulars	As at 31 March 2026						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount- trade receivables (considered good)	489.84	1,578.14	1,192.63	3,611.73	705.15	961.75	8,539.24
Gross carrying amount- trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	4%	7%	11%	42%	74%	-
Expected credit losses (loss allowance provision) – trade receivables	-	64.10	77.85	394.28	298.59	711.50	1,546.33
Carrying amount of trade receivables (net of impairment)	489.84	1,514.04	1,114.78	3,217.45	406.55	250.24	6,992.91

Particulars	As at 31 March 2025						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount- trade receivables (considered good)	69.56	6,609.24	1,294.22	987.84	990.59	86.62	10,038.07
Gross carrying amount- trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	6%	16%	30%	52%	100%	-
Expected credit losses (loss allowance provision) – trade receivables	-	427.83	213.14	295.47	518.88	86.62	1,541.93
Carrying amount of trade receivables (net of impairment)	69.56	6,181.41	1,081.08	692.37	471.71	0.00	8,496.14

Particulars	As at 01 April 2024						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount- trade receivables (considered good)	-	2,227.80	588.64	1,427.71	12.97	16.86	4,273.98
Gross carrying amount- trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	9%	21%	38%	67%	100%	-
Expected credit losses (loss allowance provision) – trade receivables	-	200.61	123.46	541.39	8.65	16.85	890.96
Carrying amount of trade receivables (net of impairment)	-	2,027.19	465.18	886.32	4.32	0.01	3,383.02

b. Liquidity risk

Liquidity risk is the risk that the Company may encounter difficulty in meeting its present and future obligations associated with financial liabilities that are required to be settled by delivering cash or another financial asset. The Company's objective is to, at all times maintain optimum levels of liquidity to meet its cash and collateral obligations. Ultimate responsibility for liquidity risk management rests with the Board of Directors. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Management monitors rolling forecasts of the Company's liquidity position and cash and cash equivalents on the basis of expected cash flows.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Maturities of financial liabilities

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

As at 31 March 2026	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	16.43	26.49	-	42.92
Lease liabilities	4,336.57	9,219.35	2,970.19	16,526.11
Trade payables	2,162.36	-	-	2,162.36
Other financial liabilities	2,569.31	-	-	2,569.31
Total	9,084.67	9,245.84	2,970.19	21,300.70

As at 31 March 2025	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	1,030.40	42.92	-	1,073.32
Lease liabilities	3,147.86	9,094.27	1,321.32	13,563.45
Trade payables	1,574.80	-	-	1,574.80
Other financial liabilities	1,360.26	-	-	1,360.26
Total	7,113.32	9,137.19	1,321.32	17,571.83

As at 01 April 2024	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	22.00	32.16	-	54.16
Lease liabilities	1,495.33	5,448.15	15.83	6,959.31
Trade payables	817.84	-	-	817.84
Other financial liabilities	867.37	-	-	867.37
Total	3,202.54	5,480.31	15.83	8,698.68

c. Market risk – Interest rate risk

The Company's policy is to minimise interest rate cash flow risk exposures on long-term financing. At the reporting periods end, the Company is not exposed to changes in market interest as it does not have any variable interest rate borrowings. The Company's investments in fixed deposits pay fixed interest rates.

d. Market risk – Price risk

The Company's exposure to price risk arises from investments held and classified in the balance sheet at fair value through profit or loss. To manage the price risk arising from investments, the Company diversifies its portfolio of assets.

Sensitivity

For the listed equity securities, an average volatility of 10% has been observed during the year ended 31 March 2026 (31 March 2025: 10%). This volatility figure is considered to be a suitable basis for estimating how profit or loss and equity would have been affected by changes in market risk that were reasonably possible at the reporting date.

The table below summarises the impact of increase/decrease of the index on the Company's profit for the year:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Equity instruments and mutual funds			
Net assets value – increase by 100 basis points	95.12	2.92	3.70
Net assets value – decrease by 100 basis points	(95.12)	(2.92)	(3.70)

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The table below summarises the impact of increase/decrease of the index on the Company's equity for the year:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Statutory tax rate	25.17%	25.17%	25.17%
Equity instruments and mutual funds			
Net assets value – increase by 100 basis points	71.18	2.18	2.77
Net assets value – decrease by 100 basis points	(71.18)	(2.18)	(2.77)

e. Market risk – Foreign exchange risk

The Company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to AED. Foreign exchange risk arises from recognised assets/liabilities denominated in a currency that is not the functional currency (INR) of the Company.

Foreign currency risk exposure

Below is the overall exposure of the Company to foreign currency risk expressed in INR:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Amount in foreign currency (lakhs)	INR (lakhs)	Amount in foreign currency (lakhs)	INR (lakhs)	Amount in foreign currency (lakhs)	INR (lakhs)
Loan given to Jeena Sikho International LLC						
– AED	40.00	1,037.40	–	–	–	–
Interest accrued on loan given to Jeena Sikho International LLC						
– AED	0.58	14.88	–	–	–	–
Total foreign currency risk exposure	40.58	1,052.28	–	–	–	–

The aggregate net foreign exchange loss recognised in statement of profit and loss is ₹ 6.62 lakhs (31 March 2025: Nil, 01 April 2024: Nil).

Sensitivity

Below is the sensitivity of profit or loss and equity to changes in the exchange rates arises mainly from foreign currency denominated financial instruments, assuming no change in other variables:

These percentages have been determined based on the average market volatility in exchange rates in the previous twelve months. Based on the movements in the foreign exchange rates historically and the prevailing market conditions as at the reporting date, the Company's management has concluded that the below mentioned rates used for sensitivity are reasonable benchmarks. The sensitivity analysis is based on the Company's foreign currency financial instruments held at each reporting date.

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
AED sensitivity			
INR/AED – increase by 1% (Previous year: 1%)	(10.52)	–	–
INR/AED – decrease by 1% (Previous year: 1%)	10.52	–	–

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

41. CAPITAL MANAGEMENT POLICIES AND PROCEDURES

The Company's objective for capital management is to maximize shareholder's value, safeguard business continuity and support the growth of the Company. The Company determines the capital requirement based on annual operating plan and other strategic investment plans. The Company aims to manage its capital efficiently so as to safeguard its ability to continue as a going concern and to optimize returns to all its shareholders. The Company's funding requirements are met through internal accruals. The Company is not subject to any externally imposed capital requirements.

The amounts managed as capital by the Company for the reporting periods under review are summarised as follows:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non current borrowings and lease liabilities (refer note 18 and 19)	9,574.75	8,556.00	4,812.94
Current maturities of non current borrowings and lease liabilities (refer note 18 and 19)	3,152.51	2,137.79	953.94
Current borrowings (refer note 18)	-	1,000.00	-
Total borrowings	12,727.26	11,693.79	5,766.88
Less:			
Cash and cash equivalents (refer note 13)	1,515.62	2,297.87	2,531.47
Other bank balances (refer note 14)	9,245.08	-	3,669.28
Net debt (A)	1,966.56	9,395.92	(433.87)
Total equity* (B)	46,740.05	25,634.28	18,592.73
Net debt to equity ratio (A/B)	0.04	0.37	(0.02)

*Equity includes equity share capital and other equity of the Company that are managed as capital.

42. CONTINGENCIES AND COMMITMENTS

Particulars	As at 31 March 2026	As at 31 March 2025
Contingent liabilities		
Claims against the company not acknowledged as debt		
- Indirect tax demand *	507.99	507.99

*Director General of GST Intelligence conducted search on the Company premises (along with other Companies owned by the same promoters) on 13 April 2018. Accordingly, SCN dated 24th August, 2022 was issued for demand of tax along with interest and penalty. Pursuant to the same, on 03 February 2025, the GST department has issued an Order under section 74(9) of the Central Goods and Service Tax Act 2017, imposing a demand for ₹ 507.99 Lakhs (Inclusive of penalty of ₹ 253.99 Lakhs). The GST department has alleged that the Company has been involved in the suppression of turnover and have sold the goods under incorrect classification. The Company is expected to get the favourable opinion from the Hon'ble High Court based on the opinion obtained from the external legal counsel and hence the amount has been disclosed as a contingent liability.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

43. CORPORATE SOCIAL RESPONSIBILITY

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. The areas for CSR activities are promoting health care, promoting education, rural development projects and environment sustainability. A CSR committee has been formed by the Company as per the Act. The funds were primarily utilized throughout the year on these activities which are specified in Schedule VII of the Companies Act, 2013.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
i) Amount required to be spent by the Company during the year	169.88	100.31
ii) Amount of expenditure incurred during the year	170.00	101.64
iii) Shortfall at the end of year	-	-
iv) Reason for shortfall	NA	NA
v) Nature of CSR activities	Eradicating Hunger, Poverty & Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water.	Eradicating Hunger, Poverty & Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water.
vi) Details of related party transactions	N/A	N/A
vii) Provision made with respect to a liability incurred by entering into a contractual obligation	N/A	N/A

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

44. RATIOS TO DISCLOSED AS PER REQUIREMENT OF SCHEDULE III TO THE ACT

Ratio	Numerator	Denominator	As at 31 March 2026	As at 31 March 2025	% change	Remarks
Current Ratio (in times)	Current assets	Current liabilities	3.19	1.84	73.60%	Refer note a. below.
Debt-Equity Ratio (in times)	Total debt (including lease liabilities)	Shareholder's equity	0.27	0.46	(40.31%)	Refer note b. below.

Ratio	Numerator	Denominator	For the year ended 31 March 2026	For the year ended 31 March 2025	% change	Remarks
Debt Service Coverage Ratio (in times)	Earnings available for debt service = Net profit after taxes + non-cash operating expenses + finance cost	Debt service = Interest and lease payments + Principal repayments	6.27	5.32	17.79%	NA
Return on Equity Ratio (in %)	Total comprehensive income	Average shareholder's equity	61.56%	36.14%	70.32%	Refer note c. below.
Trade Receivables Turnover Ratio (in times)	Revenue from operations	Average trade receivable	10.35	7.90	31.02%	Refer note d. below.
Net Capital Turnover Ratio (in times)	Revenue from operations	Working capital (current assets - current liabilities)	3.53	7.61	(53.60%)	Refer note e. below.
Net Profit Ratio (in %)	Total comprehensive income	Revenue from operations	27.80%	17.04%	63.15%	Refer note f. below.
Return on Capital Employed (in %)	Earnings before interest and taxes	Total debt + equity	52.25%	31.67%	64.96%	Refer note g. below.
Return on Investment (in %)	Income generated from invested funds	Actual investment against income	5.39%	28.07%	(-80.81%)	Refer note h. below.
Inventory Turnover Ratio (in times)	Purchase of stock and consumables	Average inventory	6.31	6.25	0.95%	NA
Trade Payable Turnover Ratio (in times)	Purchase of stock and consumables	Average trade payables	5.36	4.90	9.42%	NA

Remarks for variance (in case of variance more than 25%):

- The change in ratio is primarily attributable to the increase in current assets on account of increase of investments and bank deposits due to the profits earned during the year.
- The change is primarily attributable to increase in shareholder's equity on account of profit earned during the year.
- During the current year, net profit after tax has been increased significantly as compared to the previous year resulting in increase in ratio.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- d. The change is primarily attributable to increase in revenue from operations in the current year.
- e. The change in ratio is primarily attributable to the significant increase in the revenue from operations during the year.
- f. The change in ratio is primarily attributable to the increase in the profit and revenue during the current year in comparison to the previous year.
- g. The change in ratio is primarily attributable to increase in earnings before interest and taxes in comparison to the previous year.
- h. The change in ratio is primarily attributable to the increase in the actual investment against income generated from invested funds.

45. BUSINESS COMBINATION

a. Summary of acquisition

On 3rd October, 2024, the Company acquired five branches consisting of Ayurvedic Therapy Centres from another Company named Oregano Life Private Limited as a going concern for a consolidated price of ₹ 6,915.70 lakhs.

The five branches acquired are at locations – Kishan Kunj (Delhi), Mayur Vihar (Delhi), Jothwara (Rajasthan), Alwar (Rajasthan) and Sanganer (Rajasthan).

The aforementioned acquisition is being accounted for as a business combination in accordance with Ind AS 103 — Business Combinations, whereby the identifiable assets acquired and liabilities assumed are recognised at their respective fair values as at the acquisition date. The excess of the consideration transferred over the net fair value of identifiable assets and liabilities, if any, is recognised as goodwill.

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

Particulars	Amount (in lakhs)
Purchase consideration	6,915.70
Purchase consideration (A)	6,915.70
The assets and liabilities recognised as a result of the acquisition are as follows:	
Property, plant and equipment	132.21
Intangible assets with defined life	284.20
Inventory	37.96
Cash and cash equivalents	9.66
Trade receivables	644.43
Loans and advances	48.15
Trade payables	(26.87)
Other financial liabilities	(25.86)
Identifiable net assets acquired (B)	1,103.88
Goodwill (A-B)	5,811.82

Goodwill in acquisition represents residual asset value attributable to unidentified intangible assets acquired by acquirer. It will not be deductible for tax purposes and it will be tested for impairment annually as required by IND AS 36. (Refer Note 5 to these financial statements for impairment assessment).

b. Revenue and profit contribution

The acquired business contributed revenue of ₹ 802.76 lakhs and profit of ₹ 306.61 lakhs to the Company for the year ended 31 March 2025.

If the acquisitions had taken place on 1 April 2024, standalone revenue from operations and profit for the year ended 31 March 2025 would have been ₹ 48,108.47 lakhs and ₹ 11,215.72 lakhs respectively.

46. FIRST TIME ADOPTION OF IND AS

These are the Company's first financial statements prepared in accordance with Ind AS. For the year ended 31 March 2025, the Company prepared its financial statements in accordance with accounting standards referred to in paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP) notified under section 133 of the Companies Act, 2013.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

249

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

(All amounts are in INR Lakhs except otherwise stated)

The accounting policies set out in note 2 have been applied in preparing the financial statements for the year ended 31 March 2026, the comparative information presented in these financial statements for the year ended 31 March 2025 and in the preparation of opening IND AS balance sheet at 01 April 2024 (the Company's date of transition).

In preparing its IND AS balance sheet as at 01 April 2024 and in presenting the comparative information for the year ended 31 March 2025, the Company has adjusted its amounts reported previously in the financial statements prepared in accordance with previous GAAP.

Accordingly, the Company prepared first Ind AS financial statements which comply with Ind AS applicable for period ending on 31 March 2026, together with the comparative period data as at and for the year ended 31 March 2025, with a Ind AS transition date of 1 April 2024. This note explains the principal adjustments made by the Company in restating its financial statements prepared in accordance with previous GAAP and an explanation of how the transition from previous GAAP to Ind AS has affected the Company's financial position, financial performance and cash flows is set out in the following tables and notes.

A. Ind AS optional exemptions

1. Deemed cost for property, plant and equipment and intangible assets

Ind AS 101 permits a first-time adopter to elect to continue with the carrying value for all of its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the Previous GAAP and use that as its deemed cost as at the date of transition after making necessary adjustments for de-commissioning liabilities. This exemption can also be used for intangible assets covered by Ind AS 38 Intangible Assets. Accordingly, the Company has elected to measure all of its property, plant and equipment and intangible assets at their Previous GAAP carrying value.

2. Impairment of financial assets

At the date of transition to Ind AS, determining whether there has been a significant increase in credit risk since the initial recognition of a financial instrument would require undue cost or effort, the Company has recognised a loss allowance at an amount equal to lifetime expected credit losses at each reporting date until that financial instrument is derecognised.

3. Leases

The Company has elected to measure the right of use assets at the date of transition an amount using modified retrospective approach, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the Balance Sheet immediately before the date of transition to Ind AS. Further, the following expedients were used on transition to Ind AS:

- the use of a single discount rate to a portfolio of leases with reasonably similar characteristics.

- the accounting for operating leases with a remaining lease term of less than 12 months as on the transition date as short-term leases.
- the exclusion of initial direct costs for the measurement of the right of use asset at the date of initial application.
- use of hindsight, such as in determining the lease term as the contract contains the options to extend and terminate the lease.

B. Ind AS mandatory exceptions

1. Estimates

An entity's estimates in accordance with Ind ASs at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with Previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Ind AS estimates as at 1 April 2024 are consistent with the estimates as at the same date made in conformity with Previous GAAP. The Company made estimates for impairment of financial assets based on expected credit loss model in accordance with Ind AS at the date of transition as these were not required under Previous GAAP.

2. Classification and measurement of financial assets and liabilities

The classification and measurement of financial assets and financial liabilities will be made considering whether the conditions as per Ind AS 109, "Financial Instruments", are met based on facts and circumstances existing at the date of transition.

Financial assets can be measured using effective interest method by assessing its contractual cash flow characteristics only on the basis of facts and circumstances existing at the date of transition and if it is impracticable to assess the elements of modified time value of money, i.e., the use of effective interest method, fair value of financial asset at the date of transition shall be the new carrying amount of that asset. The measurement exemption applies for financial liabilities as well.

Applying a requirement is impracticable when the entity cannot apply it after making every reasonable effort to do so. It is impracticable to apply the:

- (a) The effects of the retrospective application or retrospective restatement are not determinable;
- (b) The retrospective application or restatement requires assumptions about what management's intent would have been in that period.

The retrospective application or retrospective restatement requires significant estimates of amounts and it is impossible to distinguish objectively information about those estimates that existed at that time.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(i) Reconciliation of the assets and liabilities presented in the balance sheet prepared as per Previous IGAAP and as per Ind AS is as follows:

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	As at 31 March 2025			As at 01 April 2024				
		Previous IGAAP (Audited)	IGAAP Reclassification [*]	Ind AS Adjustments	Ind AS	Previous IGAAP (Audited)	IGAAP Reclassification [*]	Ind AS Adjustments	Ind AS
ASSETS									
1) Non-current assets									
Property, plant and equipment		9,234.42	-	-	9,234.42	6,682.52	-	-	6,682.52
Capital work-in-progress		1,123.31	-	-	1,123.31	349.84	-	-	349.84
Right-of-use-assets	(e)	-	-	10,026.65	10,026.65	-	-	5,809.27	5,809.27
Goodwill	(a)	6,028.18	-	(216.36)	5,811.82	-	-	-	-
Other Intangible assets	(a)	2.67	-	229.98	232.65	2.13	-	(0.00)	2.13
Intangible assets under development		224.28	-	-	224.28	43.68	-	-	43.68
Financial assets									
(i) Investments		64.00	-	-	64.00	64.00	-	-	64.00
(ii) Loans		-	-	-	-	-	-	-	-
(iii) Other financial assets	(e)(i)	-	282.44	717.39	999.83	-	100.08	380.15	480.23
Deferred tax assets (Net)	(g)	0.63	-	583.56	584.19	-	-	172.16	172.16
Other non-current assets	(e)(i)	937.11	95.90	(937.11)	95.90	476.70	-	(476.70)	-
Total non-current Assets		17,614.60	378.34	10,404.11	28,397.05	7,618.87	100.08	5,884.88	13,603.83
2) Current Assets									
Inventories		1,154.58	-	-	1,154.58	718.87	-	-	718.87
Financial assets									
(i) Investments	(d)	295.00	-	(3.39)	291.61	350.00	-	19.69	369.69
(ii) Trade receivables	(f)	9,763.04	69.56	(1,336.46)	8,496.14	4,118.51	-	(735.49)	3,383.02
(iii) Cash and cash equivalents	(i)	2,596.00	(282.44)	(15.69)	2,297.87	6,200.74	-	(3,669.27)	2,531.47
(iv) Other bank balances	(i)	-	-	-	-	-	-	3,669.28	3,669.28
(v) Loans	(i)	963.64	-	(651.64)	312.00	2,737.74	-	(1,925.74)	812.00
(vi) Other financial assets	(i)	-	-	68.97	68.97	-	-	93.18	93.18
Other current assets	(i)	443.70	(165.46)	598.38	876.62	308.13	(100.08)	1,832.56	2,040.61
Total current assets		15,215.96	(378.34)	(1,339.83)	13,497.79	14,433.99	(100.08)	(715.79)	13,618.12
Total		32,830.56	-	9,064.28	41,894.84	22,052.86	-	5,169.09	27,221.95

13,603.83

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(I) Reconciliation of the assets and liabilities presented in the balance sheet prepared as per Previous IGAAP and as per Ind AS is as follows: (Contd.)
(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	As at 31 March 2025			As at 01 April 2024				
		Previous IGAAP (Audited)	IGAAP Reclassification*	Ind AS Adjustments	Ind AS	Previous IGAAP (Audited)	IGAAP Reclassification*	Ind AS Adjustments	Ind AS
EQUITY AND LIABILITIES									
Equity									
a) Equity share capital		2,486.01	-	-	2,486.01	2,486.01	-	-	2,486.01
b) Other equity	II	24,815.52	-	(1,667.25)	23,148.27	16,738.78	-	(632.06)	16,106.72
Total Equity		27,301.53	-	(1,667.25)	25,634.28	19,224.79	-	(632.06)	18,592.73
Liabilities									
1) Non-current liabilities									
Financial liabilities									
(i) Borrowings		42.92	-	-	42.92	32.16	-	-	32.16
(ii) Lease liabilities	(e)	-	-	8,513.08	8,513.08	-	-	4,780.78	4,780.78
(iii) Other financial liabilities		-	-	-	-	-	-	-	-
Provisions	(b)	259.23	-	110.08	369.31	14.95	-	243.00	257.95
Deferred tax liabilities (net)		-	-	-	-	40.42	-	(40.42)	-
Total Non Current Liabilities		302.15	-	8,623.16	8,925.31	87.53	-	4,983.36	5,070.89
2) Current liabilities									
Financial liabilities									
(i) Borrowings		1,030.40	-	0.40	1,030.80	21.79	-	0.21	22.00
(ii) Lease liabilities	(e)	-	-	2,106.99	2,106.99	-	-	931.94	931.94
(iii) Trade payables									
- Total outstanding dues of micro enterprises and small enterprises		238.29	-	-	238.29	35.48	-	(0.03)	35.45
- Total outstanding dues of creditors other than micro enterprises and small enterprises		711.28	625.23	-	1,336.51	410.30	372.08	-	782.39
(iv) Other financial liabilities	(i)	-	21.69	1,338.57	1,360.26	-	(372.08)	1,239.46	867.37
Other current liabilities	(i)	3,082.34	(646.92)	(1,338.96)	1,096.46	1876.30	-	(1,239.65)	636.65
Provisions	(b)	164.57	-	(135.91)	28.66	396.67	-	(380.17)	16.50
Current tax liabilities	(i)	-	-	137.28	137.28	-	-	266.03	266.03
Total Current Liabilities		5,226.88	-	2,108.37	7,335.25	2,740.54	-	817.79	3,558.33
Total		32,830.56	-	9,064.28	41,894.84	22,052.86	-	5,169.09	27,221.95

^{*}The previous IGAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Reconciliation of total equity as at 31 March 2025 and 01 April 2024:

Particulars	Notes	As at 31 March 2025	As at 01 April 2024
Total equity (shareholder's funds) as per previous Indian GAAP (A)		27,301.53	19,224.79
Adjustments:			
Impact of expected credit loss recognised on trade receivables	(f)	(600.97)	(735.49)
Impact due to fair valuation of current investments	(d)	(23.07)	19.69
Impact of adjustment related to provisions for employee benefits	(b)	17.39	(128.85)
Impact due to recognition of lease liability and right-of-use assets	(e)	(813.14)	-
Impact of share based payment expense recognised on the basis of fair value of option	(c)	(45.14)	-
Impact of remeasurement of employee stock options	(c)	45.14	-
Impact due to depreciation on assets acquired under business acquisition	(a)	13.62	-
Impact of deferred tax (net) on account of the above adjustments	(g)	370.98	212.59
Total		(1,035.19)	(632.06)
Net impact brought forward from opening balance sheet		(632.06)	-
Total adjustments (B)		(1,667.25)	(632.06)
Total equity as per Ind AS (A+B)		25,634.28	18,592.73

(III) Reconciliation of Statement of Profit and Loss for the year ended 31 March 2025

Particulars	Notes	Previous IGAAP (Audited)*	Ind AS Adjustments	IND AS (Restated)
INCOME				
Revenue from operations		46,907.19	-	46,907.19
Other income		640.89	32.65	673.54
Total Income		47,548.08	32.65	47,580.73
EXPENSES				
Purchases of stock-in-trade		3,561.90	2,296.09	5,857.99
Change in inventories of stock-in-trade		(435.71)	-	(435.71)
Employee benefits expense	(b),(c)	10,048.87	25.41	10,074.28
Finance costs	(a),(e)	50.60	1,014.89	1,065.49
Depreciation and amortisation expense	(a),(e)	870.80	2,039.74	2,910.54
Other expenses	(d),(e),(f)	21,244.91	(3,894.53)	17,350.38
Total Expenses		35,341.37	1,481.60	36,822.97
Profit before tax		12,206.71	(1,448.95)	10,757.76
Tax expense:				
Current tax		3,153.33	-	3,153.33
Taxation for earlier years		21.54	-	21.54
Deferred tax	(g)	(41.05)	(370.39)	(411.44)
Total tax expense		3,133.82	(370.39)	2,763.43

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(III) Reconciliation of Statement of Profit and Loss for the year ended 31 March 2025 (Contd.)

Particulars	Notes	Previous IGAAP (Audited)*	Ind AS Adjustments	IND AS (Restated)
Profit for the year		9,072.89	(1,078.56)	7,994.33
Other comprehensive income				
Items that will not be reclassified to profit or loss				
- Re-measurements of defined benefit plans	(b)	-	(2.34)	(2.34)
- Income Tax related to items that will not be reclassified to profit or loss	(g)	-	0.59	0.59
Net other comprehensive (loss) not to be reclassified to profit or loss		-	(1.75)	(1.75)
Total comprehensive income for the year		9,072.89	(1,080.31)	7,992.58

*The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

(IV) Reconciliation of total comprehensive income for the year ended 31 March 2025:

Particulars	Notes	31 March 2025
Net profit after tax as per previous Indian GAAP (Audited)	-	9,072.89
Adjustments:		
Impact of expected credit loss recognised on trade receivables	(f)	(600.97)
Impact of adjustment related to provisions for employee benefits	(b)	19.75
Impact of share based payment expense recognised on the basis of fair value of option	(c)	(45.14)
Impact due to fair valuation of current investments	(d)	(23.07)
Impact due to recognition of lease liability and right-of-use assets	(e)	(813.14)
	(a)	13.62
Impact of deferred tax (net) on account of the above adjustments	(g)	370.39
Net profit after tax as per Ind AS	-	7,994.33
Other comprehensive loss	(b)	(1.75)
Total comprehensive income as per Ind AS	-	7,992.58

Notes

- (a) Under previous IGAAP, goodwill was amortized over the period in which the economic benefit from the acquired business is expected to flow to the Company and intangible assets were amortized based on the assessed useful life. The Company has reassessed the useful life of goodwill and determined that it has an indefinite useful life. Goodwill and intangible assets with indefinite life are not amortized under Ind AS. Instead, goodwill is subject to an annual impairment test and the assumption of indefinite life of intangible assets reviewed annually. Accordingly the amortization charge under previous IGAAP has been adjusted.

Goodwill has been recomputed during the year based on the purchase price allocation (PPA) as per Ind AS. Under Ind AS, goodwill is determined based on purchase price allocation, which involves allocating the consideration paid to the identifiable assets and liabilities at fair value. Accordingly, goodwill has been recomputed during the transition.

- (b) Provision for Gratuity is recomputed based on actuarial valuation under Ind AS, resulting in adjustment to employee benefit obligations. The actuarial gain/loss have been transferred to Other Comprehensive Income (OCI) net of tax instead of profit and loss as prescribed by the IND AS.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- (c) Employee stock expenses has been recorded based on the fair value of the options at grant date under Ind AS.
- (d) The Company has valued its financial assets (current investment) at fair value. The impact for change in fair value as on date of transition (i.e., 01 April 2024), is recognized in opening equity and changes thereafter are recognized in the Statement of Profit and Loss or OCI based on the classification of same.
- (e) Under previous IGAAP, rent payments were charged to the Statement of Profit and Loss. Under Ind AS, for long-term and high-value leases, a Right-of-Use (ROU) asset and corresponding lease liability are recognized. The ROU asset is amortized over the lease term, and interest on the lease liability is recorded in the Statement of Profit and Loss, replacing the earlier rent expense.
- (f) Expected credit losses are recognized for all financial assets subsequent to initial recognition other than financial assets in FVTPL category. The impairment losses and reversals are recognised in Statement of Profit and Loss.
- (g) The impact of transition adjustment together with Ind-AS mandate of using balance sheet approach for computation of deferred taxes has resulted in charge to the reserves, on the date of transition, with consequential impact to the Profit and Loss Account for the subsequent periods.
- (h) Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

The transition from previous GAAP to Ind AS has not made a material impact on the statement of cash flows.

47. ADDITIONAL INFORMATION NOT DISCLOSED ELSEWHERE IN THE FINANCIALS STATEMENTS

(a) Borrowing secured against current assets

The Company does not have borrowings from financial institutions on the basis of security of current assets.

(b) Benami Property

The Company does not have any benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(c) Willful defaulter

The Company is not declared a willful defaulter by any bank or financial institution or any other lender.

(d) Relationship with struck off companies

The Company has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

(e) Compliance with number of layers of companies

The Company has complied with the number of layers prescribed under section 2(87) of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017.

(f) Compliance with approved scheme(s) of arrangements

The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial years.

(g) Registration of charges or satisfaction with Registrar of Companies

The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(h) Details of funds advanced or loaned or invested in intermediaries and further invested or loaned by intermediaries:

- (i) The Company has not advanced or loaned or invested funds to any other persons or entities (other than the transactions as disclosed below), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

During the year ended 31 March 2026

Intermediary in which amounts were invested by the Company	Relation	Date	Amount (AED)	Amount (INR)	Nature of transaction
Jeena Sikho International LLC	Wholly owned subsidiary	January 28, 2026	40,00,000	10,37,40,000	Loans given

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Parties to which such funds are further invested by Jeena Sikho International LLC

Name of the party	Nature of transaction	Date	Amount (AED)
Arun Paul (Back to Roots Ayurveda by Dr. Shyam LLC)			4,50,000
Jomol Mariam (Back to Roots Ayurveda by Dr. Shyam LLC)	Advance for acquisition of 51% stake	January 29, 2026	4,50,000
Shyam Vishwanathan (Back to Roots Ayurveda by Dr. Shyam LLC)			1,80,000
Manu Abraham (Back to Roots Ayurveda by Dr. Shyam LLC)			4,50,000
Back to Roots Ayurveda by Dr. Shyam LLC	Advance for Investment to set up new clinics	January 09, 2026	90,000
		February 05, 2026	4,21,088
		February 12, 2026	15,98,883

Complete details of intermediaries and ultimate beneficiaries

Name of the entity	Registered address	Relationship with the Company
Jeena Sikho International LLC	Sharjah Media City, UAE	Wholly owned subsidiary
Back to Roots Ayurveda by Dr. Shyam LLC	Abu Dhabi, UAE	Prospective investee of wholly owned subsidiary
Arun Paul (Back to Roots Ayurveda by Dr. Shyam LLC)	Abu Dhabi, UAE	Partner in prospective investee of wholly owned subsidiary
Jomol Mariam (Back to Roots Ayurveda by Dr. Shyam LLC)	Abu Dhabi, UAE	Partner in prospective investee of wholly owned subsidiary
Shyam Vishwanathan (Back to Roots Ayurveda by Dr. Shyam LLC)	Abu Dhabi, UAE	Partner in prospective investee of wholly owned subsidiary
Manu Abraham (Back to Roots Ayurveda by Dr. Shyam LLC)	Abu Dhabi, UAE	Partner in prospective investee of wholly owned subsidiary

(ii) The Company has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

(i) Undisclosed income

The Company has not entered into any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search

or survey or any other relevant provisions of the Income Tax Act, 1961.

(j) Details of Crypto Currency or Virtual Currency

The Company has not traded or invested in Crypto currency or Virtual Currency during the current or previous financial years.

(k) Valuation of Property, Plant and Equipment and intangible asset

The Company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous years.

(l) The borrowings obtained by the Company from banks and financial institutions have been applied for the purposes for which such loans were taken.

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

48. The Ministry of Corporate Affairs (MCA) has prescribed a requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules, 2021 requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled. The Company has used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software except for instances mentioned below:

Nature of exception noted	Details of exception
Instances of accounting software for maintaining books of account which did not have a feature of recording audit trail (edit log) facility	i. The accounting software used for maintenance of certain inventory and revenue records of the Company did not have a feature of recording audit trail (edit log) facility during the period 1 April 2025 to 15 January 2026 at both application level and database level. Effective 16 January the Company migrated to another accounting software for maintenance of certain inventory and revenue records. The audit trail feature of the said accounting software was not enabled at the database level to log any direct data changes.
Instances of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated throughout the year for all relevant transactions recorded in the software	ii. The audit trail feature was not enabled at the database level for an accounting software, to log any direct data changes, used for maintenance of certain revenue and inventory records by the Company.
Instances of accounting software maintained by a third party where we are unable to comment on the audit trail feature at database level	iii. The accounting software used for maintenance of certain revenue records is operated by a third-party software service provider. In the absence of any information on existence of audit trail (edit logs) for any direct changes made at the database level in the 'Independent Service Auditor's Assurance Report' ('Type 2 report' issued in accordance with ISAE 3402, Assurance Reports on Controls at a Service Organization), we are unable to assess whether audit trail feature with respect to the database of the said software was enabled and operated throughout the year.
Instance of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated effectively during the reporting period	iv. The accounting software used for maintenance of accounting records of certain branches of the Company did not capture the details of who made the changes for certain period during the year, as mentioned below: - Branch 1 – 1 April 2025 to 31 October 2025 - Branch 2 – 1 April 2025 to 21 April 2025 - Branch 3 – 2 April 2025 to 31 March 2026* - Branch 4 – 8 January 2026 to 31 March 2026* - Branch 5 – 7 February 2026 to 31 March 2026* - Branch 6 – 18 March 2026 to 31 March 2026* - Branch 7 – 31 March 2026* *Branches incorporated during the year

Notes to the Standalone Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

49. The Management has assessed the subsequent events to the year end and is of the view that there no material events which require adjustment or disclosure in the standalone financial statements.

For Walker Chandiok & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410

Place: Zirakpur, Punjab
Date: 30 May 2026

Manish Grover
Managing Director
DIN: 07557886

Nanak Chand
Chief Financial Officer

Place: Zirakpur, Punjab
Date: 30 May 2026

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Bhavna Grover
Whole Time Director
DIN: 07557913

Smita Chaturvedi
Company Secretary
M.No.: A48303

Independent Auditor’s Report

To the Members of Jeena Sikho Lifecare Limited
Report on the Audit of the Consolidated Financial Statements

OPINION

1. We have audited the accompanying consolidated financial statements of Jeena Sikho Lifecare Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), as listed in Annexure 1, which comprise the Consolidated Balance Sheet as at 31 March 2026, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity for the year then ended, and notes to the consolidated financial statements, including material accounting policy information and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate financial statements and on the other financial information of the subsidiaries, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India of the consolidated state of affairs of the Group, as at 31 March 2026, and their consolidated profit (including other comprehensive income), consolidated cash flows and the consolidated changes in equity for the year ended on that date.

BASIS FOR OPINION

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 15 of the Other Matters section below, is sufficient and appropriate to provide a basis for our unmodified opinion.

KEY AUDIT MATTERS

4. Key audit matters are those matters that, in our professional judgment and based on the consideration of the reports of the other auditors on separate financial statements of the subsidiaries, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

5. We have determined the matters described below to be the key audit matter to be communicated in our audit report.

Key audit matters	How our audit addressed the key audit matter
Revenue recognition: Refer Note 2(l) and Note 25 to the accompanying consolidated financial statements for the material accounting policy information on revenue recognition and details of revenue recognised during the year. The Holding Company earns revenue primarily from sale of ayurvedic products/medicines and providing ayurvedic healthcare services, which are sold/offered through a wide network of hospitals, clinics, day-care centers, e-commerce platforms, Holding Company's own website, dealer/franchisee networks etc. across India. The Group recognises revenue from contracts with customers in accordance with Ind AS 115 – Revenue from Contracts with Customers and requires management to make certain judgements with respect to: - Identification of distinct/bundled performance obligations;	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of the process for revenue recognition and evaluated the appropriateness of accounting policy on revenue recognition in accordance with Ind AS 115. - Evaluated the design and tested the operating effectiveness of internal financial controls, around revenue recognition. - Selected samples of customer contracts/consent forms/franchise agreements as entered in current year and evaluated management's assessment with respect to identification of distinct/bundled performance obligations in such contracts, timing of transfer of control of goods/bundled services and evaluation of principal versus agent relationship as per the requirements of Ind AS 115.

5. We have determined the matters described below to be the key audit matter to be communicated in our audit report. (Contd.)

Key audit matters	How our audit addressed the key audit matter
- Assessment of the timing of transfer of control of goods/bundled services depending on the specific terms and conditions of the customer contracts; - Evaluation of principal versus agent relationship. Revenue serves as a key performance indicator for the Group and, in accordance with the requirements of the Standards on Auditing, revenue recognition is determined to be an area involving significant risk which requires significant auditor attention. Considering the significance of amount involved, volume of transactions, multiplicity of sales/service channels which also involves sales made through cash-and-carry model and significant management judgements involved, revenue recognition has been identified as a key audit matter in the current year audit.	- Performed substantive testing, on a sample basis, on revenue transactions recorded during the year and those recorded during a specific period before and after year-end, by inspecting relevant supporting documents such as invoices, patient files, customer contracts, proof of delivery, to ensure transactions are recorded for the correct amount and in the correct period. Additionally, on a sample basis, traced sales recorded to related collection reports, cash deposit documents and bank statements. - Conducted analytical procedures, such as variance analysis on revenue, to identify any unusual trends or items. - Evaluated the appropriateness and adequacy of related presentation and disclosures made in the consolidated financial statements in accordance with applicable Ind AS.
Impairment assessment of goodwill: Refer Note 2(h), 5 and Note 45 to the accompanying consolidated financial statements for the material accounting policy information on impairment assessment of goodwill and related disclosures. As at 31 March 2026, the Group has a significant goodwill balance of ₹ 5,811.82 lakhs, arising from acquisition of ayurveda business from Oregano Life Private Limited in previous year. The Holding Company has performed an annual impairment test of goodwill as required under Ind AS 36, Impairment of Assets ('Ind AS 36') by determining the recoverable value of Cash Generating Unit (CGU) i.e., Ayurvedic Healthcare Services segment, to which such goodwill is allocated, by calculating the value-in-use (determined using discounted cash flow ('DCF') model) and comparing it with the carrying amount of CGU, as on the reporting date. The impairment assessment involves significant management judgments and estimates, particularly in: - Identifying the appropriate CGUs or group of CGUs to whom goodwill is allocated; - Forecasting future cash flows of CGU; - Determining key assumptions such as revenue and profit growth rates, operating margins, terminal growth rates of the CGU to which it relates and discount rates; and - Estimating future capital expenditure. Considering the goodwill balance is material to the consolidated financial statements and significant management judgements and estimates are involved in identification of CGU and impairment testing, impairment assessment of goodwill has been identified as a key audit matter for the current year audit.	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of management's process for annual impairment assessment, and assessed the appropriateness of the Group's accounting policy for impairment in accordance with Ind AS 36; - Evaluated the design and tested the operating effectiveness of internal financial controls implemented by the management over impairment assessment of goodwill and identification of the CGUs. - Evaluated management's assessment of identification of CGU i.e., Ayurvedic Healthcare Services segment to which goodwill is allocated, basis understanding of expected synergies arising from such business acquisition and level at which such goodwill is monitored for internal management purposes. - Obtained cash flow projections as considering in DCF model and assessed if these are in line with projections as approved by the Board of Directors of the Holding Company. - Assessed the professional competence, objectivity, and capabilities of the valuation specialist engaged by the management. - Assessed the reasonableness of key assumptions used in the cash flow projections such as revenue and profit growth rates, operating margins and terminal growth rates based on our understanding of historical trends, current market conditions, future plans of the Holding Company and also compared these assumptions with industry and economic forecasts. Also assessed the reasonableness of discount rate as considered by the management and performed sensitivity analysis on key assumptions.

5. We have determined the matters described below to be the key audit matter to be communicated in our audit report. (Contd.)

Key audit matters	How our audit addressed the key audit matter
	Involved auditor's valuation specialists to assist in evaluating the appropriateness of the valuation methodology and the reasonableness of key assumptions used by management's expert while computing the recoverable amount. Evaluated the appropriateness and adequacy of related disclosures made in the consolidated financial statements in accordance with applicable Ind AS.
Transition to Ind AS accounting framework: Refer Note 2(a) and Note 47 to the accompanying consolidated financial statements for disclosures included in respect to transition to Ind AS. The Holding Company's equity shares were migrated from the SME Emerge platform to the Main Board of both the National Stock Exchange of India Limited and BSE Limited on 11 August 2025. Accordingly, pursuant to the requirements of Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, the Group has prepared its financial statements for the year ended 31 March 2026 in accordance with Ind AS with 1 April 2024 being the transition date. This change in the financial reporting framework required an end-to-end evaluation of the potential impact on each item as included in the consolidated financial statements including presentation thereof, additional notes and disclosures as per the requirements of Ind AS including specific first-time adoption related disclosures contained under Ind-AS 101, First-time Adoption of Indian Accounting Standards and required significant audit efforts. Further, such evaluation also required management to exercise significant judgments in selecting and applying appropriate accounting policies to various transactions and balances, including election of available options for transitioning to Ind AS for the transition date being 01 April 2024. The areas having a significant impact on account of transition involved the following standards, amongst others: - Ind AS 109, Financial Instruments - Ind AS 116, Leases Considering the significance of the impact of transition to Ind AS in current year's financial statements and the audit efforts required to test these transition adjustments, this matter has been identified as a key audit matter for the current year audit.	Our audit procedures included, but were not limited to, the following: - Obtained an understanding of management's processes and controls for identification and assessment of impact on the consolidated financial statements due to transition to Ind-AS. - Evaluated the appropriateness of accounting policies selected by the management on transition, considering the requirements of the applicable Ind AS. - Reviewed the implementation of exemptions availed and options elected by the Group for transitioning account balances as at 01 April 2024, in accordance with Ind-AS 101. - Assessed the appropriateness of impact of Ind AS transition and consequent reconciliations from previous GAAP to Ind AS framework as provided in Note 47 pursuant to the requirements of Ind AS 101. - Assessed the appropriateness of the adjustments made to the comparative financial information as at and for the year-ended 31 March 2025, which were previously prepared in IGAAP, to comply with Ind AS. - Evaluated the adequacy and appropriateness of disclosures in consolidated financial statements, arising on adoption of Ind AS, in accordance with the requirements of applicable Ind-AS.

INFORMATION OTHER THAN THE CONSOLIDATED FINANCIAL STATEMENTS AND AUDITOR'S REPORT THEREON

6. The Holding Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the consolidated financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

7. The accompanying consolidated financial statements have been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India. The Holding Company's Board of Directors are also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of consolidated Ind AS financial statements. Further, in terms of the provisions of the Act the respective Board of Directors of the companies included in the Group covered under the Act are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and

presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the consolidated financial statements by the Board of Directors of the Holding Company, as aforesaid.

8. In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
9. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

10. Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
11. As part of an audit in accordance with Standards on Auditing specified under section 143(10) of the Act we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation; and
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group, to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated financial statements, of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

12. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

13. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

14. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

OTHER MATTER

15. We did not audit the financial statements of two subsidiaries, whose financial statements reflects total assets of ₹ 1212.69 lakhs as at 31 March 2026, total revenues of ₹ 7.53 lakhs and net cash inflows amounting to ₹ 121.68 lakhs for the year ended on that date, as considered in the consolidated financial statements. These financial statements have been audited by other auditors whose reports have been furnished to us by the Holding Company's management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of section 143 of the Act in so far as it relates to the aforesaid subsidiaries, are based solely on the reports of the other auditors.

Our opinion above on the consolidated financial statements, and our report on other legal and regulatory requirements below, are not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the other auditors.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

16. As required by section 197(16) of the Act, based on our audit and on the consideration of the reports of the other auditors, referred to in paragraph 15 above, on separate financial statements of the subsidiaries, we report that the Holding Company and its subsidiary, Jeena Green Resources Private Limited, incorporated in India whose financial statements have been audited under the Act have paid remuneration to their respective directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.

17. As required by clause (xxi) of paragraph 3 of Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act, based on the consideration of the Order reports issued till date by us and by the respective other auditor, of companies included in the consolidated financial statements for the year ended 31 March 2026 and covered under the Act, we report that:

Following are the qualifications/adverse remarks reported by us and the other auditor in the Order reports of the companies included in the consolidated financial statements for the year ended 31 March 2026 for which such Order reports have been issued till date and made available to us:

Sr. No.	Name	CIN	Holding Company/ subsidiary/ Associate/Joint Venture	Clause number of the CARO report which is qualified or adverse
1	Jeena Sikho Lifecare Limited	L52601PB2017PLCO46545	Holding Company	Clause vii(a) and vii(b)
2	Jeena Green Resources Private Limited	U20129PB2025PTCO63837	Subsidiary	Clause vii(a)

18. As required by section 143(3) of the Act, based on our audit and on the consideration of the reports of the other auditors on separate financial statements and other financial information of the subsidiary incorporated in India whose financial statements have been audited under the Act, we report, to the extent applicable, that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;
- b) Except for the matters stated in paragraph 18(h) (vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors;
- c) The consolidated financial statements dealt with by this report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
- d) In our opinion, the aforesaid consolidated financial statements comply with Ind AS specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015;
- e) On the basis of the written representations received from the directors of the Holding Company and taken on record by the Board of Directors of the Holding Company, and the report of the statutory auditor of its subsidiary covered under the Act, none of the directors of the Holding Company and its subsidiary are disqualified as on 31 March 2026 from being appointed as a director in terms of section 164(2) of the Act.
- f) The qualification relating to the maintenance of accounts and other matters connected therewith with respect to the consolidated financial statements are as stated in paragraph 18(b) above on reporting under section 143(3)(b) of the Act and paragraph 18(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);
- g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, and its subsidiary covered under the Act, and the operating effectiveness of such controls, refer to our separate report in 'Annexure II' wherein we have expressed an unmodified opinion; and
- h) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditors on separate financial statements and other financial information of the subsidiary incorporated in India whose financial statements have been audited under the Act:
 - i. The consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group, as detailed in Note 42 to the consolidated financial statements;
 - ii. The Holding Company and its subsidiaries did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2026;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company during the year ended 31 March 2026;
 - iv. a. The respective managements of the Holding Company and its subsidiary incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditor of such subsidiary respectively that, to the best of their knowledge and belief as disclosed in note 48(g)(i) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Holding Company or its subsidiary to or in any persons or entities, including foreign entities ('the intermediaries'),

with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company, or any such subsidiary ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;

- b. The respective managements of the Holding Company and its subsidiary incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditor of such subsidiary respectively that, to the best of their knowledge and belief, as disclosed in the note 48(g)(ii) to the accompanying consolidated financial statements, no funds have been received by the Holding Company or its subsidiary from any persons or entities, including foreign entities ('the Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Holding Company, or any such subsidiary shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party

('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

- c. Based on such audit procedures performed by us and that performed by the auditor of the subsidiary as considered reasonable and appropriate in the circumstances, nothing has come to our or other auditor's notice that has caused us or the other auditors to believe that the management representations under sub-clauses (a) and (b) above contain any material misstatement.

- v. The final dividend paid by the Holding Company during the year ended 31 March 2026 in respect of such dividend declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

As stated in note 16 to the accompanying consolidated financial statements, the Board of Directors of the Holding Company have proposed final dividend for the year ended 31 March 2026 which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend.

- vi. As stated in Note 49 to the consolidated financial statements and based on our examination which included test checks and that performed by the respective auditor of the subsidiary, except for instances mentioned below, the Holding Company and its subsidiary, in respect of financial year commencing on 1 April 2025, have used accounting software for maintaining their books of account which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we and respective auditor of the above referred subsidiary did not come across any instance of audit trail feature being tampered with, other than the consequential impact of the exceptions given below. Furthermore, the audit trails, to the extent maintained in the prior year and other than the consequential impact of the exceptions given below, have been preserved by the Holding Company and its subsidiary as per the statutory requirements for record retention.

Nature of exception noted	Details of Exception
Instances of accounting software for maintaining books of account which did not have a feature of recording audit trail (edit log) facility	The accounting software used for maintenance of certain inventory and revenue records of the Holding Company did not have a feature of recording audit trail (edit log) facility during the period 1 April 2025 to 15 January 2026, at both application level and database level.
Instances of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated throughout the year for all relevant transactions recorded in the software	i) The audit trail feature was not enabled at the database level for an accounting software to log any direct data changes, used for maintenance of certain inventory and revenue records by the Holding Company during the period 16 January 2026 to 31 March 2026.
	ii) The audit trail feature was not enabled at the database level for an accounting software to log any direct data changes, used for maintenance of certain revenue and inventory records by the Holding Company.

Nature of exception noted	Details of Exception
Instances of accounting software maintained by a third party where we are unable to comment on the audit trail feature at database level	The accounting software used for maintenance of certain revenue records is operated by a third-party software service provider. In the absence of any information on existence of audit trail (edit logs) for any direct changes made at the database level in the 'Independent Service Auditor's Assurance Report on the Description of Controls, their Design and Operating Effectiveness' ('Type 2 report' issued in accordance with ISAE 3402, Assurance Reports on Controls at a Service Organization), we are unable to comment on whether audit trail feature with respect to the database of the said software was enabled and operated throughout the year.
Instance of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated effectively during the reporting period	The accounting software used for maintenance of accounting records of certain branches of the Holding Company did not capture the details of who made the changes for certain period during the year.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410
UDIN: 26099410QSCPE1413

Place: Chandigarh
Date: 30 May 2026

Annexure I

To the Independent Auditor’s Report of even date to the members of Jeena Sikho Lifecare Limited on the consolidated financial statements for the year ended 31 March 2026

List of entities included in the Consolidated financial statements

Name of the Holding Company

- 1. Jeena Sikho Lifecare Limited

Name of the subsidiary companies

- 1. Jeena Green Resources Private Limited
- 2. Jeena Sikho International LLC

Annexure II

To the Independent Auditor's Report of even date to the members of Jeena Sikho Lifecare Limited on the consolidated financial statements for the year ended 31 March 2026

Independent Auditor's Report on the internal financial controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the consolidated financial statements of Jeena Sikho Lifecare Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), as at and for the year ended 31 March 2026, we have audited the internal financial controls with reference to financial statements of the Holding Company, which is Company covered under the Act, as at that date.

RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR INTERNAL FINANCIAL CONTROLS

2. The respective Board of Directors of the Holding Company and its subsidiary company which are companies covered under the Act, are responsible for establishing and maintaining internal financial controls based on internal financial controls with respect to financial statements criteria established by the Company considering the essential components of Internal financial controls stated in Guidance Note on Audit of internal Financial Controls over Financial Reporting ('The Guidance Note') issued by the Institute of Chartered Accountants of India (the 'ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY FOR THE AUDIT OF THE INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

3. Our responsibility is to express an opinion on the internal financial controls with reference to financial statements of the Holding Company, its subsidiary companies, as aforesaid, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India ('ICAI') prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the ICAI. Those Standards and the Guidance Note require

that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary company as aforesaid.

MEANING OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

OPINION

8. In our opinion and based on the consideration of the reports of the other auditor on internal financial controls with reference to financial statements of the subsidiary company, the Holding Company and its subsidiary company, which are companies covered under the Act, have in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2026, based on internal financial controls with respect to financial statements criteria established by

the Company considering the essential components of internal financial controls stated in Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('The Guidance Note') issued by ICAI.

OTHER MATTER

9. We did not audit the internal financial controls with reference to financial statements in so far as it relates to one subsidiary company, which is company covered under the Act, whose financial statements reflect total assets of ₹156.36 lakhs as at 31 March 2026, total revenues of ₹7.53 lakhs and net cash inflows amounting to ₹3.35 lakhs for the year ended on that date, as considered in the consolidated financial statements. The internal financial controls with reference to financial statements in so far as it relates to such subsidiary company have been audited by other auditor whose reports have been furnished to us by the management and our report on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements for the Holding Company, its subsidiary company, as aforesaid, under Section 143(3)(i) of the Act in so far as it relates to such subsidiary company is based solely on the reports of the auditor of such company. Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and on the reports of the other auditor.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Sandeep Mehta

Partner

Membership No.: 099410

UDIN: 26099410QSXCP1413

Place: Chandigarh

Date: 30 May 2026

Consolidated Balance Sheet

As at 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
ASSETS				
Non-current assets				
Property, plant and equipment	3	11,817.81	9,234.42	6,682.52
Capital work-in-progress	3A	206.15	1,123.31	349.84
Right-of-use assets	4	11,404.12	10,026.65	5,809.27
Goodwill	5	5,811.82	5,811.82	-
Other intangible assets	6	260.15	232.65	2.13
Intangible assets under development	6A	79.45	224.28	43.68
Financial assets				
i) Investments	7A	1,459.54	64.00	64.00
ii) Other financial assets	9	1,173.81	999.83	480.23
Deferred tax assets (net)	15	1,025.87	584.19	172.16
Other non-current assets	10	98.73	95.90	-
Total non-current assets		33,337.45	28,397.05	13,603.83
Current assets				
Inventories	11	2,021.82	1,154.58	718.87
Financial assets				
i) Investments	7B	9,512.24	291.61	369.69
ii) Trade receivables	12	6,992.91	8,496.14	3,383.02
iii) Cash and cash equivalents	13	1,637.30	2,297.87	2,531.47
iv) Other bank balances	14	9,245.08	-	3,669.28
v) Loans	8	-	312.00	812.00
vi) Other financial assets	9	2,269.20	68.97	93.18
Other current assets	10	2,408.16	876.62	2,040.61
Total current assets		34,086.71	13,497.79	13,618.12
Total assets		67,424.16	41,894.84	27,221.95
EQUITY AND LIABILITIES				
Equity				
Equity share capital	16	2,486.01	2,486.01	2,486.01
Other equity	17	44,221.87	23,148.27	16,106.72
Non-controlling interest		(12.82)	-	-
Total equity		46,695.06	25,634.28	18,592.73
LIABILITIES				
Non-current liabilities				
Financial liabilities				
i) Borrowings	18	26.50	42.92	32.16
ii) Lease liabilities	19	9,548.25	8,513.08	4,780.78
iii) Others financial liabilities	20	80.85	-	-
Provisions	21	562.52	369.31	257.95
Other non-current liabilities	23	12.49	-	-
Total non-current liabilities		10,230.61	8,925.31	5,070.89
Current liabilities				
Financial liabilities				
i) Borrowings	18	18.92	1,030.80	22.00
ii) Lease liabilities	19	3,136.09	2,106.99	931.94
iii) Trade payables	24			
a. total outstanding dues of micro enterprises and small enterprises		769.49	238.29	35.45
b. total outstanding dues of creditors other than micro enterprises and small enterprises		1,545.16	1,336.51	782.39
iv) Others financial liabilities	20	2,491.03	1,360.26	867.37
Other current liabilities	23	1,645.12	1,096.46	636.65
Provisions	21	77.63	28.66	16.50
Current tax liabilities	22	815.05	137.28	266.03
Total current liabilities		10,498.49	7,335.25	3,558.33
Total liabilities		20,729.10	16,260.56	8,629.22
Total equity and liabilities		67,424.16	41,894.84	27,221.95

The accompanying notes are an integral part of the consolidated financial statements
This is the consolidated balance sheet referred to in our report of even date

(1-50)

For Walker Chandio & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Nanak Chand
Chief Financial Officer

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Bhavna Grover
Whole Time Director
DIN: 07557913

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Consolidated Statement of Profit and Loss

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	25	80,136.39	46,907.19
Other income	26	849.61	673.54
Total income		80,986.00	47,580.73
Expenses			
Purchases of stock-in-trade and consumables	27	10,020.21	5,857.99
Changes in inventories of stock in trade and consumables	28	(867.23)	(435.71)
Employee benefits expense	29	14,840.48	10,074.28
Finance costs	30	1,283.35	1,065.49
Depreciation and amortization expense	31	4,769.20	2,910.54
Other expenses	32	21,200.64	17,350.38
Total expenses		51,246.65	36,822.97
Profit before tax		29,739.35	10,757.76
Tax expenses:			
Current tax	33	8,017.00	3,153.33
Adjustment of tax relating to earlier years		14.10	21.54
Deferred tax	33	(461.56)	(411.44)
Total tax expense		7,569.54	2,763.43
Profit for the year after tax		22,169.81	7,994.33
Other comprehensive income			
(i) Item that will not be reclassified to profit or loss in subsequent years			
- Remeasurement of post employment benefit obligation		79.01	(2.34)
- Income tax relating to items that will not be reclassified to profit or loss in subsequent years		(19.88)	0.59
(ii) Item that may be reclassified to profit or loss			
- Exchange differences on translation of foreign operations		0.32	-
Total other comprehensive income for the year, net of tax		59.45	(1.75)
Total comprehensive income for the year		22,229.26	7,992.58
Profit for the period attributable to:			
Owners of the parent		22,185.08	7,994.33
Non-controlling interests		(15.27)	-
Other comprehensive income for the period attributable to:			
Owners of the parent		59.45	(1.75)
Non-controlling interests		-	-
Total comprehensive income for the period attributable to:			
Owners of the parent		22,244.53	7,992.58
Non-controlling interests		(15.27)	-
Earnings per equity share (INR)*			
Basic	34	17.84	6.43
Diluted	34	17.81	6.42

*Earnings per share is computed after giving effect to 1:5 stock split effective June 12, 2025 for all the periods presented. Refer Note 16 of these financial statements for further details regarding such stock split.

The accompanying notes are an integral part of the consolidated financial statements (1-50)

This is the consolidated statement of profit and loss referred to in our report of even date

For Walker Chandiok & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Nanak Chand
Chief Financial Officer

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Bhavna Grover
Whole Time Director
DIN: 07557913

Smita Chaturvedi
Company Secretary
M.No.: A48303

Consolidated Statement of Cash Flows

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
A. Cash flow from operating activities		
Profit before tax	29,739.35	10,757.76
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation and amortization expense	4,769.20	2,910.54
Finance cost	1,268.68	933.95
Share based payment expense	196.38	88.14
Allowance for expected credit loss	598.09	650.97
Gain on investments measured at fair value through profit and Loss	(465.85)	23.07
Gain on sale of investment (net)	(5.91)	(100.95)
Loss/(gain) on sale of property, plant and equipment (net)	21.58	(233.36)
Fixed assets written off	34.33	-
Amounts written off	-	115.03
Deferred franchise deposit income	(96.79)	-
Interest income	(242.77)	(271.67)
Gain on termination of lease	(4.33)	-
Operating profit before working capital changes and other adjustments	35,811.96	14,873.48
Working capital adjustments:		
Change in inventories	(867.24)	(397.75)
Change in trade receivables	905.14	(5,234.68)
Change in financial assets	(4,416.04)	(384.03)
Change in other assets	(1,542.63)	1,140.51
Change in trade payable	731.38	730.09
Change in other financial liabilities	1,223.42	471.18
Change in other liabilities	561.15	434.09
Change in provisions	321.19	121.04
Cash generated from operating activities post working capital changes	32,728.33	11,753.93
Income tax paid	(7,353.33)	(3,303.62)
Net cash generated from operating activities (A)	25,375.00	8,450.31
B. Cash flow from investing activities		
Purchase of property, plant and equipment, intangible assets and intangible assets under development	(3,405.35)	(4,233.38)
Proceeds from sale of property, plant and equipment	139.94	323.04
Payment of initial direct costs towards leases acquired	(24.89)	-
Payment on acquisition of business	-	(6,915.70)
Investments in equity instruments	(1,395.54)	-
Investments in mutual funds	(10,957.46)	(1,417.22)
Proceeds from sale of investments in mutual funds	2,208.59	1,573.18
Loans given	-	(105.41)
Proceeds from repayment of loans	312.00	653.56
(Investments in bank deposits)/Proceeds on maturity of bank deposits (net)	(7,223.46)	3,371.14
Interest received	178.02	302.64
Net cash used in investing activities (B)	(20,168.15)	(6,448.15)
C. Cash flow from financing activities		
Proceeds from long-term borrowings	-	41.71
Repayment of long-term borrowings	(27.90)	(22.34)
Proceeds from short-term borrowings	2.50	1,000.00
Repayment of short term borrowings	(1,000.00)	-
Dividend paid	(1,367.31)	(1,039.16)
Payment of principal portion of lease liabilities	(2,214.42)	(1,291.87)
Payment of interest portion of lease liabilities	(1,255.78)	(930.59)
Interest paid	(4.83)	(3.17)
Net cash used in financing activities (C)	(5,867.74)	(2,245.42)
Net decrease in cash and cash equivalents (A+B+C)	(660.89)	(243.26)
Net foreign exchange difference	0.32	-
Cash and cash equivalents acquired as part of acquisition of business	-	9.66
Cash and cash equivalents at the beginning of the year	2,297.87	2,531.47
Cash and cash equivalents at the end of the year (refer note 13)	1,637.30	2,297.87

Consolidated Statement of Cash Flows (Contd.)

For the year ended 31 March 2026

CIN: L52601PB2017PLC046545

(All amounts are in INR Lakhs except otherwise stated)

Reconciliation of cash and cash equivalents as per the Statement of Cash Flows

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash and cash equivalents as per above comprises of the following		
- Current account	939.80	1,754.75
- Deposit account	495.00	-
- Cash in hand	202.50	543.12
Balance as per statement of cash flow	1,637.30	2,297.87

The Statement of Cash flows has been prepared under 'Indirect method' as set out in Ind AS - 7 'Statement of Cash Flows'.

(a) Reconciliation of financial liabilities arising from financing activities:

Particulars	Share Capital	Borrowings	Lease liabilities
Balance as at 01 April 2024	2,486.01	54.16	5,712.72
Cash flows:			
Proceeds from borrowings	-	1,041.71	-
Repayment of borrowings	-	(22.34)	-
Repayment of lease liabilities	-	-	(2,222.46)
Interest paid	-	(3.17)	-
Other non-cash changes:			
Additions for new leases	-	-	6,199.22
Interest on borrowings	-	3.36	-
Interest on lease liabilities	-	-	930.59
Balance as at 31 March 2025	2,486.01	1,073.72	10,620.07
Cash flows:			
Proceeds from borrowings	-	2.50	-
Repayment of borrowings	-	(1,030.40)	-
Repayment of lease liabilities	-	-	(3,470.20)
Interest paid	-	(4.83)	-
Other non-cash changes			
Additions for new leases	-	-	4,331.93
Deletion of leases	-	-	(53.24)
Interest on borrowings	-	4.43	-
Interest on lease liabilities	-	-	1,255.78
Balance as at 31 March 2026	2,486.01	45.42	12,684.34

The accompanying notes are an integral part of the consolidated financial statements (1-50)

This is the Statement of Cash flows referred to in our report of even date

For Walker Chandio & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Bhavna Grover
Whole Time Director
DIN: 07557913

Nanak Chand
Chief Financial Officer

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Consolidated Statement of Changes in Equity

For the year ended 31 March 2026

CIN: L52601PB2017PLCO46545

(All amounts are in INR Lakhs except otherwise stated)

A. EQUITY SHARE CAPITAL

Particulars	Number of shares	Amount
Equity shares of INR 10 each issued, subscribed and fully paid		
As at 01 April 2024	2,48,60,146	2,486.01
Changes in equity share capital during the year	-	-
As at 31 March 2025	2,48,60,146	2,486.01
Changes in equity share capital during the year *	9,94,40,584	-
As at 31 March 2026	12,43,00,730	2,486.01

*On 12 June 2025, the Holding Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each, fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

Refer note no 16 for details

B. OTHER EQUITY

Particulars	Reserves and Surplus			Other Reserves	Total other equity attributable to owners	Non-controlling interest (Refer Note 46b)
	Security premium (Refer Note 17.1)	Retained earnings (Refer Note 17.3)	Share options outstanding account (Refer Note 17.4)			
As at 01 April 2024	5,330.79	10,774.85	1.08	-	16,106.72	-
Profit for the year	-	7,994.33	-	-	7,994.33	-
Other comprehensive income for the year, net of income tax*	-	(1.75)	-	-	(1.75)	-
Transaction with owners in their capacity as owners						
Employee stock option expense (Refer note 37)	-	-	88.14	-	88.14	-
Dividend paid	-	(1,039.17)	-	-	(1,039.17)	-
As at 31 March 2025	5,330.79	17,728.26	89.22	-	23,148.27	-
Profit for the year	-	22,185.08	-	-	22,185.08	(15.27)
Other comprehensive income for the year, net of income tax*	-	59.13	-	0.32	59.45	-
Transaction with owners in their capacity as owners						
NCI Recognition	-	-	-	-	-	2.45
Employee stock option expense (Refer note 37)	-	-	196.38	-	196.38	-
Dividend paid	-	(1,367.31)	-	-	(1,367.31)	-
As at 31 March 2026	5,330.79	38,605.16	285.60	0.32	44,221.87	(12.82)

*Other comprehensive income/(loss) includes remeasurement of post employment benefit obligation (net of tax) and exchange differences on account of translation of foreign operations.

This is the consolidated statement of changes in equity referred to in our report of even date

As per our report of even date attached

For Walker Chandiok & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Nanak Chand
Chief Financial Officer

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Bhavna Grover
Whole Time Director
DIN: 07557913

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026

Notes to the Consolidated Financial Statements

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

1. GROUP INFORMATION

Jeena Sikho Lifecare Limited (the 'Holding Company') is a public Company domiciled in India having registered address at SCO 11 FIRST FLOOR, KALGIDHAR ENCLAVE, Mohali, ZIRAKPUR, Punjab, India, 140604 and is incorporated on 29 May 2017 under the provisions of the Companies Act applicable in India. The Company has its primary listings on BSE Limited and National Stock Exchange of India Limited

The Company's primary business is to provide healthcare services, offering a range of traditional and natural remedies to promote overall wellness. The Company's products and services cater to various health needs, from detoxification and digestion to wellness supplements and beauty care. With a strong focus on holistic health, Jeena Sikho aims to provide comprehensive Ayurvedic solutions to individuals and families.

The Holding Company, its subsidiaries (jointly referred to as the 'Group' hereinafter) considered in these consolidated financial statements are:

a) Holding Company

- Jeena Sikho Lifecare Limited

b) Subsidiaries

- Jeena Green Resources Private Limited
- Jeena Sikho International LLC

The Group is presenting consolidated financial statements for the first time in the current year. Accordingly, the comparative financial statements for the ended 31 March 2025 and 01 April 2024 as presented herein represent standalone financial statements of the Holding Company. These comparative financial statements prepared under previous IGAAP were audited KRA & Co, Chartered Accountants, the predecessor auditor, who expressed an unmodified opinion. The same have been adjusted for the differences in the accounting principles adopted by the Company on transition to Ind AS which have been audited by the statutory auditors.

2. BASIS OF PREPARATION AND SUMMARY OF MATERIAL ACCOUNTING POLICIES

This note provides a list of the material accounting policies adopted in the preparation of these consolidated financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of preparation and consolidation

These consolidated financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs pursuant to section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The consolidated financial statements are prepared in INR, which is the functional currency and all values are rounded off to nearest lakhs (INR 100000), except otherwise indicated.

These Ind AS consolidated financial statements for the year ended 31 March 2026 were approved for issue by the Board of Directors on 30 May 2026.

These financial statements for the year ended 31 March 2026 are the first financial statements prepared by the Group as per Ind AS. For all periods upto and including the year ended 31 March 2025, the Group prepared its financial statements in accordance with the accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (hereinafter referred to as 'Previous GAAP') used for its statutory reporting requirement in India immediately before adopting Ind AS. The opening balance sheet at the beginning of the comparative year have been restated in accordance with Ind AS for comparative information. Reconciliations and explanations of the effect of the transition from Previous GAAP to Ind AS on the Group's Balance Sheet, Statement of Profit and Loss and Statement of Cash Flows are provided in note 47.

The consolidated financial statements relate to the Holding Company and its subsidiaries. The financial statements of subsidiaries used for the purpose of consolidation are drawn up to the same reporting date as that of the Group. The consolidated financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner, as Company's separate financial statements.

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The consolidated financial statements of the Company and its subsidiaries have been combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after eliminating intra-group balances, intra-group transactions.

Non-controlling interests in the net assets of consolidated subsidiaries is identified and presented in the consolidated Balance Sheet separately within equity. Non-controlling interests in the net assets of consolidated subsidiaries consists of: (a) The amount of equity attributable to non-controlling interests at the date on which investment in a subsidiary is made; and (b) The non-controlling interests share of movements in equity since the date parent subsidiary relationship came into existence. The profit/loss and other comprehensive income attributable to non-controlling interests of subsidiaries are shown separately in the consolidated statement of profit and loss and consolidated statement of changes in equity

(b) Basis of measurement

The consolidated financial statements have been prepared on accrual and going concern basis under historical cost convention except for certain financial assets and financial liabilities that are measured at fair value or amortized cost, defined benefit obligations and share based payments.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(c) Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible to/by the Group.

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within fair value hierarchy, described as follows, based on the lowest level of input that is significant to the fair value measurement as a whole.

Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the consolidated financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

(d) Critical accounting estimates and judgements

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities at the end of the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods. Changes in estimates are reflected in the consolidated financial statements in the period in which changes are made and if material, their effects are disclosed in the notes to the consolidated financial statements.

Significant management judgements

Recognition of deferred tax assets – The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the Group's future taxable income against which the deferred tax assets can be utilized.

Evaluation of indicators for impairment of assets – The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.

Contingent liabilities – At each balance sheet date basis the management judgment, changes in facts and legal aspects, the Group assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.

Leases – Judgment required to ascertain lease classification, lease term, incremental borrowing rate, lease and non-lease component, and impairment of ROU.

Significant estimates

Defined benefit obligation (DBO) – Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

Allowance for expected credit losses – The allowance for doubtful debts reflects management's estimate of losses inherent in its credit portfolio. This allowance is based on Group's estimate of the losses to be incurred, which derives from past experience with similar receivables, current and historical past due amounts, write-offs and collections, the careful monitoring of portfolio credit quality and current and projected economic and market conditions. Should the present economic and financial situation persist or even worsen, there could be a further deterioration in the financial situation of the Group's debtors compared to that already taken into consideration in calculating the allowances recognised in the financial statements.

Share based payments – Measurement of share-based payments; measurement of financial guarantee contracts, provisions and contingent liabilities.

Inventory obsolescence & Valuation – Inventories are carried at the lower of cost and net realisable value. The estimation of net realisable value and provision for obsolescence involves significant judgment, including assessment of demand, market conditions, and inventory ageing. Appropriate provisions are made for slow-moving and obsolete inventories based on management's estimates.

Useful life of Fixed assets – Useful lives of property, plant and equipment are determined based on management's estimate of expected usage, wear and tear, and technological obsolescence, in line with Schedule II. These estimates are reviewed annually and revised prospectively, where necessary.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Fair valuation of investments – Investments measured at fair value involve the use of valuation techniques and significant estimates, particularly where market quotes are not available. Key assumptions include cash flow projections, discount rates, and market comparables. Changes in these assumptions may materially impact the fair value of such investments.

Recoverability of goodwill – Goodwill is tested annually for impairment based on the recoverable amount of the underlying CGU. The assessment involves significant estimates, including projected cash flows, growth rates, and discount rates. Changes in these assumptions may materially impact the carrying value of goodwill.

Probability of exercise of ESOP – The estimation of ESOP expense involves judgment in assessing the probability of vesting and exercise, based on assumptions such as employee attrition and historical trends. These estimates are reviewed periodically and revised prospectively.

There are no assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year except for as disclosed in these consolidated financial statements.

(e) Current versus non-current classification

The Group presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realized within twelve months after the reporting period; or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is treated as current when it is:

- Expected to be settled in normal operating cycle;
- Held primarily for the purpose of trading;
- Due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

Current liabilities include the current portion of non-current financial liabilities. All other liabilities are classified as non-current.

Deferred tax assets/liabilities are classified as non-current assets/liabilities.

Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realization/settlement in cash and cash equivalents. The companies have identified twelve months as their operating cycle for classification of their current assets and liabilities.

(f) Property, plant and equipment

Recognition and measurement

Items of property, plant and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses, if any.

The cost of an item of property, plant and equipment comprises its purchase price and non-refundable purchase taxes, after deducting trade discounts and rebates any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other cost directly attributable to bringing the item to working condition for its intended use.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated Statement of profit and loss when such asset is derecognised.

Subsequent cost

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that the future economic benefits associated with expenditure will flow to the Group and the cost of the item can be measured reliably. All other subsequent costs are charged to consolidated Statement of profit and loss at the time of incurrence.

Depreciation

Depreciation is calculated on cost of items of property, plant and equipment less their estimated residual value over the estimated useful lives using the straight-line method and is generally recognised in the consolidated statement of profit and loss.

Depreciation on items of property, plant and equipment of Group is provided as per Schedule II of the Companies Act, 2013 except in cases where expected useful life of the assets are different from the corresponding life prescribed as under and the Group based upon the nature of asset, the operating condition of the asset, the estimated usage of the asset, past history of replacement and anticipated technological

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

277

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

changes, believes that this is the best estimate on the basis of actual realization.

Depreciation on other items of property, plant and equipment of Group is provided as per Part C of Schedule II of the Companies Act, 2013:

Block of asset	Useful Life (in years)
Building	30
Furniture and Fixtures	10
Motor vehicles	8
Office Equipment	5
Computers	3
Leasehold improvements	Over the lease term

Depreciation method, useful lives and residual values are reviewed by management at each reporting date and adjusted prospectively, as appropriate.

Depreciation on additions/disposals is provided on pro-rata basis i.e. from (upto) the date on which asset is ready to use/disposed of.

The residual values, useful lives and methods of depreciation of property plant and equipment are reviewed by management at each reporting date and adjusted prospectively, as appropriate.

During disposal of property, plant and equipment, any profit earned/loss sustained towards excess/shortfall of sale value vis-a-vis carrying cost of assets is accounted for in Consolidated Statement of Profit and Loss.

(g) Capital work-in-progress and Intangible Assets under development:

Capital work-in-progress and intangible assets under development represent expenditure incurred in respect of capital projects/intangible assets under development and are carried at cost. Cost comprises purchase cost, related acquisition expenses, development/construction costs, borrowing costs and other direct expenditure.

(h) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost and recognised only if it is probable that the expected future economic benefits that are attributable to the asset will flow to the Group and the cost of assets can be measured reliably. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

The useful lives of intangible assets are assessed as either finite or indefinite.

(All amounts are in INR Lakhs except otherwise stated)

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates.

The amortisation expense on intangible assets with finite lives is recognised in the consolidated statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Amortization of intangible assets such as software is computed on a straight-line basis, at the rates representing estimated useful life of up to 5 years:

Block of asset	Useful Life (in years)
Softwares	5
Non-compete fee	4
Empanelment	1.93

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the consolidated statement of profit or loss when the asset is derecognised.

Goodwill

Goodwill arising on acquisition of a business represents the excess of the consideration transferred over the Group's interest in the net fair value of identifiable assets acquired and liabilities assumed at the date of acquisition, in accordance with Ind AS 103 – Business Combinations.

Goodwill is recognised as an intangible asset and is subsequently measured at cost less accumulated impairment losses. In accordance with Ind AS 38 and Ind AS 36, goodwill is not amortised but is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate potential impairment.

For the purpose of impairment testing, goodwill is allocated to the respective cash-generating units ("CGUs") or groups of CGUs that are expected to benefit from the synergies of the acquisition. Goodwill is allocated to the relevant CGUs within the Group's operating segments, representing the lowest level at which goodwill is monitored for internal management purposes.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The recoverable amount of each CGU to which goodwill is allocated is determined as the higher of its value in use and fair value less costs of disposal.

Value in use is based on discounted cash flow projections derived from management-approved budgets and forecasts, covering a defined projection period. These projections involve significant estimates and assumptions, including revenue growth rates, operating margins, patient footfall, expected capacity utilisation, and discount rates reflecting the time value of money and risks specific to the CGU.

Key assumptions are reviewed periodically and are based on management's best estimate of future economic and operating conditions.

Any impairment loss, being the excess of the carrying amount of the CGU over its recoverable amount, is first allocated to reduce the carrying amount of goodwill. Such impairment losses are recognised in the Statement of Profit and Loss.

(i) Leases

The Group as lessee

The Group enters into an arrangement for lease of buildings. Such arrangements are generally for a fixed period but may have extension or termination options. In accordance with Ind AS 116 – Leases, at inception of the contract, the Group assesses whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to control the use of an asset (the underlying asset) for a period of time in exchange for consideration'.

To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether:

- The contract involves the use of an identified asset – this may be specified explicitly or implicitly, and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified;
- The Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and
- The Group assesses whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use. At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of buildings in which it is a lessee, the Group has elected not to separate non-lease components and account for the lease and non-lease components as a single lease component.

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Measurement and recognition of leases as a lessee

The Group recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- Fixed payments, including in-substance fixed payments;
- Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable under a residual value guarantee; and
- The exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in Statement of profit and loss if the carrying amount of the right-of-use asset has been reduced to zero, as the case may be.

The Group presents right-of-use assets that do not meet the definition of investment property on the face of balance sheet below 'property, plant and equipment' and lease liabilities under 'financial liabilities' in the balance sheet.

The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognizing a right-of-use asset and lease liability,

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

279

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

(All amounts are in INR Lakhs except otherwise stated)

the payments in relation to these are recognized as an expense in consolidated statement of profit and loss on a straight-line basis over the lease term.

(j) Share based payment

Certain employees of the Group receive part of their remuneration in the form of share-based payment transactions, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).

The fair value on grant date of equity-settled share-based payment arrangements granted to eligible employees of the Group under the Employee Stock Option Plan ('ESOP') is recognised as employee stock option plan expenses in the Statement of profit and loss, in relation to options granted to employees of the Group (over the vesting period of the awards), with a corresponding increase in other equity. The total amount to be expensed is determined by reference to the fair value of the options determined under Black-Scholes model.

The amount recognised as an expense reflects the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

The increase in equity recognised in connection with a share-based payment transaction is presented in the "Employee stock options outstanding account", as separate component in other equity. At the end of each period, the Group revises its estimates of the number of options that are expected to be vested based on the non-market performance conditions at the vesting date.

If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options expected to vest. Upon exercise of share options, the proceeds received, net of any directly attributable transaction costs, are allocated to share capital up to the nominal (or par) value of the shares issued with any excess being recorded as share premium.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(k) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Recognition and initial measurement

Trade receivables and debt instruments are initially recognised when they are originated. All other financial assets are initially recognised when the Group becomes a party to the contractual provisions of the instrument.

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with Ind AS 115, all financial assets are initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are attributable to its acquisition or issue.

Classification

For the purpose of initial recognition, the Group classifies its financial assets in following categories:

- Financial assets measured at amortised cost;
- Financial assets measured at fair value through other comprehensive income (FVTOCI); and
- Financial assets measured at fair value through profit and loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Group changes its business model for managing financial assets.

A financial asset is measured at the amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- The financial asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate ('EIR') method.

A financial asset being 'debt instrument' is measured at the FVTOCI if both of the following criteria are met:

- The asset is held within the business model, whose objective is achieved both by collecting contractual cash flows and selling the financial assets, and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are SPPI on the principal amount outstanding.

On initial recognition of an equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirement to be measured at amortised cost or at FVOCI as at FVTPL if doing so

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

eliminates or significantly reduces as accounting mismatch that would otherwise arise.

Investment in equity instruments of subsidiaries

Investments in equity instruments of subsidiaries are accounted for at cost in accordance with Ind AS 27 'Separate Financial Statements'.

Investments in mutual funds

Investments in mutual funds are measured at FVTPL.

Measured at Amortized Cost

Financial assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows that are solely payments of principal and interest, are subsequently measured at amortized cost using the EIR method less impairment, if any. The amortization of EIR and loss arising from impairment, if any, is recognized in the Consolidated Statement of Profit and Loss.

Measured at Fair Value through other Comprehensive Income

Financial assets that are held within a business model whose objective is achieved by both, selling financial assets and collecting contractual cash flows that are solely payments of principal and interest, are subsequently measured at FVTOCI. Fair value movements are recognized in the other comprehensive income ('OCI'). Interest income measured using the EIR method and impairment losses, if any are recognized in the Consolidated Statement of Profit and Loss. On de-recognition, cumulative gain or loss previously recognized in OCI is reclassified from the equity to 'other income' in the Consolidated Statement of Profit and Loss.

Measured at Fair Value through Profit or Loss

A financial asset not classified as either amortized cost or FVTOCI, is classified as FVTPL. Such financial assets are measured at fair value with all changes in fair value, including interest income and dividend income, if any, recognized as 'other income' in the Consolidated Statement of Profit and Loss.

Subsequent measurement

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses, if any. Interest income and impairment are recognised in the Statement of profit and loss.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognised in the Statement of profit and loss.

Derecognition

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards

of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any gain or loss on derecognition is recognised in the consolidated Statement of profit and loss.

Impairment of financial assets (other than at fair value)

The Group recognises loss allowances using the Expected Credit Loss (ECL) model for financial assets that are not measured at fair value through profit or loss.

For trade receivables that do not contain a significant financing component, the Group applies the simplified approach prescribed under Ind AS 109 and recognises loss allowances at an amount equal to lifetime ECL. Lifetime ECL represents the expected credit losses resulting from all possible default events over the expected life of the financial asset.

The Group measures lifetime ECL for trade receivables using a provision matrix, which is based on historical credit loss experience, adjusted for current conditions and forward looking information such as changes in economic conditions, customer-specific factors, and industry trends. The assessment considers factors including ageing of receivables, past default patterns, credit risk characteristics of customers, and reasonable and supportable forecasts of future economic conditions.

For all other financial assets, expected credit losses are measured at an amount equal to 12 month ECL, unless there has been a significant increase in credit risk, since initial recognition, in which case loss allowances are measured at lifetime ECL. In assessing whether credit risk has increased significantly, the Group considers quantitative and qualitative factors, including changes in credit ratings, adverse business or economic conditions, and past due status.

The changes (incremental or reversal) in loss allowance computed using the ECL model are recognised as an impairment gain or loss in the consolidated Statement of Profit and Loss.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the counterparty does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

Financial liabilities

Recognition and initial measurement

All financial liabilities are initially recognised when the Group becomes a party to the contractual provisions of the instrument. All financial liabilities are initially measured at fair value minus, for an item not at fair value through profit and loss, transaction costs that are attributable to the liability.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Classification and subsequent measurement

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit and loss.

Financial liabilities other than classified as FVTPL, are subsequently measured at amortised cost using the effective interest method. Interest expenses are recognised in profit and loss. Any gain or loss on derecognition is also recognised in profit and loss.

Derecognition

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled or expired. The Group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on modified terms is recognised at fair value. The difference between the carrying amount of the financial liability

extinguished and the new financial liability with modified terms is recognised in the consolidated Statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount presented in the Balance Sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the assets and settle the liabilities simultaneously.

(I) Revenue recognition

Revenue from contracts with customers

Revenue from contracts with customers is recognised in accordance with Ind AS 115, when control of the promised goods or services is transferred to the customer, at an amount that reflects the consideration to which the Group expects to be entitled in exchange for such goods or services.

The Group assesses its performance obligations in each contract and recognises revenue when (or as) such performance obligations are satisfied. Control is considered to be transferred when the customer obtains the ability to direct the use of and substantially all of the remaining benefits from the goods or services.

Further, the Group evaluates whether it is acting as a principal or an agent in its revenue arrangements. The Group has generally concluded that it is acting as a principal, as it typically controls the specified goods or services prior to their transfer to the customer and is primarily responsible for fulfilling the promise to provide such goods or services.

Sale of products

In respect of sale of fast-growing Ayurvedic products where the performance obligation is satisfied at a point in time, revenue is recognised when the control of goods is transferred to the customer as per the terms & conditions of the contract. Revenue from the sale of goods is measured at the transaction price received or receivable, net of returns and allowances, trade discounts and volume rebates.

The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of the transaction price needs to be allocated.

For each performance obligation identified, the Group recognizes revenue as and when it satisfies the performance obligation at a point in time.

Sale of services

The healthcare services income includes revenue generated from in-patient services, panchakarma therapies, 72-hour health camps, home based health care services, out-patient services and day care, dietary support and nutrition guidance and comprehensive patient support anytime, anywhere.

Revenue is recognised when each performance obligation is satisfied over a period of time when inpatient/outpatients has received the service.

Other operating revenue

Revenue from testing services provided under the agreement with Chandan Healthcare Limited is recognised in accordance with Ind AS 115, when the performance obligation is satisfied.

The Group provides diagnostic and testing services to patients, and revenue is recognised at a point in time, i.e., upon completion of the testing services and issuance of test results, when control of the service is transferred to the customer.

Further, the Group has entered into an arrangement with its related party, Shuddhi Lifecare Private Limited ("SLPL"), whereby SLPL is permitted to use the Group's branding and marketing collateral, including promotional materials and related intellectual property.

Revenue from such arrangements is royalty income and is recognised in accordance with Ind AS 115 over the period to which it relates, based on the underlying sales made by SLPL as per the agreed terms. The consideration is determined as a percentage of sales of goods and services undertaken by SLPL.

Such income is considered ancillary to the main business operations of the Group and is recognised on an accrual basis in line with the substance of the contractual arrangement.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Contract liability of loyalty points

Loyalty points granted to customers are treated as a separate performance obligation under Ind AS 115, as they provide a material right for future purchases. Accordingly, a portion of the transaction price is allocated to such points based on their relative consolidated selling price and is deferred as a contract liability until redemption or expiry. Revenue is recognised net of such incentives, reflecting the effective discount provided to customers.

Interest income

For all debt instruments measured either at amortized cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortized cost of the financial liability. When calculating the effective interest rate, the Group estimates the expected cash flows by considering all the contractual terms of the financial instrument but does not consider the expected credit losses. Interest income is included in other income in the consolidated statement of profit and loss.

Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Group perform by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional.

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Group have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Group transfer goods or services to the customer, a contract liability is recognised when the payment is made, or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group perform under the contract.

Trade receivables

A receivable represents the right of entities forming part of Group to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in financial instruments – initial recognition and subsequent measurement.

(m) Foreign currency

The Group's consolidated financial statement are presented in Indian Rupees (INR), which is the Group's functional currency. Functional currency is the currency of the primary economic environment in which a Group operates and is normally the currency in which the Group primarily generates and expends cash.

Transactions in foreign currencies are initially recorded by the Group at the functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognised in consolidated statement of profit and loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of gain or loss on change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income or consolidated statement of profit and loss are also recognised in other comprehensive income or consolidated statement of profit and loss, respectively).

(n) Employee benefits

Short-term employee benefits

Employee benefit liabilities such as salaries, wages and bonus, etc. that are expected to be settled wholly within twelve months after the end of the reporting period in which the employees render the related service are recognised in respect of employee's services up to the end of the reporting period and are measured at an undiscounted amount expected to be paid when the liabilities are settled.

Post-employment benefit plans

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Group pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Payments to defined contribution plans are recognised as an expense when employees have rendered service entitling them to the contributions.

Defined benefit plans

The Group has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment, of an amount based on the respective employee's salary and the tenure of employment.

The liability recognised in the Balance Sheet in respect of defined benefit gratuity plan is the present value of the defined benefit obligation at the end of the reporting period. The defined benefit obligation is calculated by actuary using the projected unit credit method.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows by reference to market yields at the end of the

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

283

Strategic Review

Statutory Reports

Financial Statements

Jeena Sikho Lifecare Limited | Annual Report 2025-26

(All amounts are in INR Lakhs except otherwise stated)

reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation. This cost and other costs are included in employee benefits expense in the Statement of profit and loss.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in other comprehensive income and transferred to retained earnings.

Changes in the present value of the defined benefit obligation resulting from settlement or curtailments are recognised immediately in Statement of profit and loss as past service cost.

The Group's net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The Group presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date. Where Group has the unconditional legal and contractual right to defer the settlement for a period beyond 12 months, the same is presented as non-current liability.

The Group recognizes termination benefit as a liability and an expense when the Group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

If the termination benefits fall due more than 12 months after the balance sheet date, they are measured at present value of future cash flows using the discount rate determined by reference to market yields at the balance sheet date on government bonds.

The interest is calculated by applying the discount rate to the net defined benefit liability. The Group recognizes the following changes in the net defined benefit obligation as an expense in the consolidated Statement of Profit and Loss:

- Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- Interest expense

Other short-term employee benefits

Compensated absences

The Group's net obligation in respect of compensated absences is the amount of benefit to be settled in future, that employees have earned in return for their service in

the current and previous years. The benefit is discounted to determine its present value. The obligation is measured on the basis of an actuarial valuation using the projected unit credit method. Remeasurements are recognised in Statement of profit and loss in the period in which they arise.

(o) Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the consolidated statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources would be required to settle the obligation, the provision is reversed.

(p) Contingent assets/liabilities

Contingent liabilities are possible obligations that arise from past events and whose existence will only be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group. Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote.

Contingent assets are not recognised. However, when realization of income is virtually certain, then the related asset is no longer a contingent asset, and is recognised as an asset.

(q) Income taxes

Income tax expense comprises of current tax and deferred tax. It is recognised in the profit or loss except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any relating to income taxes. It is measured using tax rates enacted for the relevant reporting period.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis.

Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is also recognised in respect of carried forward losses and tax credits. Deferred tax is not recognised for temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that effects neither accounting not taxable profit or loss at the time of the transaction.

Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Group recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/reduced to the extent that it is probable/no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and deferred tax liabilities are offset only if there is a legally enforceable right to offset current tax liabilities and assets levied by the same tax authorities.

(r) Earnings per share

The Group presents basic and diluted earnings per share (EPS) data for its equity shares. Basic EPS is calculated by dividing the consolidated Statement of profit and loss attributable to equity shareholders of the Group by the weighted average number of equity shares outstanding during the year. Diluted EPS is determined by adjusting consolidated Statement of profit and loss attributable to equity shareholders and the weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares, which comprise share options granted to employees.

The number of equity shares and potentially dilutive equity shares are adjusted retrospectively for all periods presented for any share splits and bonus shares issues including for

changes effected prior to the approval of the consolidated financial statements by the Board of Directors.

(s) Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the consolidated statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above.

(t) Segment reporting

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group's other components, and for which discrete financial information is available. All operating segments' operating results are regularly reviewed by the Group's chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance. The Group's chief executive officer is the chief operating decision maker.

(u) Impairment of non-financial assets

The Group assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets.

Impairment loss is recognised when the carrying amount of an asset exceeds recoverable amount and the asset is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, Group extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

rate does not exceed the long-term average growth rate for the products, industries, or country or countries in which the entity operates, or for the market in which the asset is used.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the consolidated statement of profit and loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

(v) Inventories

Inventories are valued at the lower of cost and net realizable value in accordance with the provisions of IND AS2.

Inventories comprise medicines, healthcare products, and consumables used in providing Panchkarma and other therapies/treatment services, as well as goods held for sale.

Inventories are valued at the lower of cost and net realisable value, in accordance with Ind AS 2. Cost includes purchase price, duties and taxes (net of recoverable taxes), freight, and other costs incurred in bringing the inventories to their present location and condition. Cost is determined using the First-In-First-Out method.

Medicines and other items held for sale are recognised as inventory and expensed to cost of goods sold upon sale.

Consumables used in rendering panchkarma, and related services are recognised as expenses in the period in which such services are provided, based on actual consumption.

Net realisable value is estimated based on the expected selling price in the ordinary course of business, less estimated costs necessary to make the sale. The Group evaluates inventories at each reporting date for obsolescence, expiry, and slow-moving items, particularly for medicines with limited shelf life, and provides for diminution in value, where necessary.

(w) Events occurring after the Balance Sheet date

Impact of events occurring after the balance sheet date that provide additional information materially affecting the determination of the amounts relating to conditions existing at the balance sheet date are adjusted to respective assets and liabilities.

(x) New and amended standards adopted by the Group

The Group applied for the first-time certain standards and amendments, which are effective for annual periods beginning on or after 1 April 2025. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

The Ministry of Corporate Affairs ("MCA") notifies amendments to Indian Accounting Standards ('Ind AS') from time to time under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015.

Standards and amendments effective for the year ended 31 March 2026.

The following amendments became effective for annual reporting periods beginning on or after 1 April 2025 and have been applied by the Group where relevant:

Amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates

The amendments prescribe accounting and disclosure requirements in situations where a currency is not exchangeable, including guidance on estimating the spot exchange rate when exchangeability is lacking and related disclosures.

Amendments to Ind AS 1 – Presentation of Financial Statements

These amendments clarify the principles for classification of liabilities as current or non-current, particularly in relation to the assessment of the right to defer settlement and the impact of covenants.

Amendments to Ind AS 12 – Income Taxes

The amendments introduce a temporary exception from the recognition of deferred tax assets and liabilities arising from the OECD's Pillar Two global minimum tax regime and prescribe additional disclosures relating to exposure to such taxes.

Amendments to Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures

These amendments introduce enhanced disclosure requirements for supplier finance arrangements.

Ind AS 19 – Employee Benefits and Labour Codes

During the year, the Government of India implemented the Code on Wages, 2019; the Code on Social Security, 2020; The Industrial Relations Code, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 with effect from 21 November 2025.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The Group has evaluated the impact of the above amendments and concluded that they do not have any material impact on the Group's financial statements for the year ended 31 March 2026, considering the nature and extent of the Group's operations.

Standards issued but not yet effective Ind AS 1 – Presentation of Financial Statements

If covenant breach occurs on or before the reporting date and the liability becomes payable on demand, it must be classified as current, even if the lender subsequently agrees

not to demand repayment. It is classified as current because, at the reporting date, the entity does not have the right to defer settlement for at least 12 months. However, if the lender has already provided by the reporting date, a grace period extending at least 12 months beyond that date, during which the breach can be rectified and repayment cannot be demanded, the liability is classified as non-current. This amendment is to be applied retrospectively for annual reporting periods beginning on or after 1 April 2026, in accordance with Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors.

Notes to the Consolidated Financial Statements

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3. PROPERTY, PLANT AND EQUIPMENT

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Freehold land	1,624.76	1,618.98	1,708.16
Building	2,408.79	2,612.88	2,255.53
Plant and machinery	116.77	-	-
Furniture and fixtures	1,369.73	1,276.38	1,470.74
Office equipment	1,573.72	1,201.71	802.21
Leasehold Improvements	3,668.11	1,833.48	-
Motor Vehicles	1,055.93	691.00	445.88
	11,817.81	9,234.42	6,682.52

Particulars	Freehold land	Building	Plant and machinery	Furniture and fixtures	Office equipment	Leasehold Improvements	Motor Vehicles	Total
Gross carrying value at cost:								
As at 01 April 2024*	1,708.16	2,391.99	-	1,850.25	1,693.83	-	555.84	8,200.07
Reclassifications	-	-	-	(977.55)	(343.81)	1,321.36	-	-
Balance as at 01 April 2024 post reclassification	1,708.16	2,391.99	-	872.70	1,350.02	1,321.36	555.84	8,200.07
Additions	-	439.43	-	1,348.59	1,119.31	-	319.24	3,226.57
Disposals	(89.18)	-	-	-	(10.03)	-	-	(99.21)
Acquisition of business (Refer note 45 for details of acquisition of business.)	-	-	-	63.14	52.03	-	17.04	132.21
Reclassifications	-	-	-	(772.51)	(332.34)	1,104.84	-	-
As at 31 March 2025	1,618.98	2,831.42	-	1,511.93	2,178.99	2,426.21	892.12	11,459.64
Additions	43.73	-	128.02	266.66	797.07	2,602.64	549.20	4,387.31
Disposals	(37.95)	(127.58)	-	-	(10.25)	-	(76.21)	(251.99)
As at 31 March 2026	1,624.76	2,703.84	128.02	1,778.59	2,965.80	5,028.84	1,365.10	15,594.96

Notes to the Consolidated Financial Statements

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3. PROPERTY, PLANT AND EQUIPMENT (Contd.)

Particulars	Freehold land	Building	Plant and machinery	Furniture and fixtures	Office equipment	Leasehold Improvements	Motor Vehicles	Total
Accumulated depreciation:					-			
As at 01 April 2024*	-	136.46	-	379.51	891.62	-	109.96	1,517.55
Reclassifications	-	-	-	(224.25)	(131.80)	356.05	-	-
Balance as at 01 April 2024 post reclassification	-	136.46	-	155.26	759.82	356.05	109.96	1,517.55
Charge for the year	-	82.08	-	223.11	320.85	-	91.16	717.20
Disposals	-	-	-	-	(9.53)	-	-	(9.53)
Reclassifications	-	-	-	(142.82)	(93.86)	236.68	-	-
As at 31 March 2025	-	218.54	-	235.55	977.28	592.73	201.12	2,225.22
Charge for the year	-	89.39	11.25	173.31	420.27	768.01	145.83	1,608.07
Disposals	-	(12.89)	-	-	(5.48)	-	(37.78)	(56.14)
As at 31 March 2026	-	295.05	11.25	408.86	1,392.08	1,360.74	309.17	3,777.14
Net carrying value:					-			
As at 01 April 2024*	1,708.16	2,255.53	-	1,470.74	802.21	-	445.88	6,682.52
As at 31 March 2025	1,618.98	2,612.88	-	1,276.38	1,201.71	1,833.48	691.00	9,234.42
As at 31 March 2026	1,624.76	2,408.79	116.77	1,369.73	1,573.72	3,668.11	1,055.93	11,817.81

*Represents deemed cost on the date of transition to Ind AS (i.e. 01 April 2024) for financial statements. Gross carrying value and accumulated depreciation from the previous GAAP have been disclosed for the purpose of better understanding of the original cost of assets.

- The Group does not have assets pledged as security.
- Depreciation of property, plant and equipment has been presented in Note 31 i.e. Depreciation and amortisation expense.
- The title deeds of the immovable properties are held in the name of the Group.
- The depreciation expense for the year includes depreciation on the assets acquired as a part of business combination. (Refer note 45).
- The Holding Company has reclassified certain assets from "Furniture and Fixtures" and "Office Equipment" to "Leasehold Improvements" in order to better reflect the nature and use of such assets. This reclassification has been made as at the transition date (1 April 2024) and has been consistently applied for the comparative period ended 31 March 2025. The reclassification does not have any impact on the total carrying value of property, plant and equipment, profit for the period, or equity, as it represents only a change in presentation.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

3A. Capital work-in-progress

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Capital work-in-progress	206.15	1,123.31	349.84
	206.15	1,123.31	349.84

Reconciliation of Capital work in progress:

Particulars	Amount
As at 01 April 2024	349.84
Addition during the year	1,119.55
Capitalisations	(346.08)
As at 31 March 2025	1,123.31
Addition during the year	1,530.47
Capitalisations	(2,462.22)
As at 31 March 2026	206.15
Net carrying value:	
As at 01 April 2024	349.84
As at 31 March 2025	1,123.31
As at 31 March 2026	206.15

Capital Work in progress ageing schedule

Capital work in progress	As at 31 March 2026				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	186.47	19.68	-	-	206.15
Projects temporarily suspended	-	-	-	-	-

Capital work in progress	As at 31 March 2025				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	1,119.55	3.76	-	-	1,123.31
Projects temporarily suspended	-	-	-	-	-

Capital work in progress	As at 01 April 2024				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	237.16	112.68	-	-	349.84
Projects temporarily suspended	-	-	-	-	-

Note: No project has been identified whose completion is overdue versus original plan and which have exceeded their original budget.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

4. RIGHT-OF-USE ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Buildings	11,404.12	10,026.65	5,809.27
	11,404.12	10,026.65	5,809.27

Particulars	Amount
Gross carrying value:	
As at 01 April 2024	5,809.27
Additions	6,355.04
As at 31 March 2025	12,164.31
Additions	4,442.22
Disposals	(77.29)
As at 31 March 2026	16,529.24
Accumulated depreciation:	
As at 01 April 2024	-
Charge for the year	2,137.66
As at 31 March 2025	2,137.66
Charge for the year	3,015.38
Disposals	(27.92)
As at 31 March 2026	5,125.12
Net carrying value:	
As at 01 April 2024	5,809.27
As at 31 March 2025	10,026.65
As at 31 March 2026	11,404.12

Note: The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the consolidated Statement of Profit and Loss.

5. GOODWILL

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Goodwill on acquisition of business	5,811.82	5,811.82	-
	5,811.82	5,811.82	-

Refer note 45 for details of acquisition of business.

There has been restatement of goodwill on account of transition from previous GAAP to IND AS.

Refer note 47 for restatement of goodwill from IGAAP.

Note - Impairment tests for goodwill:

The Holding Company tests cash-generating units with goodwill annually for impairment, or more frequently if there is an indication that a cash-generating unit to which goodwill has been allocated may be impaired. The recoverable amount of a cash generating unit is the higher of the cash-generating unit's fair value less cost of disposal ('FVLCD') and its value-in-use.

For the purpose of annual impairment testing, goodwill is allocated to the operating segments expected to benefit from the synergies of the business combinations in which the goodwill arises as set out below, and is compared to its recoverable value:

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The carrying amount of goodwill is attributable to the following CGU/group of CGUs:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Ayurvedic Healthcare Segment	19,102.50	-	-
Total	19,102.50	-	-

Calculation of the value-in-use is based on cash flow projections on reasonable and supportable assumptions that represent economic conditions that will exist over the remaining useful life of the assets, approved by the management, but shall exclude any estimated future cash inflows or outflows expected to arise from future restructurings or from improving or enhancing asset performance.

As at 31 March 2026, the Group held goodwill of ₹ 5,811.82 lakhs attributable to identified Cash Generating Units (CGUs) resulting from the acquisition of business of Oregano Life Private Limited. Refer Note 45 for further details.

For CGU/Group of CGU's containing goodwill at the core business level, management conducts impairment assessment and compares the carrying amount of such CGU/Group of CGU's with its recoverable amount. Recoverable amount is value in use of the CGU/Group of CGU's computed based upon discounted cash flow projections for 5 years. The key assumptions used for computation of value in use are the growth rate and discount rate as specified below. The key assumptions have been determined based on management's calculations after considering, past experiences and other available internal information and are consistent with external sources of information to the extent applicable.

Growth rates:

Projections are based on the budgets/forecasts using a steady growth rate for subsequent years. In current scenario, terminal growth rate of 4% has been derived to offset inflation, basis past industry trend analysis.

Discount rates:

The discount rates reflect appropriate adjustments relating to market risk and specific risk factors of each segment. While calculating value in use discount rate of 13.55% has been considered.

Cash flow assumptions:

The management assumed that the business will be operated prudently and that the company shall continue to operate and that there are no unforeseen adverse changes in the economic conditions affecting the business, the market, or the industry.

Key assumptions:

Key assumptions include revenue and cost synergies over the forecast period for 5 years.

Recoverable Amount:

The recoverable amount of 'Ayurvedic Healthcare Segment' is ₹ 1,78,802 lakhs which is based on value in use.

Impairment:

For CGUs/Group of CGUs containing goodwill, the impairment assessment, taking into account above assumptions, did not result in any impairment loss and the management believes that any reasonably possible change in the key assumptions would not cause the carrying amount to exceed the recoverable amount of the said CGUs/Group of CGUs.

6. OTHER INTANGIBLE ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Softwares	140.73	2.67	2.13
Government Empanelment	34.22	110.83	-
Non-compete fees	85.20	119.15	-
	260.15	232.65	2.13

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

6. OTHER INTANGIBLE ASSETS (Contd.)

Particulars	Softwares	Government Empanelment	Non-compete fees	Amount
Gross carrying value at cost:				
As at 01 April 2024*	37.91	-	-	37.91
Additions	2.00	-	-	2.00
Acquisition^	-	148.40	135.80	284.20
Disposals/adjustments	-	-	-	-
As at 31 March 2025	39.91	148.40	135.80	324.11
Additions	173.24	-	-	173.24
Disposals/adjustments	-	-	-	-
As at 31 March 2026	213.15	148.40	135.80	497.35
Accumulated amortisation:				
As at 01 April 2024*	35.78	-	-	35.78
Amortisation expense	1.46	37.57	16.65	55.68
Disposals/adjustments	-	-	-	-
As at 31 March 2025	37.24	37.57	16.65	91.46
Amortisation expense	35.18	76.61	33.95	145.74
Disposals/adjustments	-	-	-	-
As at 31 March 2026	72.42	114.18	50.60	237.20
Net carrying value:				
As at 01 April 2024*	2.13	-	-	2.13
As at 31 March 2025	2.67	110.83	119.15	232.65
As at 31 March 2026	140.73	34.22	85.20	260.15

*Represents deemed cost on the date of transition to Ind AS (i.e. 01 April 2024) for financial statements. Gross block and accumulated amortisation from the previous GAAP have been disclosed for the purpose of better understanding of the original cost of assets.

^As a part of acquisition of the operations of Oregano Life Private Limited, the Company has acquired identifiable intangible assets namely, non-compete fees and government empanelment, along with other assets and liabilities, for a consideration agreed between the parties.

Refer note 45 for further details.

Amortisation of intangible assets has been presented in note 31, Depreciation and amortisation expense.

6A. INTANGIBLE ASSET UNDER DEVELOPMENT

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Intangible asset under development	79.45	224.28	43.68
Intangible asset under development	79.45	224.28	43.68

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Reconciliation of Intangible asset under development:

Particulars	Amount
As at 01 April 2024	43.68
Addition during the year	180.60
Disposals	-
Capitalisations	-
As at 31 March 2025	224.28
Addition during the year	79.45
Disposals	-
Adjustments*	(48.37)
Capitalisations	(175.91)
As at 31 March 2026	79.45

*Amount of ₹ 48.37 lakhs has been written off during the year

Intangible asset under development ageing schedule:

As at 31 March 2026

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	79.45	-	-	-	79.45
- Projects temporarily suspended	-	-	-	-	-
Total	79.45	-	-	-	79.45

As at 31 March 2025

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	180.60	43.68	-	-	224.28
- Projects temporarily suspended	-	-	-	-	-
Total	180.60	43.68	-	-	224.28

As at 01 April 2024

Particulars	0-1 year	1-2 years	2-3 years	More than 3 years	Total
- Projects in progress	43.68	-	-	-	43.68
- Projects temporarily suspended	-	-	-	-	-
Total	43.68	-	-	-	43.68

There are no 'Intangible assets under development' whose completion is overdue or has exceeded its cost compared to its original plan.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7A. INVESTMENTS

Non-current investments

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
(a) Investment in LLP (Unquoted, at cost) #			
Dupon Clean Biofuel LLP (5% partnership share)			
Fixed capital	5.00	5.00	5.00
Floating capital	59.00	59.00	59.00
(b) Investments in warrants (Convertible into equity shares) - Unquoted, at FVTPL			
Chandan Healthcare Limited*	1,395.54	-	-
Total non-current investments	1,459.54	64.00	64.00
Aggregate amount of quoted investments and market value thereof	-	-	-
Aggregate amount of unquoted investments	1,459.54	64.00	64.00
Aggregate amount of impairment in the value of investments	-	-	-

#Details of LLP

Particulars	Dupon Clean Biofuel LLP
Name of LLP	
Date of LLP Agreement	05.12.2022
Total capital	1,00,00,000
Partners details and their profitability ratio	
Dugar Growth Fund Private Limited	5%
Nitin Jain	30%
Paramjeet Singh Sehra	10%
Sucha Singh Sehra	20%
Manish Grover	30%
Jeena Sikho Lifecare Limited	5%

*On 03rd February 2026, the Holding Company has been allotted 18,00,000 Fully Convertible Warrants ("Warrants") of Chandan Healthcare Limited on a preferential basis. Following are the terms of allotment:

Number of Warrants allotted	18,00,000
Issue Price per Warrant	₹ 234 (includes face value + premium)
Total Warrant Issue Value	₹ 42,12,00,000
Amount Paid Upfront (25%)	₹ 10,53,00,000 (Paid on 02/02/2026)
Balance Amount Payable (75%)	₹ 31,59,00,000
Conversion Right and Period	Each Warrant is convertible into one Equity Share of the face value of ₹ 10 each at a premium of ₹ 224 per share within 18 month from the date of allotment

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7B. CURRENT INVESTMENTS

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	No. of units	Amount	No. of units	Amount	No. of units	Amount
Non-trade investments						
Investments in equity instruments. (Quoted, carried at FVTPL)						
Axis Bank Ltd	605.00	7.03	455.00	5.01	229.00	2.40
Bharat Electronics Ltd	898.00	3.60	369.00	1.11	-	-
Bharti Airtel Ltd	583.00	10.39	308.00	5.34	182.00	2.24
Britannia Industries Ltd	62.00	3.36	35.00	1.73	21.00	1.03
Central Depository Services (India) Limited Eq	328.00	3.67	-	-	-	-
Cipla Ltd	291.00	3.56	151.00	2.18	-	-
Dr Reddys Laboratories Ltd	329.00	4.13	155.00	1.77	-	-
Eternal Ltd	694.00	1.59	2,119.00	4.27	-	-
Hcl Technologies Ltd	212.00	2.84	78.00	1.24	52.00	0.80
HDFC Bank Ltd	2,767.00	20.24	679.00	12.41	507.00	7.34
HDFC Life Insurance Company Ltd	422.00	2.49	139.00	0.95	105.00	0.67
ICICI Bank Ltd	1,544.00	18.62	657.00	8.86	356.00	3.89
Infosys Ltd	795.00	9.94	356.00	5.59	257.00	3.85
Interglobe Aviation Ltd	131.00	5.17	-	-	-	-
Kotak Mahindra Bank Ltd	1,520.00	5.37	192.00	4.17	163.00	2.91
Larsen & Toubro Ltd	240.00	8.41	119.00	4.16	61.00	2.30
Mahindra & Mahindra Ltd	236.00	6.97	98.00	2.61	56.00	1.08
Reliance Industries Ltd	1,225.00	16.46	615.00	7.84	194.00	5.77
Samvardhana Motherson International Ltd	3,889.00	4.09	-	-	-	-
Share India Securities Ltd	3,663.00	4.30	-	-	-	-
Star Cement Ltd	1,976.00	4.02	-	-	-	-
State Bank Of India	793.00	7.77	527.00	4.07	415.00	3.12
Tata Steel Ltd	2,636.00	5.06	1,338.00	2.06	847.00	1.32
Tata Teleservices (Maharashtra) Ltd	12,398.00	3.89	-	-	-	-
Tribhovandas Bhimji Zaveri Ltd	2,243.00	2.50	-	-	-	-
Tata Consultancy Services Ltd	-	-	157.00	5.66	96.00	3.72
Tata Motors Ltd	-	-	395.00	2.66	-	-
Central Depository Services (India) Limited	-	-	182.00	2.22	-	-
Capital Small Finance Bank Ltd	-	-	738.00	1.92	-	-
Cipla Ltd-Equity Shares ₹ 2/- After Subdivision	-	-	-	-	62.00	0.93

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7B. CURRENT INVESTMENTS (Contd.)

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	No. of units	Amount	No. of units	Amount	No. of units	Amount
Divi's Laboratories Ltd	-	-	-	-	35.00	1.21
Dr Reddys Laboratories Ltd-Equity Shares Of ₹ 5/- Each	-	-	-	-	23.00	1.42
Eicher Motors Ltd	-	-	-	-	28.00	1.13
Hero Motocorp Ltd	-	-	-	-	34.00	1.61
One 97 Communications Ltd	-	-	-	-	811.00	3.27
SBI Cards And Payment Services Ltd	-	-	-	-	318.00	2.17
Zomato Ltd	-	-	-	-	1,054.00	1.92
Mutual Funds investment (Quoted, carried at FVTPL)						
ICICI Prudential Nifty Financial Services Exbank ETF	18,854.00	10.86	-	-	-	-
ICICI Prudential Nifty Alpha Low Volatility 30 Etf	-	-	33,146.00	8.76	-	-
ICICI Prudential Nifty 200 Momentum 30 ETF	-	-	-	-	18,595.00	4.74
Bandhan Sterling	-	-	-	-	2,34,004.96	308.89
ICICI Prudential Saving fund	-	-	36,636.78	195.00	-	-
Edelweiss Multi Asset Allocation Fund - Regular Plan Growth	17,15,386.07	208.53	-	-	-	-
ICICI- 1525 Savings Fund Growth	73,558.13	418.56	-	-	-	-
ICICI- 1525 Savings Fund Growth	91,988.39	523.43	-	-	-	-
ICICI- 1525 Savings Fund Growth	73,529.24	418.40	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	4,45,809.19	100.84	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	17,77,688.89	402.11	-	-	-	-
Kotak Saving Funds - Growth	16,20,848.40	207.35	-	-	-	-
ICICI- Prudential Balanced Advantage Fund	1,35,936.65	97.59	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	22,18,167.71	501.75	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	8,83,738.40	199.90	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	17,61,250.56	398.39	-	-	-	-
ICICI- 2556/ICICI Prudential Equity Saving Fund	13,06,554.88	295.54	-	-	-	-
ICICI- EDWRG/Prudential Balanced Advantage Fund	2,70,220.24	193.99	-	-	-	-

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

7B. CURRENT INVESTMENTS (Contd.)

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	No. of units	Amount	No. of units	Amount	No. of units	Amount
ICICI- EDWRG/Prudential Balanced Advantage Fund	3,95,053.27	283.61	-	-	-	-
Kotak Arbitrage Fund Growth	10,60,743.89	415.30	-	-	-	-
Kotak Saving Fund	13,94,588.27	624.31	-	-	-	-
Kotak Saving Fund	6,96,767.77	311.92	-	-	-	-
Kotak Saving Fund	3,47,878.88	155.73	-	-	-	-
Kotak Saving Fund	11,58,741.64	518.73	-	-	-	-
Kotak Saving Fund	4,62,921.60	207.24	-	-	-	-
Kotak Saving Fund	4,62,061.69	206.85	-	-	-	-
Kotak Saving Fund	6,85,883.81	307.05	-	-	-	-
Kotak Equity Savings Fund	3,71,931.87	96.31	-	-	-	-
Kotak Equity Savings Fund	3,71,713.43	96.26	-	-	-	-
Kotak Equity Savings Fund	7,39,446.65	191.49	-	-	-	-
Bandhan Money Market Fund	17,06,472.98	719.20	-	-	-	-
DSP Equity Saving Fund Growth	11,44,002.84	248.04	-	-	-	-
DSP Equity Saving Fund Growth	11,43,322.67	247.90	-	-	-	-
DSP Equity Saving Fund Growth	11,41,651.83	247.53	-	-	-	-
DSP Equity Saving Fund Growth	11,42,225.63	247.66	-	-	-	-
DSP Equity Saving Fund Growth	9,17,090.85	198.84	-	-	-	-
HDFC Focused Fund Growth	21,846.80	45.57	-	-	-	-
Total current investments	2,77,98,357.07	9,512.24	79,644.78	291.61	2,58,505.96	369.69
Total investments						
Aggregate amount of quoted investments and market value thereof	-	9,512.24	-	291.61	-	369.69
Aggregate amount of unquoted investments	-	-	-	-	-	-
Aggregate amount of impairment in the value of investments	-	-	-	-	-	-

8. LOANS, AT AMORTISED COST

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current			
(unsecured and considered good)			
Loans to related parties (Refer note (i) below)	-	212.00	412.00
Other loans	-	100.00	400.00
	-	312.00	812.00

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- (i) The Holding Company had granted a loan of ₹ 212 lakhs @10% p.a. repayable on demand, to Shuddhi Green Charcoal Private Limited, comprising ₹ 139 Lakh disbursed during the financial year ended 31 March 2022 and ₹ 73 Lakh disbursed during the financial year ended 31 March 2023 to support the borrower's working capital requirements and expansion of its operational capabilities. The loan has been fully repaid during the current financial year.

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Amount outstanding	Percentage to the total loans and advances in the nature of loans	Amount outstanding	Percentage to the total loans and advances in the nature of loans	Amount outstanding	Percentage to the total loans and advances in the nature of loans
a) Amounts repayable on demand						
- Promoters	-	-	-	-	-	-
- Directors	-	-	-	-	-	-
- Key managerial personnel	-	-	-	-	-	-
- Other related parties	-	-	212.00	68%	412.00	51%
b) Without specifying any terms or period of repayment						
- Promoters	-	-	-	-	-	-
- Directors	-	-	-	-	-	-
- Key managerial personnel	-	-	-	-	-	-
- Other related parties	-	-	-	-	-	-
Total	-	0.00%	212.00	67.95%	412.00	51%

9. OTHER FINANCIAL ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
(Unsecured and considered good)			
Financial assets carried at amortised cost			
Security deposits given to third parties	930.94	717.39	480.23
Bank deposits with remaining maturity of more than 12 months*	242.87	282.44	-
	1,173.81	999.83	480.23
Current			
(Unsecured and considered good)			
Financial assets carried at amortised cost			
Interest accrued on deposits with banks	40.15	53.27	93.18
Other receivables	152.16	-	-
Bank deposits with remaining maturity of less than 12 months	2,076.89	15.70	-
	2,269.20	68.97	93.18

*As at 31 March 2026 deposits amounting to ₹ 113.50 lakhs (31 March 2025: ₹150.75 lakhs and 01 April 2024: ₹ Nil) have been kept against bank guarantee provided to various government authorities for empanelment of Holding Company's Ayurvedic Treatments Centres. As at 31 March 2026, deposits amounting to ₹ 11.25 lakhs are marked against CC-lien (31 March 2025: ₹ 11.25 lakhs and 01 April 2024: ₹ Nil).

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

10. OTHER ASSETS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Prepaid expenses	34.51	23.45	-
Capital advances	64.22	72.45	-
	98.73	95.90	-
Current			
Prepaid expenses	230.79	239.69	92.14
Advances to vendors	978.12	509.20	1,688.77
Advance for investment*	938.00	-	-
Balances with government authorities	220.16	60.82	36.26
Others	41.09	66.91	223.44
	2,408.16	876.62	2,040.61

*Jeena Sikho International LLC has entered into a Share Purchase Agreement dated 07 January 2026 to acquire a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC ("BTRS"), UAE. The arrangement involves funding of AED 15.30 lakhs (approximately ₹ 394.27 lakhs) to existing shareholders and AED 60 lakhs (approximately ₹ 1,546.16 lakhs) to the Company, of which AED 15.30 lakhs (approximately ₹ 394.27 lakhs) to shareholders and AED 21.10 lakhs (approximately ₹ 543.73 lakhs) to the Company have been disbursed during the year ended 31 March 2026. As at 31 March 2026, the share transfer is pending completion of regulatory formalities, including commercial registration with the Department of Economic Development (DED), Abu Dhabi and amendment of the Memorandum of Association (MoA). Accordingly, the amount paid has been classified as advance for investment in consolidated financials.

11. INVENTORIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Stock in trade and consumables*	2,021.82	1,154.58	718.87
	2,021.82	1,154.58	718.87

*It includes medicine inventory costing ₹ 12.18 lakhs as at 31 March 2026 (31 March 2025: ₹ Nil; 01 April 2024: Nil) which is in transit.

12. TRADE RECEIVABLES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Secured, considered good	-	-	-
Unsecured, considered good (refer note (iii) below)	8,539.24	10,038.07	4,273.98
Credit impaired	-	-	-
Total	8,539.24	10,038.07	4,273.98
Less: Allowance for expected credit loss	(1,546.33)	(1,541.93)	(890.96)
	6,992.91	8,496.14	3,383.02

As at 31 March 2026

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	489.84	1,578.14	1,192.63	3,611.73	705.15	961.75	8,539.24
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

As at 31 March 2026 (Contd.)

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	8,539.24

As at 31 March 2025

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	69.56	6,609.24	1,294.22	987.84	990.59	86.62	10,038.07
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	10,038.07

As at 01 April 2024

Particulars	Outstanding for following periods from the date of transaction						
	Unbilled	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables considered good	-	2,227.80	588.64	1,427.71	12.97	16.86	4,273.98
(ii) Undisputed Trade Receivables credit impaired	-	-	-	-	-	-	-
(ii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	4,273.98

Notes:

- There are no disputed trade receivables.
- The arrangements do not contain any significant financing component or variable consideration, and the credit period is not fixed.
- Refer note 47 for reclassifications made during the year.
- All the Trade receivables of the Company are non interest bearing.
- The Group's trade receivables as at the reporting date largely comprise of amounts due from various government panels/ authorities. These receivables largely represent claims raised for services rendered to patients covered under such government schemes.
- Refer note 40 for details of the Company's credit risk policy and exposure.
- Trade receivables outstanding from related party ₹ 67.55 lakhs (31 March 2025: 6.04 and 01 April 2024: 270.41) (refer note 39)

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

13. CASH AND CASH EQUIVALENTS*

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balances with banks			
– In current account	939.80	1,754.75	1,707.38
– in deposit account	495.00	–	500.00
Cash in hand	202.50	543.12	324.09
	1,637.30	2,297.87	2,531.47

*There are no restrictions or specific conditions attached to the utilisation of the Group's cash and cash equivalents.

14. OTHER BANK BALANCES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Bank deposits with original maturity of more than three months but less than twelve months*	9,245.08	–	3,669.28
	9,245.08	–	3,669.28

*As at 31 March 2026 deposits amounting to ₹ Nil (31 March 2025: ₹ Nil and 01 April 2024: ₹ 215.23 lakhs) have been kept against bank guarantee provided to various government authorities for empanelment of Holding Company's Ayurvedic Treatments Centres. The Group do not have any other margin money with banks except as disclosed in Note 9 above.

15. DEFERRED TAX ASSETS (NET)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Deferred tax assets in relation to:			
Provision for post retirement benefits and other employee benefits (including bonus)	384.91	100.16	69.07
Impact of lease liability	3,192.40	2,672.86	1,437.78
Security deposits for leases	63.68	55.30	24.30
Allowance for expected credit loss	389.18	375.49	185.11
Intangible assets on account of business combination	32.24	13.65	–
Total	4,062.41	3,217.46	1,716.26
Deferred tax liabilities in relation to:			
Property, Plant and Equipment and other intangible assets	31.22	110.61	77.07
Fair value of FVTPL financial instruments	114.46	(0.85)	4.95
Security deposits from dealers	20.67	–	–
Impact of right of use asset	2,870.19	2,523.51	1,462.08
Total	3,036.54	2,633.27	1,544.10
Deferred tax assets (net)	1,025.87	584.19	172.16

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(a) Movement in deferred tax liabilities/(asset) for the year ended 31 March 2026 is as follows:

Particulars	As at 01 April 2025	Recognised in statement of profit or loss	Recognised in other comprehensive Income	As at 31 March 2026
Deferred tax assets in relation to:				
Provision for post retirement benefits and other employee benefits (including bonus)	100.16	304.63	(19.88)	384.91
Impact of lease liability	2,672.86	519.54	-	3,192.40
Security deposits for leases	55.30	8.38	-	63.68
Allowance for expected credit loss	375.49	13.69	-	389.18
Intangible assets on account of business combination	13.65	18.59	-	32.24
Total	3,217.46	864.83	(19.88)	4,062.41
Deferred tax liabilities in relation to:				
Property, Plant and Equipment and other intangible assets	110.61	(79.39)	-	31.22
Fair value of FVTPL financial instruments	(0.85)	115.31	-	114.46
Security deposits from dealers	-	20.67	-	20.67
Impact of right of use asset	2,523.51	346.68	-	2,870.19
Total	2,633.27	403.27	-	3,036.54
Deferred tax assets (net)	584.19	461.56	(19.88)	1,025.87

(b) Movement in deferred tax liabilities/(asset) for the year ended 31 March 2025 is as follows:

Particulars	As at 01 April 2024	Recognised in statement of profit or loss	Recognised in other comprehensive Income	As at 31 March 2025
Deferred tax assets in relation to:				
Provision for post retirement benefits and other employee benefits (including bonus)	69.07	30.50	0.59	100.16
Impact of lease liability	1,437.78	1,235.08	-	2,672.86
Security deposits for leases	24.30	31.00	-	55.30
Allowance for expected credit loss	185.11	190.38	-	375.49
Intangible assets on account of business combination	-	13.65	-	13.65
Total	1,716.26	1,500.61	0.59	3,217.46
Deferred tax liabilities in relation to:				
Property, Plant and Equipment and other intangible assets	77.07	33.54	-	110.61
Fair value of FVTPL financial instruments	4.95	(5.80)	-	(0.85)
Impact of right of use asset	1,462.08	1,061.43	-	2,523.51
Total	1,544.10	1,089.17	-	2,633.27
Deferred tax assets (net)	172.16	411.44	0.59	584.19

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

16. EQUITY SHARE CAPITAL

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Authorised share capital			
12,50,00,000 (31 March 2025: 2,50,00,000 and 01 April 2024: 2,50,00,000) equity shares of face value ₹ 2 each (31 March 2025 and 01 April 2024: ₹ 10 each)	2,500.00	2,500.00	2,500.00
Issued, subscribed and fully paid up			
12,43,00,730 (31 March 2025: 2,48,60,146 and 01 April 2024: 2,48,60,146) equity shares of face value ₹ 2 each fully paid-up (31 March 2025 and 01 April 2024: ₹ 10 each)	2,486.01	2,486.01	2,486.01
Total equity share capital	2,486.01	2,486.01	2,486.01

Notes:

(i). Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the year:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Number	Amount	Number	Amount	Number	Amount
Equity shares outstanding at the beginning of the year	2,48,60,146	2,486.01	2,48,60,146	2,486.01	2,48,60,146	2,486.01
Add: Subdivision of equity shares of ₹ 10 each to ₹ 2 each*	9,94,40,584	-	-	-	-	-
Equity shares outstanding at the end of the year	12,43,00,730	2,486.01	2,48,60,146	2,486.01	2,48,60,146	2,486.01

*On 12 June 2025, the Holding Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each, fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

(ii). Terms and rights attached to equity shares

The Holding Company has only one class of Equity Shares having a par value of ₹ 2 per share. (31 March 2025 and 01 April 2024: ₹ 10 per share). Each holder of Equity Shares is entitled to one vote per share. In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the Holding Company after distribution of all preferential amounts, in proportion to their shareholding.

In the year ended 31 March 2022, the Holding Company had issued bonus shares totalling to 1,00,00,080 equity shares on 25 August 2021 (90 equity shares for every one share held) and 1,10,48,954 equity shares on 03 November 2023 (4 equity shares for every 5 share held).

On 12 June 2025, the Holding Company sub-divided/split its equity shares from one equity share of face value ₹ 10 each,

fully paid-up, into five equity shares of face value ₹ 2 each, fully paid-up. The subdivision did not result in any change in the paid-up share capital of the Company.

The board of directors of the Holding Company in their meeting held on 16 May 2025 has recommended a dividend of ₹ 5.47 (before share split) of the face value of ₹ 10 each for the FY 2024-25, ₹ 1.10 (post share split) of face value of ₹ 2 each was approved by the shareholders in the Annual General Meeting of the Holding Company dated 29 September 2025. The same has been paid during the year.

The board of directors of the Holding Company at its meeting held on 30 May 2026, has recommended a final dividend of ₹ 4.50 per equity share to the shareholders of the Company for the year ended 31 March 2026, subject to the approval of the shareholders in the forthcoming Annual General Meeting.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(iii). Details of share holding more than 5 percent shares in the Holding company:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Numbers	% holding	Numbers	% holding	Numbers	% holding
Manish Grover	7,86,41,190	63.27%	1,57,28,328	63.27%	1,66,52,448	66.98%
Sixteenth Street Asian Gems Fund	70,33,050	5.66%	14,06,610	5.66%	–	0.00%
Oregano Life Private Limited	46,85,708	3.77%	14,43,045	5.80%	15,04,245	6.05%
	9,03,59,948	72.70%	1,85,77,983	74.73%	1,81,56,693	73.03%

(v). Equity shareholding of Promoters

As at 31 March 2026

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	7,86,41,190	63.27%	0.00%
Bhavna Grover	2,43,000	0.20%	0.00%

As at 31 March 2025

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	1,57,28,238	63.27%	(3.71%)
Bhavna Grover	48,600	0.20%	(0.57%)

As at 01 April 2024

Name of the Promoters	No. of Shares [^]	% of share holding	% Change during the year
Manish Grover	1,66,52,448	66.98%	–
Bhavna Grover	1,92,600	0.77%	–

[^]The change in the number of shares held by the promoters as at 31 March 2026 represents the change due to share split as explained in note 16(ii)

Promoter for the purpose of this disclosure means promoter as defined under section 2(69) of Companies Act, 2013.

(vi). The Holding Company has not bought back any shares and neither issued any shares for consideration other than cash.

17. OTHER EQUITY

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Securities premium	5,330.79	5,330.79	5,330.79
Foreign currency translation reserve	0.32	–	–
Retained earnings	38,605.16	17,728.26	10,774.85
Employee Stock Options Outstanding Account	285.60	89.22	1.08
	44,221.87	23,148.27	16,106.72

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

17.1 Securities premium

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	5,330.79	5,330.79	5,330.79
Balance at the end of the year	5,330.79	5,330.79	5,330.79

Note: This reserve represents the premium on issue of shares and can be utilised in accordance with the provisions of the Companies Act, 2013.

17.2 Foreign currency translation reserve

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	-	-	-
Currency translation difference during the year	0.32	-	-
Balance at the end of the year	0.32	-	-

Note: Exchange difference arising on translation of the foreign operations are recognised in other comprehensive income as described in accounting policy and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the investment is disposed-off.

17.3 Retained earnings

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	17,728.26	10,774.85	10,774.85
Profit for the year	22,185.08	7,994.33	-
Other comprehensive income	59.13	(1.75)	-
Dividend paid	(1,367.31)	(1,039.17)	-
Balance at the end of the year	38,605.16	17,728.26	10,774.85

Note: Retained earnings are created from the net profit/(loss) of the Company after all distributions and transfers to other reserves, etc.

17.4 Share options outstanding account

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Balance at the beginning of the year	89.22	1.08	1.08
Employee stock option expense	196.38	88.14	-
Balance at the end of the year	285.60	89.22	1.08

Notes:

- Refer note 37 for further details of employee stock option expense.
- The share based payment reserve represents the value of equity settled share based payment transaction with employees. The amounts recorded in share based payment reserves are transferred to share capital and share premium (excess of fair value) upon exercise of stock options by employees.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

18. BORROWINGS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
(Secured, at amortised cost)			
From banks			
Vehicle loans*	26.50	42.92	32.16
	26.50	42.92	32.16

*Vehicle loan from Banks is for a total of three vehicles (Loan from HDFC Bank and Axis Bank). The loans are secured by hypothecation of the vehicles. These vehicle loans carries an interest rate from 8.74% to 9.12% p.a. (31 March 2025 and 01 April 2024: 8.74% p.a. to 9.12% p.a.). The loans are repayable in 5 years EMI. The details for the repayment terms and other factors are listed below:

- (i) **Outstanding vehicle loan 1:** Repayable in equated monthly instalments of ₹ 0.28 lakhs over the period from 05 April 2022 to 05 March 2026.
- (ii) **Outstanding vehicle loan 2:** Repayable in equated monthly instalments of ₹ 1.78 lakhs over the period from 07 September 2021 to 07 August 2026.
- (iii) **Outstanding vehicle loan 3:** Repayable in equated monthly instalments of ₹ 0.86 lakhs over the period from 05 March 2025 to 05 February 2030.

Note: There are no covenants related to the above loans payable.

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current			
(Secured, at amortised cost)			
Current maturities of long term borrowing	16.42	30.80	22.00
(Unsecured, at amortised cost)			
Unsecured loans*	2.50	1,000.00	-
	18.92	1,030.80	22.00

*It represents interest free demand loan taken from the director of Holding Company. Refer note 39 for further details

19. LEASE LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Lease obligations	9,548.25	8,513.08	4,780.78
	9,548.25	8,513.08	4,780.78
Current			
Lease obligations	3,136.09	2,106.99	931.94
	3,136.09	2,106.99	931.94

Refer note 36 Leases for lease liability movement.

20. OTHER FINANCIAL LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Trade/security deposits from vendors and others	80.85	-	-
	80.85	-	-

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

20. OTHER FINANCIAL LIABILITIES (Contd.)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current			
Capital creditors	106.70	21.71	-
Trade/security deposits from vendors and others	329.73	488.61	340.41
Employee related payable	2,050.24	847.61	525.68
Dividend payable	2.79	2.33	1.28
Other payable	1.57	-	-
	2,491.03	1,360.26	867.37

21. PROVISIONS

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Provision for employee benefits			
Provision for gratuity (refer note 38)	562.52	369.31	257.95
	562.52	369.31	257.95
Current			
Provision for employee benefits			
Provision for compensated absences (refer note 38)	33.79	-	-
Provision for gratuity (refer note 38)	43.84	28.66	16.50
	77.63	28.66	16.50

22. CURRENT TAX LIABILITIES (NET)

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Provision for income tax (net of advance tax)	815.05	137.28	266.03
	815.05	137.28	266.03

23. OTHER LIABILITIES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non-current			
Deferred revenue*	12.49	-	-
	12.49	-	-
Current			
Revenue received in advance	1,219.13	673.47	366.60
Statutory liabilities	293.94	329.70	270.05
Deferred revenue*	7.13	-	-
Contract liability – loyalty points	124.92	-	-
Others**	-	93.29	-
	1,645.12	1,096.46	636.65

*It represents the unamortized portion of non-refundable security deposits received from franchisees/dealers.

**It represents the amount payable to the Rajasthan Government Health Scheme (government panel) against the notice received and the same has been paid during the year.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

24. TRADE PAYABLES

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
i. total outstanding dues of micro enterprises and small enterprises (refer note below)	769.49	238.29	35.45
ii. total outstanding dues of creditors other than micro enterprises and small enterprises	1,545.16	1,336.51	782.39
	2,314.65	1,574.80	817.84
Disclosures under Micro, Small and Medium Enterprises Development (MSMED) Act, 2006:			
i) Principal amount due to suppliers under MSMED Act	761.02	238.29	35.45
ii) Interest due on unpaid principal amount to MSME suppliers	8.47	-	-
iii) the amount of interest paid by the buyer under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-	-
iv) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006)	-	-	-
v) The amount of interest accrued and remaining unpaid at the end of accounting year	-	-	-
vi) The amount of further interest remaining due and payable even in the succeeding year, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23 of MSMED Act 2006	-	-	-
vii) Interest accrued and remaining unpaid at the end of the accounting year	-	-	-
	769.49	238.29	35.45

(b) Trade payables ageing is as follows: **

Particulars	As at 31 March 2026					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	594.11	18.34	4.88	-	617.33
(ii) Others	946.72	719.38	27.55	3.56	0.10	1,697.32
Total	946.72	1,313.49	45.89	8.44	0.10	2,314.65

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(b) Trade payables ageing is as follows: ** (Contd.)

Particulars	As at 31 March 2025					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	238.28	-	-	-	238.28
(ii) Others	646.95	635.53	50.25	3.79	-	1,336.52
Total	646.95	873.81	50.25	3.79	-	1,574.80

Particulars	As at 01 April 2024					
	Outstanding for following periods from the date of transaction					
	Not due*	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	35.45	-	-	-	35.45
(ii) Others	372.08	340.16	54.37	2.15	13.64	782.40
Total	372.08	375.61	54.37	2.15	13.64	817.84

*Includes unbilled payables of ₹ 22.34 lakhs (31 March 2025: ₹ 18.91 lakhs; 01 April 2024 ₹ 11.12 lakhs).

**The Group doesn't have any disputed outstanding balance as at 31 March 2026, 31 March 2025 and 01 April 2024.

Refer Note 48 for the reclassification/regrouping made during the year.

25. REVENUE FROM OPERATIONS

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of products	41,569.28	21,535.59
Sale of services	38,340.37	25,371.60
Other operating revenues		
Royalty*	53.18	-
Deferred franchise deposit income	96.79	-
Others**	76.77	-
Revenue from operations	80,136.39	46,907.19

*It represents the royalty income transaction with the related party. Refer Note 39 for further details.

**It represents the revenue share income on account of diagnostic services rendered by Chandan Healthcare Limited to the patients referred by the Holding Company.

Notes:

(a) Disaggregated revenue information

The Group has performed disaggregated analysis of revenue considering the nature, amount, timing and uncertainty of revenue, this includes disclosure of revenue by geography and timing of recognition.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue by nature		
Ayurvedic products/medicines	41,569.28	21,535.59
Ayurvedic healthcare services	38,340.37	25,371.60
Total	79,909.65	46,907.19

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(a) Disaggregated revenue information (Contd.)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue by geography		
Domestic	79,868.41	46,800.67
Export	267.98	106.52
Total	80,136.39	46,907.19
Revenue by time		
Revenue recognised at point in time	41,699.23	21,535.59
Revenue recognised over time	38,437.16	25,371.60
Total	80,136.39	46,907.19

(b) Assets and liabilities related to particular contracts with customers

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Trade receivables (Asset)	6,992.91	8,496.14
Total contract assets	6,992.91	8,496.14
Revenue received in advance (Liability)	1,219.13	673.47
Contract liability – loyalty points* (Liability)	124.92	-
Total contract liabilities	1,344.05	673.47

*The Holding Company has started giving loyalty points to the end consumers from the current financial year ending 31 March 2026.

(c) Reconciliation of contract liabilities recognised in the Balance Sheet

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening balance	673.47	366.60
Revenue received in advance and loyalty points earned during the year	2,068.83	673.47
Revenue billed/redemption/lapsed during the year	(1,398.25)	(366.60)
Closing balance	1,344.05	673.47

(d) Reconciling the amount of revenue recognised in the statement of profit and loss with the contracted price

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Contract price	80,643.51	46,907.19
Less:		
Discounts, Rebates, Credits etc.	(507.12)	-
Revenue from operations	80,136.39	46,907.19

(e) The following aggregated amounts of transaction prices relate to the performance obligations from existing contracts that are unsatisfied or partially unsatisfied:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue expected to be recognised	1,219.13	673.47

(f) No single external customer represents 10% or more of the Group's total revenue.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

26. OTHER INCOME

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest income		
Interest income earned on:		
– bank deposits (at amortised cost)	165.48	200.13
– financial assets (at amortised cost)	77.29	71.54
	242.77	271.67
Other income		
Fair value gain on financial instruments at fair value through profit or loss	465.85	–
Gain on sale of property, plant and equipment (net)	–	233.36
Gain on sale of investment (net)	5.91	100.95
Miscellaneous income*	135.08	67.56
	606.84	401.87
Total other income	849.61	673.54

*It significantly comprises income on account of rent, gain on termination of leases, referral incentives and advance from customers being written off.

27. PURCHASES OF STOCK IN TRADE AND CONSUMABLES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchases of stock in trade and consumables*	10,020.21	5,857.99
Total	10,020.21	5,857.99

*Refer note 32.2 below for the details of food and kitchen expenses included in the consumables in the current year.

28. CHANGES IN INVENTORIES OF STOCK IN TRADE AND CONSUMABLES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening Stock:		
Stock in trade and consumables	1,154.58	718.87
	1,154.58	718.87
Closing Stock:		
Stock in trade and consumables	2,021.82	1,154.58
	2,021.82	1,154.58
Net increase	(867.23)	(435.71)

29. EMPLOYEE BENEFITS EXPENSE

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Salaries and wages	13,514.56	9,316.15
Contribution to provident and other fund (refer note 38)	701.24	467.62
Defined benefit plan expense (refer note 38)	296.53	122.08
Share based payment to employees (refer note 37)	196.38	88.14
Staff welfare expenses	131.77	80.29
Total employee benefits expense	14,840.48	10,074.28

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

30. FINANCE COSTS

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest expense on borrowings- financial liability measured at amortised cost	4.43	3.36
Interest expense on financial liability measured at amortised cost	14.67	84.30
Interest on lease liabilities	1,255.78	930.59
Other finance costs	8.47	47.24
Total finance costs	1,283.35	1,065.49

31. DEPRECIATION AND AMORTISATION EXPENSE

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation of property, plant and equipment (refer note 3)	1,608.08	717.20
Amortisation of intangible assets (refer note 6)	145.74	55.68
Depreciation of right-of-use assets (refer note 4)	3,015.38	2,137.66
Total depreciation and amortisation expense	4,769.20	2,910.54

32. OTHER EXPENSES[#]

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Electricity charges	1,041.17	862.81
Telephone and communication expenses	106.41	111.08
Rent expense (variable and short term leases)	1,658.56	960.43
Repair and maintenance	509.33	482.62
Rates and taxes	269.07	238.40
Office and operational expenses	1,146.62	878.61
Postage and courier	949.98	388.31
Travelling and conveyance	665.52	515.53
Printing and stationery	227.39	139.60
Freight cartage and other distribution cost	91.97	46.65
Platform fees and franchisee (agent) service commission	130.25	453.80
CSR expenditure	170.00	101.64
Legal and professional expenses	1,170.24	981.79
Payments to auditors (refer note 32.1 below)	203.24	14.62
Advertising and sales promotion expenses	6,269.65	5,801.20
Security expenses	2,583.19	1,511.48
Advances/loans written off	184.24	115.03
Software and computer expenses	382.31	143.39
Input tax credit written off	1,192.60	936.17
Bank charges	104.82	-
Allowance for expected credit loss	598.09	650.97

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

32. OTHER EXPENSES[#] (Contd.)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Business support services	333.65	426.60
Call centre expenses	734.48	652.02
Uniform charges	51.31	40.52
Food & kitchen expenses (refer note 32.2 below)	66.19	576.50
Loss on sale of property, plant and equipment (net)	21.58	-
Write off of property, plant and equipment (net)	34.33	-
Miscellaneous expenses ^{**}	304.45	320.61
Total other expenses	21,200.64	17,350.38

Note 32.1 Payments to the auditors (excluding goods and services tax wherever applicable).

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
As auditors		
- Statutory audit fees [*]	188.00	12.00
- Tax audit fees [^]	2.50	2.00
- Out of pocket expenses	5.99	0.62
- Other services	4.25	-
	200.74	14.62

Note 32.2 The food and kitchen expenses pertaining to the hospitals, clinics and day care centres for the current year has been considered as a part of consumables and since the bifurcation of the expense for the previous year was not available, therefore, the same has been considered as a part of other expenses.

^{*}Current year expense includes ₹ 11 lakhs pertaining to the predecessor auditor.

[^]It relates to tax audit fees pertaining to predecessor auditor.

^{**}It majorly comprises of insurance charges, annual maintainence expenses, call centre expenses, cleaning expenses, fair value loss on financial instruments etc.

[#]Previous year expenses have been regrouped wherever necessary.

33. INCOME TAXES

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Income tax recognised in the statement of profit and loss		
Current tax		
In respect of the current year	8,017.00	3,153.33
In respect of the previous year	14.10	21.54
	8,031.10	3,174.87
Deferred tax		
In respect of the current year	(461.56)	(411.44)
	(461.56)	(411.44)
Total income tax expense recognised in the current year	7,569.54	2,763.43

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

33. INCOME TAXES (Contd.)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
The income tax expense for the year can be reconciled to the accounting profit as follows:		
Profit before tax	29,739.35	10,757.76
Statutory income tax rate (as per Indian Income Tax Act 1961)	25.17%	25.17%
Income tax expense at statutory income tax rate	7,484.80	2,707.51
Excess of depreciation as per books over income tax	-	-
Effect of expenses that are not deductible in determining taxable profit	53.23	28.50
Others	31.51	27.42
	7,569.54	2,763.43

34. EARNINGS PER SHARE

Basic earning per share amount is calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

Diluted earning per share amount is calculated by dividing the profit for the year attributable to equity holder by the weighted average number of equity shares outstanding during the year plus the weighted average number of equity shares that would be issued on conversion of all dilutive potential equity shares into equity shares.

The following reflects the income and share data used in the basic and diluted EPS computations:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit attributable to equity holder of the Company (A)	22,169.81	7,994.33
Number of equity shares as at 31 March 2026	12,43,00,730	2,48,60,146
Face value per share (INR)	2	10
Weighted average number of equity shares used for computing:		
Basic EPS (B)	12,43,00,730	12,43,00,730
Effect of dilutive shares (on account of ESOPs)	1,73,877	1,27,034
Diluted EPS (C)	12,44,74,607	12,44,27,764
Basic EPS (A/B)*	17.84	6.43
Diluted EPS (A/C)*	17.81	6.42

*Earnings per share is computed after giving effect to 1:5 stock split effective June 12, 2025 for all the periods presented. Accordingly, the number of equity shares for the year ended 31 March 2025 has been restated retrospectively for the purpose of EPS calculation. Refer Note 16 of these financial statements for further details regarding such stock split.

35. SEGMENT REPORTING

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Group. The CODM is considered to be the one who makes strategic decisions and is responsible for allocating resources and assessing the financial performance of the operating segments. Information reported to the CODM for the purposes of resource allocation and assessment of segment performance focuses on the types of goods delivered or services rendered.

With regard to the segment reporting, the Group has identified the following operating and reportable segments-

- Ayurvedic products/medicines
- ayurvedic healthcare services
- Others

The Group has disclosed this Segment Reporting in Financial Statements as per Ind AS 108.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The Group's CODM does not review assets and liabilities for each operating segment separately, hence segment information relating to the total assets and liabilities has not been furnished.

Particulars	Year ending 31 March 2026				
	Ayurvedic products/ medicines	Ayurvedic healthcare services	Others	Unallocable	Total
Segment Revenue					
Domestic	41,323.14	38,340.37	226.74	-	79,890.25
Export	246.14	-	-	-	246.14
Revenue from operations	41,569.28	38,340.37	226.74	-	80,136.39
Add: Other income					
Other income	-	-	-	849.61	849.61
Less: Expenses					
Purchases of stock-in-trade and consumables	6,194.88	3,825.33	-	-	10,020.21
Changes in inventories of stock in trade and consumables	(751.59)	(115.64)	-	-	(867.23)
Employee benefits expense	6,708.71	6,187.87	-	1,943.90	14,840.48
Finance costs	-	-	-	1,283.35	1,283.35
Depreciation and amortization expense	2,480.95	2,288.25	-	-	4,769.20
Other expenses	10,478.90	10,518.50	-	203.24	21,200.64
Segment results	16,457.42	15,636.07	226.74	(2,580.88)	29,739.35
Tax expense	-	-	-	-	7,569.54
Profit after tax	-	-	-	-	22,169.81

Particulars	Year ending 31 March 2025				
	Ayurvedic products/ medicines	Ayurvedic healthcare services	Others	Unallocable	Total
Segment Revenue					
Domestic	21,429.07	25,371.60	-	-	46,800.67
Export	106.52	-	-	-	106.52
Revenue from operations	21,535.59	25,371.60	-	-	46,907.19
Add: Other income					
Other income	-	-	-	673.54	673.54
Less: Expenses					
Purchases of stock-in-trade and consumables	3,561.90	2,296.09	-	-	5,857.99
Changes in inventories of stock in trade and consumables	(435.71)	-	-	-	(435.71)
Employee benefits expense	4,025.24	4,742.23	-	1,306.81	10,074.28
Finance costs	-	-	-	1,065.49	1,065.49
Depreciation and amortization expense	1,336.26	1,574.28	-	-	2,910.54
Other expenses	8,035.69	9,300.07	-	14.62	17,350.38
Segment results	5,012.21	7,458.93	-	(1,713.38)	10,757.76
Tax expense	-	-	-	-	2,763.43
Profit after tax	-	-	-	-	7994.33

Note:

- (i) No single external customer represents 10% or more of the Group's total revenue for the year ended 31 March 2026 and 31 March 2025.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- (ii) There is no inter-segment revenue for the year ended 31 March 2026 and 31 March 2025.
- (iii) There is no non current asset other than financial instruments which is located outside India.

36. LEASES

The Holding Company has leases for buildings. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Holding Company classifies its right-of-use assets in a consistent manner to its property, plant and equipment. Lease payments to be made under reasonably certain extension options are also included in the measurement of the lease liability. The lease payments are discounted using incremental borrowing rate of the Holding Company, being the rate the Holding Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar environment with similar terms, security and conditions. The average remaining lease term is 2.8 years (31 March 2025: 3.8 years). The subsidiary companies do not have any leases to be accounted for in accordance with Ind AS 116.

Following is the carrying value of lease liabilities:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Current lease liabilities (refer note 19)	3,136.09	2,106.99	931.94
Non-current lease liabilities (refer note 19)	9,548.25	8,513.08	4,780.78

Following is the movement of lease liabilities:

Particulars	Amount
Balance as at 01 April 2024	5,712.72
Additions during the year	6,199.22
Finance cost accrued during the year	930.59
Payment of lease liabilities	(2,222.46)
Balance as at 31 March 2025	10,620.07
Additions during the year	4,331.93
Finance cost accrued during the year	1,255.78
Termination during the year	(53.24)
Payment of lease liabilities	(3,470.20)
Balance as at 31 March 2026	12,684.34

Following amounts has been recognised in the statement of profit or loss:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation of right-of-use assets (refer note 4)	3,015.38	2,137.66
Interest on lease liabilities included in interest expenses (refer note 30)	1,255.78	930.59
Expenses relating to short-term leases (refer note 32)	1,628.56	960.43
Expenses related to variable lease payments	30.00	-

Total cash outflows of the leases for the year ended is ₹ 5,128.76 lakhs including payments relating to short-term leases ₹ 1,628.56 lakhs and expenses related to variable lease payments ₹ 30 lakhs. Further for the year ended 31 March 2025 the cash outflows of the leases was ₹ 3,182.90 lakhs including payments relating to short-term leases ₹ 960.43 lakhs.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Nature of the Holding Company's leasing activities by type of right-of-use-asset recognized on balance sheet date:

Particulars	As at 31 March 2026	As at 31 March 2025
Number of right-of-used assets leased	100	69
Range of remaining lease term	0.18 to 10.18 years	0.05 to 11.18 years
Average of remaining lease term	2.8 years	3.8 years
No. of lease with extension options	3	1
No. of lease with option to purchase	-	-
No. of lease with variable payments linked to an index	-	-
No. of lease with termination option	94	62

37. SHARE BASED PAYMENT

I. a. Description of share based payment arrangements- Employee Stock Option Scheme 2024

The Jeena Sikho Employee Stock Option Scheme 2024 has been adopted by the Board of Directors of the Holding Company on 27 February 2024, read with the Special Resolution passed by the Members of the Holding Company on 27 February 2024 and shall be deemed to come into force with effect from 27 February 2024 being the date of approval by the Members. Pursuant to this, the Holding Company granted options to eligible employees at an exercise price of ₹10 per option on 28 March 2024 i.e. the grant date of the employee stock option. Each option is convertible into one Equity Share of the Holding Company upon vesting subject to the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the terms and conditions of the scheme.

The maximum number of shares that may be issued pursuant to exercise of options granted to the participants under this Scheme shall not exceed 6,50,000 post split (1,30,000 pre split) shares of the Holding Company. Subject to applicable laws, the Holding Company reserves the right to increase or reduce such number of shares as it deems fit.

The maximum number of the shares that may be issued pursuant to the grant of the options to each grantee under ESOS 2024 shall be 100,000 (20,000 pre split) provided that maximum number of shares with respect to which options may be granted to a single employee shall not exceed 1% of the issued capital of the Holding Company at any point of time.

The terms and conditions of the grant as per the plan are as under:

A. Vesting period

Vesting of the options shall take place as per the following schedule:

- 25% of options shall vest at the end of a period of 2.5 years from date of grant
- 75% of options shall vest at the end of a period of 5 years from date of grant

B. Exercise period

The exercise period shall commence from the date of vesting and shall close on the expiry of one year from the last vesting date (i.e., vesting date of the second tranche) for the respective grant of option. The employee shall have a right to exercise all the option vested in him within the exercise period.

Further, during the current financial year, the Holding Company's equity shares were sub-divided (split) in the ratio of 1:5, whereby one equity share of face value ₹ 10 each was split into five equity shares of face value ₹ 2 each.

Consequent to the above sub-division and in accordance with the terms of the ESOP Scheme and the principles of Ind AS 102, the ESOPs outstanding were proportionately adjusted.

Accordingly, the number of stock options outstanding was increased, and exercise price per option was reduced proportionately, so as to preserve the economic value of the options granted to employees.

The adjustment did not result in any change in the total fair value of the stock options outstanding and, accordingly, no incremental compensation cost has been recognised due to the share split.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Vesting of options will take place in the following manner:

Tranche	Vesting date	Option to be Vested (as a % of total Granted Options)
1	Date being the date immediately after the date of expiry of two and half (2.5) years from the date of acceptance of the Options Granted to such Participant	25%
2	Date being the date immediately after the date of expiry of five (5) years from the date of acceptance of the Options Granted to such Participant	75%

Set out below is a summary of options granted under the ESOP Scheme 2024:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options	Weighted average exercise price per share option (INR)	Number of options
Opening balance	10.00	50,625.00	10.00	60,275.00	10.00	60,275.00
Adjustment due to share split	2.00	2,02,500.00	-	-	-	-
Granted during the year	-	-	-	-	-	-
Exercised during the year	-	-	-	-	-	-
Cancelled during the year	2.00	(18,500.00)	-	-	-	-
Forfeited/expired during the year	2.00	(39,250.00)	10.00	(9,650.00)	-	-
Adjustment for issue of bonus shares and sub-division of equity shares	-	-	-	-	-	-
Closing balance	2.00	1,95,375.00	10.00	50,625.00	10.00	60,275.00

Share options outstanding at the end of the year has following exercise prices and remaining contractual life:

Tranche	Grant date	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
		Exercise price*	Share options**	Remaining contractual life	Exercise price	Share options	Remaining contractual life	Exercise price	Share options	Remaining contractual life
1	28-Mar-24	2.00	48,843.75	181 days	10.00	12,656.25	546 days	10.00	15,068.75	910 days
2	28-Mar-24	2.00	1,46,531.25	1093 days	10.00	37,968.75	1458 days	10.00	45,206.25	1822 days

*The exercise price of the ESOPs has been adjusted from ₹ 10 to ₹ 2 pursuant to the share split during the current year.

**The number of share options has increased pursuant to the share split undertaken during the current year.

b. Measurement of fair values

The fair values are measured based on the Black-Scholes-Merton model. The fair value of the options and inputs used in the measurement of the grant date and measurement date fair values of the equity-settled share based payments are as follows:

Tranche	Options granted on	Fair value per Option at grant date (in INR)*	Share price at grant date (in INR)**	Exercise price (in INR)	Expected volatility	Expected life (in years)^	Expected dividend yield	Risk-free interest rate
1	28-Mar-24	825.04	841.65	2.00	50.00%	4.25	0.25%	6.35%
2	28-Mar-24	823.01	841.65	2.00	50.00%	5.50	0.25%	6.38%

*Fair value per option at the grant date has been considered without giving effect to the share split undertaken during the current year.

**Share price at the grant date has been considered without giving effect to the share split undertaken during the current year.

^It has been computed by taking into account the vesting period along with the median of the exercise period for the respective tranches.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

II. a. Description of share based payment arrangements- Employee Stock Option Scheme 2025

The Jeena Sikho Employee Stock Option Scheme 2025 has been adopted by the Board of Directors of the Holding Company on 29 September 2025, read with the Special Resolution passed by the Members of the Holding Company on 29 September 2025 and shall be deemed to come into force with effect from 29 September 2025 being the date of approval by the Members. Pursuant to this, the Holding Company granted options to eligible employees at an exercise price of ₹2 per option on 01 January 2026 and 25 March 2026 i.e. the grant date of the employee stock option as explained in note 37(II b). Each option is convertible into one Equity Share of the Company upon vesting subject to the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the terms and conditions of the scheme.

The maximum number of shares that may be issued pursuant to exercise of options granted to the participants under this Scheme shall not exceed 2,50,000 shares of the Holding Company. Subject to applicable laws, the Holding Company reserves the right to increase or reduce such number of shares as it deems fit.

The maximum number of the shares that may be issued pursuant to the grant of the options to each grantee under

ESOS 2025 shall be 25,000 provided that maximum number of shares with respect to which options may be granted to a single employee shall not exceed 1% of the issued capital of the Company at any point of time.

The terms and conditions of the grant as per the plan are as under:

A. Vesting period

Vesting of the options shall take place as per the following schedule:

- 20% of options shall vest at the end of a period of 1 year from date of grant
- 30% of options shall vest at the end of a period of 2 years from date of grant
- 50% of options shall vest at the end of a period of 3 years from date of grant

B. Exercise period

The exercise period shall commence from the date of vesting and shall close on the expiry of one year from the last vesting date (i.e., vesting date of the third tranche) for the respective grant of option. The employee shall have a right to exercise all the option vested in him within the exercise period.

Vesting of options will take place in the following manner:

Tranche	Vesting date	Option to be Vested (as a % of total Granted Options)
1	Date being the date immediately after the date of expiry of One (1) year from the date of acceptance of the Options Granted to such Participant	20%
2	Date being the date immediately after the date of expiry of Two (2) years from the date of acceptance of the Options Granted to such Participant	30%
3	Date being the date immediately after the date of expiry of Three (3) years from the date of acceptance of the Options Granted to such Participant	50%

Set out below is a summary of options granted under the ESOP plan 2025:

Particulars	As at 31 March 2026	
	Weighted average exercise price per share option (INR)	Number of options
Opening balance	-	-
Granted during the year	2.00	2,18,775.00
Forfeited/expired during the year	2.00	(6,075.00)
Closing balance	2.00	2,12,700.00

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Share options outstanding at the end of the year has following exercise prices and remaining contractual life:

Tranche	Grant date	As at 31 March 2026		
		Exercise price	Share options	Remaining contractual life
1	1-Jan-26	2.00	37,540.00	276 days
2	1-Jan-26	2.00	56,310.00	641 days
3	1-Jan-26	2.00	93,850.00	1007 days
4	25-Mar-26	2.00	5,000.00	359 days
5	25-Mar-26	2.00	7,500.00	725 days
6	25-Mar-26	2.00	12,500.00	1090 days

b. Measurement of fair values

The fair values are measured based on the Black-Scholes-Merton model. The fair value of the options and inputs used in the measurement of the grant date and measurement date fair values of the equity-settled share based payments are as follows:

Tranche	Options granted on	Fair value per Option at grant date (in INR)	Share price at grant date (in INR)	Exercise price (in INR)	Expected volatility	Expected life (in years)	Expected dividend yield	Risk-free interest rate
1	1-Jan-26	673.74	682.20	2.00	50.00%	2.50	0.40%	5.69%
2	1-Jan-26	672.45	682.20	2.00	55.00%	3.00	0.40%	5.78%
3	1-Jan-26	671.17	682.20	2.00	55.00%	3.50	0.40%	5.86%
4	25-Mar-26	586.05	594.50	2.00	50.00%	2.50	0.45%	5.84%
5	25-Mar-26	584.77	594.50	2.00	50.00%	3.00	0.45%	5.93%
6	25-Mar-26	583.49	594.50	2.00	55.00%	3.50	0.45%	6.02%

III. Effect of employee stock option schemes on the statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Employee stock option scheme expense	196.38	88.14
Total expense on share based payments	196.38	88.14

IV. Effect of employee stock option schemes on the balance sheet

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Employee stock option reserve	285.60	89.22	1.08
Total carrying amount of liabilities	285.60	89.22	1.08

V. The underlying expected volatility was determined by reference to historical data of the Company's shares over a period of time since its floatation on the National Stock Exchange. No special features inherent to the options granted were incorporated into measurement of fair value.

38. EMPLOYEE BENEFITS

The Group has adopted Indian Accounting Standard (Ind AS) – 19 on Employee Benefits as under:

38.1 Defined contribution plans

Provident fund

In accordance with the Employee's Provident Fund and Miscellaneous Provisions Act, 1952, eligible employees of the Company are entitled to receive benefits in respect of provident fund, a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the covered employees' salary. The contributions, as specified under the law, are made to the employee provident fund organization (EPFO).

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The total expenses recognised in the statement of profit and loss during the year on account of defined contribution plans amounted to ₹ 701.24 Lakhs (31 March 2025: ₹ 467.62 Lakhs).

38.2 Defined obligation plans

Gratuity

The Holding Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 26 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The Holding Company does not make any contributions to gratuity funds and the plan is unfunded. The Holding Company follows Ind AS 19 'Employee Benefits' and uses Projected Unit Credit Method to value defined benefit obligations.

The defined benefit plans expose the Company to a number of actuarial risks as below:

- Interest risk:** A decrease in the bond interest rate will increase the plan liability.
- Salary risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.
- Longevity risk:** The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants. An increase in the life expectancy of the plan participants will increase the plan's liability.

The following table sets out the amounts recognised in the financial statements in respect of retiring gratuity plan:

Grant date	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Current	Non-current	Current	Non-current	Current	Non-current
Gratuity	43.84	562.52	28.66	369.31	16.50	257.95
Total	43.84	562.52	28.66	369.31	16.50	257.95

Disclosure of gratuity

(i). Amount recognised in the statement of profit and loss is as under:

Description	During the year ended 31 March 2026	During the year ended 31 March 2025
Current service cost	146.16	102.92
Past service cost	124.86	-
Interest cost	25.51	19.16
Net impact on profit (before tax)	296.53	122.08
Actuarial loss/(gain) recognised during the year	(79.01)	2.34
Amount recognised in total comprehensive income	217.52	124.42

(ii). Reconciliation of the present value of obligation:

Description	For the year ended 31 March 2026	For the year ended 31 March 2025
Present value of defined benefit obligation as at the beginning of the year	397.98	274.45
Current service cost	146.16	102.92
Transfer in obligation	-	0.14
Interest cost	25.51	19.16
Past service cost	124.86	-
Benefits paid	(9.14)	(1.03)
Actuarial (gain)/loss (refer note iv)	(79.01)	2.34
Present value of defined benefit obligation as at the end of the year	606.36	397.98

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(iii). Breakup of actuarial (gain)/loss:

Description	For the year ended 31 March 2026	For the year ended 31 March 2025
Actuarial (gain)/loss from change in financial assumption	(26.79)	17.01
Actuarial (gain)/loss from change in demographic assumption	-	(5.58)
Actuarial (gain)/loss from experience adjustment	(52.22)	(9.09)
Total actuarial (gain)/loss	(79.01)	2.34

(iv). Actuarial assumptions

Description	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 01 April 2024
Discount rate (Per annum)	7.20%	6.65%	7.20%
Salary growth (per annum)	10.00%	10.00%	10.00%
Withdrawal rate	11.55% to 41.55%	11.55% to 41.55%	10.20% to 40.98%

(v). Sensitivity analysis for gratuity liability

Description	31 March 2026	31 March 2025
Impact of change in discount rate		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	(3.74%)	(3.90%)
- Impact due to decrease of 0.5 %	4.00%	4.18%
Impact of change in salary escalation		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	2.91%	3.12%
- Impact due to decrease of 0.5 %	(2.89%)	(3.05%)
Impact of change in withdrawal rates		
Present value of obligation at the end of the year		
- Impact due to increase of 0.5 %	(4.77%)	(5.07%)
- Impact due to decrease of 0.5 %	5.23%	5.74%

The above sensitivity analysis is based on a change an assumption while holding all other assumptions constant. In practice, this is unlikely to occur and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting year) has been applied which was applied while calculating the defined benefit obligation liability recognised in the balance sheet.

Note: Sensitivity due to mortality is not material and hence impact of change due to these not calculated.

(vi). Expected Maturity profile of defined benefit payment plan in future years:

Description	31 March 2026	31 March 2025
Within next 12 months (next annual reporting year)	43.84	28.66
Between 1-5 years	231.51	146.16
Beyond 5 years	298.16	181.05
Beyond 5 years	573.51	355.88

(vii). The best estimated expense for the next year ending 31 March 2027 is INR 223.31 lakhs.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(viii). The weighted average duration of defined benefit obligation at the end of reporting year is 6.65 years (31 March 2025: 6.7 years and 01 April 2024: 7.39 years).

38.3 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes viz Code on Wages, 2019, Industrial Relations Code, 2020, Code on Social Security, 2020, and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as 'the New Labour Codes'). The New Labour Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. Basis the Group's assessment, the estimated incremental impact amounting to ₹ 124.86 lacs has been recognized in the standalone statement of Profit and Loss for the year ended 31 March 2026. The Group continues to monitor the finalization of Central/State rules and clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect on the basis of such developments as needed.

38.4 Other short term benefits

Compensated absences

Employee benefit expenses for the year is 33.79 lacs (31 March 2025: Nil) towards compensated absences which has been recognised in the statement of profit and loss. Provision for compensated absences as on 31 march 2026 33.79 lacs (31 March 2025: Nil).

39. RELATED PARTY DISCLOSURES

(I) Relationship with related parties:

Description of relationship	Names of related parties
(a) Directors and/or Key management personnel (KMP):	Manish Grover (Managing Director)
	Bhavna Grover (Whole-time Director)
	Shreya Grover (Whole-time Director)(redesignation w.e.f 27August2025)
	Karan Vir Bindra (Non-Executive Independent Director)
	Priyanka Bansal (Non-Executive Independent Director) (w.e.f 21 April 2025)
	Chandan Kumar Kaushal (Non-Executive Independent Director) (w.e.f 29 April 2024)
	Nanak Chand (Chief Financial Officer)
	Smita Chaturvedi (Company Secretary) (w.e.f. 04 August 2025)
	Anshika Garg (Company Secretary) (till 01 August 2025)
(b) Relatives of KMP:	Akansha Jain (Sister of KMP)
	Ashish Grover (Brother of KMP)
(c) Entities in which Directors/ KMP/Close members of KMP can exercise significant influence:	Shuddhi Lifecare Private Limited (formerly Divya Upchar Sansthan)
	Manish Grover HUF
	Shuddhi Green Charcoal Private Limited
	Dupon Clean Biofuels LLP

Note: The list of related parties disclosed includes only those entities with whom transactions were carried out by the Group during the current year and previous year.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Details of related party transactions during the year ended 31 March 2026 and 31 March 2025:

Particulars	For the year ended 31 March 2026			For the year ended 31 March 2025		
	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
1 Short-term employee benefits						
-Managerial remuneration ^						
Manish Grover	240.00	-	-	240.00	-	-
Bhavna Grover	180.00	-	-	180.00	-	-
Shreya Grover	7.00	-	-	-	-	-
2 Sitting fees paid to independent director						
Karan Vir Bindra	1.66	-	-	-	-	-
Priyanka Bansal	2.20	-	-	-	-	-
Chandan Kumar Kaushal	6.50	-	-	-	-	-
3 Short-term employee benefits						
- Salary paid ^						
Nanak Chand	31.50	-	-	19.85	-	-
Smita Chaturvedi	2.00	-	-	-	-	-
Akansha Jain	-	28.50	-	-	21.00	-
Ashish Grover	-	19.60	-	-	16.50	-
Anshika Garg	1.00	-	-	3.00	-	-
4 Share based payments to KMP						
Nanak Chand	2.40	-	-	1.44	-	-
5 Sale of goods						
Shuddhi Lifecare Private Limited	-	-	438.46	-	-	498.14

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Details of related party transactions during the year ended 31 March 2026 and 31 March 2025: (Contd.)

Particulars	For the year ended 31 March 2026			For the year ended 31 March 2025		
	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
6 Sale of fixed assets						
Shuddhi Lifecare Private Limited	-	-	0.33	-	-	-
7 Rent income						
Shuddhi Lifecare Private Limited	-	-	3.72	-	-	12.18
8 Rent paid						
Manish Grover	3.00	-	-	11.00	-	-
Manish Grover HUF	-	-	6.00	-	-	6.00
9 Loans recovered						
Shuddhi Lifecare Private Limited	-	-	-	-	-	212.53
Shuddhi Green Charcoal Private Limited	-	-	212.00	-	-	-
10 Interest received						
Shuddhi Green Charcoal Private Limited	-	-	2120	-	-	-
11 Unsecured loans received/(repaid) - net						
Manish Grover	(1,000.00)	-	-	1,000.00	-	-
Manish Grover	2.50	-	-	-	-	-
12 Royalty receivable						
Shuddhi Lifecare Private Limited	-	-	53.18	-	-	-

Note: There is no allowance for receivables in relation to any outstanding balances, and no loss allowance has been recognised during the year in respect of receivables due from related parties.

^aDoesn't include the provision made for gratuity and compensated absences, as they are determined on actuarial basis for the Company as a whole.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(III) Balances outstanding as at 31 March 2026, 31 March 2025 and 01 April 2024:

Particulars	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence	KMP	Relatives of KMP	Entities in which Directors/KMP/Close members of KMP can exercise significant influence
1 Salary, allowances, bonus and imprest payable/ (Receivable)									
Manish Grover	38.67	-	-	(25.79)	-	-	(129.66)	-	-
Bhavna Grover	6.86	-	-	13.64	-	-	(39.23)	-	-
Akansha Jain	-	2.78	-	-	-	-	-	-	-
Nanak Chand	2.79	-	-	-	-	-	-	-	-
Smita Chaturvedi	0.25	-	-	-	-	-	-	-	-
Shreya Grover	1.00	-	-	-	-	-	-	-	-
Ashish Grover	-	1.31	-	-	-	-	-	-	-
2 Sitting fees									
Chandan Kumar Kaushal	0.45	-	-	-	-	-	-	-	-
3 Expenses payable (rent)									
Manish Grover (HUF)	-	-	0.49	-	-	2.45	-	-	0.45
4 Trade receivable (refer note 12)									
Shuddhi Lifecare Private Limited	-	-	67.55	-	-	6.04	-	-	270.41
5 Equity investment (refer note 7)									
Dupon Clean Biofuels LLP (fixed plus floating capital)	-	-	64.00	-	-	64.00	-	-	64.00
6 Loans receivable (refer note 8)									
Shuddhi Lifecare Private Limited	-	-	-	-	-	-	-	-	204.49
Shuddhi Green Charcoal Private Limited	-	-	-	-	-	212.00	-	-	212.00
7 Borrowings outstanding (refer note 18)									
Manish Grover	2.50	-	-	1,000.00	-	-	-	-	-

Note: Unless otherwise stated, all related party transactions have been entered on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and settlement occurs in cash.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

40. FAIR VALUE MEASUREMENTS

A) Financial instruments and Risk Management

The accounting classification of each category of financial instruments, their carrying values and fair values are set out below:

Particulars	As at 31 March 2026			As at 31 March 2025			As at 01 April 2024		
	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost	Fair value through profit or loss	Fair value through other comprehensive income	Amortised cost
Financial assets									
Investments*	10,971.78	-	-	355.61	-	-	433.69	-	-
Trade receivables	-	-	6,992.91	-	-	8,496.14	-	-	3,383.02
Cash and cash equivalents	-	-	1,637.30	-	-	2,297.87	-	-	2,531.47
Other bank balances	-	-	9,245.08	-	-	-	-	-	3,669.28
Loans	-	-	-	-	-	312.00	-	-	812.00
Other financial assets	-	-	3,443.01	-	-	1,068.80	-	-	573.41
Total	10,971.78	-	21,318.30	355.61	-	12,174.81	433.69	-	10,969.18
Borrowings	-	-	45.42	-	-	1,073.72	-	-	54.16
Lease liabilities	-	-	12,684.34	-	-	10,620.07	-	-	5,712.72
Trade payables	-	-	2,314.65	-	-	1,574.80	-	-	817.84
Other financial liabilities	-	-	2,571.88	-	-	1,360.26	-	-	867.37
Total	-	-	17,616.29	-	-	14,628.85	-	-	7,452.09

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

i) Fair value hierarchy

a. Financial assets and financial liabilities measured at fair value in the balance sheet are divided into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices in an active market. This includes listed equity instruments, traded debentures and mutual funds that have quoted price/declared NAV. The fair value of all equity instruments (including debentures) which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2: Level 2 hierarchy includes financial instruments that are not traded in an active market (for example, traded bonds/debentures, over the counter derivatives). The fair value in this hierarchy is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data. Financial instruments such as unlisted equity shares, loans are included in this hierarchy.

Financial assets and liabilities measured at fair value – recurring fair value measurements

As at 31 March 2026	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds- measured at fair value through profit and loss				
- Quoted	9,512.24	-	-	9,512.24
Investment in share warrants- unquoted measured at fair value through profit and loss	-	1,395.54	-	1,395.54
Investment in Dupon Clean Biofuel LLP	-	-	64.00	64.00
Total	-	-	-	10,971.78

As at 31 March 2025	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds- measured at fair value through profit and loss				
- Quoted	291.61	-	-	291.61
Investment in Dupon Clean Biofuel LLP	-	-	64.00	64.00
Total	-	-	-	355.61

As at 01 April 2024	Level 1	Level 2	Level 3	Total
Financial assets				
Investment in equity instruments and mutual funds- measured at fair value through profit and loss				
- Quoted	369.69	-	-	369.69
Investment in Dupon Clean Biofuel LLP	-	-	64.00	64.00
Total	-	-	-	433.69

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Valuation process and technique used to determine fair value

For level 1 instruments:

The fair value of investments in mutual fund units is based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at each reported balance sheet date. NAV represents the price at which the issuer will issue further units of mutual fund and the price at which issuers will redeem such units from the investors.

For level 2 instruments:

The Group has classified outstanding warrants within Level 2 of the fair value hierarchy, as the valuation is based on observable market inputs other than quoted prices included within Level 1. The fair value of warrants is determined using a Black-Scholes option pricing model valuation technique which incorporates observable inputs. The valuation of warrants is performed at each reporting date to reflect current market conditions, using internally developed valuation models, which are reviewed and validated by management and based on inputs that are primarily observable in the market, with limited use of judgment.

For level 3 instruments:

Investments in LLP (classified under Level 3 of fair value hierarchy) do not carry significant credit risk exposure, as these represent equity/ownership interests rather than contractual financial assets and accordingly, no expected credit loss assessment is required for such investments. Since the LLP is yet to commence operations and no material events have occurred, cost is considered a reasonable approximation of fair value.

b. Fair value of financial assets and liabilities measured at amortised cost:

The carrying amounts of trade receivables, trade payables, cash and cash equivalents, bank balances, loans, other current financial assets and liabilities are considered to be the same as their fair values, due to their short-term nature.

The management believes that the current rate of interest on the loans are in close approximation from market rates applicable to the Group Company. Therefore, the management estimates that the fair value of these borrowings are approximate to their respective carrying values.

iii) Financial risk management

The Group's activities expose it to market risk, liquidity risk and credit risk. The board of directors has overall responsibility for the establishment and oversight of the Group's risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

Risk	Exposure arising from	Measurement	Management
Credit risk	Cash and cash equivalents, trade receivables, financial assets measured at amortised cost	Ageing analysis	Bank deposits, diversification of asset base, credit limits and collateral.
Liquidity risk	Borrowings and other liabilities	Rolling cash flow forecasts	Availability of committed credit lines and borrowing facilities
Market risk – foreign currency risk	Recognised financial liabilities not denominated in Indian rupee (INR)	Sensitivity analysis	Foreign currency forwards
Market risk – interest rate risk	Borrowings at variable rates	Sensitivity analysis	Negotiation of terms that reflect the market factors
Market risk – foreign currency risk	Recognised financial liabilities not denominated in Indian rupee (INR)	Sensitivity analysis	Monitoring of exposure levels at regular intervals
Market risk – price risk	Investment in Mutual funds	Sensitivity analysis	Portfolio Diversification

a. Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is exposed to this risk for various financial instruments, for example by granting loans and receivables to customers, placing deposits, etc. The Group's maximum exposure to credit risk is limited to the carrying amount of following types of financial assets.

- cash and cash equivalents,
- trade receivables,
- loans and advances,
- investments,
- other bank balances, and
- other financial assets

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The maximum exposure to credit risks is represented by the total carrying amount of these financial assets in the balance sheet are as follows:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Loans (current and non current)	–	312.00	812.00
Investments	10,971.78	355.61	433.69
Trade receivables	6,992.91	8,496.14	3,383.02
Cash and cash equivalents	1,637.30	2,297.87	2,531.47
Other bank balances	9,245.08	–	3,669.28
Other financial assets (current and non current)	3,443.01	1,068.80	573.41

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers, loans.

Credit risk on cash and cash equivalents is limited as the Group generally invests in deposits with banks with high credit ratings assigned by domestic credit rating agencies. While cash and cash equivalents are also subject to the impairment requirements of Ind AS 109, the identified impairment loss was immaterial.

The Group has investments in mutual funds which are measured at fair value through profit and loss (FVTPL) and investment in LLP for which cost is considered a reasonable approximation of fair value since the LLP is yet to commence operations and no material events have occurred. The management considers all these investments to have low credit risk.

The maximum exposure to the credit risk at the reporting date is primarily from trade receivables. Trade receivables are unsecured and are derived from revenue earned from customers primarily located in India. India. For these trade receivables, the Group does not presume significant increase in credit risk when financial assets are past 30 days but monitor the recoverability on case to case basis. The Group does monitor the economic environment in which it operates.

The Group considers the probability of default upon initial recognition of loan and whether there has been a significant

increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Group compares the risk of a default occurring on the loan as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable and supportive forwarding-looking information. Especially the following indicators are incorporated:

- actual or expected significant adverse changes in business, financial or economic conditions that are expected to cause a significant change to the borrower's ability to meet its obligations.
- actual or expected significant changes in the operating results of the borrower.

Credit risk has always been managed by the Group through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. Credit risk in security deposits (other financial assets) is considered to be low as they form part of other commercial arrangements such as leases, therefore security deposit are impaired only when there is objective evidence of impairment. On account of adoption of Ind AS 109, the Group uses expected credit loss (ECL) model to assess the impairment loss or gain. The Group uses a provision matrix to compute the expected credit loss allowance for trade receivables. The provision matrix takes into account available external and internal credit risk factors such as Group's historical experience for customers.

Refer note 12 for bifurcation of trade receivables.

Changes in the loss allowance in respect of trade receivables	For the year ended 31 March 2026	For the year ended 31 March 2025
Balance at the beginning of the year	1,541.93	890.96
Provision for expected credit losses recognised during the year	598.09	650.97
Provision for expected credit losses utilised during the year	(593.69)	–
Balance at the end of the year	1,546.33	1,541.93

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Expected credit loss for trade receivables under simplified approach

Particulars	As at 31 March 2026						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount– trade receivables (considered good)	489.84	1,578.14	1,192.63	3,611.73	705.15	961.75	8,539.24
Gross carrying amount– trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	4%	7%	11%	42%	74%	-
Expected credit losses (loss allowance provision)– trade receivables	-	64.10	77.85	394.28	298.59	711.50	1,546.33
Carrying amount of trade receivables (net of impairment)	489.84	1,514.04	1,114.78	3,217.45	406.55	250.24	6,992.91

Particulars	As at 31 March 2025						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount– trade receivables (considered good)	69.56	6,609.24	1,294.22	987.84	990.59	86.62	10,038.07
Gross carrying amount– trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	6%	16%	30%	52%	100%	-
"Expected credit losses (loss allowance provision)– trade receivables"	-	427.83	213.14	295.47	518.88	86.62	1,541.93
Carrying amount of trade receivables (net of impairment)	69.56	6,181.41	1,081.08	692.37	471.71	0.00	8,496.14

Particulars	As at 01 April 2024						
	Unbilled dues	Less than 6 months	6 months – 1 year	1–2 years	2–3 years	More than 3 years	Total
Gross carrying amount– trade receivables (considered good)	-	2,227.80	588.64	1,427.71	12.97	16.86	4,273.98
Gross carrying amount– trade receivables (credit impaired)	-	-	-	-	-	-	-
Expected loss rate	-	9%	21%	38%	67%	100%	-
"Expected credit losses (loss allowance provision)– trade receivables"	-	200.61	123.46	541.39	8.65	16.85	890.96
Carrying amount of trade receivables (net of impairment)	-	2,027.19	465.18	886.32	4.32	0.01	3,383.02

b. Liquidity risk

Liquidity risk is the risk that the Group may encounter difficulty in meeting its present and future obligations associated with financial liabilities that are required to be settled by delivering cash or another financial asset. The Group's objective is to, at all times maintain optimum levels of liquidity to meet its cash and collateral obligations. Ultimate responsibility for liquidity risk management rests with the Board of Directors. The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities Management monitors rolling forecasts of the Group's liquidity position and cash and cash equivalents on the basis of expected cash flows.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Maturities of financial liabilities

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

As at 31 March 2026	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	16.43	26.49	-	42.92
Lease liabilities	4,336.57	9,219.35	2,970.19	16,526.11
Trade payables	2,314.65	-	-	2,314.65
Other financial liabilities	2,571.88	-	-	2,571.88
Total	9,239.53	9,245.84	2,970.19	21,455.56

As at 31 March 2025	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	1,030.40	42.92	-	1,073.32
Lease liabilities	3,147.86	9,094.27	1,321.32	13,563.45
Trade payables	1,574.80	-	-	1,574.80
Other financial liabilities	1,360.26	-	-	1,360.26
Total	7,113.32	9,137.19	1,321.32	17,571.83

As at 01 April 2024	Less than 1 year	1-5 years	More than 5 years	Total
Non-derivatives				
Borrowings	22.00	32.16	-	54.16
Lease liabilities	1,495.33	5,448.15	15.83	6,959.31
Trade payables	817.84	-	-	817.84
Other financial liabilities	867.37	-	-	867.37
Total	3,202.54	5,480.31	15.83	8,698.68

c. Market risk – Interest rate risk

The Group's policy is to minimise interest rate cash flow risk exposures on long-term financing. At the reporting periods end, the Group is not exposed to changes in market interest as it does not have any variable interest rate borrowings. The Group's investments in fixed deposits pay fixed interest rates.

d. Market risk – Price risk

The Group's exposure to price risk arises from investments held and classified in the balance sheet at fair value through profit or loss. To manage the price risk arising from investments, the Group diversifies its portfolio of assets.

Sensitivity

For the listed equity securities, an average volatility of 10% has been observed during the year ended 31 March 2026 (31 March 2025: 10%). This volatility figure is considered to be a suitable basis for estimating how profit or loss and equity would have been affected by changes in market risk that were reasonably possible at the reporting date.

The table below summarises the impact of increase/decrease of the index on the Group's profit for the year:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Equity instruments and mutual funds			
Net assets value – increase by 100 basis points	95.12	2.92	3.70
Net assets value – decrease by 100 basis points	(95.12)	(2.92)	(3.70)

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The table below summarises the impact of increase/decrease of the index on the Holding Company's equity for the year:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Statutory tax rate	25.17%	25.17%	25.17%
Equity instruments and mutual funds			
Net assets value – increase by 100 basis points	71.18	2.18	2.77
Net assets value – decrease by 100 basis points	(71.18)	(2.18)	(2.77)

e. Market risk – Foreign exchange risk

The Group is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the US dollar. Foreign exchange risk arises from recognised liabilities denominated in a currency that is not the functional currency (INR) of the Company.

Foreign currency risk exposure

Below is the overall exposure of the Company to foreign currency risk expressed in INR:

Particulars	As at 31 March 2026		As at 31 March 2025		As at 01 April 2024	
	Amount in foreign currency (lakhs)	INR (lakhs)	Amount in foreign currency (lakhs)	INR (lakhs)	Amount in foreign currency (lakhs)	INR (lakhs)
Other payables						
- AED	0.02	1.50	-	-	-	-
Total foreign currency risk exposure	36.42	939.50	-	-	-	-

Sensitivity

Below is the sensitivity of profit or loss and equity to changes in the exchange rates arises mainly from foreign currency denominated financial instruments, assuming no change in other variables:

These percentages have been determined based on the average market volatility in exchange rates in the previous twelve months. Based on the movements in the foreign exchange rates historically and the prevailing market conditions as at the reporting date, the Group's management has concluded that the below mentioned rates used for sensitivity are reasonable benchmarks. The sensitivity analysis is based on the Group's foreign currency financial instruments held at each reporting date.

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
AED sensitivity			
INR/AED – increase by 1% (Previous year: 1%)	(9.39)	-	-
INR/AED – decrease by 1% (Previous year: 1%)	9.39	-	-

41. CAPITAL MANAGEMENT POLICIES AND PROCEDURES

The Group's objective for capital management is to maximize shareholder's value, safeguard business continuity and support the growth of the Group. The Group determines the capital requirement based on annual operating plan and other strategic investment plans. The Group aims to manage its capital efficiently so as to safeguard its ability to continue as a going concern and to optimize returns to all its shareholders. The Group's funding requirements are met through internal accruals. The Group is not subject to any externally imposed capital requirements.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

The amounts managed as capital by the Group for the reporting periods under review are summarised as follows:

Particulars	As at 31 March 2026	As at 31 March 2025	As at 01 April 2024
Non current borrowings and lease liabilities (refer note 18 and 19)	9,574.75	8,556.00	4,812.94
Current maturities of non current borrowings and lease liabilities (refer note 18 and 19)	3,150.01	2,137.79	953.94
Current borrowings (refer note 18)	2.50	1,000.00	-
Total borrowings	12,727.26	11,693.79	5,766.88
Less:			
Cash and cash equivalents (refer note 13)	1,637.30	2,297.87	2,531.47
Other bank balances (refer note 14)	9,245.08	-	3,669.28
Net debt (A)	1,844.88	9,395.92	(433.87)
Total equity* (B)	46,695.06	25,634.28	18,592.73
Net debt to equity ratio (A/B)	0.04	0.37	(0.02)

*Equity includes equity share capital and other equity of the Group that are managed as capital.

42. CONTINGENCIES AND COMMITMENTS

Particulars	As at 31 March 2026	As at 31 March 2025
Contingent liabilities		
Claims against the Group not acknowledged as debt		
- Indirect tax demand *	507.99	507.99
Commitments		
- Other commitments ^	1,002.43	-
	1,510.42	507.99

*Director General of GST Intelligence conducted search on the Holding Company premises (along with other Companies owned by the same promoters) on 13 April 2018. Accordingly, SCN dated 24th August, 2022 was issued for demand of tax along with interest and penalty. Pursuant to the same, on 03 February 2025, the GST department has issued an Order under section 74(9) of the Central Goods and Service Tax Act 2017, imposing a demand for ₹ 507.99 Lakhs (Inclusive of penalty of ₹ 253.99 Lakhs). The GST department has alleged that the Holding Company has been involved in the suppression of turnover and have sold the goods under incorrect classification. The Holding Company is expected to get the favourable opinion from the Hon'ble High Court based on the opinion obtained from the external legal counsel and hence the amount has been disclosed as a contingent liability.

^Jeena Sikho International LLC ("JSIL") has entered into a Share Purchase Agreement dated 07 January 2026 to acquire a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC ("BTRS"), UAE. The arrangement involves funding of AED 15.3 lacs (approximately ₹ 394.27 lacs) to existing shareholders and AED 60 lacs (approximately ₹ 1,546.16 lacs) to the Company, of which AED 15.3 lacs (approximately ₹ 394.27 lacs) to shareholders and AED 21.10 lacs (approximately ₹ 543.73 lacs) to the Company have been disbursed during the year ended 31 March 2026. Accordingly as per the agreement 38.9 AED (approximately ₹ 1,002.43 lacs) is yet to be disbursed to BTRS.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

43. CORPORATE SOCIAL RESPONSIBILITY

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. The areas for CSR activities are promoting health care, promoting education, rural development projects and environment sustainability. A CSR committee has been formed by the Holding Company as per the Act. The funds were primarily utilized through the year on these activities which are specified in Schedule VII of the Companies Act, 2013. Section 135 is only applicable to the Holding Company for the year ending 31 March 2026.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
i) Amount required to be spent by the Holding Company during the year	169.88	100.31
ii) Amount of expenditure incurred during the year	170.00	101.64
iii) Shortfall at the end of year	-	-
iv) Reason for shortfall	NA	NA
v) Nature of CSR activities	Eradicating Hunger, Poverty & Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water.	Eradicating Hunger, Poverty & Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water.
vi) Details of related party transactions	N/A	N/A
vii) Provision made with respect to a liability incurred by entering into a contractual obligation	N/A	N/A

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

44. ADDITIONAL INFORMATION REQUIRED BY SCHEDULE III TO THE ACT:

As at 31 March 2026

Name of the entity in the group	Net assets (Total assets – Total liabilities)		Share in profit/(loss)		Share in other comprehensive income/(loss)		Share in total comprehensive income/(loss)	
	As % of consolidated Net assets	Amount	As % of consolidated profit	Amount	As % of consolidated other comprehensive income	Amount	As % of consolidated total comprehensive loss	Amount
Parent								
Jeena Sikho Lifecare Limited	100.10%	46,740.05	100.22%	22,217.57	99.46%	59.13	100.21%	22,276.70
Subsidiaries								
Indian								
Jeena Green Resource Private Limited	(0.06%)	(26.16)	(0.14%)	(31.16)	0.00%	-	(0.14%)	(31.16)
Foreign								
Jeena Sikho Lifecare LLC-Dubai	0.02%	9.17	(0.07%)	(16.60)	2.34%	1.39	(0.07%)	(15.21)
Non-controlling interests in all subsidiaries								
Inter group eliminations and adjustments	(0.06%)	(28.00)	0.00%	-	(1.80%)	(1.07)	(0.00%)	(1.07)
As at 31 March 2026	100.00%	46,695.07	100.00%	22,169.81	100.00%	59.45	100.00%	22,229.26

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

45. BUSINESS COMBINATIONS

a. Summary of acquisition

On 3rd October, 2024, the Holding Company acquired five branches consisting of Ayurvedic Therapy Centres from another Company named Oregano Life Private Limited as a going concern for a consolidated price of ₹ 6,915.70 lakhs.

The five branches acquired are at locations – Kishan Kunj & Mayur Vihar (Delhi), Jothwara, Alwar & Sanganer (Rajasthan).

The aforementioned acquisition is being accounted for as a business combination in accordance with Ind AS 103 — Business Combinations, whereby the identifiable assets acquired and liabilities assumed are recognised at their respective fair values as at the acquisition date. The excess of the consideration transferred over the net fair value of identifiable assets and liabilities, if any, is recognised as goodwill."

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

Particulars	Amount
Purchase consideration	6,915.70
Purchase consideration (A)	6,915.70
The assets and liabilities recognised as a result of the acquisition are as follows:	
Property, plant and equipment	132.21
Intangible assets	284.20
Inventory	37.96
Cash and cash equivalents	9.66
Trade receivables	644.43
Loans and advances	48.15
Trade payables	(26.87)
Other financial liabilities	(25.86)
Identifiable net assets acquired (B)	1,103.88
Goodwill (A-B-C)	5,811.82

Goodwill in acquisition represents residual asset value attributable to unidentified intangible assets acquired by acquirer. It will not be deductible for tax purposes and it will be tested for impairment annually as required by IND AS 36. (Refer Note 5 to these financial statements for impairment assessment).

b. Revenue and profit contribution

The acquired business contributed revenue of ₹ 802.76 lakhs and profit of ₹ 306.61 lakhs to the Group for the year ended 31 March 2025.

If the acquisitions had taken place on 1 April 2024, consolidated revenue from operations and profit for the year ended 31 March 2025 would have been ₹ 48,108.47 lakhs and ₹ 11,215.72 lakhs respectively.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

46. INTERESTS IN OTHER ENTITIES

(a) Subsidiaries

The Group's subsidiaries at 31 March 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of equity shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

Name of the entity	Place of business/ country of incorporation	Ownership interest held by the group		Ownership interest held by non-controlling interests		Principal activities
		31 March 2026	31 March 2025	31 March 2026	31 March 2025	
Jeena Green Resource Private Limited	India	51.00%	0.00%	49.00%	0.00%	Biofuel and Organic Fertilizer Manufacturing
Jeena Sikho Lifecare LLC-Dubai	UAE	100.00%	0.00%	100.00%	0.00%	Healthcare Services and Ayurvedic Products Distribution

The Group exercises control over the entity Jeena Green Resource Private Limited as it holds a majority of ownership interest, voting rights and has the ability to direct the relevant activities of the subsidiary. Non-controlling interest represents the 49% equity interest held by other shareholders.

(b) Non-controlling interests (NCI)

Set out below is summarised financial information for the subsidiary that has non-controlling interests that are material to the Group. The amounts disclosed for each subsidiary are before inter-company eliminations.

Summarised balance sheet		Jeena Green Resources Private Limited
		31 March 2026
Current assets		24.22
Current liabilities		182.51
Net current assets		(158.30)
Non-current assets		132.14
Non-current liabilities		-
Net non-current assets		132.14
Net assets		(26.15)
Accumulated NCI		(15.27)

Summarised statement of profit and loss		Jeena Green Resources Private Limited
		31 March 2026
Revenue		7.53
Loss for the year		(31.16)
Other comprehensive income		-
Total comprehensive loss		(31.16)
Loss allocated to NCI		(15.27)

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(b) Non-controlling interests (NCI) (Contd.)

Summarised cash flows	Jeena Green Resources Private Limited
	31 March 2026
Cash flows from operating activities	114.19
Cash flows from investing activities	(143.16)
Cash flows from financing activities	32.31
Net increase/(decrease) in cash and cash equivalents	3.35

47. FIRST TIME ADOPTION OF IND AS

These are the Group's first financial statements prepared in accordance with Ind AS. For the year ended 31 March 2025, the Group prepared its financial statements in accordance with accounting standards referred to in paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP) notified under section 133 of the Companies Act, 2013.

The accounting policies set out in note 2 have been applied in preparing the financial statements for the year ended 31 March 2026, the comparative information presented in these financial statements for the year ended 31 March 2025 and in the preparation of opening IND AS balance sheet at 01 April 2024 (the Group's date of transition).

In preparing its IND AS balance sheet as at 01 April 2024 and in presenting the comparative information for the year ended 31 March 2025, the Group has adjusted its amounts reported previously in the financial statements prepared in accordance with previous GAAP.

Accordingly, the Group prepared first Ind AS financial statements which comply with Ind AS applicable for period ending on 31 March 2026, together with the comparative period data as at and for the year ended 31 March 2025, with a Ind AS transition date of 1 April 2024. This note explains the principal adjustments made by the Group in restating its financial statements prepared in accordance with previous GAAP and an explanation of how the transition from previous GAAP to Ind AS has affected the Group's financial position, financial performance and cash flows is set out in the following tables and notes.

A. Ind AS optional exemptions

1. Deemed cost for property, plant and equipment and intangible assets

Ind AS 101 permits a first-time adopter to elect to continue with the carrying value for all of its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the Previous GAAP and use that as its deemed cost as at the date of transition after making necessary adjustments for de-commissioning liabilities. This exemption can also be used

for intangible assets covered by Ind AS 38 Intangible Assets. Accordingly, the Company has elected to measure all of its property, plant and equipment and intangible assets at their Previous GAAP carrying value.

2. Impairment of financial assets

At the date of transition to Ind AS, determining whether there has been a significant increase in credit risk since the initial recognition of a financial instrument would require undue cost or effort, the Company has recognised a loss allowance at an amount equal to lifetime expected credit losses at each reporting date until that financial instrument is derecognised.

3. Leases

The Group has elected to measure the right of use assets at the date of transition an amount using modified retrospective approach, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the Balance Sheet immediately before the date of transition to Ind AS. Further, the following expedients were used on transition to Ind AS:

- the use of a single discount rate to a portfolio of leases with reasonably similar characteristics.
- the accounting for operating leases with a remaining lease term of less than 12 months as on the transition date as short-term leases.
- the exclusion of initial direct costs for the measurement of the right of use asset at the date of initial application.
- use of hindsight, such as in determining the lease term as the contract contains the options to extend and terminate the lease.

B. Ind AS mandatory exceptions

1. Estimates

An entity's estimates in accordance with Ind ASs at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with Previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Ind AS estimates as at 1 April 2024 are consistent with the estimates as at the same date made in conformity with Previous GAAP. The Group made estimates for impairment of financial assets based on expected credit loss model in accordance with Ind AS at the date of transition as these were not required under Previous GAAP.

2. Classification and measurement of financial assets and liabilities

The classification and measurement of financial assets and financial liabilities will be made considering whether the conditions as per Ind AS 109, "Financial Instruments", are met based on facts and circumstances existing at the date of transition.

Financial assets can be measured using effective interest method by assessing its contractual cash flow characteristics only on the basis of facts and circumstances existing at the date of transition and if it is impracticable to assess the elements of modified time value of money, i.e., the use of

effective interest method, fair value of financial asset at the date of transition shall be the new carrying amount of that asset. The measurement exemption applies for financial liabilities as well.

Applying a requirement is impracticable when the entity cannot apply it after making every reasonable effort to do so. It is impracticable to apply the:

- (a) The effects of the retrospective application or retrospective restatement are not determinable;
- (b) The retrospective application or restatement requires assumptions about what management's intent would have been in that period;

The retrospective application or retrospective restatement requires significant estimates of amounts and it is impossible to distinguish objectively information about those estimates that existed at that time.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(I) Reconciliation of the assets and liabilities presented in the balance sheet prepared as per Previous IGAAP and as per Ind AS is as follows:

Particulars	Notes	As at 31 March 2025			As at 01 April 2024		
		Previous IGAAP (Audited)	IGAAP Reclassification ¹	Ind AS Adjustments	Previous IGAAP (Audited)	IGAAP Reclassification ¹	Ind AS Adjustments
ASSETS							
1) Non-current assets							
Property, plant and equipment		9,234.42	-	-	9,234.42	6,682.52	-
Capital Work in progress		1,123.31	-	-	1,123.31	349.84	-
Right-of-use-assets	(e)	-	-	10,026.65	10,026.65	-	5,809.27
Goodwill	(a)	6,028.18	-	(216.36)	5,811.82	-	-
Intangible assets	(a)	2.67	-	229.98	232.65	2.13	(0.00)
Intangible assets under development		224.28	-	-	224.28	43.68	-
Financial assets							
(i) Investments		64.00	-	-	64.00	-	-
(ii) Loans		-	-	-	-	-	-
(iii) Other financial assets	(e),(i)	-	282.44	717.39	999.83	100.08	380.15
Deferred tax assets	(g)	0.63	-	583.56	584.19	-	172.16
Other non-current assets	(e),(i)	937.11	95.90	(937.11)	95.90	476.70	(476.70)
Total non-current Assets		17,614.60	378.34	10,404.11	28,397.05	7,618.87	5,884.88
2) Current Assets							
Inventories		1,154.58	-	-	1,154.58	718.87	-
Financial assets							
(i) Investments	(d)	295.00	-	(3.39)	291.61	350.00	19.69
(ii) Trade receivables	(f)	9,763.04	69.56	(1,336.46)	8,496.14	4,118.51	(735.49)
(iii) Cash and cash equivalents	(i)	2,596.00	(282.44)	(15.69)	2,297.87	6,200.74	(3,669.27)
(iv) Bank balances other than (ii) above	(i)	-	-	-	-	-	3,669.28
(v) Loans	(i)	963.64	-	(651.64)	312.00	2,737.74	(1,925.74)
(vi) Other financial assets	(i)	-	-	68.97	68.97	-	93.18
Other current assets	(i)	443.70	(165.46)	598.38	876.62	308.13	1,832.56
Total current assets		15,215.96	(378.34)	(1,339.83)	13,497.79	14,433.99	(715.79)
Total		32,830.56	-	9,064.28	41,894.84	22,052.86	5,169.09
							27,221.95

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

Particulars	Notes	As at 31 March 2025			As at 01 April 2024		
		Previous IGAAP (Audited)	IGAAP Reclassification*	Ind AS Adjustments	Previous IGAAP (Audited)	IGAAP Reclassification*	Ind AS Adjustments
EQUITY AND LIABILITIES							
Equity							
a) Equity share capital		2,486.01	-	-	2,486.01	-	-
b) Other equity	II	24,815.52	-	(1,667.25)	16,738.78	-	(632.06)
Total Equity		27,301.53	-	(1,667.25)	19,224.79	-	(632.06)
Liabilities							
1) Non-current liabilities							
Financial liabilities							
(i) Borrowings		42.92	-	-	32.16	-	-
(ii) Lease liabilities	(e)	-	-	8,513.08	-	-	4,780.78
(iii) Other financial liabilities		-	-	-	-	-	-
Provisions	(b)	259.23	-	110.08	14.95	-	243.00
Deferred tax liabilities (net)		-	-	-	40.42	-	(40.42)
Total Non Current Liabilities		302.15	-	8,623.16	87.53	-	4,983.36
2) Current liabilities							
Financial liabilities							
(i) Borrowings		1,030.40	-	0.40	2179	-	0.21
(ii) Lease liabilities	(e)	-	-	2,106.99	-	-	931.94
(iii) Trade payables							
- Total outstanding dues of micro enterprises and small enterprises		238.29	-	-	35.48	-	(0.03)
- Total outstanding dues of creditors other than micro enterprises and small enterprises		711.28	625.23	-	410.30	372.08	-
(iv) Other financial liabilities	(i)	-	21.69	1,338.57	-	(372.08)	1,239.46
Other current liabilities	(i)	3,082.34	(646.92)	(1,338.96)	1876.30	-	(1,239.65)
Provisions	(b)	164.57	-	(135.91)	396.67	-	(380.17)
Current tax liabilities	(i)	-	-	137.28	-	-	266.03
Total Current Liabilities		5,226.88	-	2,108.37	2,740.54	-	817.79
Total		32,830.56	-	9,064.28	22,052.86	-	5,169.09
							27,221.95

*The previous IGAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(II) Reconciliation of total equity as at 31 March 2025 and 01 April 2024:

Particulars	Notes	As at 31 March 2025	As at 01 April 2024
Total equity (shareholder's funds) as per previous Indian GAAP (A)		27,301.53	19,224.79
Adjustments:			
Impact of expected credit loss recognised on trade receivables	(f)	(600.97)	(735.49)
Impact due to fair valuation of current investments	(d)	(23.07)	19.69
Impact of adjustment related to provisions for employee benefits	(b)	17.39	(128.85)
Impact due to recognition of lease liability and right-of-use assets	(e)	(813.14)	-
Impact of share based payment expense recognised on the basis of fair value of option	(c)	(45.14)	-
Impact of remeasurement of employee stock options	(c)	45.14	-
Impact due to depreciation on assets acquired under business acquisition	(a)	13.62	-
Impact of deferred tax (net) on account of the above adjustments	(g)	370.98	212.59
Total		(1,035.19)	(632.06)
Net impact brought forward from opening balance sheet		(632.06)	-
Total adjustments (B)		(1,667.25)	(632.06)
Total equity as per Ind AS (A+B)		25,634.28	18,592.73

(III) Reconciliation of Statement of Profit and Loss for the year ended 31 March 2025

Particulars	Notes	Previous IGAAP (Audited)*	Ind AS Adjustments	IND AS (Restated)
INCOME				
Revenue from operations		46,907.19	-	46,907.19
Other income		640.89	32.65	673.54
Total Income		47,548.08	32.65	47,580.73
EXPENSES				
Purchases of stock-in-trade		3,561.90	2,296.09	5,857.99
Change in inventories of stock-in-trade		(435.71)	-	(435.71)
Employee benefits expense	(b),(c)	10,048.87	25.41	10,074.28
Finance costs	(a),(e)	50.60	1,014.89	1,065.49
Depreciation and amortisation expense	(a),(e)	870.80	2,039.74	2,910.54
Other expenses	(d),(e),(f)	21,244.91	(3,894.53)	17,350.38
Total Expenses		35,341.37	1,481.60	36,822.97
Profit before tax		12,206.71	(1,448.95)	10,757.76
Tax expense:				
Current tax		3,153.33	-	3,153.33
Taxation for earlier years		21.54	-	21.54
Deferred tax	(g)	(41.05)	(370.39)	(411.44)
Total tax expense		3,133.82	(370.39)	2,763.43
Profit for the year		9,072.89	(1,078.56)	7,994.33
Other comprehensive income				
Items that will not be reclassified to profit or loss				
- Re-measurements of defined benefit plans	(b)	-	(2.34)	(2.34)

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

(III) Reconciliation of Statement of Profit and Loss for the year ended 31 March 2025 (Contd.)

Particulars	Notes	Previous IGAAP (Audited)*	Ind AS Adjustments	IND AS (Restated)
- Income Tax related to items that will not be reclassified to profit or loss	(g)	-	0.59	0.59
Net other comprehensive (loss) not to be reclassified to profit or loss		-	(1.75)	(1.75)
Total comprehensive income for the year		9,072.89	(1,082.06)	7,992.58

*The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

(IV) Reconciliation of total comprehensive income for the year ended 31 March 2025:

Particulars	Notes	31 March 2025
Net profit after tax as per previous Indian GAAP (Audited)		9,072.89
Adjustments:		
Impact of expected credit loss recognised on trade receivables	(f)	(600.97)
Impact of adjustment related to provisions for employee benefits	(b)	19.75
Impact of share based payment expense recognised on the basis of fair value of option	(c)	(45.14)
Impact due to fair valuation of current investments	(d)	(23.07)
Impact due to recognition of lease liability and right-of-use assets	(e)	(813.14)
Impact due to depreciation on assets acquired under business acquisition	(a)	13.62
Impact of deferred tax (net) on account of the above adjustments	(g)	370.39
Net profit after tax as per Ind AS		7,994.33
Other comprehensive loss	(b)	(1.75)
Total comprehensive income as per Ind AS		7,992.58

Notes

- (a) Under previous IGAAP, goodwill was amortized over the period in which the economic benefit from the acquired business is expected to flow to the Group and intangible assets were amortized based on the assessed useful life. The Group has reassessed the useful life of goodwill and determined that it has an indefinite useful life. Goodwill and intangible assets with indefinite life are not amortized under Ind AS. Instead, goodwill is subject to an annual impairment test and the assumption of indefinite life of intangible assets reviewed annually. Accordingly the amortization charge under previous IGAAP has been adjusted.

Goodwill has been recomputed during the year based on the purchase price allocation (PPA) as per Ind AS. Under Ind AS, goodwill is determined based on purchase price allocation, which involves allocating the consideration paid to the identifiable assets and liabilities at fair value. Accordingly, goodwill has been recomputed during the transition."

- (b) Provision for Gratuity is recomputed based on actuarial valuation under Ind AS, resulting in adjustment to employee benefit obligations. The actuarial gain/loss have been transferred to Other Comprehensive Income (OCI) net of tax instead of profit and loss as prescribed by the IND AS.
- (c) Employee stock expenses has been recorded based on the fair value of the options at grant date under Ind AS.
- (d) The Group has valued its financial assets (current investment) at fair value. The impact for change in fair value as on date of transition (i.e., 01 April 2024), is recognized in opening equity and changes thereafter are recognized in the Statement of Profit and Loss or OCI based on the classification of same.
- (e) Under previous IGAAP, rent payments were charged to the Statement of Profit and Loss. Under Ind AS, for long-term and high-value leases, a Right-of-Use (ROU) asset and corresponding lease liability are recognized. The ROU asset is amortized over the lease term, and interest on the lease liability is recorded in the Statement of Profit and Loss, replacing the earlier rent expense.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

- (f) Expected credit losses are recognized for all financial assets subsequent to initial recognition other than financial assets in FVTPL category. The impairment losses and reversals are recognised in Statement of Profit and Loss.
- (g) The impact of transition adjustment together with Ind-AS mandate of using balance sheet approach for computation of deferred taxes has resulted in charge to the reserves, on the date of transition, with consequential impact to the Profit and Loss Account for the subsequent periods.
- (h) Figures have been regrouped/re-classified of previous periods wherever necessary for better presentation and disclosures and the same are not considered material to these financial statements.

The transition from previous GAAP to Ind AS has not made a material impact on the statement of cash flows.

48. ADDITIONAL INFORMATION NOT DISCLOSED ELSEWHERE IN THE FINANCIALS STATEMENTS

(a) Borrowing secured against current assets

The Group does not have borrowings from financial institutions on the basis of security of current assets.

(b) Benami Property

The Group does not have any benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.

(c) Willful defaulter

The Group is not declared a willful defaulter by any bank or financial institution or any other lender.

(d) Relationship with struck off companies

The Group has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

(e) Compliance with number of layers of companies

The Group has complied with the number of layers prescribed under section 2(87) of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017.

(f) Compliance with approved scheme(s) of arrangements

The Group has not entered into any scheme of arrangement which has an accounting impact on current or previous financial years.

(g) Utilisation of Borrowed funds and share premium

- (i) The Group has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries); or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (ii) The Group has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(h) Undisclosed income

The Group has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

(i) Details of Crypto Currency or Virtual Currency

The Group has not traded or invested in Crypto currency or Virtual Currency during the current or previous financial years.

(j) Valuation of Property, Plant and Equipment and intangible asset

The Group has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous years.

- (k) The borrowings obtained by the Group from banks and financial institutions have been applied for the purposes for which such loans were taken.

Notes to the Consolidated Financial Statements (Contd.)

For the year ended 31 March 2026

(All amounts are in INR Lakhs except otherwise stated)

49. The Ministry of Corporate Affairs (MCA) has prescribed a requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules, 2021 requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled. The Holding Company and its subsidiary have used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software except for instances mentioned below:

Nature of exception noted	Details of exception
Instances of accounting software for maintaining books of account which did not have a feature of recording audit trail (edit log) facility	i. The accounting software used for maintenance of certain inventory and revenue records of the Holding Company did not have a feature of recording audit trail (edit log) facility during the period 1 April 2025 to 15 January 2026, at both application level and database level. Effective 16 January the Holding Company migrated to another accounting software for maintenance of certain inventory and revenue records. The audit trail feature of the said accounting software was not enabled at the database level to log any direct data changes.
Instances of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated throughout the year for all relevant transactions recorded in the software	ii. The audit trail feature was not enabled at the database level for an accounting software to log any direct data changes, used for maintenance of certain revenue and inventory records by the Holding Company.
Instances of accounting software maintained by a third party where we are unable to comment on the audit trail feature at database level	iii. The accounting software used for maintenance of certain revenue records is operated by a third-party software service provider. In the absence of any information on existence of audit trail (edit logs) for any direct changes made at the database level in the 'Independent Service Auditor's Assurance Report' ('Type 2 report' issued in accordance with ISAE 3402, Assurance Reports on Controls at a Service Organization), we are unable to assess whether audit trail feature with respect to the database of the said software was enabled and operated throughout the year.
Instance of accounting software for maintaining books of account for which the feature of recording audit trail (edit log) facility was not operated effectively during the reporting period	iv. The accounting software used for maintenance of accounting records of certain branches of the Holding Company did not capture the details of who made the changes for certain period during the year, as mentioned below: - Branch 1 – 1 April 2025 to 31 October 2025 - Branch 2 – 1 April 2025 to 21 April 2025 - Branch 3 – 2 April 2025 to 31 March 2026* - Branch 4 – 8 January 2026 to 31 March 2026* - Branch 5 – 7 February 2026 to 31 March 2026* - Branch 6 – 18 March 2026 to 31 March 2026* - Branch 7 – 31 March 2026* *Branches incorporated during the year

50. The Management has assessed the subsequent events to the year end and is of the view that there no material events which require adjustment or disclosure in financial statements.

For Walker Chandio & Co. LLP
Chartered Accountants
Firm's registration No.: 001076N/N500013

For and on behalf of the Board of Directors
Jeena Sikho Lifecare Limited

Sandeep Mehta
Partner
Membership No.: 099410

Manish Grover
Managing Director
DIN: 07557886

Bhavna Grover
Whole Time Director
DIN: 07557913

Nanak Chand
Chief Financial Officer

Smita Chaturvedi
Company Secretary
M.No.: A48303

Place: Zirakpur, Punjab
Date: 30 May 2026

Place: Zirakpur, Punjab
Date: 30 May 2026



Jeenasikho Lifecare Limited

Ayurveda Panchakarma Clinic, SCO 11,
Kalgidhar Enclave, Kalka Shimla Highway,
Near K – Area Road, Baltana, Light Point,
Zirakpur, Punjab – 140 603.

☎ +91 473986-73986

✉ investors@jeenasikho.com